Pyridine derivatives as protein kinase inhibitors

Abstract

The present invention relates to a compound suitable for use as a kinase inhibitor.

Description

"PYRIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS" Field of the invention

[001] The present invention is in the field of medicinal and pharmaceutical chemistry. Background of the invention

[002] Protein phosphorylation is the most common form of reversible post-translational modification, with about 50% of all proteins undergoing phosphorylation. The phosphorylation state of any protein is controlled by the coordinated action of specific kinases and phosphatases that add and remove phosphate, respectively. In particular, protein kinases are a type of protein phosphotransferase that transfers phosphate from ATP to the specific amino acid residue. They can be conventionally divided into five classes: tyrosine protein kinases, serine / threonine protein kinases, histidine protein kinases, tryptophan protein kinases, and aspartyl / glutamyl protein kinases.

[003] Signaling networks that employ phosphorylation to modulate target activities have been shown to be critically involved in all aspects of cellular function. Abnormal activation of protein phosphorylation is often a determinant or a direct consequence of disease. Dysregulation of the kinase signaling pathway is associated with cancer, inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, and metabolic diseases, through the constitutive activation of many downstream pathways, such as the murine thymoma viral oncogene homolog 1 phosphatidylinositol 3-kinase / v-akt (PIK3 / AKT), mitogen-activated protein kinase / extracellular signal-regulated kinase (MAPK / ERK), and signal transducer and activator of transcription 5 (STAT5). Consequently, protein kinases represent important therapeutic targets.

[004] In tumors, abnormal oncogenic activation of protein kinases stems from multiple types of genetic and epigenetic alterations. These alterations result in increased specific kinase activity, overexpression, or loss of downregulation, leading to uncontrolled cell growth and sustained malignant behavior. The signaling networks that Petition 870260063548, dated 06 / 26 / 2026, page 8 / 639 2 / 316 of these inhibitors, which operate in cancer cells, can also contribute to innate or acquired resistance to treatment, as they are capable of creating the most common or rare oncogenic mutations, which differ from tumor to tumor. Therefore, the search for small molecule inhibitors that target altered protein kinase molecules in tumor cells has become a major research focus in academia and pharmaceutical companies.

[005] Such inhibitors may be products derived (isolated) from sources such as plants, animals or microorganisms or may be engineered (synthesized) small molecules.

[006] Patent document no. WO 2004 / 022572 discloses classes of biologically active compounds that interact with kinases and the preparation of these compounds.

[007] In cancerology, there are currently multiple examples of small molecule kinase inhibitors with suitable selectivity and pharmaceutical properties that have produced significant clinical benefits. For example, pexidartinib is used to inhibit colony-stimulating factor receptor-1 (CSF1R), KIT proto-oncogene tyrosine kinase receptor (KIT), and FMS-like tyrosine kinase 3 (FLT3) in, for example, treatments of patients with symptomatic tenosynovial giant cell tumors (TGCT); edicotinib to inhibit CSF1R and currently in phase II for acute myeloid leukemia, cognitive disorders, or Crohn's disease; or nintedanib to inhibit the endothelial growth factor receptor (VEGFR), the fibroplast growth factor receptor (FGFR), the platelet-derived growth factor receptor (PDGFR), and CSF1R in, for example, the treatment of idiopathic pulmonary fibrosis.

[008] There is still a great need to develop potent protein kinase inhibitors that are useful in treating various protein kinase-related conditions.

[009] In this regard, patent document no. WO 2011 / 090738 A2 discloses compounds capable of inhibiting B-RAF and B-RAF mutations and methods for treating diseases related to B-RAF modulation and B-RAF mutation.

[010] Patent document US 2009 / 0325945 describes active compounds, specifically, certain imidazo[4,5-b]pyridin-2-one compounds and Petition 870260063548, dated 06 / 26 / 2026, p. 9 / 639 3 / 316 oxazolo[4,5-b]pyridin-2-one and analogues that inhibit RAF activity (e.g., B-RAF) in a cell, in vitro or in vivo, inhibiting receptor tyrosine kinase (RTK) activity, such as FGFR, Tie, VEGFR and / or Eph activity, for example, FGFR-1, FGFR-2, FGFR-3, Tie2, VEGFR-2 and / or EphB2 activity, in a cell, in vitro or in vivo.

[011] US 2015 / 0182526: This patent document describes therapeutic compounds for the treatment of proliferative disorders, cancer, etc., and more specifically certain compounds substituted with pyrido[2,3-b]pyrazine-8, which, among other things, inhibit RAF activity (e.g., B-RAF) and inhibit receptor tyrosine kinase (RTK) activity.

[012] However, despite the growing effort in developing new therapies based on protein kinase inhibitors, there is still a need for protein kinase inhibitors that can overcome the disadvantages of current protein kinase therapies, such as side effects, limited efficacy, emergence of resistance and adherence failures. Summary of the invention

[013] The inventors have surprisingly discovered that the use of protein kinase inhibitors according to the invention allows for improved treatment of diseases related to dysregulated protein kinase, developing a therapy that is more effective, reduces side effects, limits the emergence of resistance, and facilitates adherence.

[014] Therefore, the present invention provides a compound suitable for use as a protein kinase inhibitor according to any of formulas (I) to (VII) [compound (C) hereinafter in the present document], or the N-oxide, pharmaceutically acceptable salt, pharmaceutically acceptable solvate or Petition 870260063548, dated 06 / 26 / 2026, p. 10 / 639 4 / 316 Rg R4 ---THE R4' Formula (II) r4 ---A r4· -12 Formula (III) r4 ---A r4'JzFormula (IV-c) r4 ---THE R4' Formula (V) - each of A is independently selected from the group consisting of cycloalkyl, heterocyclyl, aryl, heteroaryl and aralkyl, wherein said cycloalkyl, heterocyclyl, aryl, heteroaryl and aralkyl are optionally substituted with one or more substituents independently selected from the group consisting of halo, NO2, C1-6 alkyl, C2-4 alkenyl, C2-4 alkynyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, CF3, CN, OR11, SR11, N(Rii)2, OC(Rii)2O, OC(Rii)2C(Rii)2O, S(O)Ri2, SO2R12, SO2N(Rii)2, S(O)3Rii, P(=O)(ORii)2, P(=O)(Rii)2 NR11COR12, COR11, C(O)ORii, CON(Rii)2, OC(O)Rii and OCON(Rii)2 and each optional alkyl, alkenyl, alkynyl, cycloalkyl, Petition 870260063548, dated 06 / 26 / 2026, p. 11 / 639 5 / 316 aryl, heterocyclyl and heteroaryl is additionally optionally substituted with halo, NO2, C1-6 alkyl, cycloalkyl, aryl, CF3, N(Rii)2, COR11, CON(Rii)2, OC(O)Rii, CN or OR11; and wherein each of R11 and R12, independently of each other and in each occurrence, is selected from the group consisting of hydrogen, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, aralkyl and CF3, wherein said alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, heteroaryl and aralkyl substituents are optionally substituted with halo, C1-6 alkyl, cycloalkyl, heterocyclyl, C1-6 alkyl or aryl or heteroaryl amide, OR31 or N(R32)2, wherein each of R31 and R32, independently of each other and in each occurrence, is selected from the group consisting of hydrogen and C1-4 alkyl. - each of R4 and R'4, independently of each other and in each occurrence, are selected from hydrogen or C1-6 alkyl and z is an integer in the range of 0 to 2; provided that when z = 0, then A and R7 can together form a saturated or unsaturated chemical moiety; - each of R7, independently of the other and in each occurrence, is selected from hydrogen, C1-6 alkyl, cycloalkyl, wherein said alkyl and cycloalkyl are optionally substituted by a halogen atom, CF3, N(RIi)2, CN or OR11; and wherein each of R11, independently of the other and in each occurrence, is selected from the group consisting of hydrogen, C16 alkyl and CF3; - each of R3, independently of the other and in each occurrence, is selected from the group consisting of hydrogen, halo, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, aralkyl, CF3, CN, OR21, SR21, N(R21)2, NC(O)R21, NCON(R2i)2, COR21, C(O)OR2i, CON(R2i)2, OC(O)R21, OCON(R21)2, OC(R21)2O and OC(R2i)2C(R22)2O, wherein said alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, heteroaryl and aralkyl are optionally substituted with one or more substituents selected from halo, C1-6 alkyl, CF3, N(R2i)2, CN, or OR21; and wherein each of R21 and R22, independently of the other and in each occurrence, is selected from the group consisting of hydrogen, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, and aralkyl, and wherein said substituents Petition 870260063548, dated 06 / 26 / 2026, p. 12 / 639 6 / 316 of alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, heteroaryl and aralkyl are optionally substituted with halo, C1-6 alkyl, cycloalkyl, heterocyclyl, aryl, OR31 or N(R32)2, wherein each of R31 and R32, independently of each other and in each occurrence, is selected from the group consisting of hydrogen and C1-4 alkyl; each of r is an integer in the range of 0 to 3; provided that when R3 = NR21 and R7 = H, then R3 and NR7 can together form a saturated or unsaturated chemical moiety; - each of R2, independently of the other and in each occurrence, is selected from the group consisting of hydrogen, halo, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, cycloalkyl, heterocyclyl, aryl and heteroaryl, CF3, CN, NO2, OR21, SR21, N(R21)2, COR21, C(O)OR21, CON(R21)2, OC(O)R21, OCON(R21)2, NC(O)R21, NCON(R2i)2, OC(R2i)2O and OC(R2i)2C(R22)2O, wherein said alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl and heteroaryl substituents are optionally substituted with one or more substituents selected from halo, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, cycloalkyl, heterocyclyl, CF3, COR21, CON(R2i)2, C(O)OR21, N(R2i)2, CN, or OR21, and each optional alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl or heteroaryl substituent is further optionally substituted with heterocyclyl, N(Rii)2 or OR11;and wherein each of R21 and R22, independently of each other and in each occurrence, is selected from the group consisting of hydrogen, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, cycloalkyl, heterocyclyl, aryl, heteroaryl and aralkyl and wherein said alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, heteroaryl and aralkyl substituents are optionally substituted with halo, C1-6 alkyl, cycloalkyl, heterocyclyl, aryl, OR31 or N(R32)2, wherein each of R31 and R32, independently of each other and in each occurrence, is selected from the group consisting of hydrogen and C1-4 alkyl; each of q is an integer in the range of 0 to 2; Each of x and y are independent integers equal to 0 or 1; - R8 is independently selected from the group consisting of C612 alkyl, C2-6 alkenyl, C2-6 alkynyl, cycloalkyl and heterocyclyl, wherein said alkyl, alkenyl, alkynyl, cycloalkyl and heterocyclyl are optionally substituted by a halogen atom, an aryl group, an aralkyl group, CF3, Petition 870260063548, dated 06 / 26 / 2026, p. 13 / 639 7 / 316 N(R11)2, CN or OR11; and wherein each of R11, independently of the other and in each occurrence, is selected from the group consisting of hydrogen, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, aralkyl and CF3, wherein said alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, heteroaryl and aralkyl substituents are optionally halo substituted, C1-6 alkyl, cycloalkyl, heterocyclyl, alkyl or aryl or heteroaryl amide, OR31 or N(R32)2, wherein each of R31 and R32, independently of the other and in each occurrence, is selected from the group consisting of hydrogen and C1-4 alkyl; - R9 is selected from the group consisting of hydrogen, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, cycloalkyl, heterocyclyl, N(Rii)2 and CN, wherein said alkyl, alkenyl, alkynyl, cycloalkyl and heterocyclyl are optionally substituted by a halogen atom, an aryl group, an aralkyl group, a heterocyclyl group, CF3, N(Rii)2, CN, or OR11;and wherein each of R11, independently of the other and in each occurrence, is selected from the group consisting of hydrogen, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, aralkyl and CF3, wherein said alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, heteroaryl optionally substituted with C1-4 alkyl, aryl, heteroaryl and aralkyl substituents are optionally substituted with halo, C1-6 alkyl, cycloalkyl, heterocyclyl, alkyl or aryl or heteroaryl amide, OR31 or N(R32)2, wherein each of R31 and R32, independently of the other and in each occurrence, is selected from the group consisting of hydrogen and C1-4 alkyl, provided that x = 1 and y = 0, R9 is different from heterocyclyl and C1-6 alkyl in which said alkyl is optionally substituted with a heterocyclyl;and since x = 0 and y = 0, R9 is different from hydrogen and C1-6 alkyl, where said alkyl is optionally substituted with heterocyclyl and N(Rii)2; since when x = 0 and y = 0, R9 and R2 can together form a saturated or unsaturated cyclic chemical moiety; since when x = 0 and y = 0 and when R9 and R2 together form a saturated or unsaturated cyclic chemical moiety, R9 is NR11; since when x = 1 and y = 1, R9 is different from N(Rii)2; and since when x = 0, y = 0 and z = 0, R9 is different from pyrrole. Petition 870260063548, dated 06 / 26 / 2026, p. 14 / 639 8 / 316 - each of T is independently the chemical portion of formula (Ta) in the present document below: (Εδ)η1 'Z. / u / ;uwnu—u (Ta) where: - each of U, independently of the other and in each occurrence, is selected from the group consisting of C, C-halo, CR and N; wherein R is selected from hydrogen, OR11, N(Rii)2, a C1-6 alkyl or a cycloalkyl that are optionally substituted by a halogen atom, an aryl group or an aralkyl group, wherein each of R11, independently of the other and in each occurrence, is selected from the group consisting of hydrogen or C1-4 alkyl; provided that at least one U is different from N; - each of Z, independently of the other and in each occurrence, is selected from C(R)2, O, S and NR7, wherein R, independently of the other and in each occurrence, is selected from hydrogen or a C1-6 alkyl that is optionally substituted by a halogen atom, an aryl group or an aralkyl group, wherein R7 is selected from the group consisting of hydrogen, C16 alkyl, C1-6 alkenyl, cycloalkyl, heterocyclyl, aryl, aralkyl and CF3; - each of R5, independently of the other and in each occurrence, is selected from the group consisting of C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, aralkyl, halo, CF3, OR11, SR11, N(Rii)2, COOR11, CO(Rii)2, CON(Rii)2 and each optional substituent of alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heterocyclyl, heteroaryl, aralkyl is additionally optionally substituted with halo, C1-6 alkyl, cycloalkyl, aryl, heterocyclyl, N(Rii)2, CN, OR11, C(=O)ORii, P(=O)(ORii)2, P(=O)(Rii)2, CN or CF3 and where each of R11, independently of the other and in each occurrence, is selected from the group consisting of hydrogen, C1-6 alkyl, cycloalkyl and heterocyclyl; each of n1 is an integer in the range of 0 to 2; - each of X is independently the chemical portion of formula (Xa) in the present document below: Petition 870260063548, dated 06 / 26 / 2026, p. 15 / 639 9 / 316 (Βθ)η2 V--ν <χ> ν=ν (Xa) where: - each of V, independently of the other and in each occurrence, is selected from the group consisting of C, C-halo, CR and N; wherein R is selected from hydrogen, OR11, N(Rii)2, a C1-6 alkyl or a cycloalkyl that are optionally substituted by a halogen atom, an aryl group or an aralkyl group, wherein each of R11, independently of the other and in each occurrence, is selected from hydrogen or C1-4 alkyl; - each of R6, independently of the other and in each occurrence, is selected from the group consisting of C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, aralkyl, halo, CF3, OR11, SR11, N(Rii)2, COOR11, CO(Rii)2, CON(Rii)2 and each optional substituent of alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heterocyclyl, heteroaryl, aralkyl is additionally optionally substituted with halo, C1-6 alkyl, cycloalkyl, aryl, heterocyclyl, N(Rii)2, CN, OR11, C(=O)ORii, P(=O)(ORii)2, P(=O)(Rii)2, CN or CF3 and where each of R11, independently of the other and in each occurrence, is selected among the group consisting of hydrogen, C1-6 alkyl, cycloalkyl and heterocyclyl; each of n2 is an integer in the range of 0 to 4; - the dash link represents an optional triple bond; - Ra1 is independently selected from the group consisting of hydrogen, C1-6 alkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, aralkyl, CF3, CN, OR11, SR11, N(Rii)2, COR11, C(O)ORii, wherein said alkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl and aralkyl are optionally substituted with halo, NO2, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, cycloalkyl, heterocyclyl, phenyl, heteroaryl, CF3, CN, OR11, SR11, N(Rii)2, COR11 and C(O)ORii and each optional substituent of alkyl, alkenyl, cycloalkyl, phenyl, heterocyclyl, heteroaryl is further optionally substituted with halo, NO2, C1-6 alkyl, cycloalkyl, phenyl, N(Rii)2, CN or OR11; and wherein each of R11 is selected from the group consisting of hydrogen, C1-6 alkyl, cycloalkyl, heterocyclyl, phenyl, heteroaryl Petition 870260063548, dated 06 / 26 / 2026, p. 16 / 639 10 / 316 and aralkyl, wherein said alkyl, cycloalkyl, heterocyclyl, phenyl, heteroaryl and aralkyl substituents are optionally substituted with halo, C1-6 alkyl, cycloalkyl or heterocyclyl. - Ra2 is independently selected from the group consisting of hydrogen, C1-6 alkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, aralkyl, CF3, CN, OR11, SR11, N(Rii)2, COR11, C(O)ORii, wherein said alkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl and aralkyl are optionally substituted with halo, NO2, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, cycloalkyl, heterocyclyl, phenyl, heteroaryl, CF3, CN, OR11, SR11, N(Rii)2, COR11 and C(O)ORii and each optional substituent of alkyl, alkenyl, cycloalkyl, phenyl, heterocyclyl, heteroaryl is further optionally substituted with halo, NO2, C1-6 alkyl, cycloalkyl, phenyl, N(Rii)2, CN or OR11;and wherein each of R11 is selected from the group consisting of hydrogen, C1-6 alkyl, cycloalkyl, heterocyclyl, phenyl, heteroaryl and aralkyl, wherein said alkyl, cycloalkyl, heterocyclyl, phenyl, heteroaryl and aralkyl substituents are optionally substituted with halo, C1-6 alkyl, cycloalkyl or heterocyclyl; and where n3 is an integer equal to 0 or 1; provided that when the dash link represents a triple bond, n3 is 0; wherein said cycloalkyl is a monocyclic, bicyclic or tricyclic ring system of 3-6 ring members per ring; said heterocyclyl is a saturated, partially saturated or fully saturated monocyclic, bicyclic or tricyclic group containing 3 to 12 carbon atoms and 1 or 2 heteroatoms independently selected from O or N; said aryl is a phenyl, naphthyl or anthracenyl group optionally carbocyclic fused with a cycloalkyl or heterocyclyl group of 5-7 ring members; said heteroaryl is a monocyclic ring structure containing 5 or 6 ring atoms or a bicyclic aromatic group having 8 to 10 atoms, containing 1-3 heteroatoms independently selected from O or N.

[015] The present invention further relates to a pharmaceutical composition comprising a carrier and, as an active ingredient, an effective amount of a compound as defined in any of the embodiments presented herein. Petition 870260063548, dated 06 / 26 / 2026, p. 17 / 639 11 / 316

[016] The present invention relates to a compound, as defined in any of the embodiments presented herein, for use as a medicament.

[017] The present invention relates to a compound, as defined in any of the embodiments presented herein, for use in the treatment of a disease selected from cancer, metabolic disorders (such as diabetes), inflammatory and autoimmune disorders (such as inflammatory bowel diseases, for example, Crohn's disease and ulcerative colitis, inflammatory lung diseases, rheumatoid arthritis, lupus nephritis, systemic lupus erythematosus and psoriasis and psoriatic arthritis), neurological disorders (such as Alzheimer's disease, Parkinson's disease, multiple sclerosis, Charcot-Marie-Tooth neuropathy, amyotrophic lateral sclerosis and epilepsy), atherosclerosis and cardiovascular diseases, Sjögren's syndrome, renal allograft rejection, virus-induced diseases, circulatory diseases, bone osteolysis and osteoporosis, osteoarthritis, sarcopenia, Langerhans cell histiocytosis, spinal cord injury, endometriosis, asthma and allergic asthma,Eye diseases (such as retinopathies, age-related macular degeneration, and uveitis), chronic and neuropathic pain, and fibroproliferative diseases.

[018] The present invention relates to a compound, as defined in any of the embodiments presented herein, for use in the treatment of pain sensitization.

[019] The present invention further relates to a method of inhibiting protein kinase activity in a warm-blooded animal, said method comprising administering to an animal in need thereof an effective kinase-inhibiting amount of a compound according to any of the embodiments presented herein.

[020] The present invention further relates to a method of treating a disease selected from cancer, metabolic disorders (such as diabetes), inflammatory and autoimmune disorders (such as inflammatory bowel diseases, for example, Crohn's disease and ulcerative colitis, inflammatory lung diseases, rheumatoid arthritis, lupus nephritis, systemic lupus erythematosus and psoriasis and psoriatic arthritis), neurological disorders (such as disease of Petition 870260063548, dated 06 / 26 / 2026, page 18 / 639 12 / 316 Alzheimer's disease, Parkinson's disease, multiple sclerosis, Charcot-Marie-Tooth neuropathy, amyotrophic lateral sclerosis and epilepsy), atherosclerosis and cardiovascular diseases, Sjögren's syndrome, renal allograft rejection, virus-induced diseases, circulatory diseases, bone osteolysis and osteoporosis, osteoarthritis, sarcopenia, Langerhans cell histiocytosis, spinal cord injury, endometriosis, asthma and allergic asthma, eye diseases (such as retinopathies, age-related macular degeneration and uveitis), chronic and neuropathic pain and fibroproliferative diseases in a warm-blooded animal, wherein said method comprises administering to an animal in need thereof an effective amount of a compound in accordance with any of the modalities presented herein. Detailed description of the invention

[021] A first aspect of the present invention relates to a compound suitable for use as a protein kinase inhibitor according to any of formulas (I) to (VII) [compound (C) hereinafter in the present document], or the N-oxide, pharmaceutically acceptable salt, pharmaceutically acceptable solvate or stereoisomer thereof, r4 ---A r4'JzFórmula (I) R4 ---THE R4' Formula (III) r4 ---THE R4' Formula (IV-c) Petition 870260063548, dated 06 / 26 / 2026, p. 19 / 639 13 / 316 r4 ---THE R4' Formula (V) in which: - each of A is independently selected from the group consisting of cycloalkyl, heterocyclyl, aryl, heteroaryl and aralkyl, wherein said cycloalkyl, heterocyclyl, aryl, heteroaryl and aralkyl are optionally substituted with one or more substituents independently selected from the group consisting of halo, NO2, C1-6 alkyl, C2-4 alkenyl, C2-4 alkynyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, CF3, CN, OR11, SR11, N(R11)2, OC(R11)2O, OC(R11)2C(R11)2O, S(O)R12, SO2R12, SO2N(R11)2, S(O)3R11, P(=O)(OR11)2, P(=O)(R11)2 NR11COR12, COR11, C(O)ORii, CON(Rii)2, OC(O)Rii, and OCON(Rii)2 and each optional alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heterocyclyl and heteroaryl substituent is further optionally substituted with halo, NO2, C1-6 alkyl, cycloalkyl, aryl, CF3, N(Rii)2, COR11, CON(Rii)2, OC(O)Rii, CN, or OR11; ;and wherein each of Rue R12, independently of the other and in each occurrence, is selected from the group consisting of hydrogen, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, aralkyl and CF3, wherein said alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, heteroaryl and aralkyl substituents are optionally substituted with halo, C1-6 alkyl, cycloalkyl, heterocyclyl, C1-6 alkyl or aryl or heteroaryl amide, OR31 or N(R32)2, wherein each of R31 and R32, independently of the other and in each occurrence; Petition 870260063548, dated 06 / 26 / 2026, p. 20 / 639 14 / 316 occurrence, is selected from the group consisting of hydrogen and C1-4 alkyl. - each of R4 and R'4, independently of each other and in each occurrence, are selected from hydrogen or C1-6 alkyl and z is an integer in the range of 0 to 2; provided that when z = 0, then A and R7 can together form a saturated or unsaturated chemical moiety; - each of R7, independently of the other and in each occurrence, is selected from hydrogen, C1-6 alkyl, cycloalkyl, wherein said alkyl and cycloalkyl are optionally substituted by a halogen atom, CF3, N(RIi)2, CN or OR11; and wherein each of R11, independently of the other and in each occurrence, is selected from the group consisting of hydrogen, C16 alkyl and CF3; - each of R3, independently of the other and in each occurrence, is selected from the group consisting of hydrogen, halo, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, aralkyl, CF3, CN, OR21, SR21, N(R2i)2, NC(O)R2i, NCON(R2i)2, COR21, C(O)OR2i, CON(R2i)2, OC(O)R21, OCON(R2i)2, OC(R2i)2O, and OC(R2i)2C(R22)2O, wherein said alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, heteroaryl and aralkyl are optionally substituted with one or more substituents selected from halo, C1-6 alkyl, CF3, N(R2i)2, CN, or OR21;and wherein each of R21 and R22, independently of each other and in each occurrence, is selected from the group consisting of hydrogen, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, cycloalkyl, heterocyclyl, aryl, heteroaryl and aralkyl and wherein said alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, heteroaryl and aralkyl substituents are optionally substituted with halo, C1-6 alkyl, cycloalkyl, heterocyclyl, aryl, OR31 or N(R32)2, wherein each of R31 and R32, independently of each other and in each occurrence, is selected from the group consisting of hydrogen and C1-4 alkyl; each of r is an integer in the range of 0 to 3; Since when R3 = NR21 and R7 = H, then R3 and NR7 can together form a saturated or unsaturated chemical portion; Each of R2, independently of the others and in each occurrence, is selected from the group consisting of hydrogen, halo, C1-6 alkyl, C2-6 Petition 870260063548, dated 06 / 26 / 2026, p. 21 / 639 15 / 316 alkenyl, C2-6 alkynyl, cycloalkyl, heterocyclyl, aryl and heteroaryl, CF3, CN, NO2, OR21, SR21, N(R21)2, COR21, C(O)OR21, CON(R21)2, OC(O)R21, OCON(R21)2, NC(O)R21, NCON(R2i)2, OC(R2i)2O and OC(R2i)2C(R22)2O, wherein said alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl and heteroaryl substituents are optionally substituted with one or more substituents selected from halo, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, cycloalkyl, heterocyclyl, CF3, COR21, CON(R2i)2, C(O)OR21, N(R2i)2, CN or OR21 and each optional alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl or heteroaryl substituent is additionally optionally substituted with heterocyclyl, N(R2i)2, or OR11;and wherein each of R21 and R22, independently of each other and in each occurrence, is selected from the group consisting of hydrogen, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, cycloalkyl, heterocyclyl, aryl, heteroaryl and aralkyl and wherein said alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, heteroaryl and aralkyl substituents are optionally substituted with halo, C1-6 alkyl, cycloalkyl, heterocyclyl, aryl, OR31 or N(R32)2, wherein each of R31 and R32, independently of each other and in each occurrence, is selected from the group consisting of hydrogen and C1-4 alkyl; each of q is an integer in the range of 0 to 2; Each of x and y are independent integers equal to 0 or 1; - R8 is independently selected from the group consisting of C612 alkyl, C2-6 alkenyl, C2-6 alkynyl, cycloalkyl and heterocyclyl, wherein said alkyl, alkenyl, alkynyl, cycloalkyl and heterocyclyl are optionally substituted by a halogen atom, an aryl group, an aralkyl group, CF3, N(Rii)2, CN or OR11;and wherein each of R11, independently of the other and in each occurrence, is selected from the group consisting of hydrogen, C16 alkyl, C2-6 alkenyl, C2-6 alkynyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, aralkyl and CF3, wherein said alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, heteroaryl and aralkyl substituents are optionally substituted with halo, C1-6 alkyl, cycloalkyl, heterocyclyl, alkyl or aryl or heteroaryl amide, OR31 or N(R32)2, wherein each of R31 and R32, independently of the other and in each occurrence, is selected from the group consisting of hydrogen and C1-4 alkyl; Petition 870260063548, dated 06 / 26 / 2026, p. 22 / 639 16 / 316 - R9 is selected from the group consisting of hydrogen, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, cycloalkyl, heterocyclyl, N(Rii)2 and CN, wherein said alkyl, alkenyl, alkynyl, cycloalkyl and heterocyclyl are optionally substituted by a halogen atom, an aryl group, an aralkyl group, a heterocyclyl group, CF3, N(Rii)2, CN, or OR11;and wherein each of R11, independently of the other and in each occurrence, is selected from the group consisting of hydrogen, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, aralkyl and CF3, wherein said alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, heteroaryl optionally substituted with C1-4 alkyl, aryl, heteroaryl and aralkyl substituents are optionally substituted with halo, C1-6 alkyl, cycloalkyl, heterocyclyl, alkyl or aryl or heteroaryl amide, OR31 or N(R32)2, wherein each of R31 and R32, independently of the other and in each occurrence, is selected from the group consisting of hydrogen and C1-4 alkyl, provided that x = 1 and y = 0, R9 is different from heterocyclyl and C1-6 alkyl in which said alkyl is optionally substituted with a heterocyclyl;and since x = 0 and y = 0, R9 is different from hydrogen and C1-6 alkyl, where said alkyl is optionally substituted with heterocyclyl and N(R11)2; since when x = 0 and y = 0, R9 and R2 can together form a saturated or unsaturated cyclic chemical moiety; since when x = 0 and y = 0 and when R9 and R2 together form a saturated or unsaturated cyclic chemical moiety, R9 is NR11; since when x = 1 and y = 1, R9 is different from N(Rii)2; and since when x = 0, y = 0 and z = 0, R9 is different from pyrrole. - each of T is independently the chemical portion of formula (Ta) in the present document below: (Rs)n1 (Ta) where: - each of U, independently of the other and in each occurrence, is selected from the group consisting of C, C-halo, CR and N; wherein R is selected from hydrogen, OR11, N(Rii)2, a C1-6 alkyl or a cycloalkyl that Petition 870260063548, dated 06 / 26 / 2026, p. 23 / 639 17 / 316 are optionally replaced by a halogen atom, an aryl group or an aralkyl group, wherein each of R11, independently of the other and in each occurrence, is selected from the group consisting of hydrogen or C1-4 alkyl; provided that at least one U is different from N; - each of Z, independently of the other and in each occurrence, is selected from C(R)2, O, S and NR7, wherein R, independently of the other and in each occurrence, is selected from hydrogen or a C1-6 alkyl that is optionally substituted by a halogen atom, an aryl group or an aralkyl group, wherein R7 is selected from the group consisting of hydrogen, C16 alkyl, C1-6 alkenyl, cycloalkyl, heterocyclyl, aryl, aralkyl and CF3; - each of R5, independently of the other and in each occurrence, is selected from the group consisting of C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, aralkyl, halo, CF3, OR11, SR11, N(Rii)2, COOR11, CO(Rii)2, CON(Rii)2 and each optional substituent of alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heterocyclyl, heteroaryl, aralkyl is additionally optionally substituted with halo, C1-6 alkyl, cycloalkyl, aryl, heterocyclyl, N(Rii)2, CN, OR11, C(=O)ORii, P(=O)(ORii)2, P(=O)(Rii)2, CN or CF3 and where each of R11, independently of the other and in each occurrence, is selected from the group consisting of hydrogen, C1-6 alkyl, cycloalkyl and heterocyclyl; each of n1 is an integer in the range of 0 to 2; - each of X is independently the chemical portion of formula (Xa) in the present document below: (Eδ)η2 v=v (Xa) where: - each of V, independently of the other and in each occurrence, is selected from the group consisting of C, C-halo, CR and N; wherein R is selected from hydrogen, OR11, N(Rii)2, a C1-6 alkyl or a cycloalkyl that are optionally substituted by a halogen atom, an aryl group or Petition 870260063548, dated 06 / 26 / 2026, page 24 / 639 18 / 316 an aralkyl group, wherein each of R11, independently of the other and in each occurrence, is selected from hydrogen or C1-4 alkyl; - each of R6, independently of the other and in each occurrence, is selected from the group consisting of C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, aralkyl, halo, CF3, OR11, SR11, N(Rii)2, COOR11, C0(Rii)2, CON(Rii)2 and each optional substituent of alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heterocyclyl, heteroaryl, aralkyl is additionally optionally substituted with halo, C1-6 alkyl, cycloalkyl, aryl, heterocyclyl, N(Rii)2, CN, OR11, C(=O)ORii, P(=O)(ORii)2, P(=O)(Rii)2, CN or CF3 and where each of R11, independently of the other and in each occurrence, is selected from the group consisting of hydrogen, C1-6 alkyl, cycloalkyl and heterocyclyl; each of n2 is an integer in the range of 0 to 4; - the dash link represents an optional triple bond; - Ra1 is independently selected from the group consisting of hydrogen, C1-6 alkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, aralkyl, CF3, CN, OR11, SR11, N(Rii)2, COR11, C(O)ORii, wherein said alkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl and aralkyl are optionally substituted with halo, NO2, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, cycloalkyl, heterocyclyl, phenyl, heteroaryl, CF3, CN, OR11, SR11, N(Rii)2, COR11 and C(O)ORii and each optional substituent of alkyl, alkenyl, cycloalkyl, phenyl, heterocyclyl, heteroaryl is further optionally substituted with halo, NO2, C1-6 alkyl, cycloalkyl, phenyl, N(Rii)2, CN or OR11;and wherein each of R11 is selected from the group consisting of hydrogen, C1-6 alkyl, cycloalkyl, heterocyclyl, phenyl, heteroaryl and aralkyl, wherein said alkyl, cycloalkyl, heterocyclyl, phenyl, heteroaryl and aralkyl substituents are optionally substituted with halo, C1-6 alkyl, cycloalkyl or heterocyclyl. - Ra2 is independently selected from the group consisting of hydrogen, C1-6 alkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, aralkyl, CF3, CN, OR11, SR11, N(Rii)2, COR11, C(O)ORii, wherein said alkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl and aralkyl are optionally substituted by halo, NO2, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, cycloalkyl, heterocyclyl, phenyl, heteroaryl, CF3, CN, OR11, SR11, N(Rii)2, COR11 and C(O)ORii and each substituent Petition 870260063548, dated 06 / 26 / 2026, p. 25 / 639 19 / 316 optional alkyl, alkenyl, cycloalkyl, phenyl, heterocyclyl, heteroaryl is further optionally substituted with halo, NO2, C1-6 alkyl, cycloalkyl, phenyl, N(R1i)2, CN or OR11; and wherein each of R11 is selected from the group consisting of hydrogen, C1-6 alkyl, cycloalkyl, heterocyclyl, phenyl, heteroaryl and aralkyl, wherein said alkyl, cycloalkyl, heterocyclyl, phenyl, heteroaryl and aralkyl substituents are optionally substituted with halo, C1-6 alkyl, cycloalkyl or heterocyclyl; and where n3 is an integer equal to 0 or 1; provided that when the dash link represents a triple bond, n3 is 0; wherein said cycloalkyl is a monocyclic, bicyclic or tricyclic ring system of 3-6 ring members per ring; said heterocyclyl is a saturated, partially saturated or fully saturated monocyclic, bicyclic or tricyclic group containing 3 to 12 carbon atoms and 1 or 2 heteroatoms independently selected from O or N; said aryl is a phenyl, naphthyl or anthracenyl group optionally carbocyclic fused with a cycloalkyl or heterocyclyl group of 5-7 ring members; said heteroaryl is a monocyclic ring structure containing 5 or 6 ring atoms or a bicyclic aromatic group having 8 to 10 atoms, containing 1-3 heteroatoms independently selected from O or N.

[022] In a preferred embodiment of the present invention, A in compound (C) of formulas (I) to (VII) is independently selected from the group consisting of cycloalkyl, heterocyclyl, aryl, heteroaryl and aralkyl, wherein said cycloalkyl, heterocyclyl, aryl, heteroaryl and aralkyl are optionally substituted with one or more substituents independently selected from the group consisting of halo, NO2, C1-6 alkyl, C2-4 alkenyl, C2-4 alkynyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, CF3, CN, OR11, SR11, N(Rii)2, OC(Rii)2O, OC(Rii)2C(Rii)2O, P(=O)(ORii)2, P(=O)(Rii)2 NR11COR12, COR11, C(O)ORii, CON(Rii)2, OC(O)Rii, and OCON(Rii)2 and each optional alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heterocyclyl, heteroaryl substituent is further optionally substituted with halo, NO2, C1-6 alkyl, cycloalkyl, aryl, CF3, N(Rii)2, CN, or OR11;and wherein each of R11 and R12, independently of the other and in each occurrence, is selected from the group consisting of hydrogen, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, aralkyl and CF3, wherein said; Petition 870260063548, dated 06 / 26 / 2026, p. 26 / 639 20 / 316 substituintes de alquila, alkenila, alkynila, cicloalquila, heterociclila, arilla, heteroarila e aralquila são opciónmente substituídos com halo, C1-6 alquila, cicloalquila ou heterociclila.More preferably, A is independently selected from the group consisting of cycloalkyl, heterocyclyl, aryl, heteroaryl and aralkyl, wherein said cycloalkyl, heterocyclyl, aryl, heteroaryl and aralkyl are optionally substituted with one or more substituents independently selected from the group consisting of halo, C1-6 alkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, CF3, CN, OR11, N(Rii)2, OC(Rii)2O, OC(Rii)2C(Rii)2O, P(=O)(Rii)2, COR11, C(O)ORii, CON(Rii)2, OC(O)Rii and each optional substituent of alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heterocyclyl, heteroaryl is further optionally substituted with C14 alkyl or cycloalkyl; and wherein each of R11 and R12, independently of each other and in each occurrence, is selected from the group consisting of hydrogen, C1-6 alkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, aralkyl and CF3.More preferably, A is independently selected from the group consisting of cycloalkyl, heterocyclyl, aryl, heteroaryl and aralkyl, wherein said cycloalkyl, heterocyclyl, aryl, heteroaryl and aralkyl are optionally substituted with one or more substituents independently selected from the group consisting of halo, C1-6 alkyl, CF3, CN, OR11 and P(=O)(Rii)2; and wherein each of R11, in each occurrence, is hydrogen or C1-4 alkyl such as methyl, ethyl, propyl, isopropyl, butyl, tert-butyl and isobutyl.

[023] In one embodiment of the present invention, A in compound (C) of formulas (I) to (VII) is independently selected from the following chemical moieties: Petition 870260063548, dated 06 / 26 / 2026, p. 27 / 639 21 / 316 wherein each of the halo groups is F, Cl, Br or I and each of the halo groups is hydrogen or C1-4 alkyl such as methyl, ethyl, propyl, isopropyl, butyl, tert-butyl and isobutyl, preferably R is hydrogen, methyl, ethyl, 2-methylpropyl or tert-butyl.

[024] In a preferred embodiment of the present invention, each of R4 in compound (C) of formulas (I) to (VII) is hydrogen or C1-4 alkyl such as methyl, ethyl, propyl, isopropyl, butyl, tert-butyl, isobutyl and the like. Even more preferably, R4 is hydrogen or methyl.

[025] In a preferred embodiment of the present invention, each of R4 in compound (C) of formulas (I) to (VII) is hydrogen or C1-4 alkyl such as methyl, ethyl, propyl, isopropyl, butyl, tert-butyl, isobutyl and the like. Even more preferably, R4 is hydrogen.

[026] In a preferred embodiment of the present invention, z in compound (C) of formulas (I) to (VII) is an integer equal to 0 or 1. Even more preferably, z is 1.

[027] In a preferred embodiment of the present invention, each of the compound (C) of formulas (I) to (VII), independently of each other Petition 870260063548, dated 06 / 26 / 2026, page 28 / 639 22 / 316 and in each occurrence, it is hydrogen or C1-4 alkyl such as methyl, ethyl, propyl, isopropyl, butyl, tert-butyl, isobutyl and the like. More preferably, each of R7 independently of the other and in each occurrence is hydrogen or methyl. Even more preferably, each of R7 independently of the other and in each occurrence is hydrogen.

[028] In a preferred embodiment of the present invention, each of R3 in compound (C) of formulas (I) to (VII), independently of each other and in each occurrence, is selected from the group consisting of hydrogen, halo, C1-6 alkyl, cycloalkyl, heterocyclyl, CF3, CN, OR21 and N(R2i)2, wherein said alkyl, cycloalkyl and heterocyclyl are optionally substituted with one or more substituents selected from halo, C1-6 alkyl, CF3, N(R2i)2, CN or OR21; and wherein each of R21, independently of the other and in each occurrence, is selected from the group consisting of hydrogen, C1-6 alkyl, C3-6 cycloalkyl, heterocyclyl, aryl, heteroaryl and aralkyl and wherein said alkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl and aralkyl substituents are optionally substituted with halo, C1-6 alkyl, cycloalkyl, heterocyclyl or aryl.Preferably, R3 is selected independently from the group consisting of hydrogen, halo, C1-6 alkyl, cycloalkyl, CF3, CN, OR21 and N(R2i)2, wherein said alkyl and cycloalkyl are optionally substituted with one or more substituents selected from halo, C1-6 alkyl, CF3, N(R2i)2, CN or OR21; and wherein each of R21, independently of the other and in each occurrence, is selected from the group consisting of hydrogen and C1-4 alkyl such as methyl, ethyl, propyl, isopropyl, butyl, tert-butyl and isobutyl. More preferably, R3 is selected independently from the group consisting of hydrogen, halo and C1-4 alkyl such as methyl, ethyl, propyl, isopropyl, butyl, tert-butyl, isobutyl, CF3, CN, OR21 and N(R2i)2 and wherein each of R21, independently of the other and in each occurrence, is selected from the group consisting of hydrogen and C1-4 alkyl.More preferably, R3 is independently selected from the group consisting of hydrogen, halo, OC1-4 alkyl and C1-4 alkyl such as methyl, ethyl, propyl, isopropyl, butyl, tert-butyl and isobutyl. Even more preferably, R3 is independently chosen from the group consisting of hydrogen, halo, OCH3 and methyl. Petition 870260063548, dated 06 / 26 / 2026, p. 29 / 639 23 / 316

[029] In a preferred embodiment of the present invention, each of r in the compound (C) of formulas (I) to (VII) is an integer equal to 0, 1 or 2. More preferably, each of r is an integer equal to 0 or 1. Even more preferably, each of r is an integer equal to 1.

[030] In a preferred embodiment of the present invention, each of R2 in compound (C) of formulas (I) to (VII), independently of each other and in each occurrence, is selected from the group consisting of hydrogen, halo, C1-6 alkyl, cycloalkyl, heterocyclyl, aryl and heteroaryl, CN, OR21 and N(R2i)2, wherein said alkyl, cycloalkyl, heterocyclyl, aryl and heteroaryl are optionally substituted with one or more substituents selected from halo, C1-6 alkyl, cycloalkyl, N(R2i)2, CN or OR21; wherein R21, independently of each other and in each occurrence, is selected from the group consisting of hydrogen, C16 alkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl and aralkyl.More preferably, R2 is independently selected from the group consisting of hydrogen, halo, C1-4 alkyl, cycloalkyl, heterocyclyl, CN, OR21 and N(R2i)2; wherein R21, independently of each other and in each occurrence, is selected from the group consisting of hydrogen, C1-4 alkyl such as methyl, ethyl, propyl, isopropyl, butyl, tert-butyl and isobutyl and C3-6 cycloalkyl such as cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl. Even more preferably, R2 is independently chosen from the group consisting of hydrogen, halo, C1-4 alkyl and N(R2i)2, wherein R21 is selected from the group consisting of hydrogen and C1-4 alkyl such as methyl, ethyl, propyl, isopropyl, butyl, tert-butyl and isobutyl.

[031] In a preferred embodiment of the present invention, q in compound (C) of formulas (I) to (VII) is equal to 0 or 1.

[032] According to certain embodiments of the present invention, x in the compound (C) of formula (II), (IV) or (VI) is an integer equal to 0 and y is an integer equal to 1.

[033] According to certain embodiments of the present invention, x in the compound (C) of formula (II), (IV) or (VI) is an integer equal to 1 and y is an integer equal to 0. Petition 870260063548, dated 06 / 26 / 2026, p. 30 / 639 24 / 316

[034] According to certain embodiments of the present invention, x in the compound (C) of formula (II), (IV) or (VI) is an integer equal to 1 and y is an integer equal to 1.

[035] According to certain embodiments of the present invention, x in compound (C) of formula (II), (IV) or (VI) is an integer equal to 0 and y is an integer equal to 0.

[036] In a preferred embodiment of the present invention, R8 in compound (C) of formula (I) is selected from the group consisting of C6-12 alkyl, cycloalkyl and heterocyclyl, wherein said alkyl, cycloalkyl and heterocyclyl are optionally substituted by a halogen atom, CF3, N(Rii)2, CN or OR11; and wherein each of R11, independently of the other and in each occurrence, is selected from the group consisting of hydrogen, C1-6 alkyl. More preferably, R8 is C6-12 alkyl, wherein said alkyl is optionally substituted by a halogen atom. Even more preferably, R8 is C6-12 alkyl.

[037] In a preferred embodiment of the present invention, R9 in compound (C) of formula (II) is selected from the group consisting of hydrogen, C1-6 alkyl, cycloalkyl, N(Rii)2 and CN, wherein said alkyl and cycloalkyl are optionally substituted by a halogen atom, CF3, CN or OR11; and wherein each of R11, independently of the other and in each occurrence, is selected from the group consisting of hydrogen, C1-6 alkyl, C2-6 alkenyl and CF3, wherein said alkyl and alkenyl substituents are optionally substituted with a heteroaryl group optionally substituted with a C1-4 alkyl provided that if x = 0 and y = 0, R9 is different from hydrogen and C16 alkyl, wherein said alkyl is optionally substituted with heterocyclyl and N(Rii)2; since when x = 0 and y = 0, R9 and R2 can together form a saturated or unsaturated cyclic chemical portion;provided that when x = 0 and y = 0 and when R9 and R2 together form a saturated or unsaturated cyclic chemical moiety, R9 is NR11; provided that when x = 1 and y = 1, R9 is different from N(Rii)2; and provided that when x = 0, y = 0 and z = 0, R9 is different from pyrrole. More preferably, R9 is selected from the group consisting of hydrogen, C1-6 alkyl, cycloalkyl, N(Rii)2 and CN, wherein said alkyl and cycloalkyl are optionally substituted; Petition 870260063548, dated 06 / 26 / 2026, p. 31 / 639 25 / 316 by a halogen atom, CF3, CN or OR11; and wherein each of R11, independently of the other and in each occurrence, is selected from the group consisting of hydrogen, C1-6 alkyl, C2-6 alkenyl and CF3, wherein said alkyl and alkenyl substituents are optionally substituted with a heteroaryl group optionally substituted with a C1-4 alkyl; provided that if x = 0 and y = 0, R9 is different from hydrogen and C1-6 alkyl, wherein said alkyl is optionally substituted with heterocyclyl and N(Rii)2 and provided that when x = 0 and y = 0, R9 and R2 can together form a saturated or unsaturated cyclic chemical moiety; provided that when x = 0 and y = 0 and when R9 and R2 together form a saturated or unsaturated cyclic chemical moiety, R9 is NR11; since when x = 1 and y = 1, R9 is different from N(Rii)2 ;and since when x = 0, y = 0 and z = 0, R9 is different from pyrrole. Even more preferably, R9 is selected from the group consisting of hydrogen, C1-4 alkyl such as methyl, ethyl, propyl, isopropyl, butyl, tert-butyl and isobutyl, a C2-6 alkenyl such as propene or butene, C3-6 cycloalkyl such as cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl, N(RIi)2, and CN, wherein said alkyl and cycloalkyl are optionally substituted by a halogen atom, CF3, CN or OR11; and wherein each of R11, independently of the other and in each occurrence, is selected from the group consisting of hydrogen, C1-6 alkyl, C2-6 alkenyl and CF3, wherein said alkyl and alkenyl substituents are optionally substituted with a heteroaryl group optionally substituted with a C1-4 alkyl;provided that if x = 0 and y = 0, R9 is different from hydrogen and C1-6 alkyl, wherein said alkyl is optionally substituted with heterocyclyl and N(Rii)2 and provided that when x = 0 and y = 0, R9 and R2 can together form a saturated or unsaturated cyclic chemical moiety; provided that when x = 0 and y = 0 and when R9 and R2 together form a saturated or unsaturated cyclic chemical moiety, R9 is NR11; provided that when x = 1 and y = 1, R9 is different from N(Rii)2; and provided that when x = 0, y = 0 and z = 0, R9 is different from pyrrole.

[038] In a preferred embodiment of the present invention, each of T in compound (C) of formula (III) or (IV) is independently the chemical moiety of formula (Ta) in the present document below: Petition 870260063548, dated 06 / 26 / 2026, p. 32 / 639 26 / 316 (Rõ)n1 u—U (Ta) where: - each of the U is preferably selected, independently of the other and in each occurrence, from C, C-halo, CR or N; wherein R is hydrogen or C1-4 alkyl provided that at least one U is different from N. More preferably, each of the U is selected, independently of the other and in each occurrence, from C, CR or N; wherein R is hydrogen or C1-4 alkyl provided that at least one U is different from N. Each of Z is, independently of the other and in each occurrence, preferably selected from the group consisting of CH2 and O, S and NRz wherein R7 is a hydrogen or a C1-4 alkyl such as methyl, ethyl, propyl, isopropyl, butyl, tert-butyl and isobutyl. More preferably, each of Z is, independently of the other and in each occurrence, selected from the group consisting of CH2, O and NH. - each of R5, independently of the other and in each occurrence, is preferably selected from the group consisting of C1-6 alkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, aralkyl, halo, CF3, OR11, N(Rii)2, COOR11, CO(Rii)2, CON(Rii)2 and each optional substituent of alkyl, cycloalkyl, aryl, heterocyclyl, heteroaryl, aralkyl is additionally optionally substituted with halo, C1-6 alkyl, cycloalkyl, aryl, heterocyclyl, N(Rii)2, CN, OR11, C(=O)ORii, P(=O)(ORii)2, P(=O)(Rii)2, CN or CF3 and wherein each of R11, independently of the other and in each occurrence, is selected from the group consisting of hydrogen, C1-6 alkyl, cycloalkyl and heterocyclyl.More preferably, each of R5, independently of the other and in each occurrence, is selected from the group consisting of C1-4 alkyl, cycloalkyl, heterocyclyl, CF3, OR11 and each optional substituent of alkyl, cycloalkyl, heterocyclyl is additionally optionally substituted with halo, C1-4 alkyl, cycloalkyl, CN, OC1-4 alkyl, C(=O)OC1-4 alkyl, P(=O)(OC1-4 alkyl)2, P(=O)(C14 alkyl)2. Petition 870260063548, dated 06 / 26 / 2026, p. 33 / 639 27 / 316 - n1 is preferably an integer equal to 0, 1, or 2. More preferably, n1 is an integer equal to 1 or 2.

[039] In a preferred embodiment of the present invention, each of T in compound (C) of formula (III) or (IV), independently of each other and in each instance, is selected from the chemical portion of formula (Ta-1) to (Ta- 11) in the document below: (Rõ')n1 (Ta-4) (Ta-1) (Ta-2) (Ta-7) (Ta-8) (Ta-5) (R5')n1 (Ta-9) (Ta-10) (Ta-11) wherein each R is independently selected from the group consisting of hydrogen, C1-4 alkyl, cycloalkyl, heterocyclyl, wherein said C1-4 alkyl, cycloalkyl and heterocyclyl are optionally halo substituted, CN, cycloalkyl, OC1-4 alkyl, C(=O)OC1-4 alkyl, P(=O)(C1-4 alkyl)2, P(=O)(OC1-4 alkyl)2 preferably R is hydrogen or methyl and wherein each of R5' is independently selected from the group consisting of hydrogen, C1-4 alkyl, CF3 and cycloalkyl; and where m is an integer equal to 1 or 2.

[040] In a preferred embodiment of the present invention, each of X in compound (C) of formula (V) or (VI) is independently the chemical moiety of formula (Xa) in the present document below: Petition 870260063548, dated 06 / 26 / 2026, page 34 / 639 28 / 316 (^θ)η2 v--v < ) ν=ν (Xa) where: Each of V, independently of the other and in each occurrence, is selected from the group consisting of C, C-halo, CR and N; wherein R is hydrogen or C1-4 alkyl; More preferably, each of V is selected, independently of the other and in each occurrence, from C, CR or N; wherein R is hydrogen or C1-4 alkyl. - each of R6, independently of the other and in each occurrence, is preferably selected from the group consisting of C1-6 alkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, aralkyl, halo, CF3, OR11, N(Rii)2, COOR11, CO(Rii)2, CON(Rii)2 and each optional substituent of alkyl, cycloalkyl, aryl, heterocyclyl, heteroaryl, aralkyl is additionally optionally substituted with halo, C1-6 alkyl, cycloalkyl, aryl, heterocyclyl, N(Rii)2, CN, OR11, C(=O)ORii, P(=O)(ORii)2, P(=O)(Rii)2, CN or CF3 and wherein each of R11, independently of the other and in each occurrence, is selected from the group consisting of hydrogen, C1-6 alkyl, cycloalkyl and heterocyclyl.More preferably, each of R6, independently of the other and in each occurrence, is selected from the group consisting of C1-4 alkyl, cycloalkyl, heterocyclyl, heteroaryl, halo, CF3, OR11, N(Rii)2 and each optional substituent of alkyl, cycloalkyl, heterocyclyl and heteroaryl is further optionally substituted with halo, C1-4 alkyl, cycloalkyl, heterocyclyl, CN, OC1-4 alkyl, C(=O)OC1-4 alkyl, P(=O)(OC1-4 alkyl)2, P(=O)(C1-4 alkyl)2, wherein said heterocyclyl is further optionally substituted with C1-4 alkyl and wherein each of R11, independently of the other and in each occurrence, is selected from the group consisting of hydrogen and C1-4 alkyl.Even more preferably, each of R6, independently of the other and in each occurrence, is selected from the group consisting of C1-4 alkyl, cycloalkyl, heterocyclyl, heteroaryl, halo, CF3, OR11, N(Rii)2 and each optional substituent of alkyl, cycloalkyl, heterocyclyl and heteroaryl is additionally optional. Petition 870260063548, dated 06 / 26 / 2026, p. 35 / 639 29 / 316 substituted with C1-4 alkyl or heterocyclyl, wherein said heterocyclyl is additionally optionally substituted with C1-4 alkyl and wherein each of R11, independently of the other and in each occurrence, is selected from the group consisting of hydrogen and C1-4 alkyl. - n2 is preferably an integer equal to 0, 1, or 2. More preferably, n1 is an integer equal to 0 or 1.

[041] In one embodiment of the present invention, each of X in compound (C) of formula (V) or (VI) is independently selected from the chemical portion of formula (Xa-1) to (Xa-3) in the present document below: (Xa-1) (Xa-2) (Xa-3) where - each of R6' is independently selected from hydrogen, halo, C1-4 alkyl, OC1-4 alkyl, NH2, N(C1-4 alkyl)2, heterocyclyl, heteroaryl, wherein said C1-4 alkyl, heteroaryl and heterocyclyl are optionally substituted with halo, C1-4 alkyl, heterocyclyl which are optionally substituted with C1-4 alkyl - n2 is an integer equal to 1 or 2.

[042] In a preferred embodiment of the present invention, the dash linkage in compound (C) of formula (VII) represents a triple bond.

[043] In a preferred embodiment of the present invention, Ra1 in compound (C) of formula (VII) is independently selected from the group consisting of C1-4 alkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, aralkyl, wherein said alkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl and aralkyl are optionally substituted by halo, NO2, C1-4 alkyl, cycloalkyl, heterocyclyl, phenyl, heteroaryl, CF3, CN, OR11, N(Rii)2 and wherein each of R11 is selected from the group consisting of hydrogen or C1-4 alkyl. More preferably, Ra1 is selected independently from the group consisting of C1-4 alkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, aralkyl, wherein said alkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl and aralkyl are optionally Petition 870260063548, dated 06 / 26 / 2026, p. 36 / 639 30 / 316 substituted by halo, heterocyclyl, aryl, heteroaryl, OR11, N(Rii)2 and wherein each of R11 is selected from the group consisting of hydrogen and C1-4 alkyl. Even more preferably, Ra1 is independently C1-4 alkyl, wherein said alkyl is optionally substituted by aryl, heteroaryl, OR11, N(Rii)2 and wherein each of R11 is selected from the group consisting of hydrogen and C1-4 alkyl.

[044] In a preferred embodiment of the present invention, Ra2 in compound (C) of formula (VII) is independently selected from the group consisting of C1-4 alkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, aralkyl, wherein said alkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl and aralkyl are optionally replaced by halo, NO2, C1-4 alkyl, cycloalkyl, heterocyclyl, phenyl, heteroaryl, CF3, CN, OR11, N(Rii)2 and wherein each of R11 is selected from the group consisting of hydrogen or C1-4 alkyl. More preferably, Ra2 is independently selected from the group consisting of C1-4 alkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, aralkyl, wherein said alkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl and aralkyl are optionally substituted by halo, heterocyclyl, phenyl, heteroaryl, OR11, N(Rii)2 and wherein each of R11 is selected from the group consisting of hydrogen or C1-4 alkyl.Even more preferably, Ra2 is independently C1-4 alkyl, wherein said alkyl is optionally substituted by aryl, heteroaryl, OR11, N(Rii)2 and wherein each of R11 is selected from the group consisting of hydrogen and C1-4 alkyl.

[045] In a preferred embodiment of the present invention, n3 in compound (C) of formula (VII) is an integer equal to 0.

[046] According to one embodiment of the present invention, compound (C), according to formula (II), or the N-oxide, pharmaceutically acceptable salt, pharmaceutically acceptable solvate or stereoisomer thereof, is preferably a compound chosen from those of formula (II-a) or (IIb) [compound (C) of class (II) hereinafter in this document]: Petition 870260063548, dated 06 / 26 / 2026, p. 37 / 639 31 / 316 where A, R4, R4', z, R7, R3, r, R2, qe R9 have the same meaning as defined above for formula (II).

[047] According to one embodiment of the present invention, compound (C), according to formula (III), or the N-oxide, pharmaceutically acceptable salt, pharmaceutically acceptable solvate or stereoisomer thereof, is preferably a compound of formula (III-a) [compound (C) of class (III) hereinafter in this document]: r4 ---A r4'JzFormula (III-a) where A, R4, R4', z, R7, R3, r, R2, qe T have the same meaning as defined above for formula (III).

[048] According to one embodiment of the present invention, compound (C), according to formula (IV), or the N-oxide, pharmaceutically acceptable salt, pharmaceutically acceptable solvate or stereoisomer thereof, is preferably a compound chosen from those of formula (IV-a) to (IVc) [compound (C) of class (IV) hereinafter in this document]: r4 ---THE R4' Formula (IV-a) Petition 870260063548, dated 06 / 26 / 2026, p. 38 / 639 32 / 316 where A, R4, R4', z, R7, R3, r, R2, qe T have the same meaning as defined above for formula (IV).

[049] According to one embodiment of the present invention, compound (C), according to formula (VI), or the N-oxide, pharmaceutically acceptable salt, pharmaceutically acceptable solvate or stereoisomer thereof, is preferably a compound chosen from those of formula (VI-a) to (VIc) [compound (C) of class (VI) hereinafter in this document]: r4 ---A r4' For Formula (VI-c) where A, R4, R4', z, R7, R3, r, R2, qe X have the same meaning as defined above for formula (VI).

[050] According to one embodiment of the present invention, compound (C), according to formula (VII), or the N-oxide, pharmaceutically acceptable salt, pharmaceutically acceptable solvate or stereoisomer thereof, Petition 870260063548, dated 06 / 26 / 2026, p. 39 / 639 33 / 316 is preferably a compound chosen from those of formula (VlI-a) or (VlI-b) [compound (C) of class (VI) hereinafter in this document]: where A, R4, R4', z, R7, R3, r, R2, q, Ra1, Ra2 and n3 have the same meaning as defined above for formula (VII).

[051] In compounds (C), according to the present invention, preferably R4' and R7 are hydrogen and ereq are equal to 1. Preferred compounds (C) of class (II) are then selected from those of formula (II-a1) to (II-c-1) in the present document below: wherein A, R4, R3, R2 and R9 have the same meaning as defined above for formula (II); wherein R31 is a heteroaryl that is optionally substituted with a C1-4 alkyl, wherein R11' is hydrogen or C1-4 alkyl; and wherein Rb is Petition 870260063548, dated 06 / 26 / 2026, page 40 / 639 34 / 316 selected from the group consisting of hydrogen, halo, C1-4 alkyl and C1-6 cycloalkyl. wherein said heteroaryl is a monocyclic ring structure containing 5 or 6 ring atoms or a bicyclic aromatic group containing 8 to 10 atoms, containing 1-3 heteroatoms independently selected from O or N.

[052] In one embodiment of the present invention, compounds (C) of class (II) are selected from those with formula (II-a-1) to (II-c-1).

[053] In compounds (C), according to the present invention, preferably R4' and R7 are hydrogen and ereq are equal to 1. The preferred compounds (C) of class (IV) are then selected from those of formula (IVa-1) to (IV-c-1) in the present document below: Formula (IV-a-1) where A, R4, R3, R2 and T have the same meaning as defined above for formula (IV).

[054] In one embodiment of the present invention, compounds (C) of class (IV) are selected from those with formula (IV-a-1) to (IV-c-1).

[055] In compounds (C), according to the present invention, preferably R4' and R7 are hydrogen and ereq are equal to 1. Preferred compounds (C) of class VI are then selected from those of formula (VI-a1) to (VI-c-1) in the present document below: Petition 870260063548, dated 06 / 26 / 2026, page 41 / 639 35 / 316 X Formula (VI-a-1) r2 THE N Formula (VI-b-1) Formula (VI-c-1) where A, R4, R3, R2 and X have the same meaning as defined above for formula (VI).

[056] In one embodiment of the present invention, compounds (C) of class (VI) are selected from those with formula (VI-a-1) to (VI-c-1).

[057] In compounds (C), according to the present invention, preferably R4' and R7 are hydrogen and ereq are equal to 1. The preferred compounds (C) of class (VII) are then selected from those of formula (VII- where A, R4, R3, R2, Ra1, Ra2 and n3 have the same meaning as defined above for formula (VII). Petition 870260063548, dated 06 / 26 / 2026, page 42 / 639 36 / 316

[058] In one embodiment of the present invention, compounds (C) of class (II) are selected from those of formula (VII-a-1) or (VII-b-1).

[059] In a preferred embodiment of the present invention, the compound (C) of class (II), according to the present invention, is selected from those of formula (II-a-2) or (II-b-2) or (II-c-2) in the present document below: Formula (II-a-2) in which: - each of R9' is selected from the group consisting of hydrogen, CN and C3-6 cycloalkyl such as cyclopropyl; - each of R9” is selected from the group consisting of hydrogen, C1-4 alkyl, CN and C3-6 cycloalkyl such as cyclopropyl; - each of the R2 elements is selected independently from either hydrogen or halo; Each Rq element is selected independently from the group consisting of hydrogen, CH3, OCH3, and halo elements such as F or Cl. Each R10 is selected independently from the group consisting of H, F, Cl, OCH3, or CF3; - each of U is selected from the group consisting of C, C-R10 and N; - πιο is an integer equal to 0, 1, or 2; and Petition 870260063548, dated 06 / 26 / 2026, p. 43 / 639 37 / 316 Each of R31' is selected from the group consisting of pyrazyl, N-methylpyrazyl, and pyridyl. - Rb' is selected from the group consisting of hydrogen, halo, C1-4 alkyl and C1-4 cycloalkyl; preferably Rb' is selected from the group consisting of Cl, CH3 and cyclopropyl. - The dashed line represents an optional double bond.

[060] In a preferred embodiment of the present invention, the compound (C) of class (IV), according to the present invention, are selected from those with formula (IV-a-2-1), (IV-a-2-2), (IV-b-2-1), (IV-b-2-2), or (IV-c-2) to (IV-c2-4) in the present document below: Formula (IV-a-2-1) Formula (IV-a-2-2) Formula (IV-b-2-1) Formula (IV-b-2-2) Formula (IV-c-2-1) Petition 870260063548, dated 06 / 26 / 2026, p. 44 / 639 38 / 316 Formula (IV-c-2-2) Formula (IV-c-2-3) Formula (IV-c-2-4) where: - T is, independently of each other and in each occurrence, selected from the chemical portion of formula (Taa) to (Taf) in the present document below: (Taa) / 1XN(R5)ni (Tab) (R5)ni (Tac) R'N'N^(R5)ni(Tad) (Tae) <T’a’f) em que: - each of R' is independently hydrogen, C1-4 alkyl, cycloalkyl selected from the group consisting of cyclopropyl and cyclobutyl; heterocyclyl selected from the group consisting of oxetanyl, tetrahydropyranyl, azetdinyl and piperidinyl; wherein said alkyl is additionally optionally substituted with F, OC1-4 alkyl, P(=O)(OC1-4alkyl)2, P(=O)(C1-4alkyl)2, CN, cyclopropyl or cyclobutyl; and wherein said heterocyclyl is additionally optionally substituted with C(=O)(OC1-4alkyl), Petition 870260063548, dated 06 / 26 / 2026, p. 45 / 639 39 / 316 - each of R”5 is selected independently from the group consisting of hydrogen, C1-4 alkyl, CF3 and cyclopropyl; Each of n1, independently of the others and in each occurrence, is an integer equal to 0, 1, or 2. - R2 is independently hydrogen, halo, or NH2; Each Rq group is selected independently from the group consisting of H, CH3, OCH3, and halo groups, such as F or Cl; Each of R10 is selected independently from the group consisting of hydrogen, halo, C1-4 alkyl, CF3, OC1-4 alkyl, and CN. Each of U and V are independently C, C-R10, or N; - πιο is an integer equal to 0, 1, or 2.

[061] In a preferred embodiment of the present invention, the compound (C) of class (VI), according to the present invention, is selected from those of formula (VI-a-2) to (VI-c-2) in the present document below: Formula (VI-a-2) Formula (VI-b-2) in which Formula (VI-c-2) - each of R”6 is independently selected from the group consisting of hydrogen, halo, C1-4 alkyl, N(R2i)2, OR21; heterocyclyl selected from the group consisting of pyrrolidyl, piperidyl, morpholinyl, piperazyl; a pyrazyl Petition 870260063548, dated 06 / 26 / 2026, p. 46 / 639 40 / 316 wherein said heterocyclyl and pyrazyl are optionally substituted with C1-4 alkyl and wherein R21 is a C1-4 alkyl. Each Rq group is selected independently from the group consisting of H, CH3, OCH3, and halo groups, such as F or Cl; Each of R10 is selected independently from the group consisting of hydrogen, halo, OC-4 alkyl, and CN; - each of U is independently C, C-R10 or N; - πιο is an integer equal to 0, 1, or 2. - Ϡ2 is an integer equal to 0, 1, or 2. [ 062] In a preferred embodiment of the present invention, compound (C) of class (VII), according to the present invention, is selected from those of formula (VII-a-2) in the present document below: wherein Ra'1 is selected from the group consisting of benzyl, pyrazyl, OH, OC1-4 alkyl, NH2 and NH(C1-4 alkyl) and wherein Rq is selected from the group consisting of H, CH3, OCH3 and halo, such as F or Cl; preferably Rq is H or CH3.

[063] In a preferred embodiment of the present invention, compound (C), according to general formula (II-a), is a compound chosen from those of formula (VIII) to (XXXII-3) in the present document below: Formula (VIII) Formula (IX) Petition 870260063548, dated 06 / 26 / 2026, p. 47 / 639 41 / 316 Formula (XIII) Petition 870260063548, dated 06 / 26 / 2026, p. 48 / 639 42 / 316 Petition 870260063548, dated 06 / 26 / 2026, p. 49 / 639 43 / 316 Formula(XXIII) Formula(XXIV) Petition 870260063548, dated 06 / 26 / 2026, p. 50 / 639 44 / 316 Formula(XXVIII) Formula(XXIX) Formula(XXX) Formula(XXXI) Formula(XXXII) Petition 870260063548, dated 06 / 26 / 2026, p. 51 / 639 45 / 316 f Formula(XXXII-l) Formula(XXXII-2) Formula(XXXII-3)

[064] In a preferred embodiment of the present invention, compound (C), according to general formula (II-b), is a compound chosen from those of formula (XXXIII) to (XXXIV) in the present document below:

[065] In a preferred embodiment of the present invention, compound (C), according to general formula (III-a), is a compound chosen from those of formula (XXXV) to (XXXVI) in the present document below: Formula(XXXV) Petition 870260063548, dated 06 / 26 / 2026, p. 52 / 639 46 / 316 Formula(XXXVI)

[066] In a preferred embodiment of the present invention, compound (C), according to general formula (IV-a), is a compound chosen from those of formula (XXXVII) to (LXXI-2) in the present document below: Formula(XXXVII) Formula(XLI) Formula(XLII) Formula(XLIII) Petition 870260063548, dated 06 / 26 / 2026, p. 53 / 639 47 / 316 Formula(XLVIII) Petition 870260063548, dated 06 / 26 / 2026, p. 54 / 639 48 / 316 Formula(LIV) Formula(LV) Formula(LVI) Formula(LVII) Formula(LVIII) Formula(LIX) Formula(LXIII) Petition 870260063548, dated 06 / 26 / 2026, p. 55 / 639 49 / 316 Formula(LXIV) Formula(LXX) Formula(LXXI) Formula(LXXI-l) Petition 870260063548, dated 06 / 26 / 2026, p. 56 / 639 50 / 316 Formula (LXXI-2)

[067] In a preferred embodiment of the present invention, compound (C), according to general formula (IV-b), is a compound chosen from those of formula (LXXII) to (CV) in the present document below: Formula (LXXII) Formula (LXXIII) Formula (LXXIV) Formula (LXXV) Formula (LXXVI) Formula (LXXVII) Formula (LXXVIII) Petition 870260063548, dated 06 / 26 / 2026, page 57 / 639 51 / 316 Formula (LXXIX) Formula (LXXX) Formula (LXXXIV) Formula (LXXXV) Formula (LXXXVI) Petition 870260063548, dated 06 / 26 / 2026, page 58 / 639 52 / 316 Formula (XC) Formula (XCI) Formula (XCII) Formula (XCIII) Formula (XCIV) Petition 870260063548, dated 06 / 26 / 2026, page 59 / 639 53 / 316 Formula (XCVIII) Formula (XCIX) Formula (C) Petition 870260063548, dated 06 / 26 / 2026, pp. 60 / 639 54 / 316 Formula (CIV) Formula (CV)

[068] In a preferred embodiment of the present invention, compound (C), according to general formula (IV-c), is a compound chosen from those of formula (CVI) to (CXCVIII-5) in the present document below: Petition 870260063548, dated 06 / 26 / 2026, pp. 61 / 639 55 / 316 Formula(CX) Formula(CXVII) Formula(CXVIII) Petition 870260063548, dated 06 / 26 / 2026, pp. 62 / 639 56 / 316 Formula(CXIX) Formula(CXX) Formula(CXXI) Formula(CXXII) Formula(CXXVI) Formula(CXXVII) Petition 870260063548, dated 06 / 26 / 2026, pp. 63 / 639 57 / 316 Formula(CXXVIII) Formula(CXXIX) Formula(CXXXIII) Petition 870260063548, dated 06 / 26 / 2026, pp. 64 / 639 58 / 316 Formula(CXL) Petition 870260063548, dated 06 / 26 / 2026, pp. 65 / 639 59 / 316 Formula(CXLVI) Formula(CXLVII) Formula(CXLVIII) Formula(CXLIX) Formula(CL) Formula(CLI) Formula(CLII) Formula(CLIII) Petition 870260063548, dated 06 / 26 / 2026, pp. 66 / 639 60 / 316 Petition 870260063548, dated 06 / 26 / 2026, pp. 67 / 639 61 / 316 Formula (CLXII) Formula (CLXIV) Formula (CLXVI) Formula (CLXVII) Formula (CLXVIII) Formula (CLXIII) Formula (CLXV) Formula (CLXIX) Petition 870260063548, dated 26 / 06 / 2026, p. 68 / 639 62 / 316 Formula (CLXXI) Formula (CLXXIII) Formula (CLXXV) Formula (CLXX) Formula (CLXXII) Formula (CLXXIV) Formula (CLXXVI) Petition 870260063548, dated 26 / 06 / 2026, p. 69 / 639 63 / 316 Formula (CLXXVII) Formula (CLXXVIII) Formula (CLXXIX) Formula (19th century) Formula (CLXXXII) Formula (CLXXXIII) Formula (CLXXXI) Formula (CLXXXIV) Petition 870260063548, dated 26 / 06 / 2026, p. 70 / 639 64 / 316 Formula (CLXXXV) Formula(CLXXXVI) Formula(CLXXXVII) Formula(CLXXXVIII) Formula(CLXXXIX) Formula(CXCII) Petition 870260063548, dated 06 / 26 / 2026, page 71 / 639 65 / 316 / 1¾) 1 0 F Formula(CXCIII) / / —N 1 0F Formula(CXCIV) / / ---- । 0 F Formula(CXCV) F Formula(CXCVI) / 7--- I o F Formula(CXCVII) FF F-- \ F Formula ,N=q 0 ^0 T η TN Τι η JJ / 1 HO Form Formula Form Formula ,N=. 0 Il 4^ Ál 4^ N ll 4 NJ Jl J '-' F Formula (CXCVIII) (CXCVIII-1) (CXCVIII-2) Petition 870260063548, dated 06 / 26 / 2026, page 72 / 639 66 / 316 Formula (CXCVIII-3) Formula (CXCVIII-4) Formula (CXCVIII-5)

[069] In a preferred embodiment of the present invention, compound (C), according to general formula (VI-a), is a compound chosen from those of formula (CXCIX) to (CCXII) in the present document below: Formula(CXCIX) Formula(CC) Formula (CCI) Formula(CCII) Formula(CCIII) Petition 870260063548, dated 06 / 26 / 2026, p. 73 / 639 67 / 316 Formula(CCIV) Formula(CCV) Formula(CCVI) Formula(CCVII) Formula(CCVIII) Petition 870260063548, dated 06 / 26 / 2026, p. 74 / 639 68 / 316 Formula(CCXII)

[070] In a preferred embodiment of the present invention, compound (C), according to general formula (VI-b), is a compound chosen from those of formula (CCXIII) to (CCXV) in the present document below:

[071] In a preferred embodiment of the present invention, compound (C), according to general formula (VI-c), is a compound chosen from those of formula (CCXVI) to (CCLX) in the present document below: Petition 870260063548, dated 06 / 26 / 2026, p. 75 / 639 69 / 316 Formula(CCXXII) Formula(CCXXIII) Formula(CCXXIV) Formula(CCXXV) Formula (CCXXVI) Petition 870260063548, dated 06 / 26 / 2026, p. 76 / 639 70 / 316 Formula(CCXXXI) Formula(CCXXX) Formula(CCXXXII) Formula(CCXXXIII) Petition 870260063548, dated 06 / 26 / 2026, p. 77 / 639 71 / 316 Formula(CCXXXVII) Formula(CCXXXVIII) Formula(CCXXXIX) Formula(CCXL) Petition 870260063548, dated 06 / 26 / 2026, p. 78 / 639 72 / 316 Formula(CCXLVI) Petition 870260063548, dated 06 / 26 / 2026, p. 79 / 639 73 / 316 Formula(CCXLVII) Formula(CCXLIX) Formula(CCL) Formula(CCLI) Formula(CCXLVIII) Formula(CCLII) Formula(CCLIII) Petition 870260063548, dated 06 / 26 / 2026, page 80 / 639 74 / 316 Formula(CCLV) Formula(CCLVI) Formula(CCLVII) Formula(CCLIV) Formula(CCLVIII)

[072] In a preferred embodiment of the present invention, compound (C), according to general formula (VII-a), is a compound chosen from those of formula (CCLXI) to (CCLXVII) in the present document below: Petition 870260063548, dated 06 / 26 / 2026, page 81 / 639 75 / 316 Formula(CCLXI) Formula(CCLXII) Formula(CCLXIII) Formula(CCLXVII)

[073] The present invention further relates to an in vitro method of inhibiting protein kinase activity comprising contacting a protein kinase with a compound of formulas (I) to (VII) [compound (C), hereinafter in this document], as defined above or the N-oxide, pharmaceutically acceptable salt, pharmaceutically acceptable solvate or stereoisomer thereof, Petition 870260063548, dated 06 / 26 / 2026, p. 82 / 639 76 / 316 in which: - each of A is selected independently from the group consisting of cycloalkyl, heterocyclyl, aryl, heteroaryl and aralkyl, wherein said cycloalkyl, heterocyclyl, aryl, heteroaryl and aralkyl are optionally Petition 870260063548, dated 06 / 26 / 2026, p. 83 / 639 77 / 316 substituted with one or more substituents selected independently from the group consisting of halo, NO2, C1-6 alkyl, C2-4 alkenyl, C2-4 alkynyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, CF3, CN, OR11, SR11, N(Rii)2, OC(Rii)2O, OC(Rii)2C(Rii)2O, S(O)Ri2, SO2R12, SO2N(Rii)2, S(O)3Rii, P(=O)(ORii)2, P(=O)(Rii)2 NR11COR12, COR11, C(O)ORii, CON(Rii)2, OC(O)Rii, and OCON(Rii)2 and each optional substituent of alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heterocyclyl and heteroaryl is additionally optionally substituted with halo, NO2, C1-6 alkyl, cycloalkyl, aryl, CF3, N(Rii)2, COR11, CON(Rii)2, OC(O)Rii, CN, or OR11;and wherein each of R11 and R12, independently of each other and in each occurrence, is selected from the group consisting of hydrogen, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, aralkyl and CF3, wherein said alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, heteroaryl and aralkyl substituents are optionally substituted with halo, C1-6 alkyl, cycloalkyl, heterocyclyl, C1-6 alkyl or aryl or heteroaryl amide, OR31 or N(R32)2, wherein each of R31 and R32, independently of each other and in each occurrence, is selected from the group consisting of hydrogen and C1-4 alkyl. - each of R4 and R'4, independently of each other and in each occurrence, are selected from hydrogen or C1-6 alkyl and z is an integer in the range of 0 to 2; provided that when z = 0, then A and R7 can together form a saturated or unsaturated chemical moiety; - each of R7, independently of the other and in each occurrence, is selected from hydrogen, C1-6 alkyl, cycloalkyl, wherein said alkyl and cycloalkyl are optionally substituted by a halogen atom, CF3, N(RIi)2, CN or OR11; and wherein each of R11, independently of the other and in each occurrence, is selected from the group consisting of hydrogen, C16 alkyl and CF3; - each of R3, independently of the other and in each occurrence, is selected from the group consisting of hydrogen, halo, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, aralkyl, CF3, CN, OR21, SR21, N(R2i)2, NC(O)R21, NCON(R2i)2, COR21, C(O)OR21, CON(R2i)2, OC(O)R2i, OCON(R2i)2, OC(R2i)2O, and OC(R2i)2C(R22)2O, wherein said alkyl, Petition 870260063548, dated 06 / 26 / 2026, page 84 / 639 78 / 316 Alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, heteroaryl and aralkyl are optionally substituted with one or more substituents selected from halo, C1-6 alkyl, CF3, N(R2i)2, CN or OR21; and wherein each of R21 and R22, independently of each other and in each occurrence, is selected from the group consisting of hydrogen, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, cycloalkyl, heterocyclyl, aryl, heteroaryl and aralkyl and wherein said alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, heteroaryl and aralkyl substituents are optionally substituted with halo, C1-6 alkyl, cycloalkyl, heterocyclyl, aryl, OR31 or N(R32)2, wherein each of R31 and R32, independently of each other and in each occurrence, is selected from the group consisting of hydrogen and C1-4 alkyl; each of r is an integer in the range of 0 to 3;Since when R3 = NR21 and R7 = H, then R3 and NR7 can together form a saturated or unsaturated chemical portion; - each of R2, independently of the other and in each occurrence, is selected from the group consisting of hydrogen, halo, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, cycloalkyl, heterocyclyl, aryl and heteroaryl, CF3, CN, NO2, OR21, SR21, N(R21)2, COR21, C(O)OR21, CON(R21)2, OC(O)R21, OCON(R21)2, NC(O)R21, NCON(R21)2, OC(R21)2O and OC(R2i)2C(R22)2O, wherein said alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl and heteroaryl substituents are optionally substituted with one or more substituents selected from halo, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, cycloalkyl, heterocyclyl, CF3, COR21, CON(R2i)2, C(O)OR21, N(R2i)2, CN or OR21, and each optional alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl or heteroaryl substituent is further optionally substituted with heterocyclyl, N(Rii)2 or OR11;and wherein each of R21 and R22, independently of each other and in each occurrence, is selected from the group consisting of hydrogen, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, cycloalkyl, heterocyclyl, aryl, heteroaryl and aralkyl and wherein said alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, heteroaryl and aralkyl substituents are optionally substituted with halo, C1-6 alkyl, cycloalkyl, heterocyclyl, aryl, OR31 or N(R32)2, wherein each of R31 and R32, independently of each other and in each occurrence; Petition 870260063548, dated 06 / 26 / 2026, p. 85 / 639 79 / 316 occurrence, is selected from the group consisting of hydrogen and C1-4 alkyl; each of q is an integer in the range of 0 to 2; Each of x and y are independent integers equal to 0 or 1; - R8 is independently selected from the group consisting of C612 alkyl, C2-6 alkenyl, C2-6 alkynyl, cycloalkyl and heterocyclyl, wherein said alkyl, alkenyl, alkynyl, cycloalkyl and heterocyclyl are optionally substituted by a halogen atom, an aryl group, an aralkyl group, CF3, N(Rii)2, CN or OR11;and wherein each of R11, independently of the other and in each occurrence, is selected from the group consisting of hydrogen, C16 alkyl, C2-6 alkenyl, C2-6 alkynyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, aralkyl and CF3, wherein said alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, heteroaryl and aralkyl substituents are optionally substituted with halo, C1-6 alkyl, cycloalkyl, heterocyclyl, alkyl or aryl or heteroaryl amide, OR31 or N(R32)2, wherein each of R31 and R32, independently of the other and in each occurrence, is selected from the group consisting of hydrogen and C1-4 alkyl; - R9 is selected from the group consisting of hydrogen, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, cycloalkyl, heterocyclyl, N(Rii)2 and CN, wherein said alkyl, alkenyl, alkynyl, cycloalkyl and heterocyclyl are optionally substituted by a halogen atom, an aryl group, an aralkyl group, a heterocyclyl group, CF3, N(Rii)2, CN, or OR11;and wherein each of R11, independently of the other and in each occurrence, is selected from the group consisting of hydrogen, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, aralkyl and CF3, wherein said alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, heteroaryl optionally substituted with C1-4 alkyl, aryl, heteroaryl and aralkyl substituents are optionally substituted with halo, C1-6 alkyl, cycloalkyl, heterocyclyl, alkyl or aryl or heteroaryl amide, OR31 or N(R32)2, wherein each of R31 and R32, independently of the other and in each occurrence, is selected from the group consisting of hydrogen and C1-4 alkyl, provided that x = 1 and y = 0, R9 is different from heterocyclyl and C1-6 alkyl in which said alkyl is optionally substituted with heterocyclyl; and provided that x = 0 and y = 0, R9 is different from hydrogen; Petition 870260063548, dated 06 / 26 / 2026, p. 86 / 639 80 / 316 and C1-6 alkyl, wherein said alkyl is optionally substituted with heterocyclyl and N(Rii)2; provided that when x = 0 and y = 0, R9 and R2 can together form a saturated or unsaturated cyclic chemical moiety; provided that when x = 0 and y = 0 and when R9 and R2 together form a saturated or unsaturated cyclic chemical moiety, R9 is NR11; provided that when x = 1 and y = 1, R9 is different from N(Rii)2; and provided that when x = 0, y = 0 and z = 0, R9 is different from pyrrole. - each of T is independently the chemical portion of formula (Ta) in the present document below: (Rs)n1 (Ta) where: - each of U, independently of the other and in each occurrence, is selected from the group consisting of C, C-halo, CR and N; wherein R is selected from hydrogen, OR11, N(Rii)2, a C1-6 alkyl or a cycloalkyl that are optionally substituted by a halogen atom, an aryl group or an aralkyl group, wherein each of R11, independently of the other and in each occurrence, is selected from the group consisting of hydrogen or C1-4 alkyl; provided that at least one U is different from N; - each of Z, independently of the other and in each occurrence, is selected from C(R)2, O, S and NR7, wherein R, independently of the other and in each occurrence, is selected from hydrogen or a C1-6 alkyl that is optionally substituted by a halogen atom, an aryl group or an aralkyl group, wherein R7 is selected from the group consisting of hydrogen, C16 alkyl, C1-6 alkenyl, cycloalkyl, heterocyclyl, aryl, aralkyl and CF3; - each of R5, independently of the other and in each occurrence, is selected from the group consisting of C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, aralkyl, halo, CF3, OR11, SR11, N(Rii)2, COOR11, CO(Rii)2, CON(Rii)2 and each optional substituent of alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heterocyclyl, heteroaryl, aralkyl is additionally optionally substituted with halo, C1-6 alkyl, cycloalkyl, aryl, Petition 870260063548, dated 06 / 26 / 2026, p. 87 / 639 81 / 316 heterocyclyl, N(Rii)2, CN, OR11, C(=O)ORii, P(=O)(ORii)2, P(=O)(Rii)2, CN or CF3 and wherein each of R11, independently of the other and in each occurrence, is selected from the group consisting of hydrogen, C1-6 alkyl, cycloalkyl and heterocyclyl; each of n1 is an integer in the range of 0 to 2; - each of X is independently the chemical portion of formula (Xa) in the present document below: (^6)η2 V=V (Xa) where: - each of V, independently of the other and in each occurrence, is selected from the group consisting of C, C-halo, CR and N; wherein R is selected from hydrogen, OR11, N(Rii)2, a C1-6 alkyl or a cycloalkyl that are optionally substituted by a halogen atom, an aryl group or an aralkyl group, wherein each of R11, independently of the other and in each occurrence, is selected from hydrogen or C1-4 alkyl; - each of Rg, independently of the other and in each occurrence, is selected from the group consisting of C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, aralkyl, halo, CF3, OR11, SR11, N(Rh)2, COOR11, CO(Ru)2, CON(Rh)2 and each optional substituent of alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heterocyclyl, heteroaryl, aralkyl is additionally optionally substituted with halo, C1-6 alkyl, cycloalkyl, aryl, heterocyclyl, N(Rh)2, CN, OR11, C(=O)ORu, P(=O)(ORu)2, P(=O)(Ru)2, CN or CF3 and where each of R11, independently of the other and in each occurrence, is selected from the a group consisting of hydrogen, C1-6 alkyl, cycloalkyl, and heterocyclyl; each of n2 is an integer in the range of 0 to 4; - the dash link represents an optional triple bond; - Ra1 is independently selected from the group consisting of hydrogen, C1-6 alkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, aralkyl, CF3, CN, OR11, SR11, N(Rh)2, COR11, C(O)ORu, wherein said alkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl and aralkyl are optionally replaced by halo, Petition 870260063548, dated 06 / 26 / 2026, p. 88 / 639 82 / 316 NO2, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, cycloalkyl, heterocyclyl, phenyl, heteroaryl, CF3, CN, OR11, SR11, N(Rii)2, COR11 and C(O)ORii and each optional substituent of alkyl, alkenyl, cycloalkyl, phenyl, heterocyclyl, heteroaryl is further optionally substituted with halo, NO2, C1-6 alkyl, cycloalkyl, phenyl, N(Rii)2, CN or OR11; and wherein each of R11 is selected from the group consisting of hydrogen, C1-6 alkyl, cycloalkyl, heterocyclyl, phenyl, heteroaryl and aralkyl, wherein said alkyl, cycloalkyl, heterocyclyl, phenyl, heteroaryl and aralkyl substituents are optionally substituted with halo, C1-6 alkyl, cycloalkyl or heterocyclyl. - Ra2 is independently selected from the group consisting of hydrogen, C1-6 alkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, aralkyl, CF3, CN, OR11, SR11, N(Rii)2, COR11, C(O)ORii, wherein said alkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl and aralkyl are optionally substituted with halo, NO2, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, cycloalkyl, heterocyclyl, phenyl, heteroaryl, CF3, CN, OR11, SR11, N(Rii)2, COR11 and C(O)ORii and each optional substituent of alkyl, alkenyl, cycloalkyl, phenyl, heterocyclyl, heteroaryl is further optionally substituted with halo, NO2, C1-6 alkyl, cycloalkyl, phenyl, N(Rii)2, CN or OR11;and wherein each of R11 is selected from the group consisting of hydrogen, C1-6 alkyl, cycloalkyl, heterocyclyl, phenyl, heteroaryl and aralkyl, wherein said alkyl, cycloalkyl, heterocyclyl, phenyl, heteroaryl and aralkyl substituents are optionally substituted with halo, C1-6 alkyl, cycloalkyl or heterocyclyl; and where n3 is an integer equal to 0 or 1; provided that when the dash link represents a triple bond, n3 is 0; wherein said cycloalkyl is a monocyclic, bicyclic or tricyclic ring system of 3-6 ring members per ring; said heterocyclyl is a saturated, partially saturated or fully saturated monocyclic, bicyclic or tricyclic group containing 3 to 12 carbon atoms and 1 or 2 heteroatoms independently selected from O or N; said aryl is a phenyl, naphthyl or anthracenyl group optionally carbocyclic fused with a cycloalkyl or heterocyclyl group of 5-7 ring members; said heteroaryl is a monocyclic ring structure containing 5 or 6 ring atoms or a bicyclic aromatic group having 8 to 10 atoms, containing 1-3 heteroatoms independently selected from O or N. Petition 870260063548, dated 06 / 26 / 2026, page 89 / 639 83 / 316

[074] It is further understood that all definitions and preferences as described for compound (C) above apply equally to this embodiment and to all other embodiments as described below.

[075] As used above and hereafter in this document, the following definitions apply, unless otherwise indicated.

[076] The term halo - alone or in combination - means all halogens, that is, chlorine (Cl), bromine (Br), fluorine (F), iodine (I).

[077] The term alkyl - alone or in combination - means an alkane-derived radical containing from 1 to 15 carbon atoms, unless otherwise specified, for example Cf-g alkyl defines a linear or branched alkyl radical having from F to G carbon atoms, for example, C1-4 alkyl defines a linear or branched alkyl radical having from 1 to 4 carbon atoms such as, for example, methyl, ethyl, 1-propyl, 2-propyl, l-butyl, 2-butyl, 2-methyl-1-propyl. An alkyl group may be a linear chain alkyl or a branched alkyl. Preferably, linear or branched alkyl groups containing from 1-10, more preferably 1 to 8, even more preferably 1-6 and most preferably 1-4, carbon atoms, such as methyl, ethyl, propyl, isopropyl, butyl, t-butyl and the like. Alkyl also includes a linear or branched chain alkyl group that contains or is interrupted by a cycloalkyl moiety.The linear or branched chain alkyl group is attached at any available point to produce a stable compound. Examples of this include, but are not limited to, 4-(isopropyl)-cyclohexylethyl or 2-methylcyclopropylpentyl.

[078] The term alkenyl – alone or in combination – means a linear or branched hydrocarbon containing 2-15, more preferably 2-10, even more preferably 2-8, most preferably 2-4 carbon atoms, unless otherwise specified, and at least one, preferably 1-3, more preferably 1-2, most preferably one, carbon-carbon double bond. Examples of alkenyl groups include ethenyl, propenyl, isopropenyl, butenyl, cyclohexenyl, cyclohexenylalkyl and the like. Alkenyl also includes a linear or branched chain alkenyl group containing or interrupted by a cycloalkyl moiety. Carbon double bonds Petition 870260063548, dated 06 / 26 / 2026, p. 90 / 639 84 / 316 for carbon may be contained in a cycloalkyl moiety, with the exception of cyclopropyl, or in a linear chain or branched moiety.

[079] The term alkynyl - alone or in combination means a linear or branched hydrocarbon containing 2-15, more preferably 2-10, even more preferably 2-8, most preferably 2-4, carbon atoms containing at least one, preferably one, carbon-carbon triple bond. Examples of alkynyl groups include ethynyl, propynyl, butynyl and the like.

[080] The term aryl - alone or in combination means optionally carbocyclic phenyl, naphthyl or anthracenyl fused with a cycloalkyl or heterocyclyl of preferably 5-7, more preferably 5-6, ring members and / or optionally substituted with 1 to 5 groups or substituents. An aryl may be optionally substituted so that the substituent is attached at one point to the aryl or so that the substituent is attached at two points to the aryl to form a bicyclic system, for example, benzodioxol, benzodioxane, benzimidazole.

[081] The term heteroaryl - alone or in combination - means a monocyclic aromatic ring structure containing 5 or 6 ring atoms or a bicyclic aromatic group having 8 to 10 atoms, containing 1-3 heteroatoms selected independently from the O, S and N groups and optionally substituted with 1 to 5 groups or substituents. Heteroaryl is also intended to include oxidized S or N, such as sulfinyl, sulfonyl and N-oxide of a tertiary ring nitrogen. A carbon or nitrogen atom is the attachment point of the heteroaryl ring structure, so that a stable aromatic ring is retained.More specifically, the term heteroaryl includes, but is not limited to, pyridyl, furanyl, thiophenyl, thiazolyl, isothiazolyl, triazolyl, imidazolyl, isoxazolyl, pyrroyl, pyrazolyl, pyrimidinyl, benzofuranyl, isobenzofuranyl, benzothiazolyl, benzoisothiazolyl, benzotriazolyl, indolyl, isoindolyl, benzoxazolyl, quinolyl, isoquinolyl, benzimidazolyl, benzisoxazolyl, benzothiophenyl, dibenzofuran and benzodiazepin-2-one-5-yl and the like.

[082] The term heterocycline - alone or in combination - is intended to denote a saturated, partially unsaturated or completely unsaturated monocycle, bicycle or tricycle containing from 3 to 12 carbon atoms and containing 1 Petition 870260063548, dated 06 / 26 / 2026, page 91 / 639 85 / 316 or 2 heteroatoms each independently selected from O, S, P, or N and are optionally fused with benzo or fused heteroaryl of 5-6 ring members and / or are optionally substituted as in the case of cycloalkyl. Heterocyclyl also includes S or N oxidized, such as sulfinyl, sulfonyl, and N-oxide of a nitrogen of the tertiary ring. The point of attachment is on a carbon or nitrogen atom. In each case, the heterocyclyl can be condensed with an aryl to form a bicyclic ring system.

[083] The term cycloalkyl refers to a cyclic or polycyclic alkyl group containing from 3 to 7 carbon atoms. Preferably, cycloalkyl groups are monocyclic, bicyclic or tricyclic ring systems of 3 to 6 ring members per ring, such as cyclopropyl, cyclopentyl, cyclohexyl, adamantyl and the like.

[084] The term aralkyl refers to organic compounds containing an aromatic ring to which an alkyl radical is attached. These alkyl radicals include methyl, ethyl, propyl, butyl, octyl, etc. The term aralkyl is therefore seen as including aralkyl hydrocarbons, such as alkylbenzenes and the various alkylnaphthalenes. From this definition of the term aralkyl compound, it is observed that the term includes compounds such as benzyl, the three isomeric xyles, the two isomeric trimethylbenzenes, ethylbenzene, p-methyl biphenyl, α-methyl naphthalene, etc.

[085] The present invention further relates to a pharmaceutical composition comprising a carrier and, as an active ingredient, an effective amount of a compound (C) of formulas (I) to (VII), as specified herein, or a compound of any of the compound subgroups of formula (II-a) to (II-b), (III-a), (IV-a) to (IV-c), (VI-a) to (VIc), (VII-a), (VII-b), (II-a-1) to (II-c-1), (IV-a-1) to (IV-c-1), (VI-a-1) to (VI-c-1), (VII-a-1) to (VII-b-1), (II-a-2) to (II-c-2), (IV-a-2-1) to (IV-c-2-4), (IV-a-2) to (VI-c-2), or formula (VII-a-2), as specified herein and as defined in any one of the options presented in this document.

[086] The present invention relates to a compound (C) of formulas (I) to (VII), as specified herein, or a compound of any of the subgroups of compounds of formula (II-a) to (II-b), (III-a), (IV-a) to (IV-c), (VIa) to (VI-c), (VII-a), (VII-c), (II-a-1) to (II-c-1), (IV-a-1) to (IV-c-1), (VI-a-1) to (VI-c-1), (VII-a-1) to (VII-b-1), (II-a-2) to (II-c-2), (IV-a-2-1) to (IV-c-2-4), (IV-a-2) to (VI-c-2) Petition 870260063548, dated 06 / 26 / 2026, p. 92 / 639 86 / 316 as specified in this document and as defined in any of the embodiments presented in this document, for use as a medicine.

[087] The present invention relates to a compound (C) of formulas (I) to (VII), as specified herein, or a compound of any of the compound subgroups of formula (II-a) to (II-b), (III-a), (IV-a) to (IV-c), (VIa) to (VI-c), (VII-a), (VII-b), (II-a-1) to (II-c-1), (IV-a-1) to (IV-c-1), (VI-a-1) to (VI-c-1), (VII-a-1) to (VII-b-1), (II-a-2) to (II-c-2), (IV-a-2-1) to (IV-c-2-4), (IV-a-2) to (VI-c-2), or formula (VII-a-2), as specified herein and as defined in any of the embodiments presented herein, for use in the treatment of a disease selected from cancer, disorders metabolic disorders (such as diabetes), inflammatory and autoimmune disorders (such as inflammatory bowel diseases, for example, Crohn's disease and ulcerative colitis, inflammatory lung diseases, rheumatoid arthritis, lupus nephritis, systemic lupus erythematosus, and psoriasis and psoriatic arthritis), neurological disorders (such as Alzheimer's disease,Parkinson's disease, multiple sclerosis, Charcot-Marie-Tooth neuropathy, amyotrophic lateral sclerosis and epilepsy), atherosclerosis and cardiovascular diseases, Sjögren's syndrome, renal allograft rejection, virus-induced diseases, circulatory diseases, bone osteolysis and osteoporosis, osteoarthritis, sarcopenia, Langerhans cell histiocytosis, spinal cord injury, endometriosis, asthma and allergic asthma, eye diseases (such as retinopathies, age-related macular degeneration and uveitis), chronic and neuropathic pain, and fibroproliferative diseases.

[088] The present invention further relates to a method for inhibiting protein kinase activity in a warm-blooded animal, said method comprising administering to an animal in need thereof an effective kinase-inhibiting amount of a compound (C) of formulas (I) to (VII), as specified herein, or a compound of any of the compound subgroups of formulas (II-a) to (II-b), (III-a), (IV-a) to (IV-c), (VI-a) to (VI-c), (VII-a), (VII-b), (II-a-1) to (II-c-1), (IV-a-1) to (IV-c-1), (VI-a-1) to (VI-c-1), (VIIa-1) to (VII-b-1), (II-a-2) to (II-c-2), (IV-a-2-1) to (IV-c-2-4), (IV-a-2) to (VI-c-2), or Petition 870260063548, dated 06 / 26 / 2026, p. 93 / 639 87 / 316 formula (VII-a-2), as specified in this document and in accordance with any of the embodiments presented in this document.

[089] The present invention further relates to a method for inhibiting protein kinase activity in a warm-blooded animal, said method comprising administering to an animal in need thereof an effective kinase-inhibiting amount of a compound (C) of formulas (I) to (VII), as specified herein, or a compound of any of the compound subgroups of formulas (II-a) to (II-b), (III-a), (IV-a) to (IV-c), (VI-a) to (VI-c), (VII-a), (VII-b), (II-a-1) to (II-c-1), (IV-a-1) to (IV-c-1), (VI-a-1) to (VI-c-1), (VIIa-1) to (VII-b-1), (II-a-2) to (II-c-2), (IV-a-2-1) to (IV-c-2-4), (IV-a-2) to (VI-c-2), or formula (VII-a-2), as specified herein and in accordance with any of the embodiments presented herein, wherein the protein kinase is selected from the group consisting of CSF1R, FLT3, Kit, PDGFRB (PDGFR beta), PDGFRA (PDGFR alpha), ABL1, ACVR1B (ALK4), AKT1 (PKB alpha), AMPK A1 / B1 / G1, AURKA (Aurora A),BTK, CDK1 / cyclin B, CHEK1 (CHK1), CSNK1G2 (CK1 gamma 2), CSNK2A1 (CK2 alpha 1), DYRK3, EGFR (ErbB1), EPHA2, ERBB2 (HER2), FGFR1, FRAP1 (mTOR), GSK3B (GSK3 beta), IGF1R, IKBKB (IKK beta), INSR, IRAK4, JAK3, KDR (VEGFR2), LCK, MAP2K1 (MEK1), MAP4K4 (HGK), MAPK1 (ERK2), MAPK14 (p38 alpha), MAPK3 (ERK1), MAPK8 (JNK1), MARK2, MET (cMet), NEK1, PAK4, PHKG2, PIM1, PLK1, PRKACA (PKA), PRKCB1 (PKC beta I), ROCK1, RPS6KA3 (RSK2), RPS6KB1 (p70S6K), SRC, SYK, and TEK (Tie2). Preferably, the protein kinase is selected from the group consisting of CSF1R, FLT3, Kit, PDGFRB (PDGFR beta), and PDGFRA (PDGFR alpha).

[090] The present invention further relates to a method of treating a disease selected from cancer, metabolic disorders (such as diabetes), inflammatory and autoimmune disorders (such as inflammatory bowel diseases, for example, Crohn's disease and ulcerative colitis, inflammatory lung diseases, rheumatoid arthritis, lupus nephritis, systemic lupus erythematosus and psoriasis and psoriatic arthritis), neurological disorders (such as Alzheimer's disease, Parkinson's disease, multiple sclerosis, Charcot-Marie-Tooth neuropathy, amyotrophic lateral sclerosis and epilepsy), atherosclerosis and diseases Petition 870260063548, dated 06 / 26 / 2026, page 94 / 639 88 / 316 cardiovascular diseases, Sjögren's syndrome, renal allograft rejection, virus-induced diseases, circulatory diseases, bone osteolysis and osteoporosis, osteoarthritis, sarcopenia, Langerhans cell histiocytosis, spinal cord injury, endometriosis, asthma and allergic asthma, eye diseases (such as retinopathies, age-related macular degeneration and uveitis), chronic and neuropathic pain and fibroproliferative diseases in a warm-blooded animal, wherein said method comprises administering to an animal in need thereof an effective amount of a compound (C) of formulas (I) to (VII), as specified herein, or a compound of any of the compound subgroups of formulas (II-a) to (II-b), (III-a), (IV-a) to (IV-c), (VI-a) to (VI-c), (VII-a), (VII-b), (II-a-1) to (II-c-1), (IV-a-1) to (IV-c-1), (VI-a-1) to (VI-c-1), (VIIa-1) to (VII-b-1), (II-a-2) to (II-c-2), (IV-a-2-1) to (IV-c-2-4), (IV-a-2) to (VI-c-2), or formula (VII-a-2),as specified in this document and in accordance with any of the modalities presented in this document.

[091] It should be noted that radical positions in any molecular chemical moiety used in the definitions can be anywhere in that chemical moiety, as long as it is chemically stable.

[092] The radicals used in the definitions of the variables include all possible isomers, unless otherwise indicated. For example, pyridyl includes 2-pyridyl, 3-pyridyl and 4-pyridyl; pentyl includes 1-pentyl, 2-pentyl and 3-pentyl.

[093] When any variable occurs more than once in any constituent, each definition is independent. Whenever used hereafter in this document, the term compounds (C) of formulas (I) to (VII), or the present compounds or similar terms, is intended to include all compounds (C) of formulas (I) to (VII), N-oxides, addition salts and stereochemically isomeric forms. One embodiment comprises compounds (C) of formulas (I) to (VII), or any subgroup of compounds of formula (II-a) to (II-b), (III-a), (IV-a) to (IV-c), (VI-a) to (VI-c), (VII-a), (VII-b), (II-a-1) to (II-c-1), (IV-a-1) to (IV-c-1), (VI-a-1) to (VI-c1), (VII-a-1) to (VII-b-1), (II-a-2) to (II-c-2), (IV-a-2-1) to (IV-c-2-4), (IV-a-2) to (VI-c-2), or formula (VII-a-2), specified in this document, as well as the N-oxides, salts, and possible stereoisomeric forms thereof. Another category includes compounds (C) with formulas (I) to (VII), or any subgroup of Petition 870260063548, dated 06 / 26 / 2026, p. 95 / 639 89 / 316 compounds of formula (II-a) to (II-b), (II-I-a), (IV-a) to (IV-c), (VI-I) to (VI-c), (VII-a), (VII-b), (II-a-1) to (II-c-1), (IV-a-1) to (IV-c-1), (VI-a-1) to (VI-c-1), (VII-a-1) to (VII-b-1), (II-a-2) to (II-c-2), (IV-a-2-1) to (IV-c-2-4), (IV-a-2) to (VI-c-2), or formula (VII-a-2), specified in this document, as well as the salts and possible stereoisomeric forms thereof.

[094] The compound (C) of formulas (I) to (VII), as specified in this document, or a compound of any of the subgroups of compounds of formula (II-a) to (II-b), (III-a), (IV-a) to (IV-c), (VI-a) to (VI-c), (VII-a), (VII-b), (II-a-1) to (II-c-1), (IV-a-1) to (IV-c-1), (VI-a-1) to (VI-c-1), (VII-a-1) to (VII-b-1), (II-a-2) to (II-c2), (IV-a-2-1) to (IV-c-2-4), (IV-a-2) to (VI-c-2), or formula (VII-a-2), as specified in this document, have multiple chiral centers and exist as stereochemically isomeric forms. The term stereochemically isomeric forms, as used in this document, defines all possible compounds consisting of the same atoms linked by the same sequence of bonds, but with different three-dimensional structures that are not interchangeable, such as compound (C) of formulas (I) to (VII) as specified in this document or a compound of any of the subgroups of compounds of formula (II-a) to (II-b), (III-a),(IV-a) and (IV-c), (VI-a) and (VIc), (VII-a), (VII-b), (II-a-1) and (II-c-1), (IV-a-1) and (IV-c-1), (VI-a-1) and (VI-c-1), (VII-a-2), (II-a-1) and (VII-a-c-2), (II) (IV-to-2-1) to (IV-c-2-4), (IV-to-2) to (VI-c-2), or formula (VII-to-2), as specified herein, may possess.,

[095] Unless mentioned or indicated otherwise, the chemical designation of a compound (C) of formulas (I) to (VII), as specified in this document, or a compound of any of the subgroups of compounds of formula (II-a) to (II-b), (III-a), (IV-a) to (IV-c), (VI-a) to (VI-c), (VII-a), (VII-b), (II-a-1) to (II-c-1), (IV-a-1) to (IV-c-1), (VI-a-1) to (VI-c-1), (VII-a-1) to (VII-b-1), (II-a-2) to (II-c2), (IV-a-2-1) to (IV-c-2-4), (IV-a-2) to (VI-c-2), or formula (VII-a-2), as specified in this document, encompasses the mixture of all possible stereochemically isomeric forms that The said compound may possess all diastereomers and / or enantiomers of the basic molecular structure of said compound. All stereochemically Petition 870260063548, dated 06 / 26 / 2026, p. 96 / 639 90 / 316 isomeric forms of the compounds of the present invention, both in pure form and mixed together, should be covered by the scope of the present invention.

[096] Pure stereoisomeric forms of compound (C) of formulas (I) to (VII), as specified in this document, or a compound of any of the subgroups of compounds of formula (II-a) to (II-b), (III-a), (IV-a) to (IV-c), (VIa) to (VI-c), (VII-a), (VII-b), (II-a-1) to (II-c-1), (IV-a-1) to (IV-c-1), (VI-a-1) to (VI-c-1), (VII-a-1) to (VII-b-1), (II-a-2) to (II-c-2), (IV-a-2-1) to (IV-c-2-4), (IV-a-2) to (VI-c-2), or formula (VII-a-2), as specified in this document, and intermediates as mentioned in this document, are defined as isomers substantially free of others. Enantiomers or diastereomers. Forms of the same basic molecular structure as said compounds or intermediates.In particular, the term "stereoisomerically pure" refers to compounds or intermediates that have a stereoisomeric excess of at least 80% (i.e., a minimum of 90% of one isomer and a maximum of 10% of the other possible isomers) up to a stereoisomeric excess of 100% (i.e., 100% of one isomer and none of the other), more particularly, compounds or intermediates that have a stereoisomeric excess of 90% up to 100%, even more particularly having a stereoisomeric excess of 94% up to 100%, and with maximum particularity having a stereoisomeric excess of 97% up to 100%. The terms "enantiomerically pure" and "diastereomerically pure" should be understood similarly, but taking into account the enantiomeric excess and the diastereomeric excess, respectively, of the mixture in question.

[097] Pure stereoisomeric forms of the compounds and intermediates of this invention can be obtained by known application procedures in the art. For example, the enantiomers can be separated from each other by selective crystallization of their diastereomeric salts with optically active acids or bases. Examples include tartaric acid, dibenzoyltartaric acid, ditoluoyltartaric acid, and camphorsulfonic acid. Alternatively, the enantiomers can be separated by chromatographic techniques using chiral stationary phases. Said pure stereochemically isomeric forms can also be derived from the corresponding pure stereochemically isomeric forms of the starting materials. Petition 870260063548, dated 06 / 26 / 2026, page 97 / 639 91 / 316 appropriate, provided that the reaction occurs stereospecifically. Preferably, if a specific stereoisomer is desired, said compound will be synthesized by stereospecific preparation methods. These methods will advantageously employ enantiomerically pure starting materials.

[098] Diastereomeric racemates of compounds (C) of formulas (I) to (VII), as specified in this document, or a compound of any of the subgroups of compounds of formula (II-a) to (II-b), (III-a), (IV-a) to (IV-c), (VIa) to (VI-c), (VII-a), (VII-b), (II-a-1) to (II-c-1), (IV-a-1) to (IV-c-1), (VI-a-1) to (VI-c-1), (VII-a-1) to (VII-b-1), (II-a-2) to (II-c-2), (IV-a-2-1) to (IV-c-2-4), (IV-a-2) to (VI-c-2), or formula (VII-a-2), as specified in this document, may be obtained separately by conventional methods. Suitable physical separation methods that can be advantageously employed include, for example, selective crystallization and chromatography, such as column chromatography.

[099] For some of the compounds (C) of formulas (I) to (VII), as specified in this document, or a compound of any of the subgroups of compounds of formula (II-a) to (II-b), (III-a), (IV-a) to (IV-c), (VI-a) to (VIc), (VII-a), (VII-b), (II-a-1) to (II-c-1), (IV-a-1) to (IV-c-1), (VI-a-1) to (VI-c-1), (VII-a-1) to (VII-b-1), (II-a-2) to (II-c-2), (IV-a-2-1) to (IV-c-2-4), (IV-a-2) to (VI-c-2), or formula (VII-a-2), as specified in this document, N-oxides, salts, solvates, and the intermediates used in the preparation thereof, the absolute stereochemical configuration has not been determined. experimentally.

[0100] A person skilled in the art is able to determine the absolute configuration of such compounds using methods known in the field, such as X-ray diffraction.

[0101] The present invention is also intended to include all isotopes of atoms occurring herein for a compound (C) of formulas (I) to (VII), as specified herein, or a compound of any of the subgroups of compounds of formula (II-a) to (II-b), (III-a), (IV-a) to (IV-c), (VI-a) to (VI-c), (VII-a), (VII-b), (II-a-1) to (II-c-1), (IV-a-1) to (IV-c-1), (VI-a-1) to (VI-c-1), (VIIa-1) to (VII-b-1), (II-a-2) to (II-c-2), (IV-a-2-1) to (IV-c-2-4), (IV-a-2) to (VI-c-2), or formula (VII-a-2), as specified herein. Isotopes include atoms that have the same atomic number but different mass numbers. Petition 870260063548, dated 06 / 26 / 2026, p. 98 / 639 92 / 316 different. As a general and non-limiting example, hydrogen isotopes include tritium and deuterium. Carbon isotopes include C-13 and C-14.

[0102] For therapeutic use, the salts of compound (C) of formulas (I) to (VII), as specified in this document, or a compound of any of the subgroups of compounds of formula (II-a) to (II-b), (III-a), (IV-a) to (IV-c), (VIa) to (VI-c), (VII-a), (VII-b), (II-a-1) to (II-c-1), (IV-a-1) to (IV-c-1), (VI-a-1) to (VI-c-1), (VII-a-1) to (VII-b-1), (II-a-2) to (II-c-2), (IV-a-2-1) to (IV-c-2-4), (IV-a-2) to (VI-c-2), or formula (VII-a-2), as specified in this document, are those in which the contraion is pharmaceutically acceptable, whose salts may be referred to as pharmaceutically acceptable acids and base addition salts. However, salts of acids and bases that are not pharmaceutically acceptable may also find use, for example, in the preparation or purification of a pharmaceutically acceptable compound. All salts, whether pharmaceutically acceptable or not, are included within the scope of the present invention.

[0103] Pharmaceutically acceptable acid and base addition salts, as mentioned above, are intended to comprise therapeutically active and non-toxic acid and base addition salt forms of compounds (C) of formulas (I) to (VII), as specified in this document, or a compound of any of the compound subgroups of formulas (II-a) to (II-b), (III-a), (IV-a) to (IV-c), (VI-a) to (VI-c), (VII-a), (VII-b), (II-a-1) to (II-c-1), (IV-a-1) to (IVc-1), (VI-a-1) to (VI-c-1), (VII-a-1) to (VII-b-1), (II-a-2) to (II-c-2), (IV-a-2-1) to (IV-c-24), (IV-a-2) to (VI-c-2), or formula (VII-a-2), or formula (VII-a-2), as specified in this document, are capable of forming. Pharmaceutically acceptable acid addition salts can be conveniently obtained by treating the basic form with such an appropriate acid in an anionic form.Suitable anions include, for example, trifluoroacetate, acetate, benzenesulfonate, benzoate, bicarbonate, bitartrate, bromide, calcium edetate, camsiate, carbonate, chloride, citrate, dihydrochloride, edetate, edisilate, estolate, esilate, fumarate, gluceptate, gluconate, glutamate, glycolylarsanilate, hexylresorcinate, hydrabamine, hydrobromide, hydrochloride, hydroxynaphthoate, iodide, isethionate, lactate, lactobionate, malate, maleate, mandelate, mesylate, methylbromide, methylnitrate, methylsulfate, mucate, napsylate, nitrate, pamoate. Petition 870260063548, dated 06 / 26 / 2026, page 99 / 639 93 / 316 (embonate), pantothenate, phosphate / diphosphate, polygalacturonate, salicylate, stearate, subacetate, succinate, sulfate, tannate, tartrate, theoaclate, triethiodide and the like. The counterion of choice can be introduced using ion exchange resins. Alternatively, these salt forms can be converted by treatment with an appropriate base into the free base form.

[0104] Compounds (C) of formulas (I) to (VII), as specified in this document, or a compound of any of the subgroups of compounds of formula (II-a) to (II-b), (III-a), (IV-a) to (IV-c), (VI-a) to (VI-c), (VII-a), (VII-b), (II-a-1) to (II-c-1), (IV-a-1) to (IV-c-1), (VI-a-1) to (VI-c-1), (VII-a-1) to (VII-b-1), (II-a-2) to (II-c2), (IV-a-2-1) to (IV-c-2-4), (IV-a-2) to (VI-c-2), or formula (VII-a-2), or formula (VIIa-2), as specified in this document, containing an acidic proton, may also be converted into their metal addition salt forms or Non-toxic amines are formed by treatment with appropriate organic and inorganic bases in the form of cations. Suitable basic salts include those formed with organic cations such as benzathine, chloroprocaine, choline, diethanolamine, ethylenediamine, meglumine, procaine and the like; and those formed with metallic cations such as aluminum, calcium, lithium, magnesium, potassium, sodium, zinc and the like.On the other hand, these salt forms can be converted back into their free form by treatment with an appropriate acid.

[0105] The term addition salt, as used above, also includes the solvates that compound (C) of formulas (I) to (VII), as specified herein, or a compound of any of the subgroups of compounds of formula (II-a) to (II-b), (III-a), (IV-a) to (IV-c), (VI-a) to (VI-c), (VII-a), (VII-b), (II-a-1) to (II-c-1), (IV-a-1) to (IV-c-1), (VI-a-1) to (VI-c-1), (VII-a-1) to (VII-b-1), (II-a-2) to (II-c2), (IV-a-2-1) to (IV-c-2-4), (IV-a-2) to (VI-c-2), or formula (VII-a-2), as specified herein, as well as the salts thereof, are capable of forming. Such solvates are, for example, hydrates, alcoholates, and the like.

[0106] The N-oxide forms of the present compound (C) of formulas (I) to (VII), as specified herein, or a compound of any of the subgroups of compounds of formula (II-a) to (II-b), (III-a), (IV-a) to (IV-c), (VIa) to (VI-c), (VII-a), (VII-b), (II-a-1) to (II-c-1), (IV-a-1) to (IV-c-1), (VI-a-1) to (VI-c-1), (VII-a-1) to (VII-b-1), (II-a-2) to (II-c-2), (IV-a-2-1) to (IV-c-2-4), (IV-a-2) to (VI-c-2), or Petition 870260063548, dated 06 / 26 / 2026, p. 100 / 639 94 / 316 formula (VII-a-2), as specified in this document, are intended to comprise compounds of formula (I) in which one or more nitrogen atoms are oxidized to so-called N-oxide.

[0107] It should be understood that compound (C) of formulas (I) to (VII), as specified in this document, or a compound of any of the subgroups of compounds of formula (II-a) to (II-b), (III-a), (IV-a) to (IV-c), (VI-a) to (VI-c), (VII-a), (VII-b), (II-a-1) to (II-c-1), (IV-a-1) to (IV-c-1), (VI-a-1) to (VI-c-1), (VIIa-1) to (VII-b-1), (II-a-2) to (II-c-2), (IV-a-2-1) to (IV-c-2-4), (IV-a-2) to (VI-c-2), or formula (VII-a-2), as specified in this document, may have metal-bonding, chelating, and complex metal-forming properties and therefore may exist as complexes. metallic or metallic chelates.Such metallated derivatives of compound (C) of formulas (I) to (VII), as specified in this document, or a compound of any of the compound subgroups of formula (II-a) to (II-b), (III-a), (IV-a) to (IV-c), (VI-a) to (VI-c), (VII-a), (VII-b), (II-a-1) to (II-c-1), (IV-a-1) to (IV-c-1), (VI-a-1) to (VI-c-1), (VII-a-1) to (VII-b-1), (II-a-2) to (II-c-2), (IV-a-2-1) to (IV-c-2-4), (IV-a-2) to (VI-c-2), or formula (VII-a-2), as specified in this document, are intended to be included within the scope of the present invention.

[0108] Some of the compound (C) of formulas (I) to (VII), as specified in this document, or a compound of any of the subgroups of compounds of formula (II-a) to (II-b), (III-a), (IV-a) to (IV-c), (VI-a) to (VIc), (VII-a), (VII-b), (II-a-1) to (II-c-1), (IV-a-1) to (IV-c-1), (VI-a-1) to (VI-c-1), (VII-a-1) to (VII-b-1), (II-a-2) to (II-c-2), (IV-a-2-1) to (IV-c-2-4), (IV-a-2) to (VI-c-2), or formula (VII-a-2), as specified in this document, may also exist in their tautomeric form. These forms, although not explicitly indicated in the formula above, are intended to be included within the scope of the present invention.

[0109] In a further aspect, the present invention relates to a pharmaceutical composition comprising a therapeutically effective amount of a compound (C) of formulas (I) to (VII), as specified herein, or a compound of any of the compound subgroups of formulas (II-a) to (II-b), (III-a), (IV-a) to (IV-c), (VI-a) to (VI-c), (VII-a), (VII-b), (II-a-1) to (II-c-1), (IV-a-1) to (IV-c-1), (VI-a-1) to (VI-c-1), (VII-a-1) to (VII-b-1), (II-a-2) to (II-c Petition 870260063548, dated 06 / 26 / 2026, p. 101 / 639 95 / 316 2), (IV-a-2-1) to (IV-c-2-4), (IV-a-2) to (VI-c-2), or formula (VII-a-2), as specified in this document and a pharmaceutically acceptable carrier.A therapeutically effective amount in this context is an amount sufficient to act prophylactically against, stabilize, or reduce protein kinase-mediated diseases in sick individuals or individuals at risk of becoming ill, in particular a protein kinase selected from the group consisting of CSF1R, FLT3, Kit, PDGFRB (PDGFR beta), PDGFRA (PDGFR alpha), ABL1, ACVR1B (ALK4), AKT1 (PKB alpha), AMPK A1 / B1 / G1, AURKA (Aurora A), BTK, CDK1 / cyclin B, CHEK1 (CHK1), CSNK1G2 (CK1 gamma 2), CSNK2A1 (CK2 alpha 1), DYRK3, EGFR (ErbB1), EPHA2, ERBB2 (HER2), FGFR1, FRAP1 (mTOR), GSK3B (GSK3 beta), IGF1R, IKBKB (IKK beta), INSR, IRAK4, JAK3, KDR (VEGFR2), LCK, MAP2K1 (MEK1), MAP4K4 (HGK), MAPK1 (ERK2), MAPK14 (p38 alpha), MAPK3 (ERK1), MAPK8 (JNK1), MARK2, MET (cMet), NEK1, PAK4, PHKG2, PIM1, PLK1, PRKACA (PKA), PRKCB1 (PKC beta I), ROCK1, RPS6KA3 (RSK2), RPS6KB1 (p70S6K), SRC, SYK and TEK (Tie2).Preferably, the protein kinase is selected from the group consisting of CSF1R, FLT3, Kit, PDGFRB (PDGFR beta), and PDGFRA (PDGFR alpha).

[0110] Examples of protein kinase-mediated diseases include, in particular, cancer, metabolic disorders (such as diabetes), inflammatory and autoimmune disorders (such as inflammatory bowel diseases, for example, Crohn's disease and ulcerative colitis, inflammatory lung diseases, rheumatoid arthritis, lupus nephritis, systemic lupus erythematosus, and psoriasis and psoriatic arthritis), neurological disorders (such as Alzheimer's disease, Parkinson's disease, multiple sclerosis, Charcot-Marie-Tooth neuropathy, amyotrophic lateral sclerosis, and epilepsy), atherosclerosis and cardiovascular diseases, Sjögren's syndrome, renal allograft rejection, virus-induced diseases, circulatory diseases, osteolysis and osteoporosis, osteoarthritis, sarcopenia, Langerhans cell histiocytosis, spinal cord injury, endometriosis, asthma and allergic asthma, eye diseases (such as retinopathies, age-related macular degeneration, and uveitis)Chronic and neuropathic pain and fibroproliferative diseases.

[0111] In yet another additional aspect, this invention relates to a process for preparing a pharmaceutical composition, as specified Petition 870260063548, dated 06 / 26 / 2026, p. 102 / 639 96 / 316 in this document, which comprises intimately mixing a pharmaceutically acceptable carrier with a therapeutically effective amount of a compound (C) of formulas (I) to (VII), as specified in this document, or of a compound of any of the compound subgroups of formula (II-a) to (II-b), (III-a), (IV-a) to (IV-c), (VI-a) to (VI-c), (VII-a), (VII-b), (II-a-1) to (II-c-1), (IV-a1) to (IV-c-1), (VI-a-1) to (VI-c-1), (VII-a-1) to (VII-b-1), (II-a-2) to (II-c-2), (IV-a-2-1) to (IV-c-2-4), (IV-a-2) to (VI-c-2), or formula (VII-a-2), as specified in this document.

[0112] Therefore, compound (C) of formulas (I) to (VII), as specified in this document, or a compound of any of the compound subgroups of formula (II-a) to (II-b), (III-a), (IV-a) to (IV-c), (VI-a) to (VIc), (VII-a), (VII-b), (II-a-1) to (II-c-1), (IV-a-1) to (IV-c-1), (VI-a-1) to (VI-c-1), (VII-a-1) to (VII-b-1), (II-a-2) to (II-c-2), (IV-a-2-1) to (IV-c-2-4), (IV-a-2) to (VI-c-2), or formula (VII-a-2), as specified in this document, may be formulated in various pharmaceutical forms for administration purposes. Suitable compositions include all compositions commonly used for systemic drug administration.To prepare the pharmaceutical compositions of this invention, an effective amount of the particular compound, optionally also in the form of a salt or metal complex, as the active ingredient, is combined in an intimate mixture with a pharmaceutically acceptable carrier, which can take a wide variety of forms, depending on the desired form of preparation for administration. These pharmaceutical compositions are desirable in suitable unit dosage forms, particularly for oral, rectal, percutaneous or parenteral injection administration.For example, in the preparation of compositions in oral dosage form, any of the usual pharmaceutical media can be employed, such as water, glycols, oils, alcohols and the like in the case of oral liquid preparations, such as suspensions, syrups, elixirs, emulsions and solutions; or solid carriers, such as starches, sugars, kaolin, lubricants, binders, disintegrating agents and the like in the case of powders, pills, capsules and tablets.

[0113] Due to their ease of administration, tablets and capsules represent the most advantageous oral dosage forms, being in these cases, Petition 870260063548, dated 06 / 26 / 2026, page 103 / 639 97 / 316 obviously, solid pharmaceutical carriers are employed. For parenteral compositions, the carrier will generally comprise sterile water, at least largely, although other ingredients, for example, to aid solubility, may be included. Injectable solutions, for example, may be prepared in which the carrier comprises saline solution, glucose solution, or a mixture of saline solution and glucose solution. Injectable suspensions may also be prepared, in which case appropriate liquid carriers, suspending agents, and the like may be employed. Also included are solid preparations which must be converted into liquid preparations shortly before use.In compositions suitable for percutaneous administration, the carrier optionally comprises a penetration-enhancing agent and / or a suitable humectant, optionally combined with suitable additives of any nature in smaller proportions, such additives not having a significant deleterious effect on the skin.

[0114] The compound (C) of formulas (I) to (VII), as specified in this document, or a compound of any of the compound subgroups of formula (II-a) to (II-b), (III-a), (IV-a) to (IV-c), (VI-a) to (VI-c), (VII-a), (VII-b), (II-a-1) to (II-c-1), (IV-a-1) to (IV-c-1), (VI-a-1) to (VI-c-1), (VII-a-1) to (VII-b-1), (II-a-2) to (II-c2), (IV-a-2-1) to (IV-c-2-4), (IV-a-2) to (VI-c-2), or formula (VII-a-2), as specified in this document, of the present invention may also be administered by oral inhalation or insufflation by means of methods and formulations employed in the technique for administering this form.Thus, in general, compound (C) of formulas (I) to (VII), as specified in this document, or a compound of any of the compound subgroups of formula (II-a) to (II-b), (III-a), (IV-a) to (IV-c), (VI-a) to (VI-c), (VII-a), (VII-b), (II-a-1) to (II-c-1), (IV-a-1) to (IV-c-1), (VI-a-1) to (VI-c-1), (VII-a-1) to (VII-b-1), (II-a-2) to (II-c-2), (IV-a-2-1) to (IVc-2-4), (IV-a-2) to (VI-c-2), or formula (VII-a-2), as specified in this document, may be administered to the lungs in the form of a solution, a suspension, or a dry powder, a solution being preferred. Any system developed for the administration of solutions, suspensions or dry powders by oral inhalation or insufflation is suitable for the administration of these compounds. Petition 870260063548, dated 06 / 26 / 2026, p. 104 / 639 98 / 316

[0115] Thus, the present invention also provides a pharmaceutical composition adapted for administration by inhalation or insufflation through the mouth, comprising a compound (C) of formulas (I) to (VII), as specified herein, or a compound of any of the compound subgroups of formula (II-a) to (II-b), (III-a), (IV-a) to (IV-c), (VI-a) to (VI-c), (VII-a), (VII-b), (II-a-1) to (II-c-1), (IV-a-1) to (IV-c-1), (VI-a-1) to (VI-c-1), (VII-a-1) to (VII-b-1), (II-a-2) to (II-c2), (IV-a-2-1) to (IV-c-2-4), (IV-a-2) to (VI-c-2), or formula (VII-a-2), as specified herein, and a carrier pharmaceutically acceptable. Preferably, the compounds of the present invention are administered via inhalation of a solution in nebulized or aerosolized doses.

[0116] It is especially advantageous to formulate the aforementioned pharmaceutical compositions in unit dosage forms to facilitate administration and uniformity of dosage. The unit dosage form, as used herein, refers to physically discrete units suitable as unit dosages, each unit containing a predetermined amount of active ingredient calculated to produce the desired therapeutic effect in association with the necessary pharmaceutical carrier. Examples of such unit dosage forms are tablets (including scored or coated tablets), capsules, pills, suppositories, powder packets, lozenges, injectable solutions or suspensions and the like, and segregated multiples thereof.

[0117] Compound (C) of formulas (I) to (VII), as specified in this document, or a compound of any of the compound subgroups of formula (II-a) to (II-b), (III-a), (IV-a) to (IV-c), (VI-a) to (VI-c), (VII-a), (VII-b), (II-a-1) to (II-c-1), (IV-a-1) to (IV-c-1), (VI-a-1) to (VI-c-1), (VII-a-1) to (VII-b-1), (II-a-2) to (II-c2), (IV-a-2-1) to (IV-c-2-4), (IV-a-2) to (VI-c-2), or formula (VII-a-2), as specified in this document, exhibit kinase inhibition properties. Diseases and illnesses treatable using the compounds and methods of the present invention include protein kinase-mediated diseases such as cancer, metabolic disorders (such as diabetes), inflammatory and autoimmune disorders (such as inflammatory bowel diseases, for example, Crohn's disease and ulcerative colitis, inflammatory lung diseases, rheumatoid arthritis, lupus nephritis, systemic lupus erythematosus, and psoriasis and psoriatic arthritis), and neurological disorders. Petition 870260063548, dated 06 / 26 / 2026, page 105 / 639 99 / 316 (such as Alzheimer's disease, Parkinson's disease, multiple sclerosis, Charcot-Marie-Tooth neuropathy, amyotrophic lateral sclerosis, and epilepsy), atherosclerosis and cardiovascular diseases, Sjögren's syndrome, renal allograft rejection, virus-induced diseases, circulatory diseases, bone osteolysis and osteoporosis, osteoarthritis, sarcopenia, Langerhans cell histiocytosis, spinal cord injury, endometriosis, asthma and allergic asthma, eye diseases (such as retinopathies, age-related macular degeneration, and uveitis), chronic and neuropathic pain, and fibroproliferative diseases. Many of the compounds in this invention may exhibit a favorable pharmacokinetic profile and have attractive properties in terms of bioavailability, including acceptable half-life, AUC (area under the curve), and peak values, as well as the absence of unfavorable phenomena such as rapid onset and insufficient tissue retention.

[0118] The combinations of the present invention can be used as medicaments. Said use as a medicament or method of treatment comprises the systemic administration to sick individuals of an amount effective in combating the conditions associated with the diseases. Consequently, the combinations of the present invention can be used in the manufacture of a medicament useful for treating, preventing or combating diseases or illnesses associated with protein kinases, including cancer, metabolic disorders (such as diabetes), inflammatory and autoimmune disorders (such as inflammatory bowel diseases, for example, Crohn's disease and ulcerative colitis, inflammatory lung diseases, rheumatoid arthritis, lupus nephritis, systemic lupus erythematosus and psoriasis and psoriatic arthritis), neurological disorders (such as Alzheimer's disease, Parkinson's disease, multiple sclerosis, Charcot-Marie-Tooth neuropathy, amyotrophic lateral sclerosis and epilepsy), atherosclerosis and cardiovascular diseases,Sjögren's syndrome, renal allograft rejection, virus-induced diseases, circulatory diseases, osteolysis and osteoporosis, osteoarthritis, sarcopenia, Langerhans cell histiocytosis, spinal cord injury, endometriosis, asthma and allergic asthma, eye diseases (such as retinopathies, age-related macular degeneration and uveitis), chronic and neuropathic pain, and fibroproliferative diseases. Petition 870260063548, dated 06 / 26 / 2026, page 106 / 639 100 / 316

[0119] The term therapeutically effective amount, as used in this document, means the amount of compound or active component or pharmaceutical agent that elicits the biological or medicinal response in a tissue, system, animal or human that is being sought, in light of the present invention, by a researcher, veterinarian, physician or other clinician, which includes relief of the symptoms of the disease being treated. Examples Example 1: General procedure for the preparation of analogues 49-55 47a R| — R2-R3_R4-H 47b R, = Ph, R2= R3- R4- H 47c R2- Ph R-, - R3- R4- H Method B1 49–55 Re—NH2 EDC.HCI, DMAP, □ MFouCH2CI2irt Method C2 NaOH, EtOH, rt, 1h 48a R1= R2= R3= R4= H 48b R, =Ph, R2= Ra= R4= H 48c R^= Rh, Rd= R^ = Ra= H

[0120] Method A1: To a solution of phenol derivative (1 equiv.) in DMF (5 mL / mmol) under nitrogen, solid cesium carbonate (2.5 equiv.) was added, followed by 4-chloropyridine derivative (1 equiv.). The reaction mixture was stirred at 110 °C until completion (from 2 h to overnight). After cooling to room temperature, a saturated aqueous solution of NH4Cl was added, and the aqueous layer was extracted with EtOAc. The organic layer was dried over Na2SO4, filtered, and concentrated under reduced pressure. The crude product was purified by flash column chromatography (cyclohexane / EtOAc 100 / 0 to 50 / 50) or Petition 870260063548, dated 06 / 26 / 2026, page 107 / 639 101 / 316 (DCM / MeOH from 100 / 0 to 90 / 10), or reversed-phase chromatography (H2O / MeOH: 0 to 100%) to obtain the expected compound.

[0121] Method B1: To a solution of the appropriate intermediate 47 (1 equiv.) in EtOH or MeOH (2.5 ml / mmol) was added a 1N NaOH solution (2.9 ml / mmol). The reaction mixture was stirred at room temperature until completion. EtOH or MeOH was removed under reduced pressure and the crude product was acidified with 1N HCl to pH = 2-3. The precipitate was filtered, washed with water and dried over P2O5 under vacuum to obtain the expected intermediate 48.

[0122] Method C2: To a suspension of the appropriate intermediate 48 (1 equiv.) in DCM or DMF (10 ml / mmol) under nitrogen, DMAP (2.2 equiv.), EDC.HCl (2 equiv.) and an appropriate amine (1.1-1.5 equiv.) were added. The reaction mixture was stirred at room temperature until completion (1 h - overnight). The reaction mixture was diluted with DCM and washed twice with a saturated NH4Cl solution. The organic layer was dried over Na2SO4, filtered, and concentrated under reduced pressure. The crude product was purified by flash column chromatography (DCM / MeOH 100 / 0 to 90 / 10) and reversed-phase chromatography (H2O / MeOH: 0 to 100%) to obtain the expected compound.

[0123] Method D1: To a stirred solution of 2-bromo-4-chloropyridine (192 mg, 1 mmol) in isopropanol / H2O (4 ml / 4 ml) were added phenylboronic acid (128 mg, 1.05 mmol), K3PO4 (424 mg, 2 mmol) and Pd(OAc)2 (4 mg, 0.015 mmol). The reaction mixture was stirred at 80 °C under an air atmosphere for 30 minutes. After cooling to room temperature, the reaction mixture was diluted with EtOAc and washed twice with a saturated NaCl solution. The organic layer was dried over Na2SO4, filtered and concentrated under reduced pressure. The crude product was purified by flash column chromatography (Cyclohexane / EtOAc: 100 / 0 to 90 / 10) to obtain 162 mg of 4-chloro-2-phenylpyridine 46b with a yield of 85%.

[0124] Method D2: To a stirred solution of 3-bromo-4-chloropyridine (385 mg, 2 mmol) in dioxane (10 ml) were added under nitrogen phenylboronic acid (256 mg, 2.1 mmol), solid K3PO4 (849 mg, 4 mmol) and Pd(PPh3)4 (231 mg, 0.2 mmol). The reaction mixture was stirred at 100 °C for 4 h. The solvent was removed under vacuum and the crude product was purified by column chromatography. Petition 870260063548, dated 06 / 26 / 2026, page 108 / 639 102 / 316 flash (cyclohexane / EtOAc from 100 / 0 to 75 / 25), to obtain 4-chloro-3-phenylpyridine 46c as a yellow oil with a yield of 87%. The following table 1.1 illustrates the intermediates 47 prepared from the Method A1: Table 1.1: Intermediate Structure Synthesis Procedure Compound 47a O σχA'· Method A1 Compound 47b ro OyPqV. Method A1 Compound 47c O ° 1. o JL CJ XJ Method A1 The following table 1.2 illustrates the intermediates 48 prepared from the Method B1: Petition 870260063548, dated 06 / 26 / 2026, p. 109 / 639 103 / 316 Table 1.2 Intermediate Structure Synthesis Procedure Compound 48a O crxA Method B1 Compound 48b Method B1 Compound 48c O ° JL o Method B1 The following compounds are examples that illustrate the C2 procedure: N-(cyclohexylmethyl)-3-(4-pyridyloxy)benzamide (49):

[0125] Compound 49 was synthesized from intermediate 48a (0.20 mmol) and 1-cyclohexylmethanamine (0.34 mmol) as a white solid with an 83% yield according to the general C2 method. 1H NMR (600 MHz, DMSOd6) δ (ppm): 8.51 (t, J = 5.8 Hz, 1H), 8.49-8.47 (m, 2H), 7.78 (ddd, J = 7.8 Hz, 1.5 Hz, 1.0 Hz, 1H), 7.64-7.61 (m, 1H), 7.57 (t, J = 7.9 Hz, 1H), 7.35 (ddd, J = 8.1 Hz, 2.5 Hz, 1.0 Hz, 1H), 6.96-6.93 (m, 2H), 3.09 (dd, J = 6.8 Hz, 6.0 Hz, 2H), 1.68 (t, J = 13.5 Hz, 4H), 1.63-1.49 (m, 2H), 1.23-1.09 (m, 3H), 0.95-0.84 (m, 2H). N-(cyclohexylmethyl)-3-[(2-phenyl-4-pyridyl)oxy]benzamide (50):

[0126] Compound 50 was synthesized from intermediate 48b (0.20 mmol) and 1-cyclohexylmethanamine (0.30 mmol) as a white solid with a Petition 870260063548, dated 06 / 26 / 2026, p. 110 / 639 104 / 316 70% yield according to the general method C2.1H NMR (400 MHz, CDCI3) δ (ppm): 8.56 (d, J = 5.6 Hz, 1H), 7.94-7.88 (m, 2H), 7.66-7.61 (m, 1H), 7.57-7.54 (m, 1H), 7.52-7.39 (m, 4H), 7.28-7.24 (m, 2H), 6.79 (dd, J = 5.6 Hz, 2.4 Hz, 1H), 6.14 (bs, 1H), 3.35-3.28 (m, 2H), 1.83-1.54 (m, 6H), 1.27-1.15 (m, 3H), 1.05-0.94 (m, 2H). Example 2: General procedure for the synthesis of analogues 68-101

[0127] Method E: To a solution of carboxylic acid derivative (1 equiv.) in CH2Cl2 (5 mL / mmol) under nitrogen, oxalyl chloride (3 equiv.) and 50 µL of DMF were added. The reaction mixture was stirred at room temperature overnight. The reaction mixture was concentrated under reduced pressure to obtain the acyl chloride derivative. To a solution of this previous intermediate in pyridine (3 mL / mmol) under nitrogen, 2-amino-4-chloropyridine (1 equiv.) was added, and the reaction mixture was stirred at room temperature until completion (from 2 h to overnight). The reaction mixture was concentrated under reduced pressure. The crude product was purified by flash column chromatography (DCM / MeOH 100 / 0 to 95 / 5) to obtain the expected compound. The following compound 65a is an example illustrating Method E: Preparation of / V-(4-chloro-2-pyridyl)-1-methyl-pyrazole-4-carboxamide (65a): Petition 870260063548, dated 06 / 26 / 2026, page 111 / 639 105 / 316

[0128] Intermediate 65a was synthesized from 1-methyl-1H-pyrazol-4-carboxylic acid (2.37 mmol) and 2-amino-4-chloropyridine (2.37 mmol) as a white powder with an 84% yield according to general method E. ESI-MS: 237.10 (M+H)+. Table 1.3 below illustrates the intermediates 65 prepared using method E: Table 1.3 Intermediate Structure Synthesis procedure Compound 65a \i___ / ^| NKIH χχ .n. hey Ο Ν·χόχ. Method E Compound 65b C / VT—Z o—Ç ZI 0 Method E Compound 65c H \ .Cl / T xj Method E Compound 65d \j.__ O Νκ Π H 2JL n. _____ ci O 11 Cl Method E The following compound, 65e, is an example that illustrates the C2 Method: Preparation of N-(4-chloro-2-pyridyl)pyridine-3-carboxamide (65e): Petition 870260063548, dated 06 / 26 / 2026, p. 112 / 639 106 / 316

[0129] Intermediate 65e was synthesized from nicotinic acid (1.28 mmol) and 2-amino-4-chloropyridine (1.16 mmol) as a white powder with a yield of 84% according to the general C2 method. ESI-MS: 234.10 (M+H)+.

[0130] Method A2: To a solution of phenol derivative (1 equiv.) in DMF (2 ml / mmol) under nitrogen, solid cesium carbonate (2.5 equiv.) was added followed by 4-chloropyridine derivative (1 equiv.). The reaction mixture was stirred at 140 °C overnight. The reaction mixture was concentrated under reduced pressure to obtain the expected compound, which was used in the next step without purification. The following compound 66a is an example that illustrates Method A2: Preparation of ethyl 3-({2-[(1-methylpyrazol-4-carbonyl)amino]-4-pyridyl}oxy)benzoate (66a):

[0131] Intermediate 66a was synthesized from ethyl 3-hydroxy-2-methylbenzoate (0.91 mmol) and compound 65a (0.91 mmol) as a brown powder according to general method A2. ESI-MS: 381.20 (M+H)+ The following Table 1.4 illustrates the 66 intermediates prepared from method A2: Petition 870260063548, dated 06 / 26 / 2026, page 113 / 639 107 / 316 The reaction mixture was stirred at 50 °C for 1 h. EtOH was evaporated under reduced pressure, and the residue was dissolved in water and washed three times with CH2Cl2. The aqueous layer was then acidified with concentrated HCl to pH 2-3. The resulting precipitate was filtered, washed with H2O, and dried over P2O5 to yield the expected compound. If necessary, the filtrate was evaporated under reduced pressure and purified by reversed-phase chromatography (H2O / MeOH 100 / 0 to 0 / 100) to obtain more of the expected compound. The following compound 67a is an example that illustrates Method B2: Preparation of 2-methyl-3-({2-[(1-methylpyrazol-4-carbonyl)amino]-4-pyridyl}oxy)benzoic acid (67a):

[0133] Intermediate 67a was synthesized from intermediate 66a (0.91 mmol) as a white solid with a yield of 32% (in 2 steps) according to general method B2. ESI-MS: 353.15 (M+H)+. Table 1.5 below illustrates the 67 intermediates prepared using method B2: Petition 870260063548, dated 06 / 26 / 2026, p. 114 / 639 108 / 316 Table 1.5 Intermediate Structure Synthesis Procedure Compound 67a 'λ-ί i ° Method B2 Compound 67b / N---- 1 ° t xjr xj Method B2 Compound 67c XtxXX Method B2 Compound 67d XvX1 Method B2 The following compounds are examples that illustrate the C2 Method: N-(4-{3-[(2,6-difluoro-4-pyridyl)methylcarbamoyl]-2-methyl-phenoxy}-2-pyridyl)-1methyl-pyrazol-4-carboxamide (68):

[0134] Compound 68 was synthesized from intermediate 67a (0.42 mmol) and (2,6-difluoro-4-pyridyl)methanamine (0.63 mmol) as a white solid in a 23% yield according to the general C2 method. 1H NMR (400 MHz, DMSO-cfe) δ (ppm): 10.59 (s, 1H), 9.16 (t, J = 6.0 Hz, 1H), 8.40 (s, 1H), 8.24 (d, J = 5.7 Hz, 1H), 8.09 (s, 1H), 7.75 (d, J = 2.3 Hz, 1H), 7.50-7.37 (m, 2H), 7.30-7.24 (m, 1H), 7.14 (s, 2H), 6.63 (dd, J = 5.7 Hz, 2.4 Hz, 1H), 4.57 (d, J = 5.9 Hz, 2H), 3.86 (s, 3H), 2.15 (s, 3H). ESI-MS: 479.20 (M+H)+. N-(4-{3-[(4-cyano-3-fluorophenyl)methylcarbamoyl]-2-methylphenoxy}-2-pyridyl)-1 Petition 870260063548, dated 06 / 26 / 2026, p. 115 / 639 109 / 316 methyl-pyrazol-4-carboxamide (69):

[0135] Compound 69 was synthesized from intermediate 67a (0.10 mmol) and 4-aminomethyl-2-fluorobenzonitrile (0.11 mmol) as a white solid with a yield of 71% according to the general C2 method. 1H NMR (400 MHz, DMSO-d6) δ (ppm): 10.59 (s, 1H), 9.14 (t, J = 6.0 Hz, 1H), 8.40 (s, 1H), 8.23 ​​(d, J = 5.7 Hz, 1H), 8.09 (d, J = 0.6 Hz, 1H), 7.97-7.88 (m, 1H), 7.74 (d, J = 2.3 Hz, 1H), 7.48 (d, J = 10.4 Hz, 1H), 7.43-7.37 (m, 3H), 7.26 (t, J = 4.7 Hz, 1H), 6.63 (dd, J = 5.7 Hz, 2.4Hz, 1H), 4.54 (d, J = 5.9 Hz, 2H), 3.86 (s, 3H), 2.14 (s, 3H). ESI-MS: 485.15 (M+H)+. N-(4-{3-[(3,5-difluorophenyl)methylcarbamoyl]-2-methyl-phenoxy}-2-pyridyl)-1-methylpyrazol-4-carboxamide (70):

[0136] Compound 70 was synthesized from intermediate 67a (0.10 mmol) and 3,5-difluorobenzylamine (0.11 mmol) as a white solid with a yield of 64% according to the general C2 method. 1H NMR (400 MHz, DMSOd6) δ (ppm): 10.56 (s, 1H), 9.05 (t, J = 6.1 Hz, 1H), 8.40 (s, 1H), 8.23 ​​(d, J = 5.7 Hz, 1H), 8.09 (s, 1H), 7.75 (d, J = 2.3 Hz, 1H), 7.44-7.35 (m, 2H), 7.25 (dd, J = 7.3 Hz, 2.0 Hz, 1H), 7.18-7.03 (m, 3H), 6.62 (dd, J = 5.7 Hz, 2.4 Hz, 1H), 4.47 (d, J = 6.0 Hz, 2H), 3.86 (s, 3H), 2.14 (s, 3H). N-(4-{3-[(6-methoxy-3-pyridyl)methylcarbamoyl]-2-methyl-phenoxy}-2-pyridyl)-1-methylpyrazol-4-carboxamide (71): Petition 870260063548, dated 06 / 26 / 2026, p. 116 / 639 110 / 316

[0137] Compound 71 was synthesized from intermediate 67a (0.10 mmol) and (6-methoxypyridin-3-yl)methanamine (0.11 mmol) as a white solid with a yield of 61% according to the general C2 method. 1H NMR (400 MHz, DMSO-d6) δ (ppm): 10.56 (s, 1H), 8.95 (t, J = 5.9 Hz, 1H), 8.40 (s, 1H), 8.22 (d, J = 5.7 Hz, 1H), 8.14 (d, J = 2.2 Hz, 1H), 8.09 (s, 1H), 7.74 (d, J = 2.3 Hz, 1H), 7.69 (dd, J = 8.5 Hz, 2.5 Hz, 1H), 7.40-7.19 (m, 3H), 6.81 (d, J = 8.5 Hz, 1H), 6.61 (dd, J = 5.7 Hz, 2.4Hz, 1H), 4.38 (d, J = 5.9 Hz, 2H), 3.86 (s, 3H), 3.83 (s, 3H), 2.11 (s, 3H). N-(4-{3-[(3-fluorophenyl)methylcarbamoyl]-2-methyl-phenoxy}-2-pyridyl)-1-methylpyrazol-4-carboxamide (72):

[0138] Compound 72 was synthesized from intermediate 67a (0.09 mmol) and 3-fluorobenzylamine (0.13 mmol) as a white solid with a yield of 26% according to the general C2 method. 1H NMR (400 MHz, DMSOd6) δ (ppm): 10.54 (s, 1H), 9.01 (t, J = 6.1 Hz, 1H), 8.40 (s, 1H), 8.23 ​​(d, J = 5.8 Hz, 1H), 8.09 (d, J = 0.6 Hz, 1H), 7.75 (d, J = 2.3 Hz, 1H), 7.45-7.20 (m, 6H), 7.24 (dd, J = 7.9 Hz, 1.3 Hz, 1H), 6.62 (dd, J = 5.7 Hz, 2.4 Hz, 1H), 4.46 (d, J = 6.0 Hz, 2H), 3.86 (s, 3H), 2.14 (s, 3H). ESI-MS: 460.15 (M+H)+. N-(4-{3-[(4-fluorophenyl)methylcarbamoyl]-2-methyl-phenoxy}-2-pyridyl)-1-methylpyrazol-4-carboxamide (73):

[0139] Compound 73 was synthesized from intermediate 67a (0.09 mmol) and 4-fluorobenzylamine (0.13 mmol) as a white solid with a yield of 26% according to the general C2 method. 1H NMR (400 MHz, DMSOd6) δ (ppm): 10.53 (s, 1H), 9.00 (t, J = 6.0 Hz, 1H), 8.40 (s, 1H), 8.23 ​​(d, J = 5.7 Hz, 1H), 8.09 (d, J = 0.5 Hz, 1H), 7.75 (d, J = 2.3 Hz, 1H), 7.46-7.32 (m, 3H), 7.26-7.04 Petition 870260063548, dated 06 / 26 / 2026, p. 117 / 639 111 / 316 (m, 4H), 6.62 (dd, J = 5.7 Hz, 2.4 Hz, 1H), 4.47 (d, J = 6.0 Hz, 2H), 3.86 (s, 3H), 2.14 (s, 3H). ESI-MS: 460.15 (M+H)+. N-(4-{3-[(3-chlorophenyl)methylcarbamoyl]-2-methyl-phenoxy}-2-pyridyl)-1-methylpyrazol-4-carboxamide (74):

[0140] Compound 74 was synthesized from intermediate 67a (0.09 mmol) and 3-chlorobenzylamine (0.13 mmol) as a white solid in a 30% yield according to the general C2 method. 1H NMR (400 MHz, DMSOd6) δ (ppm): 10.53 (s, 1H), 8.97 (t, J = 6.2 Hz, 1H), 8.40 (s, 1H), 8.23 ​​(d, J = 5.7 Hz, 1H), 8.09 (d, J = 0.5 Hz, 1H), 7.75 (d, J = 2.3 Hz, 1H), 7.47-7.30 (m, 4H), 7.25-7.12 (m, 3H), 6.61 (dd, J = 5.7 Hz, 2.4 Hz, 1H), 4.43 (d, J = 5.9 Hz, 2H), 3.86 (s, 3H), 2.13 (s, 3H). ESI-MS: 476.10 (M+H)+ N-(4-{3-[(4-chlorophenyl)methylcarbamoyl]-2-methyl-phenoxy}-2-pyridyl)-1-methylpyrazol-4-carboxamide (75):

[0141] Compound 75 was synthesized from intermediate 67a (0.09 mmol) and 4-chlorobenzylamine (0.13 mmol) as a white solid in a 30% yield according to the general C2 method. 1H NMR (400 MHz, DMSOd6) δ (ppm): 10.56 (s, 1H), 9.01 (t, J = 6.0 Hz, 1H), 8.40 (s, 1H), 8.23 ​​(d, J = 5.7 Hz, 1H), 8.09 (d, J = 0.4 Hz, 1H), 7.75 (d, J = 2.3 Hz, 1H), 7.47-7.31 (m, 6H), 7.23 (dd, J = 7.8 Hz, 1.3 Hz, 1H), 6.62 (dd, J = 5.7 Hz, 2.4 Hz, 1H), 4.43 (d, J = 6.0 Hz, 2H), 3.86 (s, 3H), 2.13 (s, 3H). ESI-MS: 476.10 (M+H)+ N-{4-[3-(imidazo[1,2-a]pyridin-6-ylmethylcarbamoyl)-2-methyl-phenoxy]-2-pyridyl}-1 Petition 870260063548, dated 06 / 26 / 2026, p. 118 / 639 112 / 316 methyl-pyrazol-4-carboxamide (76):

[0142] Compound 76 was synthesized from intermediate 67a (0.09 mmol) and imidazo[1,2-a]pyridin-6-ylmethanamine (0.13 mmol) as a white solid with a yield of 22% according to the general C2 method. 1H NMR (400 MHz, DMSO-d6) δ (ppm): 10.56 (s, 1H), 9.01 (t, J = 5.9 Hz, 1H), 8.50 (s, 1H), 8.40 (s, 1H), 8.23 ​​(d, J = 5.7 Hz, 1H), 8.09 (d, J = 0.5 Hz, 1H), 7.97 (s, 1H), 7.74 (d, J = 2.3 Hz, 1H), 7.58-7.52 (m, 2H), 7.45-7.32 (m, 2H), 7.29-7.19 (m, 2H), 6.62 (dd, J = 5.7 Hz, 2.4 Hz, 1H), 4.44 (d, J = 5.9 Hz, 2H), 3.86 (s, 3H), 2.13 (s, 3H). ESI-MS: 482.20 (M+H)+. N-{4-[3-(imidazo[1,2-a]pyridin-7-ylmethylcarbamoyl)-2-methyl-phenoxy]-2-pyridyl}-1methyl-pyrazol-4-carboxamide (77):

[0143] Compound 77 was synthesized from intermediate 67a (0.09 mmol) and imidazo[1,2-a]pyridin-7-ylmethanamine (0.13 mmol) as a white solid in a 15% yield according to the general C2 method. 1H NMR (400 MHz, DMSO-d6) δ (ppm): 10.56 (s, 1H), 9.05 (t, J = 6.1 Hz, 1H), 8.51 (dd, J = 7.0 Hz, 0.7 Hz, 1H), 8.40 (s, 1H), 8.23 ​​(d, J = 5.7 Hz, 1H), 8.09 (d, J = 0.5 Hz, 1H), 7.90 (s, 1H), 7.75 (d, J = 2.3 Hz, 1H), 7.53 (d, J = 1.2 Hz, 1H), 7.47-7.35 (m, 3H), 7.25 (dd, J = 7.4 Hz, 1.9 Hz, 1H), 6.89 (dd, J = 7.0 Hz, 1.6 Hz, 1H), 6.62 (dd, J = 5.7 Hz, 2.4 Hz, 1H), 4.49 (d, J = 5.9 Hz, 2H), 3.86 (s, 3H), 2.15 (s, 3H). ESI-MS: 482.2 (M+H)+ 1-methyl-N-[4-(2-methyl-3-{[6-(trifluoromethyl)-3-pyridyl]methylcarbamoyl}phenoxy)-2pyridyl]pyrazol-4-carboxamide (78): Petition 870260063548, dated 06 / 26 / 2026, p. 119 / 639 113 / 316

[0144] Compound 78 was synthesized from intermediate 67a (0.09 mmol) and [6-(trifluoromethyl)-3-pyridyl]methanamine (0.13 mmol) as a white solid with a yield of 44% according to the general C2 method. 1H NMR (400 MHz, DMSO-d6) δ (ppm): 10.88 (s, 1H), 9.12 (t, J = 5.9 Hz, 1H), 8.76 (s, 1H), 8.27 (d, J = 5.7 Hz, 1H), 8.05 (d, J = 9.3 Hz, 1H), 7.91 (d, J = 8.1 Hz, 1H), 7.71 (d, J = 2.3 Hz, 1H), 7.50 (d, J = 2.1 Hz, 1H), 7.46-7.35 (m, 2H), 7.30-7.23 (m, 2H), 6.65 (dd, J = 5.7 Hz, 2.3 Hz, 1H), 4.58 (d, J = 5.8 Hz, 2H), 4.04 (s, 3H), 2.14 (s, 3H). ESI-MS: 511.15 (M+H)+. N-(4-{3-[(5-fluoro-6-methoxy-3-pyridyl)methylcarbamoyl]-2-methyl-phenoxy}-2pyridyl)-1-methyl-pyrazol-4-carboxamide (79):

[0145] Compound 79 was synthesized from intermediate 67a (0.09 mmol) and (5-fluoro-6-methoxy-3-pyridyl)methanamine (0.13 mmol) as a white solid with a yield of 38% according to the general C2 method. 1H NMR (400 MHz, DMSO-d6) δ (ppm): 10.54 (s, 1H), 8.95 (t, J = 5.9 Hz, 1H), 8.40 (s, 1H), 8.23 ​​(d, J = 5.7 Hz, 1H), 8.09 (d, J = 0.4 Hz, 1H), 7.98 (d, J = 1.8 Hz, 1H), 7.74 (d, J = 2.3 Hz, 1H), 7.65 (dd, J = 11.4 Hz, 1.9 Hz, 1H), 7.41 -7.30 (m, 2H), 7.23 (dd, J = 7.8 Hz, 1.4 Hz, 1H), 6.61 (dd, J = 5.7 Hz, 2.4 Hz, 1H), 4.41 (d, J = 5.9 Hz, 2H), 3.93 (s, 3H), 3.86 (s, 3H), 2.12 (s, 3H). ESI-MS: 491.05 (M+H)+ N-(4-{3-[(3-fluorophenyl)methylcarbamoyl]-2-methyl-phenoxy}-2-pyridyl)-1-methylpyrazol-3-carboxamide (80): Petition 870260063548, dated 06 / 26 / 2026, p. 120 / 639 114 / 316

[0146] Compound 80 was synthesized from intermediate 67b (0.11 mmol) and 3-fluorobenzylamine (0.17 mmol) as a white solid with a yield of 37% according to the general C2 method. 1H NMR (400 MHz, DMSOd6) δ (ppm): 9.54 (s, 1H), 9.03 (t, J = 6.0 Hz, 1H), 8.23 ​​(d, J = 5.8 Hz, 1H), 7.87 (d, J = 2.3 Hz, 1H), 7.71 (d, J = 2.3 Hz, 1H), 7.45-7.34 (m, 3H), 7.29-7.14 (m, 3H), 7.09 (td, J = 8.5 Hz, 2.5 Hz, 1H), 6.81 (d, J = 2.3 Hz, 1H), 6.65 (dd, J = 5.7 Hz, 2.4 Hz, 1H), 4.47 (d, J = 6.0 Hz, 2H), 3.95 (s, 3H), 2.14 (s, 3H). ESI-MS: 460.30 (M+H)+. N-(4-{3-[(4-fluorophenyl)methylcarbamoyl]-2-methyl-phenoxy}-2-pyridyl)-1-methylpyrazol-3-carboxamide (81):

[0147] Compound 81 was synthesized from intermediate 67b (0.11 mmol) and 4-fluorobenzylamine (0.17 mmol) as a white solid with a yield of 37% according to the general C2 method. 1H NMR (400 MHz, DMSOd6) δ (ppm): 9.54 (s, 1H), 8.99 (t, J = 6.1 Hz, 1H), 8.23 ​​(d, J = 5.7 Hz, 1H), 7.88 (d, J = 2.3 Hz, 1H), 7.71 (d, J = 2.3 Hz, 1H), 7.42-7.33 (m, 4H), 7.25 (dd, J = 7.8 Hz, 1.4 Hz, 1H), 7.22-7.12 (m, 2H), 6.81 (d, J = 2.3 Hz, 1H), 6.65 (dd, J = 5.7 Hz, 2.4 Hz, 1H), 4.43 (d, J = 6.0 Hz, 2H), 3.95 (s, 3H), 2.13 (s, 3H). ESI-MS: 460.25 (M+H)+ N-(4-{3-[(3-chlorophenyl)methylcarbamoyl]-2-methyl-phenoxy}-2-pyridyl)-1-methylpyrazol-3-carboxamide (82): Petition 870260063548, dated 06 / 26 / 2026, p. 121 / 639 115 / 316

[0148] Compound 82 was synthesized from intermediate 67b (0.11 mmol) and 3-chlorobenzylamine (0.17 mmol) as a white solid with a yield of 41% according to the general C2 method. 1H NMR (400 MHz, DMSOd6) δ (ppm): 9.54 (s, 1H), 9.03 (t, J = 6.1 Hz, 1H), 8.23 ​​(d, J = 5.7 Hz, 1H), 7.87 (d, J = 2.3 Hz, 1H), 7.71 (d, J = 2.3 Hz, 1H), 7.45-7.30 (m, 6H), 7.26 (dd, J = 7.8 Hz, 1.2 Hz, 1H), 6.81 (d, J = 2.3 Hz, 1H), 6.65 (dd, J = 5.7 Hz, 2.4 Hz, 1H), 4.46 (d, J = 6.0 Hz, 2H), 3.95 (s, 3H), 2.14 (s, 3H). ESI-MS: 476.10 (M+H)+. N-(4-{3-[(4-chlorophenyl)methylcarbamoyl]-2-methyl-phenoxy}-2-pyridyl)-1-methylpyrazol-3-carboxamide (83):

[0149] Compound 83 was synthesized from intermediate 67b (0.11 mmol) and 4-chlorobenzylamine (0.17 mmol) as a white solid with a yield of 48% according to the general C2 method. 1H NMR (400 MHz, DMSOd6) δ (ppm): 9.52 (s, 1H), 8.99 (t, J = 6.0 Hz, 1H), 8.23 ​​(d, J = 5.7 Hz, 1H), 7.87 (d, J = 2.3 Hz, 1H), 7.71 (d, J = 2.3 Hz, 1H), 7.44-7.32 (m, 6H), 7.25 (dd, J = 7.8 Hz, 1.4 Hz, 1H), 6.80 (d, J = 2.3 Hz, 1H), 6.65 (dd, J = 5.7 Hz, 2.4 Hz, 1H), 4.44 (d, J = 6.0 Hz, 2H), 3.95 (s, 3H), 2.13 (s, 3H). ESI-MS: 476.10 (M+H)+ N-{4-[3-(imidazo[1,2-a]pyridin-6-ylmethylcarbamoyl)-2-methyl-phenoxy]-2-pyridyl}-1methyl-pyrazol-3-carboxamide (84):

[0150] Compound 84 was synthesized from intermediate 67b (0.11 mmol) and imidazo[1,2-a]pyridin-6-ylmethanamine (0.17 mmol) as a white solid in a 35% yield according to the general C2 method. 1H NMR (400 MHz, DMSO-d6) δ (ppm): 9.52 (s, 1H), 8.99 (t, J = 6.0 Hz, 1H), 8.50 (s, 1H), 8.22 (d, J = Petition 870260063548, dated 06 / 26 / 2026, p. 122 / 639 116 / 316 5.8 Hz, 1H), 7.96 (s, 1H), 7.87 (d, J = 2.3 Hz, 1H), 7.70 (d, J = 2.3 Hz, 1H), 7.597.52 (m, 2H), 7.44-7.34 (m, 2H), 7.28-7.22 (m, 2H), 6.80 (d, J = 2.3 Hz, 1H), 6.65 (dd, J = 5.7 Hz, 2.4 Hz, 1H), 4.45 (d, J = 5.8 Hz, 2H), 3.95 (s, 3H), 2.14 (s, 3H). ESI-MS: 482.20 (M+H)+. N-{4-[3-(imidazo[1,2-a]pyridin-7-ylmethylcarbamoyl)-2-methyl-phenoxy]-2-pyridyl}-1methyl-pyrazol-3-carboxamide (85):

[0151] Compound 85 was synthesized from intermediate 67b (0.11 mmol) and imidazo[1,2-a]pyridin-7-ylmethanamine (0.17 mmol) as a white solid with a yield of 22% according to the general C2 method. 1H NMR (400 MHz, DMSO-d6) δ (ppm): 9.52 (s, 1H), 9.04 (t, J = 6.0 Hz, 1H), 8.51 (dd, J = 7.0 Hz, 0.7 Hz, 1H), 8.23 ​​(d, J = 5.8 Hz, 1H), 7.90 (s, 1H), 7.87 (d, J = 2.3 Hz, 1H), 7.72 (d, J = 2.3 Hz, 1H), 7.53 (d, J = 1.1 Hz, 1H), 7.45-7.37 (m, 3H), 7.26 (dd, J = 7.1 Hz, 2.2 Hz, 1H), 6.89 (dd, J = 7.0 Hz, 1.6 Hz, 1H), 6.81 (d, J = 2.3 Hz, 1H), 6.65 (dd, J = 5.7 Hz, 2.4 Hz, 1H), 4.49 (d, J = 5.9 Hz, 2H), 3.95 (s, 3H), 2.16 (s, 3H). ESI-MS: 482.15 (M+H)+ N-(4-{3-[(3,5-difluorophenyl)methylcarbamoyl]-2-methyl-phenoxy}-2-pyridyl)-1-methylpyrazol-3-carboxamide (86):

[0152] Compound 86 was synthesized from intermediate 67b (0.09 mmol) and 3,5-difluorobenzylamine (0.13 mmol) as a white solid with a yield of 49% according to the general C2 method. 1H NMR (400 MHz, DMSOd6) δ (ppm): 9.53 (s, 1H), 9.03 (t, J = 6.0 Hz, 1H), 8.23 ​​(d, J = 5.8 Hz, 1H), 7.87 (d, J = 2.3 Hz, 1H), 7.71 (d, J = 2.3 Hz, 1H), 7.44-7.35 (m, 2H), 7.26 (dd, J = 7.2 Hz, 2.1 Hz, 1H), 7.17-7.02 (m, 3H), 6.81 (d, J = 2.3 Hz, 1H), 6.65 (dd, J = 5.7 Hz, 2.4 Hz, 1H), 4.47 (d, J = 6.0 Hz, 2H), 3.95 (s, 3H), 2.14 (s, 3H). Petition 870260063548, dated 06 / 26 / 2026, p. 123 / 639 117 / 316 ESI-MS: 478.15 (M+H)+. N-(4-{3-[(6-methoxy-3-pyridyl)methylcarbamoyl1-2-methyl-phenoxy}-2-pyridyl)-1-methylpyrazol-3-carboxamide (87):

[0153] Compound 87 was synthesized from intermediate 67b (0.09 mmol) and (6-methoxypyridin-3-yl)methanamine (0.13 mmol) as a white solid with a yield of 45% according to the general C2 method. 1H NMR (400 MHz, DMSO-d6) δ (ppm): 9.52 (s, 1H), 8.93 (t, J = 5.9 Hz, 1H), 8.22 (d, J = 5.7 Hz, 1H), 8.14 (d, J = 2.0 Hz, 1H), 7.87 (d, J = 2.3 Hz, 1H), 7.71-7.69 (m, 2H), 7.38 (t, J = 7.7 Hz, 1H), 7.32 (dd, J = 7.6 Hz, 1.3 Hz, 1H), 7.24 (dd, J = 7.9 Hz, 1.2 Hz, 1H), 6.826.80 (m, 2H), 6.64 (dd, J = 5.7 Hz, 2.4 Hz, 1H), 4.38 (d, J = 5.9 Hz, 2H), 3.95 (s, 3H), 3.83 (s, 3H), 2.12 (s, 3H). ESI-MS: 473.15 (M+H)+ 1-methyl-N-[4-(2-methyl-3-{[6-(trifluoromethyl)-3-pyridyl1methylcarbamoyl} phenoxy)-2pyridyl1pyrazol-3-carboxamide (88):

[0154] Compound 88 was synthesized from intermediate 67b (0.09 mmol) and [6-(trifluoromethyl)-3-pyridyl1-methanamine (0.13 mmol) as a white solid with a yield of 48% according to the general C2 method. 1H NMR (400 MHz, DMSO-d6) δ (ppm): 9.54 (s, 1H), 9.13 (t, J = 5.9 Hz, 1H), 8.77 (d, J = 1.2 Hz, 1H), 8.23 ​​(d, J = 5.7 Hz, 1H), 8.05 (dd, J = 8.1 Hz, 1.4 Hz, 1H), 7.91 (d, J = 8.1 Hz, 1H), 7.87 (d, J = 2.3 Hz, 1H), 7.70 (d, J = 2.3 Hz, 1H), 7.44-7.36 (m, 2H), 7.31-7.24 (m, 1H), 6.81 (d, J = 2.3Hz, 1H), 6.66 (dd, J = 5.7 Hz, 2.4 Hz, 1H), 4.58 (d, J = 5.8 Hz, 2H), 3.95 (s, 3H), 2.14 (s, 3H). ESI-MS: 511.15 (M+H)+ Petition 870260063548, dated 06 / 26 / 2026, p. 124 / 639 118 / 316 N-(4-{3-[(3-fluorophenyl)methylcarbamoyl]-2-methyl-phenoxy}-2-pyridyl)-2-methylpyrazol-3-carboxamide (89):

[0155] Compound 89 was synthesized from intermediate 67c (0.09 mmol) and 3-fluorobenzylamine (0.13 mmol) as a white solid with a yield of 33% according to the general C2 method. 1H NMR (600 MHz, DMSOd6) δ (ppm): 10.85 (s, 1H), 9.00 (t, J = 6.1 Hz, 1H), 8.27 (d, J = 5.8 Hz, 1H), 7.72 (d, J = 2.2 Hz, 1H), 7.50 (d, J = 2.1 Hz, 1H), 7.41-7.35 (m, 3H), 7.26-7.24 (m, 2H), 7.20 (d, J = 7.6 Hz, 1H), 7.16 (d, J = 10.2 Hz, 1H), 7.09 (td, J = 8.3 Hz, 2.0 Hz, 1H), 6.65 (dd, J = 5.7 Hz, 2.4 Hz, 1H), 4.47 (d, J = 6.0 Hz, 2H), 4.05 (s, 3H), 2.15 (s, 3H). ESI-MS: 460.20 (M+H)+. N-(4-{3-[(4-fluorophenyl)methylcarbamoyl]-2-methyl-phenoxy}-2-pyridyl)-2-methylpyrazol-3-carboxamide (90):

[0156] Compound 90 was synthesized from intermediate 67c (0.09 mmol) and 4-fluorobenzylamine (0.13 mmol) as a white solid with a yield of 32% according to the general C2 method. 1H NMR (600 MHz, DMSOd6) δ (ppm): 10.85 (s, 1H), 8.96 (t, J = 6.1 Hz, 1H), 8.29-8.24 (m, 1H), 7.72 (d, J = 2.2 Hz, 1H), 7.50 (d, J = 2.1 Hz, 1H), 7.41-7.37 (m, 3H), 7.33 (dd, J = 7.6 Hz, 1.1 Hz, 1H), 7.27-7.23 (m, 2H), 7.20-7.14 (m, 2H), 6.64 (dd, J = 5.7 Hz, 2.4 Hz, 1H), 4.43 (d, J = 6.0Hz, 2H), 4.05 (s, 3H), 2.14 (s, 3H). ESI-MS: 460.20 (M+H)+ N-(4-{3-[(3-chlorophenyl)methylcarbamoyl]-2-methyl-phenoxy}-2-pyridyl)-2-methylpyrazol-3-carboxamide (91): Petition 870260063548, dated 06 / 26 / 2026, p. 125 / 639 119 / 316

[0157] Compound 91 was synthesized from intermediate 67c (0.09 mmol) and 3-chlorobenzylamine (0.13 mmol) as a white solid with a yield of 37% according to the general C2 method. 1H NMR (600 MHz, DMSOd6) δ (ppm): 10.85 (s, 1H), 9.00 (t, J = 6.0 Hz, 1H), 8.31-8.23 (m, 1H), 7.72 (d, J = 2.3, 1H), 7.50 (d, J = 2.1 Hz, 1H), 7.43-7.30 (m, 6H), 7.25 (m, 2H), 6.65 (dd, J = 5.7 Hz, 2.4 Hz, 1H), 4.46 (d, J = 6.0 Hz, 2H), 4.05 (s, 3H), 2.15 (s, 3H). ESI-MS: 476.15 (M+H)+. N-(4-{3-[(4-chlorophenyl)methylcarbamoyl]-2-methyl-phenoxy}-2-pyridyl)-2-methylpyrazol-3-carboxamide (92):

[0158] Compound 92 was synthesized from intermediate 67c (0.09 mmol) and 4-chlorobenzylamine (0.13 mmol) as a white solid with a yield of 35% according to the general C2 method. 1H NMR (600 MHz, DMSOd6) δ (ppm): 10.85 (s, 1H), 8.98 (t, J = 6.1 Hz, 1H), 8.29-8.24 (m, 1H), 7.72 (d, J = 2.2 Hz, 1H), 7.50 (d, J = 2.1 Hz, 1H), 7.42-7.33 (m, 5H), 7.26 (d, J = 2.1 Hz, 2H), 7.25 (dd, J = 8.0 Hz, 1.1 Hz, 1H) 6.64 (dd, J = 5.7 Hz, 2.4 Hz, 1H), 4.44 (d, J = 6.0 Hz, 2H), 4.05 (s, 3H), 2.14 (s, 3H). ESI-MS: 476.15 (M+H)+ N-{4-[3-(imidazo[1,2-a]pyridin-6-ylmethylcarbamoyl)-2-methyl-phenoxy]-2-pyridyl}-2methyl-pyrazol-3-carboxamide (93):

[0159] Compound 93 was synthesized from intermediate 67c (0.09 mmol) and imidazo[1,2-a]pyridin-6-ylmethanamine (0.13 mmol) as a white solid in a 15% yield according to the general C2 method. 1H NMR (600 MHz, DMSO-d6) δ (ppm): 10.85 (s, 1H), 8.98 (t, J = 6.0 Hz, 1H), 8.52-8.49 (m, 1H), 8.26 (d, J = 5.7 Hz, 1H), 7.98-7.95 (m, 1H), 7.71 (d, J = 2.3 Hz, 1H), 7.58-7.54 (m, 2H), 7.50 (d, J = 2.1 Hz, 1H), 7.41-7.34 (m, 2H), 7.27-7.22 (m, 3H), 6.64 (dd, J = 5.7 Hz, 2.3 Hz, 1H), 4.45 (d, J = 5.8 Hz, 2H), 4.04 (s, 3H), 2.14 (s, 3H). Petition 870260063548, dated 06 / 26 / 2026, pp. 126 / 639 120 / 316 ESI-MS: 482.20 (M+H)+. N-{4-[3-(imidazo[1,2-a]pyridin-7-ylmethylcarbamoyl)-2-methyl-phenoxy]-2-pyridyl}-2methyl-pyrazol-3-carboxamide (94):

[0160] Compound 94 was synthesized from intermediate 67c (0.09 mmol) and imidazo[1,2-a]pyridin-7-ylmethanamine (0.13 mmol) as a white solid in 20% yield according to the general C2 method. 1H NMR (600 MHz, DMSO-d6) δ (ppm): 10.85 (s, 1H), 9.03 (t, J = 6.0 Hz, 1H), 8.51 (dd, J = 7.0 Hz, 0.9 Hz, 1H), 8.27 (d, J = 5.7 Hz, 1H), 7.91 -7.88 (m, 1H), 7.72 (d, J = 2.3 Hz, 1H), 7.53 (d, J = 1.2 Hz, 1H), 7.50 (d, J = 2.1 Hz, 1H), 7.45-7.36 (m, 3H), 7.28-7.24 (m, 2H), 6.89 (dd, J = 7.0Hz, 1.7Hz, 1H), 6.65 (dd, J = 5.7 Hz, 2.3 Hz, 1H), 4.49 (d, J = 5.8 Hz, 2H), 4.05 (s, 3H), 2.17 (s, 3H). ESI-MS: 482.20 (M+H)+ N-(4-{3-[(3,5-difluorophenyl)methylcarbamoyl]-2-methyl-phenoxy}-2-pyridyl)-2-methylpyrazol-3-carboxamide (95):

[0161] Compound 95 was synthesized from intermediate 67c (0.09 mmol) and 3,5-difluorobenzylamine (0.13 mmol) as a white solid with a yield of 42% according to the general C2 method. 1H NMR (600 MHz, DMSOd6) δ (ppm): 10.85 (s, 1H), 9.02 (t, J = 6.1 Hz, 1H), 8.27 (d, J = 5.7 Hz, 1H), 7.72 (d, J = 2.3 Hz, 1H), 7.50 (d, J = 2.1 Hz, 1H), 7.43-7.36 (m, 2H), 7.27-7.25 (m, 2H), 7.12 (tt, J = 9.3 Hz, 2.4 Hz, 1H), 7.08-7.04 (m, 2H), 6.65 (dd, J = 5.5 Hz, 2.3 Hz, 1H), 4.47 (d, J = 6.0 Hz, 2H), 4.05 (s, 3H), 2.15 (s, 3H). ESI-MS: 478.15 (M+H)+ N-(4-{3-[(6-methoxy-3-pyridyl)methylcarbamoyl]-2-methyl-phenoxy}-2-pyridyl)-2-methylpyrazol-3-carboxamide (96): Petition 870260063548, dated 06 / 26 / 2026, p. 127 / 639 121 / 316

[0162] Compound 96 was synthesized from intermediate 67c (0.09 mmol) and (6-methoxypyridin-3-yl)methanamine (0.13 mmol) as a white solid with a yield of 38% according to the general C2 method. 1H NMR (600 MHz, DMSO-d6) δ (ppm): 10.85 (s, 1H), 8.92 (t, J = 5.9 Hz, 1H), 8.33-8.22 (m, 1H), 8.14 (dd, J = 2.4 Hz, 0.6 Hz, 1H), 7.76-7.64 (m, 2H), 7.50 (d, J = 2.1 Hz, 1H), 7.39-7.36 (m, 1H), 7.31 (dd, J = 7.6 Hz, 1.1 Hz, 1H), 7.26-7.22 (m, 2H), 6.81 (dd, J = 8.5 Hz, 0.6 Hz, 1H), 6.63 (dd, J = 5.7 Hz, 2.4 Hz, 1H), 4.38 (d, J = 5.9 Hz, 2H), 4.05 (s, 3H), 3.83 (s, 3H), 2.12 (s, 3H). ESI-MS: 473.20 (M+H)+. 2-methyl-N-[4-(2-methyl-3-{[6-(trifluoromethyl)-3-pyridyl]methylcarbamoyl} phenoxy)-2pyridyl]pyrazol-3-carboxamide (97):

[0163] Compound 97 was synthesized from intermediate 67c (0.09 mmol) and [6-(trifluoromethyl)-3-pyridyl]methanamine (0.13 mmol) as a white solid with a yield of 44% according to the general C2 method. 1H NMR (400 MHz, DMSO-d6) δ (ppm): 10.88 (s, 1H), 9.12 (t, J = 5.9 Hz, 1H), 8.76 (s, 1H), 8.27 (d, J = 5.7 Hz, 1H), 8.05 (d, J = 9.3 Hz, 1H), 7.91 (d, J = 8.1 Hz, 1H), 7.71 (d, J = 2.3 Hz, 1H), 7.50 (d, J = 2.1 Hz, 1H), 7.44-7.36 (m, 2H), 7.28-7.25 (m, 2H), 6.65 (dd, J = 5.7 Hz, 2.3 Hz, 1H), 4.58 (d, J = 5.8 Hz, 2H), 4.04 (s, 3H), 2.14 (s, 3H). ESI-MS: 511.15 (M+H)+ N-(4-{3-[(5-fluoro-6-methoxy-3-pyridyl)methylcarbamoyl]-2-methyl-phenoxy}-2pyridyl)-2-methyl-pyrazol-3-carboxamide (98): Petition 870260063548, dated 06 / 26 / 2026, pp. 128 / 639 122 / 316

[0164] Compound 98 was synthesized from intermediate 67c (0.09 mmol) and (5-fluoro-6-methoxy-3-pyridyl)methanamine (0.13 mmol) as a white solid with a yield of 36% according to the general C2 method. 1H NMR (400 MHz, DMSO-d6) δ (ppm): 10.86 (s, 1H), 8.95 (t, J = 5.8 Hz, 1H), 8.27 (d, J = 5.7 Hz, 1H), 7.98 (d, J = 1.7 Hz, 1H), 7.71 (d, J = 2.3 Hz, 1H), 7.65 (dd, J=11.4Hz, 1.9Hz, 1H), 7.50 (d, J=2.1Hz, 1H), 7.44-7.31 (m, 2H), 7.26-7.23 (m, 2H), 6.64 (dd, J=5.7Hz, 2.3Hz, 1H), 4.41 (d, J = 5.9 Hz, 2H), 4.05 (s, 3H), 3.93 (s, 3H), 2.13 (s, 3H). ESI-MS: 491.10 (M+H)+. N-{4-[2-methyl-3-(4-pyridylmethylcarbamoyl)phenoxy]-2-pyridyl}pyridine-3carboxamide (99):

[0165] Compound 99 was synthesized from intermediate 67d (0.13 mmol) and 4-(aminomethyl)pyridine (0.19 mmol) as a white solid with a yield of 7% according to the general C2 method. 1H NMR (400 MHz, DMSOd6) δ (ppm): 11.14 (s, 1H), 9.08-9.05 (m, 2H), 8.73 (dd, J = 4.8 Hz, 1.6 Hz, 1H), 8.53 (dd, J = 4.4 Hz, 1.5 Hz, 2H), 8.35-8.24 (m, 2H), 7.77 (d, J = 2.3 Hz, 1H), 7.52 (dd, J = 7.7 Hz, 5.1 Hz, 1H), 7.45-7.39 (m, 2H), 7.35 (d, J = 5.9 Hz, 2H), 7.31 -7.24 (m, 1H), 6.70 (dd, J = 5.7 Hz, 2.4 Hz, 1H), 4.48 (d, J = 6.0 Hz, 2H), 2.17 (s, 3H). ESI-MS: 440.15 (M+H)+ N-(4-{3-[(2,6-difluoro-4-pyridyl)methylcarbamoyl]-2-methyl-phenoxy}-2-pyridyl) pyridine-3-carboxamide (100):

[0166] Compound 100 was synthesized from intermediate 67d (0.13 mmol) and (2,6-difluoro-4-pyridyl)methanamine (0.38 mmol) as a white solid in a 14% yield according to the general C2 method. 1H NMR (400 MHz, DMSO-d6) δ (ppm): 11.14 (s, 1H), 9.12 (t, J = 5.8 Hz, 1H), 9.08 (d, J = 1.7 Hz, 1H), Petition 870260063548, dated 06 / 26 / 2026, pp. 129 / 639 123 / 316 8.73 (dd, J = 4.8 Hz, 1.5 Hz, 1H), 8.34-8.24 (m, 2H), 7.76 (d, J = 2.2 Hz, 1H), 7.52 (dd, J = 7.5 Hz, 4.8 Hz, 1H), 7.48-7.40 (m, 2H), 7.28 (dd, J = 7.6 Hz, 1.4 Hz, 1H), 7.13 (s, 2H), 6.71 (dd, J = 5.7 Hz, 2.3 Hz, 1H), 4.57 (d, J = 5.9 Hz, 2H), 2.17 (s, 3H). ESI-MS: 476.20 (M+H)+. N-(4-{3-[(4-cyano-3-fluoro-phenyl)methylcarbamoyl]-2-methyl-phenoxy}-2pyridyl)pyridine-3-carboxamide (101):

[0167] Compound 101 was synthesized from intermediate 67d (0.13 mmol) and 4-aminomethyl-2-fluorobenzonitrile (0.14 mmol) as a white solid with an 8% yield according to the general C2 method. 1H NMR (400 MHz, DMSO-d6) δ (ppm): 1H NMR (400 MHz, DMSO) δ 11.14 (s, 1H), 9.15-9.05 (m, 2H), 8.73 (dd, J = 4.7 Hz, 1.5 Hz, 1H), 8.34-8.26 (m, 2H), 7.97-7.88 (m, 1H), 7.76 (d, J = 2.2 Hz, 1H), 7.55-7.38 (m, 5H), 7.30-7.25 (m, 1H), 6.70 (dd, J = 5.7 Hz, 2.3 Hz, 1H), 4.55 (d, J = 5.9 Hz, 2H), 2.16 (s, 3H). ESI-MS: 482.15 (M+H)+ Petition 870260063548, dated 06 / 26 / 2026, pp. 130 / 639 124 / 316 Example 3: General procedure for the synthesis of analogues 103-105 EDC.HCI, HOBt, DMF.ta C3 Method 102 t-BuOK, DMF, 140°C, overnight A3 Method 65a R, = H 65d Rq= Cl Preparation of 3-hydroxy-2-methyl- / \ / -(4-pyridylmethyl)benzamide (102):

[0168] Intermediate 102 was synthesized from 3-hydroxy-2-methylbenzoic acid (19.6 mmol) and 4-(aminomethyl)pyridine (19.6 mmol) as a white solid with a yield of 93% according to the general C3 method.

[0169] Method A3: To a solution of phenol derivative (1 equiv.) in DMF (5 ml / mmol) under nitrogen, f-BuOK (1.5 equiv.) was added. 4-Chloropyridine derivative (1 equiv.) was added and the reaction mixture was stirred at 140 °C until completion (24 to 48 hours). The reaction mixture was concentrated under reduced pressure. The crude product was purified by flash column chromatography (DCM / MeOH 100 / 0 to 90 / 10) and reversed-phase chromatography (hW / MeOH 100 / 0 to 0 / 100) to obtain the expected compound.

[0170] Method F: To a stirred solution of 104 (30 mg, 0.063 mmol) in EtOH / hW (0.75 ml / 0.25 ml) were added (L)-sodium ascorbate (2 mg, 0.006 mmol), sodium azide (9 mg, 0.126 mmol), copper iodide (3 mg, 0.013 mmol) and Petition 870260063548, dated 06 / 26 / 2026, page 131 / 639 125 / 316 DMEDA (2 μL, 0.019 mmol). The reaction mixture was stirred at 100 °C overnight. The reaction mixture was concentrated under reduced pressure. The crude product was purified by flash column chromatography (DCM / MeOH 100 / 0 to 80 / 20) and reversed-phase chromatography (H2O / MeOH: 0 to 100%) to obtain 6 mg of N-{6-amino-4-[2-methyl-3-(4-pyridylmethylcarbamoyl)phenoxy]-2-pyridyl}-1-methylpyrazol-4-carboxamide 105 with a yield of 21%. 1H NMR (500 MHz, DMSO-cfe) δ (ppm): 9.94 (s, 1H), 9.05 (t, J = 6.1 Hz, 1H), 8.54-8.52 (m, 2H), 8.36 (s, 1H), 8.05 (d, J = 0.6 Hz, 1H), 7.40-7.29 (m, 4H), 7.19 (dd, J=7.0Hz, 2.3Hz, 1H), 7.07 (d, J=2.0Hz, 1H), 5.79 (bs, 2H), 5.56 (d, J=2.0Hz, 1H), 4.47 (d, J=6.0Hz, 2H), 3.85 (s, 3H), 2.16 (s, 3H). ESI-MS: 458.15 (M+H)+. The following compounds are examples that illustrate Method A3: 1-methyl-N-{4-[2-methyl-3-(4-pyridylmethylcarbamoyl)phenoxy]-2-pyridyl} pyrazol-4carboxamide (103):

[0171] Compound 103 was synthesized from intermediates 102 (0.22 mmol) and 65a (0.22 mmol) as a white solid with a yield of 19% according to general method A3. 1H NMR (400 MHz, DMSO-cfe) δ (ppm): 10.53 (s, 1H), 9.05 (t, J = 6.0 Hz, 1H), 8.53 (dd, J = 4.5 Hz, 1.5 Hz, 2H), 8.40 (s, 1H), 8.23 ​​(d, J = 5.7 Hz, 1H), 8.09 (s, 1H), 7.75 (d, J = 2.3 Hz, 1H), 7.42-7.33 (m, 4H), 7.28-7.20 (m, 1H), 6.62 (dd, J = 5.7 Hz, 2.4 Hz, 1H), 4.48 (d, J = 6.0 Hz, 2H), 3.86 (s, 3H), 2.16 (s, 3H). N-{6-chloro-4-[2-methyl-3-(4-pyridylmethylcarbamoyl)phenoxy]-2-pyridyl}-1-methylpyrazol-4-carboxamide (104):

[0172] Compound 104 was synthesized from intermediates 102 (0.22 mmol) and 65d (0.22 mmol) as a white solid with a yield of 23% Petition 870260063548, dated 06 / 26 / 2026, p. 132 / 639 8.41 (s, 1H), 8.10 (d, J = 0.5 Hz, 1H), 7.73 (d, J = 2.0 Hz, 1H), 7.44-7.40 (m, 2H), 7.35 (d, J = 6.0 Hz, 2H), 7.33-7.28 (m, 1H), 6.73 (d, J = 2.0 Hz, 1H), 4.48 (d, J = 6.0 Hz, 2H), 3.85 (s, 3H), 2.16 (s, 3H). ESI-MS: 477.15 (M+H)+ Exemplo 4: Proceedimento geral para a sontese de análogos 106-108 3-[(2-amino-4-piridil)oxi]-2-metil- / \ / -(4-piridilmetil)benzamida (106):

[0173] Compound 106 was synthesized from intermediate 102 (0.39 mmol) and 2-amino-4-chloropyridine (0.39 mmol) as a white solid with a yield of 23% according to general method A3. 1H NMR (400 MHz, DMSOd6) δ (ppm): 8.99 (t, J = 6.0 Hz, 1H), 8.54-8.52 (m, 2H), 7.79 (d, J = 5.8 Hz, 1H), 7.36-7.33 (m, 4H), 7.17 (dd, J = 6.4 Hz, 2.9 Hz, 1H), 6.08 (dd, J = 5.8 Hz, 2.3 Hz, 1H), 5.92 (s, 2H), 5.74 (d, J = 2.2 Hz, 1H), 4.47 (d, J = 6.0 Hz, 2H), 2.13 (s, 3H). Petition 870260063548, dated 06 / 26 / 2026, p. 133 / 639 127 / 316 3-[(2-amino-4-pyridyl)oxy]-2-methyl-N-(4-pyridylmethyl)benzamide (107): Cl

[0174] Compound 107 was synthesized from intermediate 102 (0.61 mmol) and 2-amino-4,6-dichloropyridine (0.61 mmol) as a white solid in a 30% yield according to general method A3. 1H NMR (400 MHz, DMSOd6) δ (ppm): 9.05 (t, J = 6.0 Hz, 1H), 8.53 (d, J = 5.4 Hz, 2H), 7.40-7.31 (m, 4H), 7.25-7.20 (m, 1H), 6.45 (s, 2H), 6.13 (d, J = 1.9 Hz, 1H), 5.65 (d, J = 1.9 Hz, 1H), 4.47 (d, J = 6.0 Hz, 2H), 2.12 (s, 3H). 3-{[2-amino-6-(1-methylpyrazol-4-yl)-4-pyridyl]oxy}-2-methyl-N-(4-pyridyl methyl)benzamide (108):

[0175] Method D3: To a stirred solution of 107 (32 mg, 0.086 mmol) in dioxane (1 ml) under nitrogen were added PdCl2dppf (7 mg, 0.009 mmol), 1-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-1H-pyrazole) (27 mg, 0.13 mmol) and 1M Cs2CO3 (0.215 ml, 0.215 mmol). The reaction mixture was stirred at 100 °C for 2 h. The reaction mixture was concentrated under reduced pressure. (400 MHz, DMSO-d6) δ (ppm): 9.03 (t, J = 6.0 Hz, 1H), 8.54-8.52 (m 2H), 8.06 (s, 1H), 7.83 (d, J = 0.6 Hz, 1H), 7.41-7.32 (m, 4H), 7.20 (dd, J = 6.7 Hz, 2.6 Hz, 1H), 6.51 (d, J = 2.0 Hz, 1H), 5.92 (s, 2H), 5.49 (d, J = 2.0 Hz, 1H), 4.47 (d, J = 6.0 Hz, 2H), 3.84 (s, 3H), 2.16 (s, 3H). Example 5: General procedure for synthesizing analogues 110 - 116 Petition 870260063548, dated 06 / 26 / 2026, p. 134 / 639 128 / 316 Pd(PPh3)CI21Cui, Et3N, THF, 50°C, overnight. Method G Benzamide preparation (109): 3-[(2-bromo-4-pyridyl)oxyl-2-methyl- / V-(4-pyridylmethyl)

[0176] Intermediate 109 was synthesized from intermediate 102 (5.87 mmol) and 2-bromo-4-chloropyridine (5.87 mmol) as a white solid with a yield of 84% according to general method A1. ESI-MS: 398.10-400.10 (M+H)+

[0177] Method G: To a solution of 109 (1 equiv.) in THF (20 mL / mmol) under nitrogen, alkyne derivatives (3 equiv.), Pd(PPh3)Cl2 (0.1 equiv.), Cul (0.2 equiv.) and triethylamine (3 equiv.) were added. The mixture was stirred at 50 °C overnight. The reaction mixture was concentrated under reduced pressure. The crude product was purified by flash column chromatography (DCM / MeOH 100 / 0 to 90 / 10) and reversed-phase chromatography (H2O / MeOH 100 / 0 to 0 / 100) to obtain the expected compound. 2-methyl-3-{[2-(3-phenylprop-1-ynyl)-4-pyridyl]oxy}- / \ / -(4-pyridylmethyl) benzamide (110): Petition 870260063548, dated 06 / 26 / 2026, page 135 / 639 129 / 316

[0178] Compound 110 was synthesized from intermediate 109 (0.10 mmol) and 3-phenyl-1-propyne (0.30 mmol) as a white solid with a yield of 21% according to general method G. 1H NMR (400 MHz, DMSO-cfe) δ (ppm): 9.03 (t, J = 6.0 Hz, 1H), 8.55-8.52 (m, 2H), 8.41 (d, J = 5.7 Hz, 1H), 7.44-7.32 (m, 9H), 7.28-7.23 (m, 1H), 6.89 (d, J = 2.4 Hz, 1H), 6.85 (dd, J = 5.7 Hz, 2.5 Hz, 1H), 4.48 (d, J = 6.0 Hz, 2H), 3.90 (s, 2H), 2.12 (s, 3H). ESI-MS: 434.25 (M+H)+. 3-{[2-(3-hydroxyprop-1-ynyl)-4-pyridyl]oxy}-2-methyl-N-(4-pyridylmethyl) benzamide (111):

[0179] Compound 111 was synthesized from intermediate 109 (0.10 mmol) and propargyl alcohol (0.30 mmol) as a white solid in a 22% yield according to general method G. 1H NMR (400 MHz, DMSO-cfe) δ (ppm): 9.05 (t, J = 6.0 Hz, 1H), 8.54-8.52 (m, 2H), 8.43 (d, J = 5.7 Hz, 1H), 7.44-7.39 (m, 2H), 7.34 (d, J = 6.0 Hz, 2H), 7.29-7.23 (m, 1H), 6.91 (dd, J = 5.7 Hz, 2.5 Hz, 1H), 6.80 (d, J = 2.4 Hz, 1H), 5.41 (bs, 1H), 4.48 (d, J = 6.0 Hz, 2H), 4.28 (s, 2H), 2.11 (s, 3H). ESI-MS: 374.20 (M+H)+ 3-{[2-(3-aminoprop-1-ynyl)-4-pyridyl]oxy}-2-methyl-N-(4-pyridylmethyl) benzamide (112):

[0180] Compound 112 was synthesized from intermediate 109 (0.10 mmol) and propargylamine (0.30 mmol) as a white solid with a yield of 22% according to general method G. 1H NMR (400 MHz, DMSO-cfe) δ (ppm): Petition 870260063548, dated 06 / 26 / 2026, pp. 136 / 639 130 / 316 9.05 (t, J = 6.0 Hz, 1H), 8.54-8.52 (m, 2H), 8.41 (d, J = 5.7 Hz, 1H), 7.44-7.39 (m, 2H), 7.34 (d, J = 5.9 Hz, 2H), 7.26 (dd, J = 8.7 Hz, 4.3 Hz, 1H), 6.90 (dd, J = 5.7 Hz, 2.5 Hz, 1H), 6.75 (d, J = 2.4 Hz, 1H), 4.48 (d, J = 6.0 Hz, 3H), 3.47 (s, 2H), 2.11 (s, 4H). ESI-MS: 373.20 (M+H)+. 3-{[2-(3-methoxyprop-1-ynyl)-4-pyridyl]oxy}-2-methyl-N-(4-pyridylmethyl) benzamide (113):

[0181] Compound 113 was synthesized from intermediate 109 (0.10 mmol) and methylpropargyl ether (0.30 mmol) as a white solid with a yield of 31% according to general method G. 1H NMR (400 MHz, DMSOd6) δ (ppm): 9.04 (t, J = 5.9 Hz, 1H), 8.54-8.52 (m, 2H), 8.44 (d, J = 5.6 Hz, 1H), 7.41 (d, J = 4.5 Hz, 2H), 7.35 (d, J = 5.7 Hz, 2H), 7.25 (t, J = 4.7 Hz, 1H), 6.93-6.86 (m, 2H), 4.48 (d, J = 5.9 Hz, 2H), 4.32 (s, 2H), 3.31 (s, 3H), 2.12 (s, 3H). ESI-MS: 388.20 (M+H)+ 2-methyl-3-({2-[3-(methylamino)prop-1-ynyl]-4-pyridyl}oxy)-N-(4-pyridylmethyl) benzamide (114):

[0182] Compound 114 was synthesized from intermediate 109 (0.10 mmol) and N-methyl-N-prop-2-ynylamine (0.30 mmol) as a white solid in 18% yield according to general method G. 1H NMR (400 MHz, DMSOd6) δ (ppm): 9.05 (t, J = 5.9 Hz, 1H), 8.54-8.52 (m, 2H), 8.41 (d, J = 5.8 Hz, 1H), 7.41-7.38 (m, 3H), 7.34 (d, J = 5.8 Hz, 2H), 7.25 (t, J = 4.7 Hz, 1H), 6.87 (dd, J = 5.7 Hz, 2.5 Hz, 1H), 6.80 (d, J = 2.4 Hz, 1H), 4.48 (d, J = 5.9 Hz, 2H), 3.48 (d, J = 5.7 Hz, 2H), 2.30 (d, J = 5.0 Hz, 3H), 2.11 (s, 3H). ESI-MS: 387.25 (M+H)+ 3-{[2-(3-imidazol-1-ylprop-1-ynyl)-4-pyridyl]oxy}-2-methyl-N-(4-pyridylmethyl) Petition 870260063548, dated 06 / 26 / 2026, p. 137 / 639 131 / 316 benzamide (115):

[0183] Compound 115 was synthesized from intermediate 109 (0.20 mmol) and 1-(2-propyn-1-yl)-1H-imidazole (0.40 mmol) as a white solid in a 4% yield according to general method G. 1H NMR (400 MHz, DMSOd6) δ (ppm): 9.04 (t, J = 5.9 Hz, 1H), 8.54-8.52 (m, 2H), 8.44 (d, J = 5.7 Hz, 1H), 7.73 (s, 1H), 7.41 (d, J = 4.3 Hz, 2H), 7.34 (d, J = 5.8 Hz, 2H), 7.27-7.23 (m, 2H), 6.94-6.93 (m, 2H), 6.89 (dd, J = 5.7 Hz, 2.5 Hz, 1H), 5.19 (s, 2H), 4.48 (d, J = 5.9 Hz, 2H), 2.11 (s, 3H). ESI-MS: 424.30 (M+H)+. 2-methyl-3-({2-[3-(methylamino)prop-1-ynyl]-4-pyridyl}oxy)-N-(4-pyridylmethyl) benzamide (116):

[0184] Compound 116 was synthesized from intermediate 109 (0.20 mmol) and 1-(2-propyn-1-yl)-1H-pyrazole (0.30 mmol) as a white solid in a 12% yield according to general method G. 1H NMR (400 MHz, DMSOd6) δ (ppm): 9.04 (t, J = 6.0 Hz, 1H), 8.54-8.52 (m, 2H), 8.46-8.41 (m, 1H), 7.83 (d, J = 1.8 Hz, 1H), 7.49 (d, J = 1.2 Hz, 1H), 7.40 (d, J = 4.2 Hz, 2H), 7.34 (d, J = 6.0 Hz, 2H), 7.25 (t, J = 4.7 Hz, 1H), 6.98-6.88 (m, 2H), 6.30-6.29 (m, 1H), 5.30 (s, 2H), 4.48 (d, J = 6.0 Hz, 2H), 2.11 (s, 3H). ESI-MS: 424.25 (M+H)+ Example 6: General procedure for the synthesis of analogues 120 - 197, 350, 355 and 359 Petition 870260063548, dated 06 / 26 / 2026, pp. 138 / 639 132 / 316 R?—NH2 120-197 350-355, 359 EDC.HCI, DMAP, CH2ci2,ta Method C2 The following compound 117a is an example illustrating Method A1: Preparation of ethyl 3-[(2-chloro-4-pyridyl)oxy]-2-methylbenzoate (117a):

[0185] Intermediate 117a was synthesized from ethyl 3-hydroxy-2-methylbenzoate (6.30 mmol) and 2-chloro-4-nitropyridine (6.30 mmol) as a colorless oil with a 95% yield according to general method A1. ESI-MS: 292.00 (M+H)+ Table 1.6 below illustrates the intermediates 117 prepared from method A1: Table 1.6 Intermediate Structure Synthesis Procedure Compound 117a I ° Cl xx. O JL x*x. Xj XX Method A1 Compound 117b o Cl .XX. O XX 1L X- CrXi Method A1 Petition 870260063548, dated 06 / 26 / 2026, pp. 139 / 639 133 / 316 The following compound 118a is an example that illustrates the D2 Method: Preparation of ethyl 2-methyl-3-{[2-(1-methylpyrazol-4-yl)-4-pyridyl]oxy} benzoate (118a):

[0186] Intermediate 118a was synthesized from 117a (1.71 mmol) and pinacol ester of 1-methylpyrazol-4-boronic acid (2.05 mmol) as a colorless oil in quantitative yield according to general method D2. ESI-MS: 338.15 (M+H)+. Table 1.7 below illustrates the intermediates 118 prepared using method D2: Table 1.7 Intermediate Structure Synthesis Procedure Compound 118a 1 0 Method D2 Petition 870260063548, dated 06 / 26 / 2026, p. 140 / 639 134 / 316 Compound 118b / X íj -----N | / X / iCOQx Method D2 Compound 118c / X íj -----N | \zX>X. .zs. / °\ S___ Method D2 Compound 118d / X fl -----N 1 / X zX ZX > <Z ΧγΖ^ ΧγΧΧ' ΧγΧ^ Xd^ ^X U XJ Método D2 Composto 118h / X fi -----N 1 / X z*X s' iÍYXj ° Método D2 Composto 118i / X H -----N I zX zX s' ifXXX / XsX^ X> X^ Method D2

[0187] Method H: To a solution of 117 (1 equiv.) in dioxane (10 ml / mmol) under nitrogen, amine derivatives (2 equiv.), Pd2dba3 (0.1 equiv.), Xanthos (0.2 equiv.) and Cs2CO3 (2 equiv.) were added. The mixture was stirred at 100 °C until completion (from 2 h to overnight). The reaction mixture was concentrated under reduced pressure. The crude product was purified by flash column chromatography (DCM / MeOH 100 / 0 to 90 / 10) to obtain the expected compound. The following compound, 118e, is an example that illustrates the H-method: Preparation of ethyl 2-methyl-3-({2-[(1-methylpyrazol-3-yl)amino]-4-pyridyl}oxy)benzoate (118e):

[0188] Intermediate 118e was synthesized from 117a (1.37 mmol) and 1-methylpyrazol-3-amine (2.74 mmol) as a yellow oil with a 90% yield according to general method H. ESI-MS: 353.05 (M+H)+. Petition 870260063548, dated 06 / 26 / 2026, p. 141 / 639 135 / 316 Table 1.8 below illustrates the intermediates 113 prepared from method H: Table 1.8 Intermediate Structure Synthesis Procedure Compound 118e Q ΖΞ ^z / O y Method H Compound 118f 1 1Z. -q zi o Method H Compound 118g Q-- ZI 0 O y--o Method H Compound 118j ___ u. o' z^ IZ b 1 Method H Compound 118k 1 z ΖΞ ^z / O y Method H

[0189] Method I: To a stirred solution of 117a (250 mg, 0.86 mmol) in CH3CN (6 ml) were added pyrazole (123 mg, 1.79 mmol), Cs2CO3 (1.12 g, 3.42 mmol), CuI (360 mg, 1.88 mmol) and DMEDA (0.323 ml, 3 mmol). The reaction mixture was stirred at 100 °C for 48 h. The reaction mixture was concentrated under reduced pressure. The crude product was purified by flash column chromatography (Cyclohexane / EtOAc 100 / 0 to 75 / 25) to obtain 58 mg of ethyl 2-methyl-3-[(2-pyrazol-1-yl 4-pyridyl)oxy]benzoate 118h with a yield of 11%. The following compound 119a is an example that illustrates Method B2: Preparation of 2-methyl-3-{[2-(1-methylpyrazol-4-yl)-4-pyridyl]oxy}benzoic acid (119a): Petition 870260063548, dated 06 / 26 / 2026, p. 142 / 639 136 / 316

[0190] Intermediate 119a was synthesized from 118a (1.88 mmol) as a white powder with a yield of 79% according to general method B2. ESI-MS: 292.00 (M+H)+. Table 1.9 below illustrates the intermediates 119 prepared using method B2: Table 1.9 Intermediate Structure Synthesis procedure Compound 119a Method B2 Compound 119b fi -----N 1 iXYX OH Method B2 Compound 119c / ^1 fi -----NI ΥΊι ° n^s. / Method B2 Compound 119d Method B2 Compound 119e -xxrW'- Method B2 Compound 119f O 0 P zz hz 1 Method B2 Compound 119g Method B2 Compound 119h I o Method B2 Petition 870260063548, dated 06 / 26 / 2026, p. 143 / 639 137 / 316 Compound 119i / ^1 fj -----N 1 / X / °\ / X 0H Method B2 Compound 119j H -----N | Xx-^k. / \ O oh Method B2 Compound 119k OHN JL / ^τ 7Γ 7Γ ^OH —\ tt jr t í Method B2 Compound 119l Method B2 The following compounds are examples that illustrate the C2 Method: N-[(6-methoxy-3-pyridyl)methyl]-2-methyl-3-{[2-(1-methylpyrazol-4-yl)-4pyridyl]oxy}benzamide (120):

[0191] Compound 120 was synthesized from intermediate 119a (0.10 mmol) and (6-methoxypyridin-3-yl)methanamine (0.12 mmol) as a white solid with a 60% yield according to the general C2 method. 1H NMR (400 MHz, DMSO-d6) δ (ppm): 8.91 (t, J = 5.9 Hz, 1H), 8.35 (d, J = 5.7 Hz, 1H), 8.25 (s, 1H), 8.14 (d, J = 2.2 Hz, 1H), 7.96 (s, 1H), 7.69 (dd, J = 8.5 Hz, 2.4 Hz, 1H), 7.39-7.28 (m, 2H), 7.24 (d, J = 2.3 Hz, 1H), 7.20 (dd, J = 7.9 Hz, 1.0 Hz, 1H), 6.81 (d, J = 8.5 Hz, 1H), 6.47 (dd, J = 5.7 Hz, 2.4 Hz, 1H), 4.39 (d, J = 5.9 Hz, 2H), 3.86 (s, 3H), 3.83 (s, 3H), 2.11 (s, 3H). ESI-MS: 430.10 (M+H)+. 2-methyl-3-{[2-(1-methylpyrazol-4-yl)-4-pyridyl]oxy}-N-(4-pyridylmethyl) benzamide (121): Petition 870260063548, dated 06 / 26 / 2026, p. 144 / 639 138 / 316

[0192] Compound 121 was synthesized from intermediate 119a (0.10 mmol) and 4-(aminomethyl)pyridine (0.12 mmol) as a white solid with a yield of 69% according to the general C2 method. 1H NMR (400 MHz, DMSOd6) δ (ppm): 9.04 (t, J = 6.0 Hz, 1H), 8.54-8.52 (m, 2H), 8.36 (d, J = 5.7 Hz, 1H), 8.25 (s, 1H), 7.96 (s, 1H), 7.43-7.32 (m, 4H), 7.25-7.22 (m, 2H), 6.49 (dd, J = 5.7 Hz, 2.4 Hz, 1H), 4.48 (d, J = 6.0 Hz, 2H), 3.86 (s, 3H), 2.15 (s, 3H). ESI-MS: 400.05 (M+H)+. 2-methyl-3-{[2-(1-methylpyrazol-4-yl)-4-pyridyl]oxy}-N-(3-pyridylmethyl) benzamide (122):

[0193] Compound 122 was synthesized from intermediate 119a (0.10 mmol) and 3-(aminomethyl)pyridine (0.12 mmol) as a white solid with a yield of 59% according to the general C2 method. 1H NMR (400 MHz, DMSOd6) δ (ppm): 9.00 (t, J = 5.9 Hz, 1H), 8.57 (d, J = 1.7 Hz, 1H), 8.48 (dd, J = 4.7 Hz, 1.4 Hz, 1H), 8.35 (d, J = 5.7 Hz, 1H), 8.25 (s, 1H), 7.96 (s, 1H), 7.76 (dt, J = 7.8 Hz, 1.8 Hz, 1H) 7.43-7.30 (m, 3H), 7.27-7.20 (m, 2H), 6.47 (dd, J = 5.7 Hz, 2.4 Hz, 1H), 4.48 (d, J = 5.9 Hz, 2H), 3.86 (s, 3H), 2.12 (s, 3H). ESI-MS: 400,10 (M+H)+ N-[(3,5-difluorophenyl)methyl]-2-methyl-3-{[2-(1-methylpyrazol-4-yl)-4-pyridyl]oxy}benzamide (123):

[0194] Compound 123 was synthesized from intermediate 119a (0.10 mmol) and 3,5-difluorobenzylamine (0.12 mmol) as a white solid with an 85% yield according to the general C2 method. 1H NMR (400 MHz, DMSOd6) δ (ppm): 9.01 (t, J = 6.0 Hz, 1H), 8.36 (d, J = 5.7 Hz, 1H), 8.25 (s, 1H), 7.96 (s, 1H), 7.42-7.34 (m, 2H), 7.26-7.22 (m, 2H), 7.17-7.03 (m, 3H), 6.48 (dd, J = 5.7 Hz, 2.4 Hz, 1H), 4.48 (d, J = 6.0 Hz, 2H), 3.86 (s, 3H), 2.14 (s, 3H). Petition 870260063548, dated 06 / 26 / 2026, p. 145 / 639 139 / 316 ESI-MS: 435.15 (M+H)+. N-[(3-fluorophenyl)methyl]-2-methyl-3-{[2-(1-methylpyrazol-4-yl)-4-pyridyl]oxy} benzamide (124):

[0195] Compound 124 was synthesized from intermediate 119a (0.10 mmol) and 3-fluorobenzylamine (0.12 mmol) as a white solid with a yield of 82% according to the general C2 method. 1H NMR (400 MHz, DMSOd6) δ (ppm): 8.98 (t, J = 6.0 Hz, 1H), 8.35 (d, J = 5.7 Hz, 1H), 8.25 (s, 1H), 7.96 (d, J = 0.5 Hz, 1H), 7.43-7.31 (m, 3H), 7.26-7.13 (m, 4H), 7.09 (td, J = 8.4 Hz, 2.3 Hz, 1H), 6.48 (dd, J = 5.7 Hz, 2.4 Hz, 1H), 4.47 (d, J = 6.0 Hz, 2H), 3.86 (s, 3H), 2.14 (s, 3H). ESI-MS: 417.20 (M+H)+ N-[(4-fluorophenyl)methyl]-2-methyl-3-{[2-(1-methylpyrazol-4-yl)-4-pyridyl]oxy} benzamide (125):

[0196] Compound 125 was synthesized from intermediate 119a (0.10 mmol) and 4-fluorobenzylamine (0.12 mmol) as a white solid with a yield of 92% according to the general C2 method. 1H NMR (400 MHz, DMSOd6) δ (ppm): 8.94 (t, J = 6.0 Hz, 1H), 8.35 (d, J = 5.7 Hz, 1H), 8.25 (s, 1H), 7.96 (d, J = 0.5 Hz, 1H), 7.43-7.30 (m, 4H), 7.26-7.14 (m, 4H), 6.47 (dd, J = 5.7 Hz, 2.4 Hz, 1H), 4.43 (d, J = 6.0 Hz, 2H), 3.86 (s, 3H), 2.12 (s, 3H). ESI-MS: 417.15 (M+H)+ N-[(3-chlorophenyl)methyl]-2-methyl-3-{[2-(1-methylpyrazol-4-yl)-4-pyridyl]oxy} benzamide (126): Petition 870260063548, dated 06 / 26 / 2026, p. 146 / 639 140 / 316

[0197] Compound 126 was synthesized from intermediate 119a (0.10 mmol) and 3-chlorobenzylamine (0.12 mmol) as a white solid with a yield of 72% according to the general C2 method. 1H NMR (400 MHz, DMSOd6) δ (ppm): 8.98 (t, J = 6.0 Hz, 1H), 8.35 (d, J = 5.7 Hz, 1H), 8.25 (s, 1H), 7.96 (s, 1H), 7.44-7.30 (m, 6H), 7.25 (d, J = 2.4 Hz, 1H), 7.22 (dd, J = 7.8 Hz, 1.2 Hz, 1H), 6.48 (dd, J = 5.7 Hz, 2.4 Hz, 1H), 4.46 (d, J = 6.0 Hz, 2H), 3.86 (s, 3H), 2.13 (s, 3H). ESI-MS: 433.15 (M+H)+. N-[(4-chlorophenyl)methyl]-2-methyl-3-{[2-(1-methylpyrazol-4-yl)-4-pyridyl]oxy} benzamide (127):

[0198] Compound 127 was synthesized from intermediate 119a (0.10 mmol) and 4-chlorobenzylamine (0.12 mmol) as a white solid with a yield of 83% according to the general C2 method. 1H NMR (400 MHz, DMSOd6) δ (ppm): 8.97 (t, J = 6.0 Hz, 1H), 8.35 (d, J = 5.7 Hz, 1H), 8.25 (s, 1H), 7.96 (s, 1H), 7.45-7.30 (m, 6H), 7.25-7.20 (m, 2H), 6.48 (dd, J = 5.7 Hz, 2.4 Hz, 1H), 4.44 (d, J = 6.0 Hz, 2H), 3.86 (s, 3H), 2.13 (s, 3H). ESI-MS: 433.05 (M+H)+ N-[(2,4-difluorophenyl)methyl]-2-methyl-3-{[2-(1-methylpyrazol-4-yl)-4-pyridyl]oxy}benzamide (128):

[0199] Compound 128 was synthesized from intermediate 119a (0.065 mmol) and 2,4-difluorobenzylamine (0.097 mmol) as a white solid with a yield of 53% according to the general C2 method. 1H NMR (400 MHz, DMSOd6) δ (ppm): 8.93 (t, J = 5.6 Hz, 1H), 8.35 (d, J = 5.7 Hz, 1H), 8.25 (s, 1H), 7.96 (s, 1H), 7.51-7.43 (m, 1H), 7.40-7.18 (m, 5H), 7.09 (dd, J = 8.5 Hz, 7.0 Hz, 1H), 6.47 (dd, J = 5.6 Hz, 2.2 Hz, 1H), 4.46 (d, J = 5.5 Hz, 2H), 3.86 (s, 3H), 2.11 (s, 3H). ESI-MS: 435.15 (M+H)+ N-[(3,4-difluorophenyl)methyl]-2-methyl-3-{[2-(1-methylpyrazol-4-yl)-4-pyridyl] Petition 870260063548, dated 06 / 26 / 2026, p. 147 / 639 141 / 316 oxybenzamide (129):

[0200] Compound 129 was synthesized from intermediate 119a (0.065 mmol) and 3,4-difluorobenzylamine (0.097 mmol) as a white solid with a yield of 57% according to the general C2 method. 1H NMR (400 MHz, DMSOd6) δ (ppm): 8.98 (t, J = 6.0 Hz, 1H), 8.35 (d, J = 5.7 Hz, 1H), 8.25 (s, 1H), 7.96 (s, 1H), 7.47-7.30 (m, 4H), 7.27-7.17 (m, 3H), 6.48 (dd, J = 5.7 Hz, 2.4 Hz, 1H), 4.44 (d, J = 6.0 Hz, 2H), 3.86 (s, 3H), 2.13 (s, 3H). ESI-MS: 435.15 (M+H)+. N-[(4-chloro-3-fluoro-phenyl)methyl]-2-methyl-3-{[2-(1-methylpyrazol-4-yl)-4pyridyl]oxy}benzamide (130):

[0201] Compound 130 was synthesized from intermediate 119a (0.065 mmol) and 4-chloro-3-fluorobenzylamine (0.097 mmol) as a white solid with a yield of 34% according to the general C2 method. 1H NMR (400 MHz, DMSOd6) δ (ppm): 9.00 (t, J = 6.0 Hz, 1H), 8.35 (d, J = 5.7 Hz, 1H), 8.25 (s, 1H), 7.96 (s, 1H), 7.58 (t, J = 8.0 Hz, 1H), 7.43-7.32 (m, 3H), 7.28-7.18 (m, 3H), 6.48 (dd, J = 5.7 Hz, 2.4 Hz, 1H), 4.46 (d, J = 6.0 Hz, 2H), 3.86 (s, 3H), 2.13 (s, 3H). ESI-MS: 451.10 (M+H)+ N-(imidazo[1,2-a]pyridin-6-ylmethyl)-2-methyl-3-{[2-(1-methylpyrazol-4-yl)-4pyridyl]oxy}benzamide (131):

[0202] Compound 131 was synthesized from intermediate 119a (0.065 mmol) and imidazo[1,2-a]pyridin-6-ylmethanamine (0.097 mmol) as a white solid in a 57% yield according to the general C2 method. 1H NMR (400 MHz, Petition 870260063548, dated 06 / 26 / 2026, p. 148 / 639 142 / 316 DMSO-d6) δ (ppm): 8.97 (t, J = 5.9 Hz, 1H), 8.51 (s, 1H), 8.35 (d, J = 5.7 Hz, 1H), 8.25 (s, 1H), 7.97-7.95 (m, 2H), 7.57-5.55 (m, 2H), 7.41 -7.32 (m, 2H), 7.26-7.20 (m, 3H), 6.47 (dd, J = 5.7 Hz, 2.4 Hz, 1H), 4.45 (d, J = 5.8 Hz, 2H), 3.86 (s, 3H), 2.13 (s, 3H). ESI-MS: 439.15 (M+H)+. N-(imidazo[1,2-a]piridin-7-ilmetil)-2-metil-3-{[2-(1-metilpirazol-4-il)-4piridil]oxy}benzamida (132):

[0203] Compound 132 was synthesized from intermediate 119a (0.065 mmol) and imidazo[1,2-a]pyridin-7-ylmethanamine (0.097 mmol) as a white solid in 50% yield according to the general C2 method. 1H NMR (400 MHz, DMSO-d6) δ (ppm): 9.01 (t, J = 6.0 Hz, 1H), 8.51 (d, J = 7.0 Hz, 1H), 8.36 (d, J = 5.7 Hz, 1H), 8.25 (s, 1H), 7.96 (s, 1H), 7.90 (s, 1H) Hz, 2.4Hz, 1H), 4.49 (d, J = 5.9 Hz, 2H), 3.86 (s, 3H), 2.15 (s, 3H). ESI-MS: 439.15 (M+H)+ 2-methyl-3-{[2-(1-methylpyrazol-4-yl)-4-pyridyl]oxy}-N-{[6-(trifluoromethyl)-3pyridyl]methyl}benzamide (133):

[0204] Compound 133 was synthesized from intermediate 119a (0.065 mmol) and [6-(trifluoromethyl)-3-pyridyl]methanamine (0.097 mmol) as a white solid with a yield of 79% according to the general C2 method. 1H NMR (400 MHz, DMSO-d6) δ (ppm): 9.09 (t, J = 5.9 Hz, 1H), 8.76 (s, 1H), 8.35 (d, J = 5.7 Hz, 1H), 8.25 (s, 1H), 8.08-8.02 (m, 1H), 7.96 (s, 1H), 7.92 (d, J = 8.1 Hz, 1H), 7.437.35 (m, 2H), 7.27-7.20 (m, 2H), 6.48 (dd, J = 5.7 Hz, 2.4 Hz, 1H), 4.59 (d, J = 5.8 Hz, 2H), 3.86 (s, 3H), 2.14 (s, 3H). ESI-MS: 468.15 (M+H)+ Petition 870260063548, dated 06 / 26 / 2026, p. 149 / 639 143 / 316 N-[(2,3-difluorophenyl)methyl]-2-methyl-3-{[2-(1-methylpyrazol-4-yl)-4-pyridyl]oxy}benzamide (134):

[0205] Compound 134 was synthesized from intermediate 119a (0.074 mmol) and 2,3-difluorobenzylamine (0.111 mmol) as a white solid in 60% yield according to the general C2 method. 1H NMR (400 MHz, DMSOd6) δ (ppm): 8.97 (t, J = 5.8 Hz, 1H), 8.35 (d, J = 5.7 Hz, 1H), 8.24 (s, 1H), 7.95 (d, J = 0.6 Hz, 1H), 7.40-7.29 (m, 3H), 7.28-7.18 (m, 4H), 6.48 (dd, J = 5.7 Hz, 2.4 Hz, 1H), 4.53 (d, J = 5.8 Hz, 2H), 3.86 (s, 3H), 2.13 (s, 3H). ESI-MS: 435.15 (M+H)+. N-[(3-methoxyphenyl)methyl]-2-methyl-3-{[2-(1-methylpyrazol-4-yl)-4-pyridyl]oxy}benzamide (135):

[0206] Compound 135 was synthesized from intermediate 119a (0.074 mmol) and 3-methoxybenzylamine (0.111 mmol) as a white solid with a yield of 78% according to the general C2 method. 1H NMR (400 MHz, DMSOd6) δ (ppm): 8.90 (t, J = 6.0 Hz, 1H), 8.35 (d, J = 5.7 Hz, 1H), 8.24 (s, 1H), 7.95 (d, J = 0.6 Hz, 1H), 7.43-7.16 (m, 5H), 6.98-6.90 (m, 2H), 6.86-6.80 (m, 1H), 6.49 (dd, J = 5.7 Hz, 2.4 Hz, 1H), 4.44 (d, J = 6.0 Hz, 2H), 3.86 (s, 3H), 3.74 (s, 3H), 2.14 (s, 3H). ESI-MS: 429.20 (M+H)+ N-[(4-methoxyphenyl)methyl]-2-methyl-3-{[2-(1-methylpyrazol-4-yl)-4-pyridyl]oxy}benzamide (136): Petition 870260063548, dated 06 / 26 / 2026, p. 150 / 639 144 / 316

[0207] Compound 136 was synthesized from intermediate 119a (0.074 mmol) and 4-methoxybenzylamine (0.111 mmol) as a white solid with a yield of 63% according to the general C2 method. 1H NMR (400 MHz, DMSOd6) δ (ppm): 8.83 (t, J = 6.0 Hz, 1H), 8.35 (d, J = 5.7 Hz, 1H), 8.24 (s, 1H), 7.95 (d, J = 0.6 Hz, 1H), 7.36 (t, J = 7.8 Hz, 1H), 7.30-7.18 (m, 5H), 6.92-6.88 (m, 2H), 6.48 (dd, J = 5.7 Hz, 2.4 Hz, 1H), 4.38 (d, J = 6.0 Hz, 2H), 3.86 (s, 3H), 3.73 (s, 3H), 2.12 (s, 3H). ESI-MS: 429.15 (M+H)+. N-[(5-fluoro-3-pyridyl)methyl]-2-methyl-3-{[2-(1-methylpyrazol-4-yl)-4-pyridyl]oxy}benzamide (137):

[0208] Compound 137 was synthesized from intermediate 119a (0.10 mmol) and 5-fluoro-3-pyridinomethanamine (0.15 mmol) as a white solid in 50% yield according to the general C2 method. 1H NMR (400 MHz, DMSO-d6) δ (ppm): 9.01 (t, J = 5.9 Hz, 1H), 8.52-8.45 (m, 2H), 8.36 (d, J = 5.7 Hz, 1H), 8.24 (s, 1H), 7.95 (d, J = 0.6 Hz, 1H), 7.71-7.64 (m, 1H), 7.41-7.33 (m, 2H), 7.27-7.20 (m, 2H), 6.48 (dd, J = 5.7 Hz, 2.4 Hz, 1H), 4.53 (d, J = 5.9 Hz, 2H), 3.86 (s, 3H), 2.13 (s, 3H). ESI-MS: 418.15 (M+H)+ N-[(5-fluoro-6-methoxy-3-pyridyl)methyl]-2-methyl-3-{[2-(1-methylpyrazol-4-yl)-4pyridyl]oxy}benzamide (138):

[0209] Compound 138 was synthesized from intermediate 119a (0.10 mmol) and (5-fluoro-6-methoxy-3-pyridyl)methanamine (0.15 mmol) as a white solid with a yield of 62% according to the general C2 method. 1H NMR (400 MHz, DMSO-d6) δ (ppm): 8.91 (t, J = 5.9 Hz, 1H), 8.35 (d, J = 5.7 Hz, 1H), 8.24 (s, 1H), 7.98-7.95 (m, 2H), 7.65 (dd, J = 11.4 Hz, 1.9 Hz, 1H), 7.42-7.31 (m, 2H), Petition 870260063548, dated 06 / 26 / 2026, p. 151 / 639 145 / 316 7.26-7.19 (m, 2H), 6.48 (dd, J = 5.7 Hz, 2.4 Hz, 1H), 4.41 (d, J = 5.9 Hz, 2H), 3.93 (s, 3H), 3.86 (s, 3H), 2.12 (s, 3H). ESI-MS: 448.15 (M+H)+. N-[(5-fluoro-2-methoxy-3-pyridyl)methyl]-2-methyl-3-{[2-(1-methylpyrazol-4-yl)-4pyridyl]oxy}benzamide (139):

[0210] Compound 139 was synthesized from intermediate 119a (0.10 mmol) and 5-fluoro-2-methoxy-3-pyridinomethanamine (0.24 mmol) as a white solid in 40% yield according to the general C2 method. 1H NMR (400 MHz, DMSO-d6) δ (ppm): 8.85 (t, J = 5.7 Hz, 1H), 8.36 (d, J = 5.7 Hz, 1H), 8.24 (s, 1H), 8.07 (d, J = 3.0 Hz, 1H), 7.96 (d, J = 0.6 Hz, 1H), 7.57 (dd, J = 8.6 Hz, 3.0 Hz, 1H), 7.41-7.36 (m, 2H), 7.24-7.21 (m, 2H), 6.49 (dd, J = 5.7 Hz, 2.4 Hz, 1H), 4.39 (d, J = 5.7 Hz, 2H), 3.91 (s, 3H), 3.86 (s, 3H), 2.15 (s, 3H). ESI-MS: 448.20 (M+H)+ N-[(3-fluoro-4-methoxy-phenyl)methyl]-2-methyl-3-{[2-(1-methylpyrazol-4-yl)-4pyridyl]oxy}benzamide (140):

[0211] Compound 140 was synthesized from intermediate 119a (0.10 mmol) and (3-fluoro-4-methoxyphenyl)methanamine (0.15 mmol) as a white solid with a yield of 58% according to the general C2 method. 1H NMR (400 MHz, DMSO-d6) δ (ppm): 8.88 (t, J = 6.0 Hz, 1H), 8.35 (d, J = 5.7 Hz, 1H), 8.24 (s, 1H), 7.95 (d, J = 0.6 Hz, 1H), 7.37 (t, J = 7.8 Hz, 1H), 7.31 (dd, J = 7.6 Hz, 1.3 Hz, 1H), 7.24-7.09 (m, 5H), 6.48 (dd, J = 5.7 Hz, 2.4 Hz, 1H), 4.39 (d, J = 6.0 Hz, 2H), 3.86 (s, 3H), 3.82 (s, 3H), 2.13 (s, 3H). ESI-MS: 447.20 (M+H)+ N-[(4-fluoro-3-methoxy-phenyl)methyl]-2-methyl-3-{[2-(1-methylpyrazol-4-yl)-4pyridyl]oxy}benzamide (141): Petition 870260063548, dated 06 / 26 / 2026, p. 152 / 639 146 / 316

[0212] Compound 141 was synthesized from intermediate 119a (0.10 mmol) and 5-(aminomethyl)-2-fluoroanisole (0.15 mmol) as a white solid with a 70% yield according to the general C2 method. 1H NMR (400 MHz, DMSOd6) δ (ppm): 8.90 (t, J = 6.0 Hz, 1H), 8.35 (d, J = 5.7 Hz, 1H), 8.24 (s, 1H), 7.95 (d, J = 0.6 Hz, 1H), 7.42-7.30 (m, 2H), 7.25-7.12 (m, 4H), 6.92-6.88 (m, 1H), 6.49 (dd, J = 5.7 Hz, 2.4 Hz, 1H), 4.43 (d, J = 6.0 Hz, 2H), 3.86 (s, 3H), 3.82 (s, 3H), 2.14 (s, 3H). ESI-MS: 447.20 (M+H)+. N-(cyclohexylmethyl)-2-methyl-3-{[2-(1-methylpyrazol-4-yl)-4-pyridyl]oxy} benzamide (142):

[0213] Compound 142 was synthesized from intermediate 119a (0.10 mmol) and 1-cyclohexylmethanamine (0.15 mmol) as a white solid with a yield of 69% according to the general C2 method. 1H NMR (400 MHz, DMSOd6) δ (ppm): 8.36-3.81 (m, 2H), 8.24 (s, 1H), 7.96 (s, 1H), 7.35 (t, J = 7.8 Hz, 1H), 7.27-7.22 (m, 2H), 7.18 (d, J = 8.0 Hz, 1H), 6.48 (dd, J = 5.7 Hz, 2.4 Hz, 1H), 3.87 (s, 3H), 3.09 (t, J = 6.4 Hz, 2H), 2.13 (s, 3H), 1.77-1.47 (m, 6H), 1.27-1.12 (m, 3H), 0.99-0.89 (m, 2H). ESI-MS: 405.20 (M+H)+ 2-methyl-3-{[2-(1-methylpyrazol-4-yl)-4-pyridyl]oxy}-N-(tetrahydropyran-4ylmethyl)benzamide (143):

[0214] Compound 143 was synthesized from intermediate 119a (0.10 mmol) and 4-(aminomethyl)tetrahydropyran (0.15 mmol) as a white solid with Petition 870260063548, dated 06 / 26 / 2026, p. 153 / 639 147 / 316 has a 71% return on the keyboard on the C2 device. 1H NMR (400 MHz, DMSO-d6) δ (ppm): 8.39 (t, J = 5.8 Hz, 1H), 8.36 (d, J = 5.7 Hz, 1H), 8.24 (s, 1H), 7.96 (d, J = 0.6 Hz, 1H), 7.35 (t, J = 7.7 Hz, 1H), 7.28-7.21 (m, 2H), 7.19 (dd, J = 8.0 Hz, 1.0 Hz, 1H), 6.48 (dd, J = 5.7 Hz, 2.4 Hz, 1H), 3.89-3.82 (m, 5H), 3.27-3.24 (m, 2H), 3.18-3.12 (m, 2H), 2.13 (s, 3H), 1.80-1.74 (m, 1H), 1.63-1.60 (m, 2H), 1,261.16 (m, 2H). ESI-MS: 407.15 (M+H)+. N-[(1 R)-1 -ciclo-hexiletil]-2-metil-3-{[2-(1-metilpirazol-4-il)-4-piridil]oxi} benzamida (144):

[0215] Compound 144 was synthesized from intermediate 119a (0.10 mmol) and (R)-1-cyclohexylethanolamine (0.15 mmol) as a white solid in 60% yield according to the general C2 method. 1H NMR (400 MHz, DMSOd6) δ (ppm): 8.36 (d, J = 5.7 Hz, 1H), 8.25 (s, 1H), 8.15 (d, J = 8.7 Hz, 1H), 7.96 (d, J = 0.5 Hz, 1H), 7.35 (t, J = 7.8 Hz, 1H), 7.27-7.14 (m, 3H), 6.48 (dd, J = 5.7 Hz, 2.4 Hz, 1H), 3.92-3.76 (m, 4H), 2.12 (s, 3H), 1.83-1.57 (m, 5H), 1.38-1.33 (m, 1H), 1,240.92 (m, 8H). ESI-MS: 419.20 (M+H)+ N-[(1S)-1-cyclohexylethyl]-2-methyl-3-{[2-(1-methylpyrazol-4-yl)-4-pyridyl]oxy} benzamide (145):

[0216] Compound 145 was synthesized from intermediate 119a (0.10 mmol) and (S)-1-cyclohexylethanolamine (0.15 mmol) as a white solid with a yield of 54% according to the general C2 method. 1H NMR (400 MHz, DMSOd6) δ (ppm): 8.36 (d, J = 5.7 Hz, 1H), 8.25 (s, 1H), 8.15 (d, J = 8.8 Hz, 1H), 7.96 (s, 1H), 7.35 (t, J = 7.7 Hz, 1H), 7.26-7.15 (m, 3H), 6.48 (dd, J = 5.7 Hz, 2.4 Hz, 1H), Petition 870260063548, dated 06 / 26 / 2026, p. 154 / 639 148 / 316 3.90-3.75 (m, 4H), 2.12 (s, 3H), 1.82-1.58 (m, 5H), 1.42-1.33 (m, 1H), 1.24-1.06 (m, 6H), 1.03-0.94 (m, 2H). ESI-MS: 419.20 (M+H)+. 2-methyl-N-[(1-methylpyrazol-4-yl)methyl]-3-{[2-(1-methylpyrazol-4-yl)-4pyridyl]oxy}benzamide (146):

[0217] Compound 146 was synthesized from intermediate 119a (0.10 mmol) and C-(1-methyl-1H-pyrazol-4-yl)-methylamine (0.15 mmol) as a white solid with a yield of 62% according to the general C2 method. 1H NMR (400 MHz, DMSO-d6) δ (ppm): 8.69 (t, J = 5.7 Hz, 1H), 8.35 (d, J = 5.7 Hz, 1H), 8.24 (s, 1H), 7.95 (d, J = 0.6 Hz, 1H), 7.61 (s, 1H), 7.37-7.32 (m, 2H), 7.27 (dd, J = 7.6 Hz, 1.2 Hz, 1H), 7.22 (d, J = 2.3 Hz, 1H), 7.18 (dd, J = 8.0 Hz, 1.1 Hz, 1H), 6.47 (dd, J = 5.7 Hz, 2.4 Hz, 1H), 4.27 (d, J = 5.7 Hz, 2H), 3.86 (s, 3H), 3.79 (s, 3H), 2.12 (s, 3H). ESI-MS: 403.15 (M+H)+ 2-methyl-N-[(2-methylpyrazol-3-yl)methyl]-3-{[2-(1-methylpyrazol-4-yl)-4pyridyl]oxy}benzamide (147):

[0218] Compound 147 was synthesized from intermediate 119a (0.10 mmol) and C-(2-methyl-2H-pyrazol-3-yl)-methylamine (0.15 mmol) as a white solid with a yield of 69% according to the general C2 method. 1H NMR (400 MHz, DMSO-d6) δ (ppm): 8.89 (t, J = 5.7 Hz, 1H), 8.35 (d, J = 5.7 Hz, 1H), 8.24 (s, 1H), 7.95 (d, J = 0.6 Hz, 1H), 7.36 (t, J = 7.8 Hz, 1H), 7.32-7.28 (m, 2H), 7.23 (d, J = 2.3 Hz, 1H), 7.21 (dd, J = 7.9 Hz, 1.2 Hz, 1H), 6.48 (dd, J = 5.7 Hz, 2.4 Hz, 1H), 6.19 (d, J = 1.8 Hz, 1H), 4.51 (d, J = 5.7 Hz, 2H), 3.86 (s, 3H), 3.83 (s, 3H), 2.13 (s, 3H). ESI-MS: 403.20 (M+H)+ 2-methyl-N-[(1-methylpyrazol-3-yl)methyl]-3-{[2-(1-methylpyrazol-4-yl)-4pyridyl]oxy}benzamide (148): Petition 870260063548, dated 06 / 26 / 2026, p. 155 / 639 149 / 316

[0219] Compound 148 was synthesized from intermediate 119a (0.10 mmol) and (1-methyl-1H-pyrazol-3-yl)methanamine (0.15 mmol) as a white solid with a yield of 72% according to the general C2 method. 1H NMR (400 MHz, DMSO-d6) δ (ppm): 8.74 (t, J = 5.9 Hz, 1H), 8.35 (d, J = 5.7 Hz, 1H), 8.24 (s, 1H), 7.95 (d, J = 0.6 Hz, 1H), 7.59 (d, J = 2.1 Hz, 1H), 7.35 (t, J = 7.7 Hz, 1H), 7.27 (dd, J = 7.6 Hz, 1.2 Hz, 1H), 7.22 (d, J = 2.3 Hz, 1H), 7.18 (dd, J = 7.9 Hz, 1.1 Hz, 1H), 6.49 (dd, J = 5.7 Hz, 2.4Hz, 1H), 6.16 (d, J = 2.2 Hz, 1H), 4.38 (d, J = 5.9 Hz, 2H), 3.86 (s, 3H), 3.78 (s, 3H), 2.13 (s, 3H). ESI-MS: 403.15 (M+H)+. N-[(4-fluoro-3-methyl-phenyl)methyl]-2-methyl-3-{[2-(1-methylpyrazol-4-yl)-4pyridyl]oxy}benzamide (149):

[0220] Compound 149 was synthesized from intermediate 119a (0.10 mmol) and (4-fluoro-3-methylphenyl)methanamine (0.15 mmol) as a white solid with a yield of 67% according to the general C2 method. 1H NMR (400 MHz, DMSO-d6) δ (ppm): 8.88 (t, J = 6.0 Hz, 1H), 8.35 (d, J = 5.7 Hz, 1H), 8.24 (s, 1H), 7.95 (s, 1H), 7.42-7.29 (m, 2H), 7.28-7.16 (m, 4H), 7.13-7.06 (m, 1H), 6.48 (dd, J = 5.7 Hz, 2.4 Hz, 1H), 4.40 (d, J = 6.0 Hz, 2H), 3.86 (s, 3H), 2.22 (d, J = 1.5 Hz, 3H), 2.13 (s, 3H). ESI-MS: 431.15 (M+H)+ N-[(3-fluoro-4-methyl-phenyl)methyl]-2-methyl-3-{[2-(1-methylpyrazol-4-yl)-4pyridyl]oxy}benzamide (150): Petition 870260063548, dated 06 / 26 / 2026, p. 156 / 639 150 / 316

[0221] Compound 150 was synthesized from intermediate 119a (0.10 mmol) and 3-fluoro-4-methylbenzylamine (0.15 mmol) as a white solid with a yield of 69% according to the general C2 method. 1H NMR (400 MHz, DMSOd6) δ (ppm): 8.91 (t, J = 6.0 Hz, 1H), 8.35 (d, J = 5.7 Hz, 1H), 8.24 (s, 1H), 7.95 (d, J = 0.6 Hz, 1H), 7.40-7.30 (m, 2H), 7.27-7.17 (m, 3H), 7.13-7.07 (m, 2H), 6.49 (dd, J = 5.7 Hz, 2.4 Hz, 1H), 4.42 (d, J = 6.0 Hz, 2H), 3.86 (s, 3H), 2.21 (d, J = 1.2 Hz, 3H), 2.13 (s, 3H). ESI-MS: 431.15 (M+H)+. 2-methyl-3-{[2-(1-methylpyrazol-4-yl)-4-pyridyl]oxy}-N-[(2-oxo-1H-pyridin-3yl)methyl]benzamide (151):

[0222] Compound 151 was synthesized from intermediate 119a (0.10 mmol) and 3-(aminomethyl)-2(1H)-pyridinone (0.24 mmol) as a white solid with a 40% yield according to the general C2 method. 1H NMR (400 MHz, DMSO-d6) δ (ppm): 11.62 (bs, 1H), 8.66 (t, J = 5.8 Hz, 1H), 8.36 (d, J = 5.7 Hz, 1H), 8.24 (s, 1H), 7.96 (d, J = 0.6 Hz, 1H), 7.37-7.35 (m, 3H), 7.30 (dd, J = 6.5 Hz, 2.0 Hz, 1H), 7.25-7.18 (m, 2H), 6.49 (dd, J = 5.7 Hz, 2.4 Hz, 1H), 6.20 (t, J = 6.6 Hz, 1H), 4.21 (d, J = 5.8 Hz, 2H), 3.86 (s, 3H), 2.15 (s, 3H). ESI-MS: 416.15 (M+H)+ 2-methyl-N-[(1-methyl-2-oxo-3-piperidyl)methyl]-3-{[2-(1-methylpyrazol-4-yl)-4pyridyl]oxy}benzamide(152):

[0223] Compound 152 was synthesized from intermediate 119a (0.10 mmol) and 3-(aminomethyl)-1-methyl-2-piperidinone (0.24 mmol) as a white solid with a yield of 69% according to the general C2 method. 1H NMR (400 MHz, DMSO-d6) δ (ppm): 8.36 (d, J = 5.7 Hz, 1H), 8.30 (t, J = 5.8 Hz, 1H), 8.24 (s, 1H), 7.96 (s, 1H), 7.35 (t, J = 7.8 Hz, 1H), 7.28 (d, J = 6.6 Hz, 1H), 7.23 (d, J = 2.4 Hz, Petition 870260063548, dated 06 / 26 / 2026, p. 157 / 639 151 / 316 1H), 7.19 (d, J = 7.9 Hz, 1H), 6.49 (dd, J = 5.7 Hz, 2.4 Hz, 1H), 3.87 (s, 3H), 3.673.61 (m, 1H), 3.41-3.33 (m, 2H), 3.27-3.20 (m, 2H), 2.81 (s, 3H), 2.13 (s, 3H), 1,921.84 (m, 2H), 1.72-1.54 (m, 2H). ESI-MS: 434.20 (M+H)+. 2-methyl-N-[(1-methyl-2-oxo-3-pyridyl)methyl]-3-{[2-(1-methylpyrazol-4-yl)-4pyridyl]oxy}benzamide(153):

[0224] Compound 153 was synthesized from intermediate 119a (0.07 mmol) and 3-(aminomethyl)-1-methyl-2(1H)-pyridinone (0.15 mmol) as a white solid with a yield of 53% according to the general C2 method. 1H NMR (400 MHz, DMSO-d6) δ (ppm): 8.69 (t, J = 5.8 Hz, 1H), 8.36 (d, J = 5.8 Hz, 1H), 8.25 (s, 1H), 7.96 (d, J = 0.7 Hz, 1H), 7.63 (dd, J = 6.7 Hz, 1.9 Hz, 1H), 7.41-7.33 (m, 3H), 7.27-7.18 (m, 2H), 6.49 (dd, J = 5.7 Hz, 2.4 Hz, 1H), 6.24 (t, J = 6.8 Hz, 1H), 4.24 (d, J = 5.8 Hz, 2H), 3.86 (s, 3H), 3.46 (s, 3H), 2.15 (s, 3H). ESI-MS: 430.20 (M+H)+ N-[(5-fluoro-2-pyridyl)methyl]-2-methyl-3-{[2-(1-methylpyrazol-4-yl)-4-pyridyl]oxy}benzamide (154):

[0225] Compound 154 was synthesized from intermediate 119a (0.06 mmol) and 5-fluoro-2-pyridinomethanamine (0.10 mmol) as a white solid with a yield of 41% according to the general C2 method. 1H NMR (400 MHz, DMSO-d6) δ (ppm): 8.99 (t, J = 6.0 Hz, 1H), 8.52 (d, J = 2.9 Hz, 1H), 8.36 (d, J = 5.7 Hz, 1H), 8.24 (s, 1H), 7.96 (s, 1H), 7.73 (td, J = 8.8 Hz, 3.0 Hz, 1H), 7.47 (dd, J = 8.7 Hz, 4.5 Hz, 1H), 7.43-7.35 (m, 2H), 7.28-7.19 (m, 2H), 6.49 (dd, J = 5.7 Hz, 2.4 Hz, 1H), 4.54 (d, J = 6.0 Hz, 2H), 3.86 (s, 3H), 2.16 (s, 3H). ESI-MS: 418.20 (M+H)+ Petition 870260063548, dated 06 / 26 / 2026, p. 158 / 639 152 / 316 N-[(6-dimethylphosphoryl-3-pyridyl)methyl]-2-methyl-3-{[2-(1-methylpyrazol-4-yl)-4pyridyl]oxy}benzamide(155):

[0226] Compound 155 was synthesized from intermediate 119a (0.10 mmol) and (5-(aminomethyl)pyridin-2-yl)dimethylphosphine oxide (0.29 mmol) as a white solid with a yield of 78% according to the general C2 method. 1H NMR (400 MHz, DMSO-d,) δ (ppm): 9.04 (t, J = 5.9 Hz, 1H), 8.75 (s, 1H), 8.35 (d, J = 5.7 Hz, 1H), 8.24 (s, 1H), 7.98-7.90 (m, 3H), 7.44-7.33 (m, 2H), 7.24-7.21 (m, 2H), 6.48 (dd, J = 5.7 Hz, 2.4 Hz, 1H), 4.54 (d, J = 5.9 Hz, 2H), 3.86 (s, 3H), 2.14 (s, 3H), 1.66 (s, 3H), 1.63 (s, 3H).31P NMR (162 MHz, DMSO-d6) δ (ppm): 33.89. ESI-MS: 476.10 (M+H)+. N-[(3,5-difluorophenyl)methyl]-4-methyl-3-{[2-(1-methylpyrazol-4-yl)-4-pyridyl]oxy}benzamide (156):

[0227] Compound 156 was synthesized from intermediate 119b (0.10 mmol) and 3,5-difluorobenzylamine (0.15 mmol) as a white solid with a yield of 67% according to the general C2 method. 1H NMR (400 MHz, DMSOd6) δ (ppm): 9.10 (t, J = 6.0 Hz, 1H), 8.36 (d, J = 5.7 Hz, 1H), 8.25 (s, 1H), 7.97 (d, J = 0.7 Hz, 1H), 7.79 (dd, J = 7.9 Hz, 1.7 Hz, 1H), 7.64 (d, J = 1.7 Hz, 1H), 7.51 (d, J = 8.3 Hz, 1H), 7.29-7.20 (m, 1H), 7.13-7.05 (m, 1H), 7.04-6.98 (m, 2H), 6.55 (dd, J = 5.7 Hz, 2.4Hz, 1H), 4.46 (d, J = 5.9 Hz, 2H), 3.86 (s, 3H), 2.20 (s, 3H). ESI-MS: 435.00 (M+H)+ Petition 870260063548, dated 06 / 26 / 2026, p. 159 / 639 153 / 316 N-[(3,4-difluorophenyl)methyl]-4-methyl-3-{[2-(1-methylpyrazol-4-yl)-4-pyridyl]oxy}benzamide (157):

[0228] Compound 157 was synthesized from intermediate 119b (0.10 mmol) and 3,4-difluorobenzylamine (0.15 mmol) as a white solid in a 45% yield according to the general C2 method. 1H NMR (400 MHz, DMSOd6) δ (ppm): 9.07 (t, J = 5.9 Hz, 1H), 8.40-8.33 (m, 1H), 8.25 (s, 1H), 7.97 (d, J = 0.7 Hz, 1H), 7.78 (dd, J = 7.9 Hz, 1.7 Hz, 1H), 7.63 (d, J = 1.7 Hz, 1H), 7.50 (d, J = 8.4 Hz, 1H), 7.42-7.31 (m, 2H), 7.23 (d, J = 2.1 Hz, 1H), 7.16-7.13 (m, 1H), 6.54 (dd, J = 5.7 Hz, 2.4Hz, 1H), 4.42 (d, J = 5.9 Hz, 2H), 3.86 (s, 3H), 2.20 (s, 3H). ESI-MS: 435.00 (M+H)+. N-[(4-chloro-3-fluoro-phenyl)methyl]-4-methyl-3-{[2-(1-methylpyrazol-4-yl)-4pyridyl]oxy}benzamide (158):

[0229] Compound 158 was synthesized from intermediate 119b (0.10 mmol) and 4-chloro-3-fluorobenzylamine (0.15 mmol) as a white solid with a yield of 57% according to the general C2 method. 1H NMR (400 MHz, DMSOd6) δ (ppm): 9.09 (t, J = 6.0 Hz, 1H), 8.39-8.34 (m, 1H), 8.25 (s, 1H), 7.97 (d, J = 0.7 Hz, 1H), 7.79 (dd, J = 7.9 Hz, 1.7 Hz, 1H), 7.63 (d, J = 1.7 Hz, 1H), 7.55-7.47 (m, 2H), 7.33 (dd, J = 10.4 Hz, 1.9 Hz, 1H), 7.27-7.21 (m, 1H), 7.17 (dd, J = 8.2 Hz, 1.3 Hz, 1H), 6.54 (dd, J = 5.7 Hz, 2.4 Hz, 1H), 4.44 (d, J = 5.9 Hz, 2H), 3.86 (s, 3H), 2.20 (s, 3H). ESI-MS: 451.05 (M+H)+ Petition 870260063548, dated 06 / 26 / 2026, p. 160 / 639 154 / 316 N-[(4-chlorophenyl)methyl]-4-methyl-3-{[2-(1-methylpyrazol-4-yl)-4-pyridyl]oxy} benzamide (159):

[0230] Compound 159 was synthesized from intermediate 119b (0.10 mmol) and 4-chlorobenzylamine (0.15 mmol) as a white solid with a yield of 92% according to the general C2 method. 1H NMR (400 MHz, DMSOd6) δ (ppm): 9.07 (t, J = 6.0 Hz, 1H), 8.38-8.34 (m, 1H), 8.25 (s, 1H), 7.97 (d, J = 0.7 Hz, 1H), 7.78 (dd, J = 7.9 Hz, 1.7 Hz, 1H), 7.63 (d, J = 1.7 Hz, 1H), 7.50 (d, J = 8.4 Hz, 1H), 7.40-7.29 (m, 4H), 7.23 (d, J = 2.1 Hz, 1H), 6.54 (dd, J = 5.7 Hz, 2.4 Hz, 1H), 4.43 (d, J = 5.9 Hz, 2H), 3.86 (s, 3H), 2.20 (s, 3H). ESI-MS: 433.00 (M+H)+. N-[(4-fluorophenyl)methyl]-4-methyl-3-{[2-(1-methylpyrazol-4-yl)-4-pyridyl]oxy} benzamide (352):

[0231] Compound 352 was synthesized from intermediate 119b (0.08 mmol) and 4-fluorobenzylamine (0.12 mmol) as a white solid with an 80% yield according to the general C2 method. 1H NMR (400 MHz, DMSOd6) δ (ppm): 9.05 (t, J = 6.0 Hz, 1H), 8.36 (d, J = 5.6 Hz, 1H), 8.25 (s, 1H), 7.97 (s, 1H), 7.78 (d, J = 7.8 Hz, 1H), 7.63 (d, J = 1.6 Hz, 1H), 7.50 (d, J = 8.2 Hz, 1H), 7,367.31 (m, 2H), 7.23 (d, J = 2.4 Hz, 1H), 7.16-7.10 (m, 2H), 6.54 (dd, J = 5.7 Hz, 2.5 Hz, 1H), 4.42 (d, J = 5.8 Hz, 2H), 3.86 (s, 3H), 2.20 (s, 3H). ESI-MS: 417.10 (M+H)+ 4-fluoro-N-[(4-fluorophenyl)methyl]-3-{[2-(1-methylpyrazol-4-yl)-4-pyridyl]oxy} benzamide (353): Petition 870260063548, dated 06 / 26 / 2026, p. 161 / 639 155 / 316

[0232] Compound 353 was synthesized from intermediate 119i (0.08 mmol) and 4-fluorobenzylamine (0.12 mmol) as a white solid with a yield of 63% according to the general C2 method. 1H NMR (400 MHz, DMSOd6) δ (ppm): 9.14 (t, J = 5.9 Hz, 1H), 8.40 (d, J = 5.7 Hz, 1H), 8.28 (s, 1H), 7.99 (s, 1H), 7.94-7.87 (m, 2H), 7.61-7.56 (m, 1H), 7.37-7.30 (m, 3H), 7.19-7.10 (m, 2H), 6.71 (dd, J = 5.7 Hz, 2.4 Hz, 1H), 4.44 (d, J = 5.8 Hz, 2H), 3.86 (s, 3H). ESI-MS: 421.05 (M+H)+. N-[(3,5-difluorophenyl)methyl]-2-methyl-5-{[2-(1-methylpyrazol-4-yl)-4-pyridyl]oxy}benzamide (160):

[0233] Compound 160 was synthesized from intermediate 119c (0.10 mmol) and 3,5-difluorobenzylamine (0.15 mmol) as a white solid in 90% yield according to the general C2 method. 1H NMR (400 MHz, DMSOd6) δ (ppm): 8.92 (t, J = 6.0 Hz, 1H), 8.40-8.35 (m, 1H), 8.25 (s, 1H), 7.96 (d, J = 0.7 Hz, 1H), 7.36 (d, J = 8.4 Hz, 1H), 7.27-7.23 (m, 2H), 7.19 (dd, J = 8.2 Hz, 2.6 Hz, 1H), 7.14-7.07 (m, 1H), 7.07-7.02 (m, 2H), 6.66 (dd, J = 5.7 Hz, 2.4 Hz, 1H), 4.44 (d, J = 6.0Hz, 2H), 3.86 (s, 3H), 2.36 (s, 3H). ESI-MS: 435.00 (M+H)+ N-[(3,4-difluorophenyl)methyl]-2-methyl-5-{[2-(1-methylpyrazol-4-yl)-4-pyridyl]oxy}benzamide (161):

[0234] Compound 161 was synthesized from intermediate 119c (0.10 mmol) and 3,4-difluorobenzylamine (0.15 mmol) as a white solid with a yield of 41% according to the general C2 method. 1H NMR (400 MHz, DMSOd6) δ (ppm): 8.90 (t, J = 6.0 Hz, 1H), 8.39-8.35 (m, 1H), 8.25 (s, 1H), 7.96 (d, J = 0.7 Hz, 1H), 7.44-7.34 (m, 3H), 7.25 (d, J = 2.1 Hz, 1H), 7.22 (d, J = 2.6 Hz, 1H), 7.20 Petition 870260063548, dated 06 / 26 / 2026, p. 162 / 639 156 / 316 7.15 (m, 2H), 6.65 (dd, J = 5.7 Hz, 2.4 Hz, 1H), 4.41 (d, J = 5.9 Hz, 2H), 3.86 (s, 3H), 2.35 (s, 3H). ESI-MS: 435.05 (M+H)+. N-[(4-chloro-3-fluoro-phenyl)methyl]-2-methyl-5-{[2-(1-methylpyrazol-4-yl)-4pyridyl]oxy}benzamide (162):

[0235] Compound 162 was synthesized from intermediate 119c (0.10 mmol) and 4-chloro-3-fluorobenzylamine (0.15 mmol) as a white solid in 60% yield according to the general C2 method. 1H NMR (400 MHz, DMSOd6) δ (ppm): 8.92 (t, J = 6.0 Hz, 1H), 8.40-8.35 (m, 1H), 8.25 (s, 1H), 7.96 (d, J = 0.7 Hz, 1H), 7.54 (t, J = 8.0 Hz, 1H), 7.37-7.33 (m, 2H), 7.28-7.15 (m, 4H), 6.65 (dd, J = 5.7 Hz, 2.4 Hz, 1H), 4.43 (d, J = 6.0 Hz, 2H), 3.86 (s, 3H), 2.35 (s, 3H). ESI-MS: 451.05 (M+H)+ N-[(4-chlorophenyl)methyl]-2-methyl-5-{[2-(1-methylpyrazol-4-yl)-4-pyridyl]oxy} benzamide (163):

[0236] Compound 163 was synthesized from intermediate 119c (0.10 mmol) and 4-chlorobenzylamine (0.15 mmol) as a white solid with a yield of 79% according to the general C2 method. 1H NMR (400 MHz, DMSOd6) δ (ppm): 8.98 (t, J = 6.0 Hz, 1H), 8.48-8.45 (m, 1H), 8.34 (s, 1H), 8.05 (d, J = 0.7 Hz, 1H), 7.51-7.41 (m, 5H), 7.34 (d, J = 2.1 Hz, 1H), 7.30-7.23 (m, 2H), 6.74 (dd, J = 5.7 Hz, 2.4 Hz, 1H), 4.50 (d, J = 6.0 Hz, 2H), 3.95 (s, 3H), 2.44 (s, 3H). ESI-MS: 433.00 (M+H)+ N-[(2-methoxyphenyl)methyl]-2-methyl-5-{[2-(1-methylpyrazol-4-yl)-4-pyridyl]oxy}benzamide (351): Petition 870260063548, dated 06 / 26 / 2026, pp. 163 / 639 157 / 316

[0237] Compound 351 was synthesized from intermediate 119c (0.07 mmol) and 2-methoxybenzylamine (0.10 mmol) as a white solid with a yield of 71% according to the general C2 method. 1H NMR (400 MHz, DMSOd6) δ (ppm): 8.70 (t, J = 5.8 Hz, 1H), 8.37 (d, J = 5.7 Hz, 1H), 8.26 (s, 1H), 7.97 (s, 1H), 7.35 (d, J = 8.2 Hz, 1H), 7.28-7.21 (m, 3H), 7.20-7.16 (m, 2H), 6.98 (d, J = 8.2 Hz, 1H), 6.90 (t, J = 7.4 Hz, 1H), 6.66 (dd, J = 5.7 Hz, 2.4 Hz, 1H), 4.39 (d, J = 5.9 Hz, 2H), 3.86 (s, 3H), 3.79 (s, 3H), 2.36 (s, 3H). ESI-MS: 429.10 (M+H)+. 2-methyl-5-{[2-(1-methylpyrazol-4-yl)-4-pyridyl]oxy}-N-{[3-(trifluoromethyl)phenyl]methyl}benzamide (354):

[0238] Compound 354 was synthesized from intermediate 119c (0.07 mmol) and 3-trifluoromethylbenzylamine (0.10 mmol) as a white solid with a yield of 73% according to the general C2 method. 1H NMR (400 MHz, DMSOd6) δ (ppm): 8.97 (t, J = 6.0 Hz, 1H), 8.37 (d, J = 5.7 Hz, 1H), 8.25 (s, 1H), 7.96 (s, 1H), 7.72-7.53 (m, 4H), 7.36 (d, J = 7.8 Hz, 1H), 7.26 (d, J = 2.3 Hz, 1H), 7.21-7.16 (m, 2H), 6.66 (dd, J = 5.7 Hz, 2.4 Hz, 1H), 4.52 (d, J = 6.0 Hz, 2H), 3.86 (s, 3H), 2.35 (s, 3H). ESI-MS: 467.10 (M+H)+ N-[(3,4-difluorophenyl)methyl]-2-methoxy-5-{[2-(1-methylpyrazol-4-yl)-4-pyridyl]oxy}benzamide (359):

[0239] Compound 359 was synthesized from intermediate 119j (0.08 mmol) and 3,4-difluorobenzylamine (0.12 mmol) as a white solid with a Petition 870260063548, dated 06 / 26 / 2026, p. 164 / 639 158 / 316 yield of 72 % agreement with the C2 geral method. 1H NMR (400 MHz, DMSOd6) δ (ppm): 8.87 (t, J = 6.1 Hz, 1H), 8.36 (d, J = 5.7 Hz, 1H), 8.24 (s, 1H), 7.95 (d, J = 0.7), 1 Hz, 1, Hz, 1H), 7.43–7.32 (m, 3H), 7.28–7.15 (m, 3H), 6.61 (dd, J = 5.7 Hz, 2.4 Hz, 1H), 4.47 (d, J = 6.1 Hz, 2H), 3.94 (s, 3H), 3.H6). ESI-MS: 451.10 (M+H)+. N-[(3,5-difluorophenyl)methyl]-3-methyl-5-{[2-(1-methylpyrazol-4-yl)-4-pyridyl] oxy}benzamide (164):

[0240] Compound 164 was synthesized from intermediate 119d (0.10 mmol) and 3,5-difluorobenzylamine (0.15 mmol) as a white solid with a yield of 43% according to the general C2 method. 1H NMR (400 MHz, DMSOd6) δ (ppm): 9.12 (t, J = 5.9 Hz, 1H), 8.39 (d, J = 5.7 Hz, 1H), 8.27 (s, 1H), 7.97 (d, J = 0.5 Hz, 1H), 7.66 (s, 1H), 7.49 (s, 1H), 7.28 (d, J = 2.2 Hz, 1H), 7.22 (s, 1H), 7.13-7.07 (m, 1H), 7.04-6.99 (m, 2H), 6.68 (dd, J = 5.7 Hz, 2.4 Hz, 1H), 4.47 (d, J = 5.9 Hz, 2H), 3.86 (s, 3H), 2.40 (s, 3H). ESI-MS: 435.00 (M+H)+ N-[(3,4-difluorophenyl)methyl]-3-methyl-5-{[2-(1-methylpyrazol-4-yl)-4-pyridyl]oxy}benzamide (165):

[0241] Compound 165 was synthesized from intermediate 119d (0.10 mmol) and 3,4-difluorobenzylamine (0.15 mmol) as a white solid with a yield of 29% according to the general C2 method. 1H NMR (400 MHz, DMSOd6) δ (ppm): 9.09 (t, J = 5.9 Hz, 1H), 8.39 (d, J = 5.7 Hz, 1H), 8.26 (s, 1H), 7.97 (d, J = 0.7 Hz, 1H), 7.66-7.64 (m, 1H), 7.48-7.47 (m, 1H), 7.42-7.32 (m, 2H), 7.28 (d, J = 2.1 Hz, 1H), 7.22-7.21 (m, 1H), 7.19-7.11 (m, 1H), 6.67 (dd, J = 5.7 Hz, 2.4 Hz, 1H), 4.43 (d, J = 5.9 Hz, 2H), 3.86 (s, 3H), 2.39 (s, 3H). Petition 870260063548, dated 06 / 26 / 2026, p. 165 / 639 159 / 316 ESI-MS: 435.00 (M+H)+. N-[(4-chloro-3-fluoro-phenyl)methyl]-3-methyl-5-{[2-(1-methylpyrazol-4-yl)-4pyridyl]oxy}benzamide (166):

[0242] Compound 166 was synthesized from intermediate 119d (0.10 mmol) and 4-chloro-3-fluorobenzylamine (0.15 mmol) as a white solid with a yield of 46% according to the general C2 method. 1H NMR (400 MHz, DMSOd6) δ (ppm): 9.11 (t, J = 5.9 Hz, 1H), 8.41-8.36 (m, 1H), 8.26 (s, 1H), 7.97 (d, J = 0.7 Hz, 1H), 7.66-7.65 (m, 1H), 7.53 (t, J = 8.0 Hz, 1H), 7.48-7.47 (m, 1H), 7.33 (dd, J = 10.4 Hz, 1.9 Hz, 1H), 7.28 (d, J = 2.1 Hz, 1H), 7.22-7.21 (m, 1H), 7.18 (dd, J = 8.3 Hz, 1.3Hz, 1H), 6.67 (dd, J = 5.7 Hz, 2.4 Hz, 1H), 4.45 (d, J = 5.9, 2H), 3.86 (s, 3H), 2.39 (s, 3H). ESI-MS: 451.05 (M+H)+ N-[(4-chlorophenyl)methyl]-3-methyl-5-{[2-(1-methylpyrazol-4-yl)-4-pyridyl]oxy} benzamide (167):

[0243] Compound 167 was synthesized from intermediate 119d (0.10 mmol) and 4-chlorobenzylamine (0.15 mmol) as a white solid with a yield of 53% according to the general C2 method. 1H NMR (400 MHz, DMSOd6) δ (ppm): 9.09 (t, J = 5.9 Hz, 1H), 8.41 -8.37 (m, 1H), 8.26 (s, 1H), 7.97 (d, J = 0.7 Hz, 1H), 7.66-7.65 (m, 1H), 7.49-7.45 (m, 1H), 7.40-7.30 (m, 4H), 7.28 (d, J = 2.0 Hz, 1H), 7.22-7.21 (m, 1H), 6.66 (dd, J = 5.7 Hz, 2.4 Hz, 1H), 4.43 (d, J = 5.9 Hz, 2H), 3.86 (s, 3H), 2.39 (s, 3H). ESI-MS: 433.00 (M+H)+ N-[(3-fluorophenyl)methyl]-2-methyl-3-({2-[(1-methylpyrazol-3-yl)amino]-4pyridyl}oxy)benzamide (168): Petition 870260063548, dated 06 / 26 / 2026, p. 166 / 639 160 / 316

[0244] Compound 168 was synthesized from intermediate 119e (0.09 mmol) and 3-fluorobenzylamine (0.14 mmol) as a white solid with a yield of 53% according to the general C2 method. 1H NMR (400 MHz, DMSOd6) δ (ppm): 9.17 (s, 1H), 8.94 (t, J = 6.0 Hz, 1H), 7.98 (d, J = 5.7 Hz, 1H), 7.46 (d, J = 2.2 Hz, 1H), 7.42-7.31 (m, 3H), 7.22-7.13 (m, 3H), 7.08 (td, J = 8.3 Hz, 2.1 Hz, 1H), 6.88 (d, J = 2.1 Hz, 1H), 6.18 (dd, J = 5.8 Hz, 2.3 Hz, 1H), 6.15 (d, J = 2.2 Hz, 1H), 4.47 (d, J = 6.0 Hz, 2H), 3.67 (s, 3H), 2.14 (s, 3H). ESI-MS: 432.15 (M+H)+. N-[(4-fluorophenyl)methyl]-2-methyl-3-({2-[(1-methylpyrazol-3-yl)amino]-4pyridyl}oxy)benzamide (169):

[0245] Compound 169 was synthesized from intermediate 119e (0.09 mmol) and 4-fluorobenzylamine (0.14 mmol) as a white solid in 50% yield according to the general C2 method. 1H NMR (400 MHz, DMSOd6) δ (ppm): 9.17 (s, 1H), 8.91 (t, J = 6.0 Hz, 1H), 7.98 (d, J = 5.8 Hz, 1H), 7.46 (d, J = 2.2 Hz, 1H), 7.42-7.27 (m, 4H), 7.21-7.13 (m, 3H), 6.88 (d, J = 2.1 Hz, 1H), 6.17 (dd, J = 5.8 Hz, 2.3 Hz, 1H), 6.15 (d, J = 2.2 Hz, 1H), 4.43 (d, J = 6.0 Hz, 2H), 3.67 (s, 3H), 2.13 (s, 3H). ESI-MS: 432.15 (M+H)+ N-[(3-chlorophenyl)methyl]-2-methyl-3-({2-[(1-methylpyrazol-3-yl)amino]-4pyridyl}oxy)benzamide (170):

[0246] Compound 170 was synthesized from intermediate 119e (0.09 mmol) and 3-chlorobenzylamine (0.14 mmol) as a white solid with a Petition 870260063548, dated 06 / 26 / 2026, p. 167 / 639 161 / 316 yield of 63 % in agreement with the C2 geral method. 1H NMR (400 MHz, DMSOd6) δ (ppm): 9.17 (s, 1H), 8.95 (t, J = 6.1 Hz, 1H), 7.98 (d, J = 5.8 Hz, 1H), 7.46 (d, J = 2.8 Hz), 1H7 ,6, Hz, 7.18 (dd, J = 7.8 Hz, 1.2 Hz, 1H), 6.88 (d, J = 2.1 Hz, 1H), 6.18 (dd, J = 5.8 Hz, 2.3 Hz, 1H), 6.15 (d, J = 2.6, 4, 4, 4 H 2H), 3.67 (s, 3H), 2.14 (s, 3H). ESI-MS: 448.15 (M+H)+. N-[(4-chlorophenyl)methyl]-2-methyl-3-({2-[(1-methylpyrazol-3-yl)amino]-4pyridyl}oxy)benzamide (171):

[0247] Compound 171 was synthesized from intermediate 119e (0.09 mmol) and 4-chlorobenzylamine (0.14 mmol) as a white solid with a yield of 49% according to the general C2 method. 1H NMR (400 MHz, DMSOd6) δ (ppm): 9.17 (s, 1H), 8.93 (t, J = 6.0 Hz, 1H), 7.98 (d, J = 5.8 Hz, 1H), 7.46 (d, J = 2.2 Hz, 1H), 7.43-7.28 (m, 6H), 7.18 (dd, J = 7.8 Hz, 1.3 Hz, 1H), 6.88 (d, J = 2.1 Hz, 1H), 6.17 (dd, J = 5.8 Hz, 2.3 Hz, 1H), 6.15 (d, J = 2.2 Hz, 1H), 4.43 (d, J = 6.0 Hz, 2H), 3.67 (s, 3H), 2.13 (s, 3H). ESI-MS: 448.15 (M+H)+ 2-methyl-3-({2-[(1-methylpyrazol-3-yl)amino]-4-pyridyl}oxy)-N-{[6-(trifluoromethyl)3-pyridyl]methyl}benzamide (172):

[0248] Compound 172 was synthesized from intermediate 119e (0.09 mmol) and [6-(trifluoromethyl)-3-pyridyl]methanamine (0.14 mmol) as a white solid with a yield of 57% according to the general C2 method. 1H NMR (400 MHz, DMSO-d6) δ (ppm): 9.17 (s, 1H), 9.05 (t, J = 5.9 Hz, 1H), 8.76-8.75 (m, 1H), 8.04 (d, J = 8.1 Hz, 1H), 7.98 (d, J = 5.8 Hz, 1H), 7.91 (d, J = 8.0 Hz, 1H), 7.46 (d, J = 2.2 Hz, 1H), 7.40-7.33 (m, 2H), 7.19 (dd, J = 7.0 Hz, 2.4 Hz, 1H), 6.88 (d, J = 2.1 Hz, Petition 870260063548, dated 06 / 26 / 2026, pp. 168 / 639 162 / 316 1H), 6.18 (dd, J = 5.8 Hz, 2.3 Hz, 1H), 6.15 (d, J = 2.2 Hz, 1H), 4.58 (d, J = 5.9 Hz, 2H), 3.67 (s, 3H), 2.14 (s, 3H). ESI-MS: 483.15 (M+H)+. N-(imidazo[1,2-a]pyridin-6-ylmethyl)-2-methyl-3-({2-[(1-methylpyrazol-3-yl)amino]4-pyridyl}oxy)benzamide (173):

[0249] Compound 173 was synthesized from intermediate 119e (0.09 mmol) and imidazo[1,2-a]pyridin-6-ylmethanamine (0.14 mmol) as a white solid in 50% yield according to the general C2 method. 1H NMR (400 MHz, DMSO-d6) δ (ppm): 9.17 (s, 1H), 8.93 (t, J = 5.9 Hz, 1H), 8.50-8.49 (m, 1H), 7,997.95 (m, 2H), 7.57-7.54 (m, 2H), 7.46 (d, J = 2.2 Hz, 1H), 7.38-7.31 (m, 2H), 7.25 (dd, J = 9.3 Hz, 1.7 Hz, 1H), 7.18 (dd, J = 7.4 Hz, 1.8 Hz, 1H), 6.88 (d, J = 2.1 Hz, 1H), 6.17 (dd, J = 5.8Hz, 2.3 Hz, 1H), 6.15 (d, J = 2.2 Hz, 1H), 4.44 (d, J = 5.8 Hz, 2H), 3.67 (s, 3H), 2.13 (s, 3H). ESI-MS: 454.15 (M+H)+ N-(imidazo[1,2-a]pyridin-7-ylmethyl)-2-methyl-3-({2-[(1-methylpyrazol-3-yl)amino]4-pyridyl}oxy)benzamide (174):

[0250] Compound 174 was synthesized from intermediate 119e (0.09 mmol) and imidazo[1,2-a]pyridin-7-ylmethanamine (0.14 mmol) as a white solid with a yield of 41% according to the general C2 method. 1H NMR (400 MHz, DMSO-d6) δ (ppm): 9.17 (s, 1H), 8.98 (t, J = 6.0 Hz, 1H), 8.51 (dd, J = 7.0 Hz, 0.7 Hz, 1H), 7.98 (d, J = 5.8 Hz, 1H), 7.90 (s, 1H), 7.53 (d, J = 1.1 Hz, 1H), 7.46 (d, J = 2.2 Hz, 1H), 7.44 (s, 1H), 7.40-7.33 (m, 2H), 7.19 (dd, J = 7.4 Hz, 1.8 Hz, 1H), 6,906.87 (m, 2H), 6.18 (dd, J = 5.8 Hz, 2.3 Hz, 1H), 6.15 (d, J = 2.2 Hz, 1H), 4.49 (d, J = 5.9 Hz, 2H), 3.67 (s, 3H), 2.16 (s, 3H). ESI-MS: 454.15 (M+H)+ Petition 870260063548, dated 06 / 26 / 2026, p. 169 / 639 163 / 316 N-[(5-fluoro-3-pyridyl)methyl]-2-methyl-3-({2-[(1-methylpyrazol-3-yl)amino]-4pyridyl}oxy)benzamide (175):

[0251] Compound 175 was synthesized from intermediate 119e (0.06 mmol) and 5-fluoro-3-pyridinomethanamine (0.09 mmol) as a white solid with a yield of 37% according to the general C2 method. 1H NMR (400 MHz, DMSO-d6) δ (ppm): 9.17 (s, 1H), 9.00 (t, J = 5.9 Hz, 1H), 8.49 (d, J = 2.8 Hz, 1H), 8.47-8.46 (m, 1H), 7.98 (d, J = 5.8 Hz, 1H), 7.69-7.65 (m, 1H), 7.46 (d, J = 2.2 Hz, 1H), 7.39-7.32 (m, 2H), 7.19 (dd, J = 7.2 Hz, 2.0 Hz, 1H), 6.88 (d, J = 2.1 Hz, 1H), 6.18 (dd, J = 5.8 Hz, 2.3Hz, 1H), 6.15 (d, J = 2.2 Hz, 1H), 4.52 (d, J = 5.9 Hz, 2H), 3.67 (s, 3H), 2.13 (s, 3H). ESI-MS: 433.20 (M+H)+. N-[(3,4-difluorophenyl)methyl]-2-fluoro-5-({2-[(1-methylpyrazol-3-yl)amino]-4pyridyl}oxy)benzamide (355):

[0252] Compound 355 was synthesized from intermediate 119k (0.08 mmol) and 3,4-difluorobenzylamine (0.11 mmol) as a white solid in a 30% yield according to the general C2 method. 1H NMR (400 MHz, DMSOd6) δ (ppm): 9.21 (s, 1H), 8.98 (t, J = 5.0 Hz, 1H), 8.01 (d, J = 5.7 Hz, 1H), 7.49-7.33 (m, 6H), 7.22-7.14 (m, 1H), 6.93 (d, J = 2.1 Hz, 1H), 6.30 (dd, J = 5.7 Hz, 2.3 Hz, 1H), 6.16 (d, J = 2.2 Hz, 1H), 4.44 (d, J = 6.0 Hz, 2H), 3.67 (s, 3H). ESI-MS: 454.00 (M+H)+ N-[(5-fluoro-6-methoxy-3-pyridyl)methyl]-2-methyl-3-({2-[(1-methylpyrazol-4yl)amino]-4-pyridyl}oxy)benzamide (176): Petition 870260063548, dated 06 / 26 / 2026, p. 170 / 639 164 / 316

[0253] Compound 176 was synthesized from intermediate 119e (0.06 mmol) and (5-fluoro-6-methoxy-3-pyridyl)methanamine (0.09 mmol) as a white solid with a yield of 59% according to the general C2 method. 1H NMR (400 MHz, DMSO-d6) δ (ppm): 9.17 (s, 1H), 8.90 (t, J = 5.9 Hz, 1H), 7.98-7.96 (m, 2H), 7.64 (dd, J = 11.4 Hz, 1.9 Hz, 1H), 7.46 (d, J = 2.2 Hz, 1H), 7.37-7.28 (m, 2H), 7.17 (dd, J = 7.8 Hz, 1.2 Hz, 1H), 6.87 (d, J = 2.1 Hz, 1H), 6.17 (dd, J = 5.8 Hz, 2.3 Hz, 1H), 6.14 (d, J = 2.2Hz, 1H), 4.41 (d, J = 5.9 Hz, 2H), 3.93 (s, 3H), 3.67 (s, 3H), 2.12 (s, 3H). ESI-MS: 463.25 (M+H)+. N-[(5-fluoro-2-methoxy-3-pyridyl)methyl]-2-methyl-3-({2-[(1-methylpyrazol-4yl)amino]-4-pyridyl}oxy)benzamide (177):

[0254] Compound 177 was synthesized from intermediate 119e (0.06 mmol) and 5-fluoro-3-pyridinomethanamine (0.09 mmol) as a white solid with a yield of 48% according to the general C2 method. 1H NMR (400 MHz, DMSO-d6) δ (ppm): 9.17 (s, 1H), 8.84 (t, J = 5.8 Hz, 1H), 8.07 (d, J = 3.0 Hz, 1H), 7.98 (d, J = 5.8 Hz, 1H), 7.55 (dd, J = 8.6 Hz, 3.0 Hz, 1H), 7.46 (d, J = 2.2 Hz, 1H), 7.39-7.34 (m, 2H), 7.21-7.17 (m, 1H), 6.88 (d, J = 2.1 Hz, 1H), 6.18 (dd, J = 5.8 Hz, 2.3 Hz, 1H), 6.15 (d, J = 2.2 Hz, 1H), 4.38 (d, J = 5.7 Hz, 2H), 3.91 (s, 3H), 3.67 (s, 3H), 2.14 (s, 3H). ESI-MS: 463.20 (M+H)+ N-(imidazo[1,2-a]pyridin-6-ylmethyl)-2-methyl-3-({2-[(1-methylpyrazol-4-yl)amino]4-pyridyl}oxy)benzamide (178):

[0255] Compound 178 was synthesized from intermediate 119f (0.09 mmol) and imidazo[1,2-a]pyridin-6-ylmethanamine (0.14 mmol) as a white solid in a 53% yield according to the general C2 method. 1H NMR (400 MHz, Petition: 870260063548, on June 26, 2026, page. 171 / 639 165 / 316 DMSO-d6) δ (ppm): 8.95 (t, J = 5.9 Hz, 1H), 8.74 (s, 1H), 8.50 (s, 1H), 7.99-7.96 (m, 2H), 7.86 (s, 1H), 7.57-7.55 (m, 2H), 7.38-7.31 (m, 3H), 7.24 (dd, J = 9.3 Hz, 1.6 Hz, 1H), 7.19 (dd, J = 7.4 Hz, 1.8 Hz, 1H), 6.23 (dd, J = 5.8 Hz, 2.2 Hz, 1H), 5.93 (d, J = 2.1 Hz, 1H), 4.44 (d, J = 5.9 Hz, 2H), 3.76 (s, 3H), 2.12 (s, 3H). ESI-MS: 454.15 (M+H)+. N-(imidazo[1,2-a]piridin-7-ilmetil)-2-metil-3-({2-[(1-metilpirazol-4-il)amino]4-piridil}oxi)benzamida (179):

[0256] Compound 179 was synthesized from intermediate 119f (0.09 mmol) and imidazo[1,2-a]pyridin-7-ylmethanamine (0.14 mmol) as a white solid with a yield of 46% according to the general C2 method. 1H NMR (400 MHz, DMSO-d6) δ (ppm): 9.00 (t, J = 6.0 Hz, 1H), 8.75 (s, 1H), 8.51 (d, J = 7.0 Hz, 1H), 7.99 (d, J = 5.8 Hz, 1H), 7.90 (s, 1H), 7.86 (s, 1H) Hz, 1H), 6.24 (dd, J = 5.8 Hz, 2.2 Hz, 1H), 5.94 (d, J = 2.2 Hz, 1H), 4.49 (d, J = 5.9 Hz, 2H), 3.76 (s, 3H), 2.15 (s, 3H). ESI-MS: 454.15 (M+H)+ 2-methyl-3-({2-[(1-methylpyrazol-4-yl)amino]-4-pyridyl}oxy)-N-{[6-(trifluoromethyl)3-pyridyl]methyl}benzamide (180):

[0257] Compound 180 was synthesized from intermediate 119f (0.09 mmol) and [6-(trifluoromethyl)-3-pyridyl]methanamine (0.14 mmol) as a white solid with a yield of 58% according to the general C2 method. 1H NMR (400 MHz, DMSO-d6) δ (ppm): 9.07 (t, J = 5.9 Hz, 1H), 8.76-8.74 (m, 2H), 8.04 (dd, J = 8.0 Hz, 1.5 Hz, 1H), 7.99 (d, J = 5.8 Hz, 1H), 7.92 (d, J = 8.1 Hz, 1H), 7.86 (s, 1H), 7,397.34 (m, 2H), 7.31 (s, 1H), 7.21 (dd, J = 6.7 Hz, 2.6 Hz, 1H), 6.24 (dd, J = 5.8 Hz, Petition 870260063548, dated 06 / 26 / 2026, p. 172 / 639 166 / 316 2.2 Hz, 1H), 5.93 (d, J = 2.2 Hz, 1H), 4.58 (d, J = 5.9 Hz, 2H), 3.76 (s, 3H), 2.12 (s, 3H). ESI-MS: 483.15 (M+H)+. N-[(5-fluoro-3-pyridyl)methyl]-2-methyl-3-({2-[(1-methylpyrazol-4-yl)amino]-4pyridyl}oxy)benzamide (181):

[0258] Compound 181 was synthesized from intermediate 119f (0.09 mmol) and 5-fluoro-3-pyridinomethanamine (0.14 mmol) as a white solid with a yield of 73% according to the general C2 method. 1H NMR (400 MHz, DMSO-d6) δ (ppm): 9.00 (t, J = 5.9 Hz, 1H), 8.73 (s, 1H), 8.49 (d, J = 2.8 Hz, 1H), 8.47-8.46 (m, 1H), 7.99 (d, J = 5.8 Hz, 1H), 7.86 (s, 1H), 7.69-7.65 (m, 1H), 7,397.33 (m, 2H), 7.31 (d, J = 0.6 Hz, 1H), 7.20 (dd, J = 7.2 Hz, 2.1 Hz, 1H), 6.23 (dd, J = 5.8 Hz, 2.2 Hz, 1H), 5.94 (d, J = 2.2 Hz, 1H), 4.52 (d, J = 5.9 Hz, 2H), 3.77 (s, 3H), 2.12 (s, 3H). ESI-MS: 433.20 (M+H)+ N-[(5-fluoro-6-methoxy-3-pyridyl)methyl]-2-methyl-3-({2-[(1-methylpyrazol-4yl)amino]-4-pyridyl}oxy)benzamide (182):

[0259] Compound 182 was synthesized from intermediate 119f (0.09 mmol) and (5-fluoro-6-methoxy-3-pyridyl)methanamine (0.14 mmol) as a white solid with a yield of 86% according to the general C2 method. 1H NMR (400 MHz, DMSO-d6) δ (ppm): 8.90 (t, J = 5.8 Hz, 1H), 8.72 (s, 1H), 7.99-7.97 (m, 2H), 7.86 (s, 1H), 7.64 (dd, J = 11.4 Hz, 1.9 Hz, 1H), 7.37-7.29 (m, 3H), 7.19 (dd, J = 7.8 Hz, 1.3 Hz, 1H), 6.23 (dd, J = 5.8 Hz, 2.2 Hz, 1H), 5.94 (d, J = 2.1 Hz, 1H), 4.41 (d, J = 5.9 Hz, 2H), 3.93 (s, 3H), 3.77 (s, 3H), 2.11 (s, 3H). ESI-MS: 463.20 (M+H)+ N-[(5-fluoro-2-methoxy-3-pyridyl)methyl]-2-methyl-3-({2-[(1-methylpyrazol-4yl)amino]-4-pyridyl}oxy)benzamide (183): Petition 870260063548, dated 06 / 26 / 2026, p. 173 / 639 167 / 316

[0260] Compound 183 was synthesized from intermediate 119f (0.09 mmol) and 5-fluoro-2-methoxy-3-pyridinomethanamine (0.14 mmol) as a white solid in 70% yield according to the general C2 method. 1H NMR (400 MHz, DMSO-d6) δ (ppm): 8.84 (t, J = 5.8 Hz, 1H), 8.73 (s, 1H), 8.07 (d, J = 3.0 Hz, 1H), 7.99 (d, J = 5.8 Hz, 1H), 7.86 (s, 1H), 7.55 (dd, J = 8.6 Hz, 3.0 Hz, 1H), 7.39-7.34 (m, 2H), 7.31 (d, J = 0.5 Hz, 1H), 7.22-7.18 (m, 1H), 6.24 (dd, J = 5.8 Hz, 2.2 Hz, 1H), 5.94 (d, J = 2.2Hz, 1H), 4.38 (d, J = 5.7 Hz, 2H), 3.91 (s, 3H), 3.77 (s, 3H), 2.13 (s, 3H). ESI-MS: 463.20 (M+H)+. N-[(3-fluorophenyl)methyl]-2-methyl-3-({2-[(2-methylpyrazol-3-yl)amino]-4pyridyl}oxy)benzamide (184):

[0261] Compound 184 was synthesized from intermediate 119g (0.15 mmol) and 3-fluorobenzylamine (0.23 mmol) as a white solid with a yield of 18% according to the general C2 method. 1H NMR (400 MHz, DMSOd6) δ (ppm): 8.95 (t, J = 6.1 Hz, 1H), 8.75 (s, 1H), 8.00 (d, J = 5.8 Hz, 1H), 7.43-7.32 (m, 3H), 7.27 (d, J = 1.9 Hz, 1H), 7.23-7.13 (m, 3H), 7.09 (td, J = 8.4 Hz, 2.4 Hz, 1H), 6.36 (dd, J = 5.8 Hz, 2.2 Hz, 1H), 6.16 (d, J = 1.9 Hz, 1H), 6.12 (d, J = 2.2 Hz, 1H), 4.47 (d, J = 6.0 Hz, 2H), 3.61 (s, 3H), 2.13 (s, 3H). ESI-MS: 432.15 (M+H)+ N-[(4-fluorophenyl)methyl]-2-methyl-3-({2-[(2-methylpyrazol-3-yl)amino]-4pyridyl}oxy)benzamide (185): Petition 870260063548, dated 06 / 26 / 2026, p. 174 / 639 168 / 316

[0262] Compound 185 was synthesized from intermediate 119g (0.15 mmol) and 4-fluorobenzylamine (0.23 mmol) as a white solid with a yield of 21% according to the general C2 method. 1H NMR (400 MHz, DMSOd6) δ (ppm): 8.92 (t, J = 6.0 Hz, 1H), 8.75 (s, 1H), 8.00 (d, J = 5.8 Hz, 1H), 7.40-7.34 (m, 3H), 7.31 (dd, J = 7.6 Hz, 1.3 Hz, 1H), 7.27 (d, J = 1.9 Hz, 1H), 7.22-7.14 (m, 3H), 6.36 (dd, J = 5.8 Hz, 2.2 Hz, 1H), 6.16 (d, J = 1.9 Hz, 1H), 6.11 (d, J = 2.2 Hz, 1H), 4.43 (d, J = 6.0 Hz, 2H), 3.61 (s, 3H), 2.12 (s, 3H). ESI-MS: 432.15 (M+H)+. N-[(3-chlorophenyl)methyl]-2-methyl-3-({2-[(2-methylpyrazol-3-yl)amino]-4pyridyl}oxy)benzamide (186):

[0263] Compound 186 was synthesized from intermediate 119g (0.15 mmol) and 3-chlorobenzylamine (0.23 mmol) as a white solid with a yield of 13% according to the general C2 method. 1H NMR (400 MHz, DMSOd6) δ (ppm): 8.96 (t, J = 6.0 Hz, 1H), 8.75 (s, 1H), 8.00 (d, J = 5.8 Hz, 1H), 7.41 -7.36 (m, 3H), 7.34-7.30 (m, 3H), 7.27 (d, J = 1.9 Hz, 1H), 7.22 (dd, J = 7.8 Hz, 1.2 Hz, 1H), 6.36 (dd, J = 5.8 Hz, 2.2 Hz, 1H), 6.16 (d, J = 1.9 Hz, 1H), 6.12 (d, J = 2.2 Hz, 1H), 4.46 (d, J = 6.0 Hz, 2H), 3.61 (s, 3H), 2.13 (s, 3H). ESI-MS: 448.10 (M+H)+ N-[(4-chlorophenyl)methyl]-2-methyl-3-({2-[(2-methylpyrazol-3-yl)amino]-4pyridyl}oxy)benzamide (187):

[0264] Compound 187 was synthesized from intermediate 119g (0.15 mmol) and 4-chlorobenzylamine (0.23 mmol) as a white solid with a yield of 18% according to the general C2 method. 1H NMR (400 MHz, DMSOd6) δ (ppm): 9.17 (s, 1H), 8.94 (t, J = 6.0 Hz, 1H), 8.75 (s, 1H), 8.00 (d, J = 5.8 Hz, 1H), 7.43-7.30 (m, 6H), 7.27 (d, J = 1.9 Hz, 1H), 7.21 (dd, J = 7.8 Hz, 1.3 Hz, 1H), Petition 870260063548, dated 06 / 26 / 2026, p. 175 / 639 169 / 316 6.36 (dd, J = 5.8 Hz, 2.2 Hz, 1H), 6.16 (d, J = 1.9 Hz, 1H), 6.11 (d, J = 2.2 Hz, 1H), 4.43 (d, J = 6.0 Hz, 2H), 3.61 (s, 3H), 2.12 (s, 3H). ESI-MS: 448.15 (M+H)+. N-(imidazo[1,2-a]pyridin-6-ylmethyl)-2-methyl-3-({2-[(2-methylpyrazol-3-yl)amino]4-pyridyl}oxy)benzamide (188):

[0265] Compound 188 was synthesized from intermediate 119g (0.15 mmol) and imidazo[1,2-a]pyridin-6-ylmethanamine (0.23 mmol) as a white solid with a yield of 18% according to the general C2 method. 1H NMR (400 MHz, DMSO-d6) δ (ppm): 8.94 (t, J = 5.9 Hz, 1H), 8.75 (s, 1H), 8.50 (s, 1H), 7.99 (d, J = 5.8 Hz, 1H), 7.96 (s, 1H), 7.57-7.54 (m, 2H), 7.39-7.32 (m, 2H), 7.27 (d, J = 1.9 Hz, 1H), 7.26-7.20 (m, 2H), 6.35 (dd, J = 5.8 Hz, 2.2 Hz, 1H), 6.16 (d, J = 1.9 Hz, 1H), 6.11 (d, J = 2.2Hz, 1H), 4.44 (d, J = 5.8 Hz, 2H), 3.61 (s, 3H), 2.13 (s, 3H). ESI-MS: 454.15 (M+H)+ N-(imidazo[1,2-a]pyridin-7-ylmethyl)-2-methyl-3-({2-[(2-methylpyrazol-3-yl)amino]4-pyridyl}oxy)benzamide (189):

[0266] Compound 189 was synthesized from intermediate 119g (0.15 mmol) and imidazo[1,2-a]pyridin-7-ylmethanamine (0.23 mmol) as a white solid with a yield of 13% according to the general C2 method. 1H NMR (400 MHz, DMSO-d6) δ (ppm): 8.99 (t, J = 6.0 Hz, 1H), 8.75 (s, 1H), 8.51 (d, J = 6.9 Hz, 1H), 8.00 (d, J = 5.8 Hz, 1H), 7.90 (s, 1H), 7.53 (d, J = 1.1 Hz, 1H), 7.44 (s, 1H), 7,417.34 (m, 2H), 7.27 (d, J = 1.9 Hz, 1H), 7.23 (dd, J = 7.3 Hz, 1.9 Hz, 1H), 6.88 (dd, J = 7.0 Hz, 1.6 Hz, 1H), 6.37 (dd, J = 5.8 Hz, 2.2 Hz, 1H), 6.16 (d, J = 1.9 Hz, 1H), 6.12 (d, J = 2.2 Hz, 1H), 4.49 (d, J = 5.9 Hz, 2H), 3.61 (s, 3H), 2.15 (s, 3H). ESI-MS: 454.15 (M+H)+ Petition 870260063548, dated 06 / 26 / 2026, p. 176 / 639 170 / 316 N-[(3,5-difluorophenyl)methyl]-2-methyl-3-({2-[(2-methylpyrazol-3-yl)amino]-4pyridyl}oxy)benzamide (190):

[0267] Compound 190 was synthesized from intermediate 119g (0.15 mmol) and 3,5-difluorobenzylamine (0.23 mmol) as a white solid with a yield of 16% according to the general C2 method. 1H NMR (400 MHz, DMSOd6) δ (ppm): 8.99 (t, J = 6.0 Hz, 1H), 8.75 (s, 1H), 8.00 (d, J = 5.8 Hz, 1H), 7.41 -7.34 (m, 2H), 7.27 (d, J = 1.9 Hz, 1H), 7.23 (dd, J = 7.4 Hz, 1.8 Hz, 1H), 7.13 (tt, J = 9.4 Hz, 2.3 Hz, 1H), 7.08-7.03 (m, 2H), 6.36 (dd, J = 5.8 Hz, 2.2 Hz, 1H), 6.16 (d, J = 1.9 Hz, 1H), 6.12 (d, J = 2.1 Hz, 1H), 4.47 (d, J = 6.0 Hz, 2H), 3.61 (s, 3H), 2.13 (s, 3H). ESI-MS: 450.10 (M+H)+. N-[(6-methoxy-3-pyridyl)methyl]-2-methyl-3-({2-[(2-methylpyrazol-3-yl)amino]-4pyridyl}oxy)benzamide (191):

[0268] Compound 191 was synthesized from intermediate 119g (0.15 mmol) and (6-methoxypyridin-3-yl)methanamine (0.23 mmol) as a white solid with a 15% yield according to the general C2 method. 1H NMR (400 MHz, DMSO-d6) δ (ppm): 8.88 (t, J = 6.0 Hz, 1H), 8.74 (s, 1H), 8.13 (d, J = 2.0 Hz, 1H), 7.99 (d, J = 5.8 Hz, 1H), 7.69 (dd, J = 8.5 Hz, 2.5 Hz, 1H), 7.36 (t, J = 7.7 Hz, 1H), 7.30-7.27 (m, 2H), 7.20 (dd, J = 7.9 Hz, 1.1 Hz, 1H), 6.81 (d, J = 8.1 Hz, 1H), 6.35 (dd, J = 5.8 Hz, 2.2Hz, 1H), 6.16 (d, J = 1.9 Hz, 1H), 6.11 (d, J = 2.2 Hz, 1H), 4.38 (d, J = 5.9 Hz, 2H), 3.83 (s, 3H), 3.61 (s, 3H), 2.11 (s, 3H). ESI-MS: 445.15 (M+H)+ Petition 870260063548, dated 06 / 26 / 2026, p. 177 / 639 171 / 316 2-methyl-3-({2-[(2-methylpyrazol-3-yl)amino]-4-pyridyl}oxy)-N-{[6-(trifluoro methyl) 3-pyridyl]methyl}benzamide (192):

[0269] Compound 192 was synthesized from intermediate 119g (0.15 mmol) and [6-(trifluoromethyl)-3-pyridyl]methanamine (0.23 mmol) as a white solid in 10% yield according to the general C2 method. 1H NMR (400 MHz, DMSO-d6) δ (ppm): 9.08 (t, J = 5.9 Hz, 1H), 8.77 (s, 2H), 8.04 (d, J = 9.0 Hz, 1H), 8.00 (d, J = 5.8 Hz, 1H), 7.92 (d, J = 8.1 Hz, 1H), 7.40-7.35 (m, 2H), 7.27 (d, J = 1.8 Hz, 1H), 7.23 (dd, J = 6.8 Hz, 2.5 Hz, 1H), 6.36 (dd, J = 5.8 Hz, 2.2 Hz, 1H), 6.16 (d, J = 1.8 Hz, 1H), 6.11 (d, J = 2.1 Hz, 1H), 4.58 (d, J = 5.8 Hz, 2H), 3.61 (s, 3H), 2.13 (s, 3H). ESI-MS: 483.15 (M+H)+. N-[(5-fluoro-3-pyridyl)methyl]-2-methyl-3-({2-[(2-methylpyrazol-3-yl)amino]-4pyridyl}oxy)benzamide (193):

[0270] Compound 193 was synthesized from intermediate 119g (0.09 mmol) and 5-fluoro-3-pyridinomethanamine (0.14 mmol) as a white solid with a yield of 13% according to the general C2 method. 1H NMR (400 MHz, DMSO-d6) δ (ppm): 9.01 (t, J = 5.9 Hz, 1H), 8.75 (s, 1H), 8.49 (d, J = 2.8 Hz, 1H), 8.47 (s, 1H), 8.00 (d, J = 5.8 Hz, 1H), 7.69-7.65 (m, 1H), 7.40-7.34 (m, 2H), 7.27 (d, J = 1.9 Hz, 1H), 7.22 (dd, J = 7.2 Hz, 2.1 Hz, 1H), 6.36 (dd, J = 5.8 Hz, 2.2 Hz, 1H), 6.16 (d, J = 1.9 Hz, 1H), 6.11 (d, J = 2.2 Hz, 1H), 4.52 (d, J = 5.9 Hz, 2H), 3.61 (s, 3H), 2.12 (s, 3H). ESI-MS: 433.20 (M+H)+ Petition 870260063548, dated 06 / 26 / 2026, p. 178 / 639 172 / 316 N-[(5-fluoro-6-methoxy-3-pyridyl)methyl]-2-methyl-3-({2-[(2-methylpyrazol-3yl)amino]-4-pyridyl}oxy)benzamide (194):

[0271] Compound 194 was synthesized from intermediate 119g (0.09 mmol) and (5-fluoro-6-methoxy-3-pyridyl)methanamine (0.14 mmol) as a white solid with a yield of 19% according to the general C2 method. 1H NMR (400 MHz, DMSO-d6) δ (ppm): 8.91 (t, J = 5.9 Hz, 1H), 8.75 (s, 1H), 8.00 (d, J = 5.8 Hz, 1H), 7.97 (d, J = 1.7 Hz, 1H), 7.64 (dd, J = 11.4 Hz, 1.9 Hz, 1H), 7.38-7.30 (m, 2H), 7.27 (d, J = 1.9 Hz, 1H), 7.21 (dd, J = 7.8 Hz, 1.3 Hz, 1H), 6.35 (dd, J = 5.8 Hz, 2.2 Hz, 1H), 6.16 (d, J = 1.9Hz, 1H), 6.11 (d, J = 2.2 Hz, 1H), 4.41 (d, J = 5.8 Hz, 2H), 3.93 (s, 3H), 3.61 (s, 3H), 2.11 (s, 3H). ESI-MS: 463.25 (M+H)+. N-[(5-fluoro-2-methoxy-3-pyridyl)methyl]-2-methyl-3-({2-[(2-methylpyrazol-3yl)amino]-4-pyridyl}oxy)benzamide (195):

[0272] Compound 195 was synthesized from intermediate 119g (0.09 mmol) and 5-fluoro-2-methoxy-3-pyridinomethanamine (0.14 mmol) as a white solid with a yield of 14% according to the general C2 method. 1H NMR (400 MHz, DMSO-d6) δ (ppm): 8.85 (t, J = 5.7 Hz, 1H), 8.75 (s, 1H), 8.07 (d, J = 3.0 Hz, 1H), 8.00 (d, J = 5.8 Hz, 1H), 7.55 (dd, J = 8.6 Hz, 3.0 Hz, 1H), 7.40-7.35 (m, 2H), 7.27 (d, J = 1.9 Hz, 1H), 7.25-7.20 (m, 1H), 6.36 (dd, J = 5.8 Hz, 2.2 Hz, 1H), 6.16 (d, J = 1.9 Hz, 1H), 6.12 (d, J = 2.2 Hz, 1H), 4.38 (d, J = 5.7 Hz, 2H), 3.91 (s, 3H), 3.61 (s, 3H), 2.14 (s, 3H). ESI-MS: 463.25 (M+H)+ Petition 870260063548, dated 06 / 26 / 2026, p. 179 / 639 173 / 316 N-[(5-fluoro-6-methoxy-3-pyridyl)methyl]-2-methyl-3-({2-[(2-methyltriazol-4yl)amino]-4-pyridyl}oxy)benzamide (350):

[0273] Compound 350 was synthesized from intermediate 119l (0.08 mmol) and (5-fluoro-6-methoxy-3-pyridyl)methanamine (0.12 mmol) as a white solid with a yield of 56% according to the general C2 method. 1H NMR (400 MHz, DMSO-d6) δ (ppm): 9.59 (s, 1H), 8.90 (t, J = 5.8 Hz, 1H), 8.06 (d, J = 5.9 Hz, 1H), 7.97 (s, 1H), 7.80 (s, 1H), 7.68-7.61 (m, 1H), 7.38-7.30 (m, 2H), 7.21-7.18 (m, 1H), 6.47 (d, J = 2.2 Hz, 1H), 6.30 (dd, J = 5.8 Hz, 2.3 Hz, 1H), 4.41 (d, J = 5.6 Hz, 2H), 4.00 (s, 3H), 3.93 (s, 3H), 2.11 (s, 3H). ESI-MS: 464.05 (M+H)+. N-[(6-methoxy-3-pyridyl)methyl]-2-methyl-3-[(2-pyrazol-1-yl-4-pyridyl)oxy] benzamide (196):

[0274] Compound 196 was synthesized from intermediate 119h (0.09 mmol) and 6-methoxypyridin-3-yl)methanamine (0.14 mmol) as a white solid with a yield of 53% according to the general C2 method. 1H NMR (400 MHz, DMSO-d6) δ (ppm): 9.00 (t, J = 5.9 Hz, 1H), 8.59 (d, J = 2.5 Hz, 1H), 8.37 (d, J = 5.7 Hz, 1H), 8.14 (d, J = 2.2 Hz, 1H), 7.75 (d, J = 1.1 Hz, 1H), 7.69 (dd, J = 8.5 Hz, 2.4 Hz, 1H), 7.41 (t, J = 7.7 Hz, 1H), 7.36-7.29 (m, 2H), 7.18 (d, J = 2.3 Hz, 1H), 6.93 (dd, J = 5.7 Hz, 2.3Hz, 1H), 6.81 (d, J = 8.5 Hz, 1H), 6.55-6.54 (m, 1H), 4.38 (d, J = 5.9 Hz, 2H), 3.82 (s, 3H), 2.11 (s, 3H). ESI-MS: 416.05 (M+H)+ Petition 870260063548, dated 06 / 26 / 2026, p. 180 / 639 174 / 316 A / -[(3,5-difluorophenyl)methyl-2-methyl-3-[(2-pyrazol-1-yl-4-pyridyl)oxy] benzamide [197L

[0275] Compound 197 was synthesized from intermediate 119h (0.09 mmol) and 3,5-difluorobenzylamine (0.14 mmol) as a white solid in a 74% yield according to general method D. 1H NMR (400 MHz, DMSOd6) δ (ppm): 9.09 (s, 1H), 8.59 (d, J = 1.9 Hz, 1H), 8.37 (d, J = 5.6 Hz, 1H), 7.75 (s, 1H), 7.46-7.32 (m, 3H), 7.19-7.06 (m, 4H), 6.95-6.93 (m, 1H), 6.55 (s, 1H), 4.47 (d, J = 5.8 Hz, 2H), 2.14 (s, 3H). ESI-MS: 421.05 (M+H)+ Example 7: General procedure for synthesizing analogues 200 - 247 NaOH2N, EtOH, 50°C, 1h Method B2 198 R1—NH2 Boromic acid or ester Pd(PPh3)4,Cs2CO3 1M, dioxane, 100°C D2 Method Amine, Pd2dba3, Xantphos, Cs2CO3, dioxane, 100°C Method H 200-247 EDC.HCI, DMAP, CH2CI2, ta Method C2 199 Preparation of 3-[(2-chloro-4-pyridyl)oxy]-2-methylbenzoic acid (198): Petition 870260063548, dated 06 / 26 / 2026, p. 181 / 639 175 / 316

[0276] Intermediate 198 was synthesized from 117a (1.37 mmol) as a white solid in quantitative yield according to general method B2.

[0277] Table 1.10 below illustrates the intermediates 199 prepared from Method C2. The following compounds are examples that illustrate the D2 Method: N-[(6-methoxy-3-pyridyl)methyl]-2-methyl-3-{[2-(4-pyridyl)-4-pyridyl]oxy} benzamide (200):

[0278] Compound 200 was synthesized from intermediate 199a (0.07 mmol) and pyridine-4-boronic acid hydrate (0.10 mmol) as a white solid with a yield of 61% according to general method D2. 1H NMR (400 MHz, DMSO-d6) δ (ppm): 8.89 (t, J = 5.9 Hz, 1H), 8.70-8.68 (m, 2H), 8.59 (d, J = 5.6 Hz, 1H), 8.14 (d, J = 2.0 Hz, 1H), 8.02-8.00 (m, 2H) 1H), 6.76 (dd, J = 5.6 Hz, 2.4 Hz, 1H), 4.39 (d, J = 5.9 Hz, 2H), 3.83 (s, 3H), 2.13 (s, 3H). ESI-MS: 427.10 (M+H)+. N-[(6-methoxy-3-pyridyl)methyl]-2-methyl-3-{[2-(3-pyridyl)-4-pyridyl]oxy} benzamide (201): Petition 870260063548, dated 06 / 26 / 2026, p. 182 / 639 176 / 316

[0279] Compound 201 was synthesized from intermediate 199a (0.07 mmol) and pyridine-3-boronic acid (0.10 mmol) as a white solid with a yield of 61% according to general method D2. 1H NMR (400 MHz, DMSOd6) δ (ppm): 9.21 (d, J = 1.6 Hz, 1H), 8.89 (t, J = 5.9 Hz, 1H), 8.64 (dd, J = 4.8 Hz, 1.6 Hz, 1H), 8.56 (d, J = 5.7 Hz, 1H), 8.40-8.37 (m, 1H), 8.14 (d, J = 2.0 Hz, 1H), 7.70 (dd, J = 8.5 Hz, 2.5 Hz, 1H), 7.63 (d, J = 2.2 Hz, 1H), 7.51 (ddd, J = 8.0 Hz, 4.8 Hz, 0.7 Hz, 1H), 7.38 (t, J = 7.8 Hz, 1H), 7.32 (dd, J = 7.6 Hz, 1.3 Hz, 1H), 7.25 (dd, J = 7.9 Hz, 1.2 Hz, 1H), 6.81 (d, J = 8.5 Hz, 1H), 6.71 (dd, J = 5.7 Hz, 2.4 Hz, 1H), 4.39 (d, J = 5.9 Hz, 2H), 3.83 (s, 3H), 2.13 (s, 3H). ESI-MS: 427.10 (M+H)+. N-[(6-methoxy-3-pyridyl)methyl]-2-methyl-3-[(2-pyrimidin-5-yl-4-pyridyl)oxy] benzamide (202):

[0280] Compound 202 was synthesized from intermediate 199a (0.07 mmol) and pyrimidine-5-boronic acid (0.10 mmol) as a white solid with a yield of 72% according to general method D2. 1H NMR (400 MHz, DMSOd6) δ (ppm): 9.41 (s, 2H), 9.26 (s, 1H), 8.89 (t, J = 5.9 Hz, 1H), 8.59 (d, J = 5.7 Hz, 1H), 8.14 (d, J = 2.0 Hz, 1H), 7.80 (d, J = 2.2 Hz, 1H), 7.70 (dd, J = 8.5 Hz, 2.5 Hz, 1H), 7.39 (t, J = 7.8 Hz, 1H), 7.32 (dd, J = 7.6 Hz, 1.3 Hz, 1H), 7.25 (dd, J = 7.9 Hz, 1.2 Hz, 1H), 6.81 (d, J = 8.5 Hz, 1H), 6.72 (dd, J = 5.7 Hz, 2.4 Hz, 1H), 4.39 (d, J = 5.9 Hz, 2H), 3.83 (s, 3H), 2.13 (s, 3H). ESI-MS: 428.05 (M+H)+ N-[(6-methoxy-3-pyridyl)methyl]-2-methyl-3-{[2-(2-methylpyrazol-3-yl)-4pyridyl]oxy}benzamide (203): Petition 870260063548, dated 06 / 26 / 2026, p. 183 / 639 177 / 316

[0281] Compound 203 was synthesized from intermediate 199a (0.07 mmol) and pinacol ester of 1-methyl-1H-pyrazol-5-boronic acid (0.10 mmol) as a white solid with a yield of 43% according to general method D2. 1H NMR (400 MHz, DMSO-cfe) δ (ppm): 8.89 (t, J = 5.9 Hz, 1H), 8.53 (d, J = 5.7 Hz, 1H), 8.14 (d, J = 2.0 Hz, 1H), 7.69 (dd, J = 8.5 Hz, 2.5 Hz, 1H), 7.46 (d, J = 2.0 Hz, 1H), 7.38 (t, J = 7.8 Hz, 1H), 7.32-7.30 (m, 2H), 7.24 (dd, J = 7.9 Hz, 1.2 Hz, 1H), 6.81 (d, J = 8.5 Hz, 1H), 6.73 (d, J = 2.0Hz, 1H), 6.71 (dd, J = 5.7 Hz, 2.5 Hz, 1H), 4.39 (d, J = 5.9 Hz, 2H), 4.11 (s, 3H), 3.83 (s, 3H), 2.12 (s, 3H). ESI-MS: 430.10 (M+H)+. 3-{[2-(3,5-dimethylisoxazol-4-yl)-4-pyridyl]oxy}-N-[(6-methoxy-3-pyridyl)methyl]-2methyl-benzamide (204):

[0282] Compound 204 was synthesized from intermediate 199a (0.07 mmol) and pinacol ester of 3,5-dimethylisoxazol-4-boronic acid (0.10 mmol) as a white solid with a yield of 35% according to general method D2. 1H NMR (400 MHz, DMSO-cfe) δ (ppm): 8.88 (t, J = 5.9 Hz, 1H), 8.52 (d, J = 5.7 Hz, 1H), 8.14 (d, J = 1.9 Hz, 1H), 7.69 (dd, J = 8.5 Hz, 2.5 Hz, 1H), 7.38 (t, J = 7.8 Hz, 1H), 7.31 (dd, J = 7.6 Hz, 1.3 Hz, 1H), 7.25 (dd, J = 7.9 Hz, 1.2 Hz, 1H), 6.99 (d, J = 2.2 Hz, 1H), 6.81 (d, J = 8.5 Hz, 1H), 6.73 (dd, J = 5.7 Hz, 2.4 Hz, 1H), 4.39 (d, J = 5.9 Hz, 2H), 3.83 (s, 3H), 2.31 (s, 3H), 2.12 (s, 3H). ESI-MS: 445.10 (M+H)+ 3-{[2-(1,3-dimethylpyrazol-4-yl)-4-pyridyl]oxy]-N-[(6-methoxy-3-pyridyl)methyl]-2methyl-benzamide (205): Petition 870260063548, dated 06 / 26 / 2026, p. 184 / 639 178 / 316

[0283] Compound 205 was synthesized from intermediate 199a (0.07 mmol) and pinacol ester of 1,3-dimethyl-1H-pyrazol-4-boronic acid (0.10 mmol) as a white solid with a yield of 86% according to general method D2. 1H NMR (400 MHz, DMSO-cfe) δ (ppm): 8.88 (t, J = 5.9 Hz, 1H), 8.39 (d, J = 5.7 Hz, 1H), 8.14 (d, J = 2.0 Hz, 1H), 8.10 (s, 1H), 7.69 (dd, J = 8.5 Hz, 2.5 Hz, 1H), 7.36 (t, J = 7.8 Hz, 1H), 7.30 (dd, J = 7.6 Hz, 1.3 Hz, 1H), 7.21 (dd, J = 7.9 Hz, 1.2 Hz, 1H), 7.01 (d, J = 2.3 Hz, 1H), 6.81 (d, J = 8.5Hz, 1H), 6.54 (dd, J = 5.7 Hz, 2.4 Hz, 1H), 4.39 (d, J = 5.9 Hz, 2H), 3.83 (s, 3H), 3.77 (s, 3H), 2.35 (s, 3H), 2.11 (s, 3H). ESI-MS: 444.15 (M+H)+. N-[(3,5-difluorophenyl)methyl]-2-methyl-3-{[2-(4-pyridyl)-4-pyridyl]oxy} benzamide (206):

[0284] Compound 206 was synthesized from intermediate 199b (0.08 mmol) and pyridine-4-boronic acid hydrate (0.12 mmol) as a white solid with a yield of 67% according to the general method D2.1H NMR (400 MHz, DMSO-d6) δ (ppm): 9.03 (t, J = 6.0 Hz, 1H), 8.70-8.68 (m, 2H), 8.60 (d, J = 5.6 Hz, 1H), 8.03-8.01 (m, 2H), 7.73 (d, J = 2.3 Hz, 1H), 7.44-7.38 (m, 2H), 7.29 (dd, J = 7.1 Hz, 2.2 Hz, 1H), 7.13 (tt, J = 9.4 Hz, 2.3 Hz, 1H), 7.09-7.04 (m, 2H), 6.77 (dd, J = 5.6 Hz, 2.4 Hz, 1H), 4.48 (d, J = 6.0 Hz, 2H), 2.15 (s, 3H). ESI-MS: 432.20 (M+H)+ N-[(3,5-difluorophenyl)methyl]-2-methyl-3-{[2-(3-pyridyl)-4-pyridyl]oxy} benzamide í20Zi

[0285] Compound 207 was synthesized from intermediate 199b (0.07 mmol) and pyridine-3-boronic acid (0.12 mmol) as a white solid with an 85% yield according to the general D2.1H NMR method (500 MHz, DMSO). Petition 870260063548, dated 06 / 26 / 2026, p. 185 / 639 179 / 316 de) δ (ppm): 9.22 (d, J = 1.7 Hz, 1H), 9.04 (t, J = 6.0 Hz, 1H), 8.64 (dd, J = 4.8 Hz, 1.6 Hz, 1H), 8.57 (d, 7), J = 8.41–8.38 (m, 1H), 7.66 (d, J = 2.3 Hz, 1H), 7.51 (ddd, J = 8.0 Hz, 4.8 Hz, 0.7 Hz, 1H), 7.43–7.37 (m, 1d, 27, 7.28) ( 1H), 7.14 (tt, J = 9.4 Hz, 2.4 Hz, 1H), 7.09–7.05 (m, 2H), 6.71 (dd, J = 5.7 Hz, 2.4 Hz, 1H), 4.48 (d, J = 6.0 Hz (2, 2H), 2H). ESI-MS: 432.05 (M+H)+. N-[(3,5-difluorophenyl)methyl]-2-methyl-3-[(2-pyrimidine-5-yl-4-pyridyl)oxi] benzamide (208):

[0286] Compound 208 was synthesized from intermediate 199b (0.08 mmol) and pyrimidine-5-boronic acid (0.12 mmol) as a white solid with a yield of 85% according to general method D2. 1H NMR (500 MHz, DMSOd6) δ (ppm): 9.43 (s, 2H), 9.26 (s, 1H), 9.03 (t, J = 6.0 Hz, 1H), 8.60 (d, J = 5.7 Hz, 1H), 7.84 (d, J = 2.2 Hz, 1H), 7.43-7.38 (m, 2H), 7.28 (dd, J = 7.3 Hz, 2.0 Hz, 1H), 7.16-7.11 (m, 1H), 7.09-7.05 (m, 2H), 6.73 (dd, J = 5.7 Hz, 2.4 Hz, 1H), 4.48 (d, J = 6.0Hz, 2H), 2.15 (s, 3H). ESI-MS: 433.05 (M+H)+ N-[(3,5-difluorophenyl)methyl]-2-methyl-3-{[2-(2-methylpyrazol-3-yl)-4-pyridyl]oxy}benzamide (209):

[0287] Compound 209 was synthesized from intermediate 199b (0.08 mmol) and pinacol ester of 1-methyl-1H-pyrazol-5-boronic acid (0.12 mmol) as a white solid with a yield of 45% according to general method D2. 1H NMR (500 MHz, DMSO-d6) δ (ppm): 9.04 (t, J = 6.1 Hz, 1H), 8.54 (d, J = 5.8 Hz, 1H), 7.47 (d, J = 2.0 Hz, 1H), 7.42-7.37 (m, 2H), 7.34 (d, J = 2.4 Hz, 1H), 7.27 (dd, J = 7.5 Hz, 1.8 Hz, 1H), 7.16-7.11 (m, 1H), 7.09-7.04 (m, 2H), 6.75 (d, J = 2.0 Hz, Petition 870260063548, dated 06 / 26 / 2026, p. 186 / 639 180 / 316 1H), 6.71 (dd, J = 5.7 Hz, 2.5 Hz, 1H), 4.47 (d, J = 6.0 Hz, 2H), 4.12 (s, 3H), 2.14 (s, 3H). ESI-MS: 435.15 (M+H)+. N-[(3,5-difluorophenyl)methyl]-3-{[2-(3,5-dimethylisoxazol-4-yl)-4-pyridyl]oxy}-2methyl-benzamide (210):

[0288] Compound 210 was synthesized from intermediate 199b (0.08 mmol) and pinacol ester of 3,5-dimethylisoxazol-4-boronic acid (0.12 mmol) as a white solid with a yield of 35% according to general method D2. 1H NMR (500 MHz, DMSO-cfe) δ (ppm): 9.02 (t, J = 6.0 Hz, 1H), 8.53 (d, J = 5.7 Hz, 1H), 7.42-7.37 (m, 2H), 7.29 (dd, J = 7.4 Hz, 1.9 Hz, 1H), 7.14-7.11 (m, 1H), 7.087.04 (m, 2H), 7.00 (d, J = 2.3 Hz, 1H), 6.74 (dd, J = 5.7 Hz, 2.4 Hz, 1H), 4.47 (d, J = 6.0 Hz, 2H), 2.31 (s, 3H), 2.14 (s, 3H). ESI-MS: 450.20 (M+H)+ N-[(3,5-difluorophenyl)methyl]-3-{[2-(1,3-dimethylpyrazol-4-yl)-4-pyridyl]oxy}-2-methylbenzamide (211):

[0289] Compound 211 was synthesized from intermediate 199b (0.08 mmol) and pinacol ester of 1,3-dimethyl-1H-pyrazol-4-boronic acid (0.12 mmol) as a white solid with an 80% yield according to general method D2. 1H NMR (500 MHz, DMSO-cfe) δ (ppm): 9.02 (t, J = 6.0 Hz, 1H), 8.40 (d, J = 5.7 Hz, 1H), 8.12 (s, 1H), 7.41-7.35 (m, 2H), 7.24 (dd, J = 7.5 Hz, 1.8 Hz, 1H), 7.14 (tt, J = 9.4Hz, 2.4Hz, 1H), 7.08-7.04 (m, 2H), 7.03 (d, J = 2.3Hz, 1H), 6.55 (dd, J = 5.7Hz, 2.4Hz, 1H), 4.47 (d, J = 6.0 Hz, 2H), 3.77 (s, 3H), 2.35 (s, 3H), 2.13 (s, 3H). ESI-MS: 449.90 (M+H)+ Petition 870260063548, dated 06 / 26 / 2026, p. 187 / 639 181 / 316 N-[(3,5-difluorophenyl)methyl]-2-methyl-3-{[2-(1-methylpyrazol-3-yl)-4-pyridyl]oxy}benzamide (212):

[0290] Compound 212 was synthesized from intermediate 199b (0.06 mmol) and 1-methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole (0.10 mmol) as a branch only in 64% yield com the general method D2.1H NMR (400 MHz, DMSO-cfe) δ (ppm): 9.07 (t, J = 6.0 Hz, 1H), 8.46 (d, J = 5.7 Hz, 1H), 7.74 (d, J = 2.2 Hz, 1H), 7.74 (Hz, 7.4), 7.27 (dd, J = 7.4 Hz, 1.8 Hz, 1H), 7.20 (d, J = 2.5 Hz, 1H), 7.13 (tt, J = 9.4 Hz , 2.3 Hz, 1H), 7.107.04 (m, 2H), 6.8 (dd, J = 7.5 Hz, 2.5 Hz 1H), 6.77 (d, J = 2.2 Hz, 1H), 4.47 (d, J = 6.0 Hz, 2H), 3.85 (s, 3H), 2.13 (s, 3H). ESI-MS: 435.10 (M+H)+. N-[(3,5-difluorophenyl)methyl]-3-{[2-(1,5-dimethylpyrazol-4-yl)-4-pyridyl]oxy}-2-methylbenzamide (213):

[0291] Compound 213 was synthesized from intermediate 199b (0.07 mmol) and pinacol ester of 1,3-dimethyl-1H-pyrazol-4-boronic acid (0.10 mmol) as a white solid with a yield of 70% according to general method D2. 1H NMR (400 MHz, DMSO-cfe) δ (ppm): 9.00 (t, J = 6.0 Hz, 1H), 8.40 (d, J = 5.8 Hz, 1H), 7.81 (s, 1H), 7.41-7.35 (m, 2H), 7.23 (dd, J = 7.4 Hz, 1.9 Hz, 1H), 7.16-7.04 (m, 4H), 6.51 (dd, J = 5.7 Hz, 2.4 Hz, 1H), 4.48 (d, J = 6.0 Hz, 2H), 3.76 (s, 3H), 2.55 (s, 3H), 2.14 (s, 3H). ESI-MS: 449.20 (M+H)+ N-[(3,5-difluorophenyl)methyl]-2-methyl-3-{[2-(1H-pyrazol-4-yl)-4-pyridyl]oxy} benzamide (214): Petition 870260063548, dated 06 / 26 / 2026, p. 188 / 639 182 / 316

[0292] Compound 214 was synthesized from intermediate 199b (0.07 mmol) and pinacol ester of 1H-pyrazol-4-boronic acid (0.10 mmol) as a white solid with a yield of 41% according to general method D2. 1H NMR (400 MHz, DMSO-d6) δ (ppm): 13.06 (bs, 1H), 8.99 (t, J = 6.0 Hz, 1H), 8.36 (d, J = 5.8 Hz, 1H), 8.17 (bs, 2H), 7.41-7.33 (m, 3H), 7.22 (dd, J = 7.4 Hz, 1.9 Hz, 1H), 7.13 (tt, J = 9.5 Hz, 2.4 Hz, 1H), 7.09-7.04 (m, 2H), 6.46 (dd, J = 5.7 Hz, 2.4 Hz, 1H), 4.48 (d, J = 6.0 Hz, 2H), 2.15 (s, 3H). ESI-MS: 421.10 (M+H)+. N-[(3,5-difluorophenyl)methyl]-2-methyl-3-{[2-(1-tetrahydropyran-4-ylpyrazol-4-yl)4-pyridyl]oxy}benzamide (215):

[0293] Compound 215 was synthesized from intermediate 199b (0.07 mmol) and 1-(tetrahydro-2H-pyran-4-yl)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)1H-pyrazole (0.10 mmol) as a white solid in a 42% yield according to general method D2. 1H NMR (400 MHz, DMSO-cfe) δ (ppm): 8.99 (t, J = 6.0 Hz, 1H), 8.37-8.35 (m, 2H), 8.00 (s, 1H), 7.42-7.34 (m, 2H), 7.30 (d, J = 2.3 Hz, 1H), 7.22 (dd, J = 7.3 Hz, 1.8 Hz, 1H), 7.16-7.04 (m, 3H), 6.48 (dd, J = 5.7 Hz, 2.4 Hz, 1H), 4.48-4.38 (m, 3H), 3.98-3.94 (m, 2H), 3.50-3.43 (m, 2H), 2.14 (s, 3H), 2,001,91 (m, 4H). ESI-MS: 505.20 (M+H)+ 3-{[2-(1-cyclopropylpyrazol-4-yl)-4-pyridyl]oxy}-N-[(3,5-difluorophenyl)methyl]-2methyl-benzamide (216): Petition 870260063548, dated 06 / 26 / 2026, p. 189 / 639 183 / 316

[0294] Compound 216 was synthesized from intermediate 199b (0.07 mmol) and 1-cyclopropyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole (0.10 mmol) as a white solid with a yield of 63% according to the general method D2.1H NMR (400 MHz, DMSO-cfe) δ (ppm): 8.99 (t, J = 6.0 Hz, 1H), 8.36-8.35 (m, 2H), 7.96 (d, J = 0.6 Hz, 1H), 7.41-7.34 (m, 2H), 7.30 (d, J = 2.4 Hz, 1H), 7.22 (dd, J = 7.2 Hz, 2.1 Hz, 1H), 7.13-7.04 (m, 3H), 6.47 (dd, J = 5.7 Hz, 2.4 Hz, 1H), 4.48 (d, J = 6.0 Hz, 2H), 3.79-3.74 (m, 1H), 2.14 (s, 3H), 1.10-0.95 (m, 4H). ESI-MS: 461.20 (M+H)+. 3-({2-[1-(difluoromethyl)pyrazol-4-yl]-4-pyridyl}oxy)-N-[(3,5-difluorophenyl)methyl]-2methyl-benzamide (217):

[0295] Compound 217 was synthesized from intermediate 199b (0.06 mmol) and 1-(difluoromethyl)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole (0.10 mmol) as a white solid in 100% yield according to the general method D2.1H NMR (400 MHz, DMSO-cfe) δ (ppm): 8.99 (t, J = 6.0 Hz, 1H), 8.82 (s, 1H), 8.43 (d, J = 5.7 Hz, 1H), 8.35 (s, 1H), 7.85 (t, J = 59.0 Hz, 1H), 7.49 (d, J = 2.3 Hz, 1H), 7.42-7.37 (m, 2H), 7.24 (dd, J = 7.2 Hz, 2.2 Hz, 1H), 7.16-7.04 (m, 3H), 6.57 (dd, J = 5.7 Hz, 2.4 Hz, 1H), 4.48 (d, J = 6.0 Hz, 2H), 2.15 (s, 3H). ESI-MS: 471.20 (M+H)+ N-[(3,5-difluorophenyl)methyl]-2-methyl-3-[(2-phenyl-4-pyridyl)oxy]benzamide (218): Petition 870260063548, dated 06 / 26 / 2026, p. 190 / 639 184 / 316

[0296] Compound 218 was synthesized from intermediate 199b (0.05 mmol) and benzene boric acid (0.08 mmol) as a white solid with a yield of 82% according to general method D2. 1H NMR (400 MHz, DMSOd6) δ (ppm): 9.01 (t, J = 6.0 Hz, 1H), 8.54 (d, J = 5.8 Hz, 1H), 8.03-8.01 (m, 2H), 7.50-7.36 (m, 6H), 7.27 (dd, J = 7.4 Hz, 1.9 Hz, 1H), 7.16-7.09 (m, 1H), 7.08-7.04 (m, 2H), 6.71 (dd, J = 5.6 Hz, 2.4 Hz, 1H), 4.48 (d, J = 6.0 Hz, 2H), 2.16 (s, 3H). ESI-MS: 431.05 (M+H)+. N-[(3,5-difluorophenyl)methyl]-3-{[2-(2-fluorophenyl)-4-pyridyl]oxy}-2-methylbenzamide (219):

[0297] Compound 219 was synthesized from intermediate 199b (0.05 mmol) and 2-fluorobenzeneboronic acid (0.08 mmol) as a white solid with a yield of 74% according to general method D2. 1H NMR (600 MHz, DMSO-d6) δ (ppm): 9.00 (t, J = 6.1 Hz, 1H), 8.60-8.58 (m, 1H), 7.93 (td, J = 7.9 Hz, 1.8 Hz, 1H), 7.50-7.46 (m, 1H), 7.42-7.37 (m, 2H), 7.34-7.27 (m, 3H), 7.23-7.22 (m, 1H), 7.12 (tt, J = 9.4 Hz, 2.4 Hz, 1H), 7.08-7.04 (m, 2H), 6.86 (dd, J = 5.7 Hz, 2.4 Hz, 1H), 4.47 (d, J = 6.0 Hz, 2H), 2.15 (s, 3H). ESI-MS: 449.05 (M+H)+ N-[(3,5-difluorophenyl)methyl]-3-{[2-(3-fluorophenyl)-4-pyridyl]oxy}-2-methylbenzamide (220):

[0298] Compound 220 was synthesized from intermediate 199b (0.05 mmol) and 3-fluorobenzeneboronic acid (0.08 mmol) as a white solid with an 83% yield according to the general method D2. 1H NMR (600 MHz, DMSO-d6) δ (ppm): 9.00 (t, J = 6.1 Hz, 1H), 8.55-8.54 (m, 1H), 7.90-7.85 (m, 2H), 7.61-7.60 (m, 1H), 7.54-7.51 (m, 1H), 7.42-7.37 (m, 2H), 7.30-7.26 (m, 2H), 7.12 (tt, Petition 870260063548, dated 06 / 26 / 2026, p. 191 / 639 185 / 316 J = 9.3 Hz, 2.4 Hz, 1H), 7.08-7.05 (m, 2H), 6.71 (dd, J = 5.6 Hz, 2.4 Hz, 1H), 4.48 (d, J = 6.0 Hz, 2H), 2.16 (s, 3H). ESI-MS: 449.05 (M+H)+. N-[(3,5-difluorophenyl)methyl]-3-{[2-(4-fluorophenyl)-4-pyridyl]oxy}-2-methylbenzamide (221):

[0299] Compound 221 was synthesized from intermediate 199b (0.05 mmol) and 4-fluorobenzeneboronic acid (0.08 mmol) as a white solid with a yield of 91% according to general method D2. 1H NMR (600 MHz, DMSO-d6) δ (ppm): 9.00 (t, J = 6.0 Hz, 1H), 8.52 (d, J = 5.7 Hz, 1H), 8.10-8.07 (m, 2H), 7.50 (d, J = 2.3 Hz, 1H), 7.42-7.3 (m, 2H) 2.16 (s, 3H). ESI-MS: 449.05 (M+H)+ N-[(3,5-difluorophenyl)methyl]-3-{[2-(2-methoxyphenyl)-4-pyridyl]oxy}-2-methylbenzamide (222):

[0300] Compound 222 was synthesized from intermediate 199b (0.05 mmol) and 2-methoxybenzeneboronic acid (0.08 mmol) as a white solid with a yield of 75% according to general method D2. 1H NMR (600 MHz, DMSO-d6) δ (ppm): 9.00 (t, J = 6.1 Hz, 1H), 8.53 (dd, J = 5.7 Hz, 0.4 Hz, 1H), 7.78 (dd, J = 7.7 Hz, 1.8 Hz, 1H), 7.42-7.36 (m, 3H), 7.27-7.25 (m, 2H), 7.14-7.02 (m, 5H), 6.85 (dd, J = 5.7 Hz, 2.5 Hz, 1H), 4.48 (d, J = 6.0 Hz, 2H), 3.74 (s, 3H), 2.15 (s, 3H). ESI-MS: 461.05 (M+H)+ Petition 870260063548, dated 06 / 26 / 2026, p. 192 / 639 186 / 316 N-[(3,5-difluorophenyl)methyl]-3-{[2-(3-methoxyphenyl)-4-pyridyl]oxy}-2-methylbenzamide (223):

[0301] Compound 223 was synthesized from intermediate 199b (0.05 mmol) and 3-methoxybenzeneboronic acid (0.08 mmol) as a white solid with a yield of 84% according to general method D2. 1H NMR (600 MHz, DMSO-d6) δ (ppm): 9.00 (t, J = 6.0 Hz, 1H), 8.53 (d, J = 5.6 Hz, 1H), 7.60-7.59 (m, 1H), 7.57 (dd, J = 7.7 Hz, 0.9 Hz, 1H), 7.51 (d, J = 2.3 Hz, 1H), 7.42-7.37 (m, 3H), 7.26 (d, J = 7.7 Hz, 1H), 7.14-7.10 (m, 1H), 7.08-7.05 (m, 2H), 7.02-7.00 (m, 1H), 6.70-6.68 (m, 1H), 4.48 (d, J = 6.0 Hz, 2H), 3.82 (s, 3H), 2.16 (s, 3H). ESI-MS: 461.05 (M+H)+. N-[(3,5-difluorophenyl)methyl]-3-{[2-(4-methoxyphenyl)-4-pyridyl]oxy}-2-methylbenzamide (224):

[0302] Compound 224 was synthesized from intermediate 199b (0.05 mmol) and 4-methoxybenzeneboronic acid (0.08 mmol) as a white solid with a yield of 92% according to general method D2. 1H NMR (600 MHz, DMSO-d6) δ (ppm): 9.00 (t, J = 6.1 Hz, 1H), 8.48-8.47 (m, 1H), 8.00-7.97 (m, 2H), 7.41-7.36 (m, 3H), 7.26 (dd, J = 7.7 Hz, 1.4 Hz, 1H), 7.12 (tt, J = 9.4 Hz, 2.4 Hz, 1H), 7.08-7.05 (m, 2H), 7.03-7.00 (m, 2H), 6.63 (dd, J = 5.6 Hz, 2.4 Hz, 1H), 4.48 (d, J = 6.0 Hz, 2H), 3.81 (s, 3H), 2.15 (s, 3H). ESI-MS: 461.05 (M+H)+ Petition 870260063548, dated 06 / 26 / 2026, p. 193 / 639 187 / 316 N-[(3,5-difluorophenyl)methyl]-2-methyl-3-{[2-(o-tolyl)-4-pyridyl]oxy}benzamide (225):

[0303] Compound 225 was synthesized from intermediate 199b (0.05 mmol) and o-tolylboronic acid (0.08 mmol) as a white solid with a yield of 83% according to general method D2. 1H NMR (600 MHz, DMSOd6) δ (ppm): 8.99 (t, J = 6.0 Hz, 1H), 8.54 (dd, J = 5.7 Hz, 0.5 Hz, 1H), 7.41 -7.23 (m, 7H), 7.12 (tt, J = 9.4 Hz, 2.4 Hz, 1H), 7.07-7.04 (m, 2H), 6.86 (dd, J = 2.5 Hz, 0.5 Hz, 1H), 6.84 (dd, J = 5.7 Hz, 2.5 Hz, 1H), 4.47 (d, J = 6.0 Hz, 2H), 2.27 (s, 3H), 2.15 (s, 3H). ESI-MS: 445.05 (M+H)+. N-[(3,5-difluorophenyl)methyl]-2-methyl-3-{[2-(m-tolyl)-4-pyridyl]oxy}benzamide (226):

[0304] Compound 226 was synthesized from intermediate 199b (0.05 mmol) and 3-tolylboronic acid (0.08 mmol) as a white solid with a yield of 83% according to general method D2. 1H NMR (600 MHz, DMSOd6) δ (ppm): 9.00 (t, J = 6.1 Hz, 1H), 8.52 (dd, J = 5.7 Hz, 0.4 Hz, 1H), 7.87 (s, 1H), 7.79 (d, J = 7 Hz.8, 1H), 7.48-7.46 (m, 1H), 7.42-7.34 (m, 3H), 7.27-7.24 (m, 2H), 7.12 (tt, J = 9.4 Hz, 2.4 Hz, 1H), 7.08-7.05 (m, 2H), 6.69 (dd, J = 5.6 Hz, 2.4 Hz, 1H), 4.48 (d, J = 6.0 Hz, 2H), 2.38 (s, 3H), 2.16 (s, 3H). ESI-MS: 445.05 (M+H)+ Petition 870260063548, dated 06 / 26 / 2026, p. 194 / 639 188 / 316 N-[(3,5-difluorophenyl)methyl]-2-methyl-3-{[2-(p-tolyl)-4-pyridyl]oxy}benzamide (227)1

[0305] Compound 227 was synthesized from intermediate 199b (0.05 mmol) and 4-tolylboronic acid (0.08 mmol) as a white solid with a yield of 91% according to general method D2. 1H NMR (600 MHz, DMSOd6) δ (ppm): 9.00 (t, J = 6.1 Hz, 1H), 8.51-8.50 (m, 1H), 7.92-7.91 (m, 2H), 7.44 (d, J = 2.0 Hz, 1H), 7.42-7.36 (m, 2H), 7.29-7.25 (m, 3H), 7.12 (tt, J = 9.4 Hz, 2.4 Hz, 1H), 7.08-7.05 (m, 2H), 6.67 (dd, J = 5.6 Hz, 2.4 Hz, 1H), 4.48 (d, J = 6.0 Hz, 2H), 2.35 (s, 3H), 2.15 (s, 3H). ESI-MS: 445.05 (M+H)+. The following compounds are examples that illustrate the H Method: N-[(6-methoxy-3-pyridyl)methyl]-2-methyl-3-({2-[(1-methylpyrazol-4-yl)amino]-4pyridyl}oxy)benzamide (228):

[0306] Compound 228 was synthesized from intermediate 199a (0.09 mmol) and 1-methyl-1H-pyrazol-4-ylamine (0.18 mmol) as a white solid in a 54% yield according to the general H method. 1H NMR (400 MHz, DMSOd6) δ (ppm): 8.89 (t, J = 5.9 Hz, 1H), 8.74 (s, 1H), 8.13 (d, J = 2.3 Hz, 1H), 7.98 (d, J = 5.8 Hz, 1H), 7.86 (s, 1H), 7.69 (dd, J = 8.5 Hz, 2.4 Hz, 1H), 7.37-7.26 (m, 3H), 7.18 (dd, J = 7.9 Hz, 1.0 Hz, 1H), 6.81 (d, J = 8.5 Hz, 1H), 6.23 (dd, J = 5.8 Hz, 2.2 Hz, 1H), 5.93 (d, J = 2.2 Hz, 1H), 4.38 (d, J = 5.9 Hz, 2H), 3.83 (s, 3H), 3.76 (s, 3H), 2.10 (s, 3H). ESI-MS: 445.25 (M+H)+ Petition 870260063548, dated 06 / 26 / 2026, p. 195 / 639 189 / 316 N-[(6-methoxy-3-pyridyl)methyl]-2-methyl-3-({2-[(1-methylpyrazol-3-yl)amino]-4pyridyl}oxy)benzamide (229):

[0307] Compound 229 was synthesized from intermediate 199a (0.09 mmol) and 1-methylpyrazol-3-amine (0.18 mmol) as a white solid with a yield of 44% according to the general H method. 1H NMR (400 MHz, DMSOd6) δ (ppm): 9.18 (s, 1H), 8.89 (t, J = 5.9 Hz, 1H), 8.13 (d, J = 2.3 Hz, 1H), 7.97 (d, J = 5.8 Hz, 1H), 7.69 (dd, J = 8.5 Hz, 2.4 Hz, 1H), 7.46 (d, J = 2.2 Hz, 1H), 7.34 (t, J = 7.8 Hz, 1H), 7.27 (dd, J = 7.6 Hz, 1.1 Hz, 1H), 7.17 (dd, J = 7.9 Hz, 1.0 Hz, 1H), 6.87 (d, J = 2.0 Hz, 1H), 6.81 (d, J = 8.5 Hz, 1H), 6.17 (dd, J = 5.8 Hz, 2.3 Hz, 1H), 6.14 (d, J = 2.2 Hz, 1H), 4.38 (d, J = 5.9 Hz, 2H), 3.83 (s, 3H), 3.67 (s, 3H), 2.11 (s, 3H). ESI-MS: 445.90 (M+H)+. N-[(3,5-difluorophenyl)methyl]-2-methyl-3-({2-[(1-methylpyrazol-4-yl)amino]-4pyridyl}oxy)benzamide (230):

[0308] Compound 230 was synthesized from intermediate 199b (0.08 mmol) and 1-methyl-1H-pyrazol-4-ylamine (0.15 mmol) as a white solid with a 72% yield according to the general H method. 1H NMR (500 MHz, DMSOd6) δ (ppm): 9.01 (t, J = 6.1 Hz, 1H), 8.76 (s, 1H), 7.99 (d, J = 5.8 Hz, 1H), 7.87 (s, 1H), 7.39-7.33 (m, 2H), 7.31 (d, J = 0.6 Hz, 1H), 7.21 (dd, J = 7.6 Hz, 1.6 Hz, 1H), 7.16-7.11 (m, 1H), 7.08-7.03 (m, 2H), 6.24 (dd, J = 5.8 Hz, 2.2 Hz, 1H), 5.93 (d, J = 2.2 Hz, 1H), 4.47 (d, J = 6.0 Hz, 2H), 3.76 (s, 3H), 2.12 (s, 3H). ESI-MS: 450.25 (M+H)+ Petition 870260063548, dated 06 / 26 / 2026, p. 196 / 639 190 / 316 N-[(3,5-difluorophenyl)methyl]-2-methyl-3-({2-[(1-methylpyrazol-3-yl)amino]-4pyridyl}oxy)benzamide (231):

[0309] Compound 231 was synthesized from intermediate 199b (0.08 mmol) and 1-methylpyrazol-3-amine (0.15 mmol) as a white solid with a 63% yield according to the general H method. 1H NMR (500 MHz, DMSOd6) δ (ppm): 9.21 (s, 1H), 9.01 (t, J = 6.1 Hz, 1H), 7.98 (d, J = 5.8 Hz, 1H), 7.46 (d, J = 2.2 Hz, 1H), 7.39-7.33 (m, 2H), 7.20 (dd, J = 7.7 Hz, 1.5 Hz, 1H), 7.15-7.11 (m, 1H), 7.08-7.04 (m, 2H), 6.88 (d, J = 1.6 Hz, 1H), 6.18 (dd, J = 5.8 Hz, 2.3 Hz, 1H), 6.14 (d, J = 2.1 Hz, 1H), 4.47 (d, J = 6.0 Hz, 2H), 3.67 (s, 3H), 2.13 (s, 3H). ESI-MS: 450.25 (M+H)+. N-[(3,5-difluorophenyl)methyl]-2-methyl-3-{[2-(2-pyridylamino)-4-pyridyl]oxy} benzamide (232):

[0310] Compound 232 was synthesized from intermediate 199b (0.10 mmol) and 2-aminopyridine (0.20 mmol) as a white solid with a yield of 33% according to the general H method. 1H NMR (400 MHz, DMSO-d6) δ (ppm): 9.70 (s, 1H), 9.01 (t, J = 6.1 Hz, 1H), 8.15-8.13 (m, 1H), 8.10 (d, J = 5.8 Hz, 1H), 7.65-7.59 (m, 2H), 7.43 (d, J = 2.3 Hz, 1H), 7.41-7.34 (m, 2H), 7.22 (dd, J = 7.3 Hz, 2.0 Hz, 1H), 7.13 (tt, J = 9.3 Hz, 2.3 Hz, 1H), 7.08-7.04 (m, 2H), 6.85-6.82 (m, 1H), 6.32 (dd, J = 5.8 Hz, 2.3 Hz, 1H), 4.48 (d, J = 6.0 Hz, 2H), 2.15 (s, 3H). ESI-MS: 447.15 (M+H)+ Petition 870260063548, dated 06 / 26 / 2026, p. 197 / 639 191 / 316 N-[(3,5-difluorophenyl)methyl]-2-methyl-3-{[2-(4-pyridylamino)-4-pyridyl]oxy} benzamide (233):

[0311] Compound 233 was synthesized from intermediate 199b (0.10 mmol) and 4-aminopyridine (0.20 mmol) as a white solid with a yield of 44% according to the general H method. 1H NMR (600 MHz, DMSO-cfe) δ (ppm): 9.48 (s, 1H), 8.98 (t, J = 6.0 Hz, 1H), 8.27 (d, J = 6.4 Hz, 2H), 8.17 (d, J = 5.8 Hz, 1H), 7.61-7.60 (m, 2H), 7.42-7.37 (m, 2H), 7.26 (dd, J = 7.5 Hz, 1.6 Hz, 1H), 7.13 (tt, J = 9.4 Hz, 2.3 Hz, 1H), 7.08-7.04 (m, 2H), 6.55 (dd, J = 5.8 Hz, 2.2 Hz, 1H), 6.21 (d, J = 2.2 Hz, 1H), 4.48 (d, J = 6.0 Hz, 2H), 2.14 (s, 3H). ESI-MS: 447.15 (M+H)+. N-[(3,5-difluorophenyl)methyl]-2-methyl-3-{[2-(pyrimidin-2-ylamino)-4-pyridyl]oxy}benzamide (234):

[0312] Compound 234 was synthesized from intermediate 199b (0.08 mmol) and pyrimidin-2-amine (0.17 mmol) as a white solid with a yield of 32% according to the general H method. 1H NMR (400 MHz, DMSO-cfe) δ (ppm): 9.87 (s, 1H), 9.00 (t, J = 6.1 Hz, 1H), 8.51 (s, 1H), 8.50 (s, 1H), 8.14 (d, J = 5.7 Hz, 1H), 7.95 (d, J = 2.1 Hz, 1H), 7.41-7.34 (m, 2H), 7.23 (dd, J = 7.4 Hz, 1.8 Hz, 1H), 7.13 (tt, J = 9.5 Hz, 2.4 Hz, 1H), 7.09-7.04 (m, 2H), 6.93 (t, J = 4.8 Hz, 1H), 6.37 (dd, J = 5.7 Hz, 2.4 Hz, 1H), 4.48 (d, J = 6.0 Hz, 2H), 2.15 (s, 3H). ESI-MS: 448.05 (M+H)+ Petition 870260063548, dated 06 / 26 / 2026, p. 198 / 639 192 / 316 N-[(3,5-difluorophenyl)methyl]-2-methyl-3-{[2-(pyrimidin-4-ylamino)-4-pyridyl]oxy}benzamide (235):

[0313] Compound 235 was synthesized from intermediate 199b (0.08 mmol) and 4-aminopyrimidine (0.17 mmol) as a white solid in 50% yield according to the general H method. 1H NMR (400 MHz, DMSO-cfe) δ (ppm): 10.21 (s, 1H), 9.00 (t, J = 6.1 Hz, 1H), 8.65 (d, J = 0.8 Hz, 1H), 8.41-8.39 (m, 1H), 8.18 (d, J = 5.8 Hz, 1H), 7.70 (dd, J = 5.9 Hz, 1.2 Hz, 1H), 7.42-7.34 (m, 3H), 7.24 (dd, J = 7.1 Hz, 2.2 Hz, 1H), 7.12 (tt, J = 9.5 Hz, 2.4 Hz, 1H), 7.09-7.03 (m, 2H), 6.47 (dd, J = 5.8 Hz, 2.3 Hz, 1H), 4.48 (d, J = 6.0 Hz, 2H), 2.14 (s, 3H). ESI-MS: 448.05 (M+H)+. N-[(3,5-difluorophenyl)methyl]-2-methyl-3-{[2-(pyrimidin-5-ylamino)-4-pyridyl]oxy}benzamide (236):

[0314] Compound 236 was synthesized from intermediate 199b (0.08 mmol) and 5-aminopyrimidine (0.17 mmol) as a white solid with a yield of 19% according to the general H method. 1H NMR (400 MHz, DMSO-cfe) δ (ppm): 9.40 (s, 1H), 9.08 (s, 2H), 8.99 (t, J = 6.0 Hz, 1H), 8.69 (s, 1H), 8.13 (d, J = 5.8 Hz, 1H), 7.42-7.37 (m, 2H), 7.26 (dd, J = 7.3 Hz, 2.0 Hz, 1H), 7.13 (tt, J = 9.4 Hz, 2.4 Hz, 1H), 7.09-7.03 (m, 2H), 6.53 (dd, J = 5.8 Hz, 2.2 Hz, 1H), 6.15 (d, J = 2.1 Hz, 1H), 4.48 (d, J = 6.0 Hz, 2H), 2.14 (s, 3H). ESI-MS: 448.05 (M+H)+ Petition 870260063548, dated 06 / 26 / 2026, p. 199 / 639 193 / 316 N-[(3,5-difluorophenyl)methyl]-2-methyl-3-{[2-(1H-pyrazol-3-ylamino)-4-pyridyl]oxy}benzamide (237):

[0315] Compound 237 was synthesized from intermediate 199b (0.08 mmol) and 3-aminopyrazole (0.17 mmol) as a white solid with a yield of 17% according to the general H method. 1H NMR (400 MHz, DMSO-cfe) δ (ppm): 12.00 (bs, 1H), 9.22 (s, 1H), 8.98 (t, J = 6.0 Hz, 1H), 8.00 (d, J = 5.8 Hz, 1H), 7.51 (d, J = 1.7 Hz, 1H), 7.39-7.31 (m, 2H), 7.21-7.03 (m, 4H), 6.83 (bs, 1H), 6.18 (dd, J = 5.6 Hz, 1.8 Hz, 2H), 4.47 (d, J = 6.0 Hz, 2H), 2.14 (s, 3H). ESI-MS: 436.00 (M+H)+. N-[(3,5-difluorophenyl)methyl]-2-methyl-3-({2-[(1-methyl-1,2,4-triazol-3-yl)amino]-4pyridyl}oxy)benzamide (238):

[0316] Compound 238 was synthesized from intermediate 199b (0.08 mmol) and 1-methyl-1H-1,2,4-triazol-3-amine (0.17 mmol) as a white solid with a yield of 77% according to the general H method. 1H NMR (400 MHz, DMSO-d6) δ (ppm): 9.63 (s, 1H), 8.98 (t, J = 6.0 Hz, 1H), 8.20 (s, 1H), 8.04 (d, J = 5.7 Hz, 1H), 7.51 (d, J = 2.2 Hz, 1H), 7.40-7.33 (m, 2H), 7.20 (dd, J = 7.4 Hz, 1.8 Hz, 1H), 7.12 (tt, J = 9.4 Hz, 2.4 Hz, 1H), 7.10-7.03 (m, 2H), 6.21 (dd, J = 5.7 Hz, 2.3 Hz, 1H), 4.47 (d, J = 6.0 Hz, 2H), 3.73 (s, 3H), 2.14 (s, 3H). ESI-MS: 451.05 (M+H)+ N-[(3,5-difluorophenyl)methyl]-2-methyl-3-({2-[(2-methyltriazol-4-yl)amino]-4pyridyl}oxy)benzamide (239): Petition 870260063548, dated 06 / 26 / 2026, p. 200 / 639 194 / 316

[0317] Compound 239 was synthesized from intermediate 199b (0.08 mmol) and 2-methyltriazol-4-amine (0.15 mmol) as a white solid with a yield of 57% according to the general H method. 1H NMR (400 MHz, DMSOd6) δ (ppm): 9.61 (s, 1H), 8.99 (t, J = 6.0 Hz, 1H), 8.06 (d, J = 5.8 Hz, 1H), 7.81 (s, 1H), 7.41-7.34 (m, 2H), 7.21 (dd, J = 7.3 Hz, 2.0 Hz, 1H), 7.13 (tt, J = 9.4 Hz, 2.3 Hz, 1H), 7.08-7.03 (m, 2H), 6.48 (d, J = 2.2 Hz, 1H), 6.31 (dd, J = 5.8 Hz, 2.3 Hz, 1H), 4.47 (d, J = 6.0 Hz, 2H), 4.00 (s, 3H), 2.14 (s, 3H). ESI-MS: 451.10 (M+H)+. N-[(3,5-difluorophenyl)methyl]-2-methyl-3-({2-[(1-methyltriazol-4-yl)amino]-4pyridyl}oxy)benzamide (240):

[0318] Compound 240 was synthesized from intermediate 199b (0.08 mmol) and 1-methyltriazol-4-amine (0.15 mmol) as a white solid in a 30% yield according to the general H method. 1H NMR (400 MHz, DMSOd6) δ (ppm): 9.63 (s, 1H), 8.98 (t, J = 6.0 Hz, 1H), 8.10 (s, 1H), 8.05 (d, J = 5.8 Hz, 1H), 7.40-7.34 (m, 2H), 7.20 (dd, J = 7.3 Hz, 2.0 Hz, 1H), 7.13 (tt, J = 9.4 Hz, 2.4 Hz, 1H), 7.09-7.03 (m, 2H), 6.36 (d, J = 2.2 Hz, 1H), 6.29 (dd, J = 5.8 Hz, 2.3 Hz, 1H), 4.47 (d, J = 6.0 Hz, 2H), 4.00 (s, 3H), 2.14 (s, 3H). ESI-MS: 451.10 (M+H)+ N-[(3,5-difluorophenyl)methyl]-2-methyl-3-{[2-(2-methylanilino)-4-pyridyl]oxy} benzamide (241):

[0319] Compound 241 was synthesized from intermediate 199b (0.06 mmol) and o-toluidine (0.13 mmol) as a white solid with a 64% yield according to the general H method. 1H NMR (600 MHz, DMSO-d6) δ (ppm): 8.96 (t, J = 6.1 Hz, 1H), 8.15 (s, 1H), 7.94 (d, J = 5.7 Hz, 1H), 7.51 (dd, J = 8.0 Hz, 0.9 Hz, 1H), 7.38-7.32 (m, 2H), 7.21 (dd, J = 7.8 Hz, 1.3 Hz, 1H), 7.16 (d, J = 7.5 Hz, Petition 870260063548, dated 06 / 26 / 2026, p. 201 / 639 195 / 316 1H), 7.14-7.08 (m, 2H), 7.07-7.03 (m, 2H), 6.95 (td, J = 7.4 Hz, 1.2 Hz, 1H), 6.25 (dd, J = 5.8 Hz, 2.3 Hz, 1H), 6.11 (d, J = 2.2 Hz, 1H), 4.47 (d, J = 6.0 Hz, 2H), 2.17 (s, 3H), 2.14 (s, 3H). ESI-MS: 460.05 (M+H)+. N-[(3,5-difluorophenyl)methyl]-2-methyl-3-{[2-(3-methylanilino)-4-pyridyl]oxy} benzamide (242):

[0320] Compound 242 was synthesized from intermediate 199b (0.06 mmol) and m-toluidine (0.13 mmol) as a white solid with a 74% yield according to the general H method. 1H NMR (600 MHz, DMSO-cfe) δ (ppm): 8.97 (t, J = 6.1 Hz, 1H), 8.89 (s, 1H), 8.05 (d, J = 5.8 Hz, 1H), 7.41-7.35 (m, 4H), 7.23 (dd, J = 7.7 Hz, 1.4 Hz, 1H), 7.14-7.04 (m, 4H), 6.69-6.67 (m, 1H), 6.37 (dd, J = 5.8 Hz, 2.3 Hz, 1H), 6.12 (d, J = 2.2 Hz, 1H), 4.47 (d, J = 6.0 Hz, 2H), 2.24 (s, 3H), 2.15 (s, 3H). ESI-MS: 460.10 (M+H)+ N-[(3,5-difluorophenyl)methyl]-2-methyl-3-{[2-(4-methylanilino)-4-pyridyl]oxy} benzamide (243):

[0321] Compound 243 was synthesized from intermediate 199b (0.06 mmol) and p-polyuidine (0.13 mmol) as a white solid with a yield of 74% according to the general H method. 1H NMR (600 MHz, DMSO-cfe) δ (ppm): 8.97 (t, J = 6.1 Hz, 1H), 8.85 (s, 1H), 8.02 (d, J = 5.8 Hz, 1H), 7.49-7.46 (m, 2H), 7.40-7.34 (m, 2H), 7.22 (dd, J = 7.8 Hz, 1.4 Hz, 1H), 7.12 (tt, J = 9.4 Hz, 2.4 Hz, 1H), 7.08-7.04 (m, 2H), 7.02 (d, J = 8.1 Hz, 2H), 6.34 (dd, J = 5.8 Hz, 2.2 Hz, 1H), 6.09 (d, J = 2.2 Hz, 1H), 4.47 (d, J = 6.0 Hz, 2H), 2.22 (s, 3H), 2.14 (s, 3H). ESI-MS: 460.10 (M+H)+ N-[(3,5-difluorophenyl)methyl]-3-{[2-(2-methoxyanilino)-4-pyridyl]oxy}-2-methylPetition 870260063548, of 06 / 26 / 2026, p. 202 / 639 196 / 316 benzamide (244):

[0322] Compound 244 was synthesized from intermediate 199b (0.06 mmol) and o-anisidine (0.13 mmol) as a white solid with a yield of 47% according to the general H method. 1H NMR (400 MHz, DMSO-cfe) δ (ppm): 8.96 (t, J = 6.1 Hz, 1H), 8.15 (s, 1H), 8.11 (dd, J = 7.8 Hz, 1.7 Hz, 1H), 8.00 (d, J = 5.8 Hz, 1H), 7.40-7.33 (m, 2H), 7.20 (dd, J = 7.4 Hz, 1.9 Hz, 1H), 7.13 (tt, J = 9.4 Hz, 2.3 Hz, 1H), 7.09-7.03 (m, 2H), 6.98-6.83 (m, 3H), 6.39 (d, J = 2.2 Hz, 1H), 6.31 (dd, J = 5.8 Hz, 2.2 Hz, 1H), 4.47 (d, J = 6.0 Hz, 2H), 3.79 (s, 3H), 2.14 (s, 3H). ESI-MS: 476.10 (M+H)+. N-[(3,5-difluorophenyl)methyl]-3-{[2-(3-methoxyanilino)-4-pyridyl]oxy}-2-methylbenzamide (245):

[0323] Compound 245 was synthesized from intermediate 199b (0.06 mmol) and m-anisidine (0.13 mmol) as a white solid with an 84% yield according to the general H method. 1H NMR (600 MHz, DMSO-cfe) δ (ppm): 8.98-8.96 (m, 2H), 8.06 (d, J = 5.8 Hz, 1H), 7.41-7.35 (m, 3H), 7.23 (dd, J = 7.7 Hz, 1.4 Hz, 1H), 7.14-7.09 (m, 3H), 7.08-7.04 (m, 2H), 6.45 (dt, J = 6.7 Hz, 2.4 Hz, 1H), 6.39 (dd, J = 5.8 Hz, 2.3 Hz, 1H), 6.12 (d, J = 2.2 Hz, 1H), 4.48 (d, J = 6.0 Hz, 2H), 3.70 (s, 3H), 2.14 (s, 3H). ESI-MS: 476.10 (M+H)+ N-[(3,5-difluorophenyl)methyl]-3-{[2-(4-methoxyanilino)-4-pyridyl]oxy}-2-methylbenzamide (246): Petition 870260063548, dated 06 / 26 / 2026, p. 203 / 639 197 / 316

[0324] Compound 246 was synthesized from intermediate 199b (0.06 mmol) and p-anisidine (0.13 mmol) as a white solid with an 81% yield according to the general H.1H NMR method (600 MHz, DMSO-cfe) δ (ppm): 8.97 (t, J = 6.1 Hz, 1H), 8.75 (s, 1H), 7.99 (d, J = 5.8 Hz, 1H), 7.59-7.46 (m, 2H), 7.40-7.34 (m, 2H), 7.22 (dd, J = 7.8 Hz, 1.4 Hz, 1H), 7.12 (tt, J = 9.4 Hz, 2.4 Hz, 1H), 7.08-7.04 (m, 2H), 6.84-6.81 (m, 2H), 6.30 (dd, J = 5.8 Hz, 2.2 Hz, 1H), 6.04 (d, J = 2.2 Hz, 1H), 4.47 (d, J = 6.0 Hz, 2H), 3.69 (s, 3H), 2.14 (s, 3H). ESI-MS: 476.10 (M+H)+ A / -[(3,5-difluorophenyl)methyl]-3-({2-[(6-methoxy-2-pyridyl)amino]-4-pyridyl}oxy)-2methyl-benzamide (247):

[0325] Compound 247 was synthesized from intermediate 199b (0.06 mmol) and 2-amino-6-methoxypyridine (0.13 mmol) as a white solid with a 68% yield according to the general H method. 1H NMR (600 MHz, DMSOd6) δ (ppm): 9.65 (s, 1H), 8.95 (t, J = 6.1 Hz, 1H), 8.13-8.12 (m, 1H), 7.50-7.47 (m, 2H), 7.37-7.35 (m, 2H), 7.25-7.22 (m, 1H), 7.12 (tt, J = 9.4 Hz, 2.4 Hz, 1H), 7.08-7.04 (m, 2H), 6.89 (d, J = 7.5 Hz, 1H), 6.56 (dd, J = 5.7 Hz, 2.3 Hz, 1H), 6.18 (dd, J = 7.9 Hz, 0.6 Hz, 1H), 4.47 (d, J = 6.0 Hz, 2H), 3.34 (s, 3H), 2.14 (s, 3H). ESI-MS: 477.10 (M+H)+ Example 8: General procedure for synthesizing analogues 248 - 261

[0326] Method I: To a solution of 214 (1 equiv.) in DMF (10 ml / mmol) under nitrogen, derivatives of RiX, Ri-OMs or Ri-OTs (1-2 equiv.) and CS2CO3 (1.5 equiv.) were added. The mixture was stirred at 90 °C overnight. Petition 870260063548, dated 06 / 26 / 2026, p. 204 / 639 198 / 316 The reaction mixture was concentrated under reduced pressure. The crude product was purified by flash column chromatography (DCM / MeOH 100 / 0 to 95 / 5) and reversed-phase chromatography (H2O / MeOH 100 / 0 to 0 / 100) to obtain the expected compound. The following compound 248 is an example that illustrates Method I: N-[(3,5-difluorophenyl)methyl1-3-{[2-(1-isopropylpyrazol-4-yl)-4-pyridyl1oxy}-2-methylbenzamide (248):

[0327] Compound 248 was synthesized from intermediate 214 (0.05 mmol) and 2-iodopropane (0.05 mmol) as a white solid in 50% yield according to general method I. 1H NMR (400 MHz, DMSO-cfe) δ (ppm): 8.99 (t, J = 6.0 Hz, 1H), 8.36 (d, J = 5.7 Hz, 1H), 8.33 (s, 1H), 7.97 (s, 1H), 7.41-7.35 (m, 2H), 7.29 (d, J = 2.3 Hz, 1H), 7.22 (dd, J = 7.4 Hz, 1.8 Hz, 1H), 7.13 (tt, J = 9.5 Hz, 2.3 Hz, 1H), 7.09-7.04 (m, 2H), 6.48 (dd, J = 5.7 Hz, 2.4 Hz, 1H), 4.55-4.47 (m, 3H), 2.14 (s, 3H), 1.44 (d, J = 6.7 Hz, 6H). ESI-MS: 463.10 (M+H)+. tert-butyl 3-[4-(4-{3-[(3,5-difluorophenyl)methylcarbamoyl]-2-methyl-phenoxy}-2pyridyl)pyrazol-1-yl]azetidine-1-carboxylate (249):

[0328] Compound 249 was synthesized from intermediate 214 (0.10 mmol) and tert-butyl 3-iodoazetidine-1-carboxylate (0.11 mmol) as a white solid in a 76% yield according to general method I. 1H NMR (400 MHz, DMSO-d6) δ (ppm): 8.99 (t, J = 6.0 Hz, 1H), 8.46 (s, 1H), 8.38 (d, J = 5.7 Hz, 1H), 8.12 (s, 1H), 7.41-7.35 (m, 2H), 7.31 (d, J = 2.3 Hz, 1H), 7.23 (dd, J = 7.3 Hz, 2.0 Hz, 1H), 7.13 (tt, J = 9.5 Hz, 2.4 Hz, 1H), 7.09-7.04 (m, 2H), 6.51 (dd, J = 5.7 Petition 870260063548, dated 06 / 26 / 2026, p. 205 / 639 199 / 316 Hz, 2.4 Hz, 1H), 5.27-5.20 (m, 1H), 4.48 (d, J = 6.0 Hz, 2H), 4.30 (t, J = 8.2 Hz, 2H), 4.15 (bs, 2H), 2.14 (s, 3H), 1.41 (s, 9H). ESI-MS: 576.20 (M+H)+. tert-butyl 3-{[4-(4-{3-[(3,5-difluorophenyl)methylcarbamoyl]-2-methyl-phenoxy}-2pyridyl)pyrazol-1-yl]methyl}azetidine-1-carboxylate (250):

[0329] Compound 250 was synthesized from intermediate 214 (0.10 mmol) and tert-butyl 3-(bromomethyl)azetidine-1-carboxylate (0.11 mmol) as a white solid with a yield of 63% according to general method I. 1H NMR (400 MHz, DMSO-cfe) δ (ppm): 8.99 (t, J = 6.0 Hz, 1H), 8.37-8.35 (m, 2H), 8.00 (s, 1H), 7.41-7.34 (m, 2H), 7.27 (d, J = 2.3 Hz, 1H), 7.22 (dd, J = 7.3 Hz, 1.9 Hz, 1H), 7.13 (tt, J = 9.5 Hz, 2.4 Hz, 1H), 7.10-7.04 (m, 2H), 6.49 (dd, J = 5.7 Hz, 2.4 Hz, 1H), 4.48 (d, J = 6.0 Hz, 2H), 4.35 (d, J = 7.2 Hz, 2H), 3.88 (t, J = 7.3 Hz, 2H), 3.68 (bs, 2H), 3.04-2.94 (m, 1H), 2.14 (s, 3H), 1.36 (s, 9H). ESI-MS: 590.30 (M+H)+ N-[(3,5-difluorophenyl)methyl]-2-methyl-3-({2-[1-(oxetan-3-yl)pyrazol-4-yl]-4pyridyl}oxy)benzamide (251):

[0330] Compound 251 was synthesized from intermediate 214 (0.05 mmol) and 3-bromooxethane (0.06 mmol) as a white solid with a yield of 35% according to general method I. 1H NMR (400 MHz, DMSO-cfe) δ (ppm): 8.99 (bs, 1H), 8.46 (s, 1H), 8.38 (d, J = 5.3 Hz, 1H), 8.13 (s, 1H), 7.41-7.31 (m, 3H), 7.23 (d, J = 7.0 Hz, 1H), 7.15-7.06 (m, 3H), 6.51 (d, J = 3.6 Hz, 1H), 5.62-5.57 (m, 1H), 4.93-4.91 (m, 4H), 4.48 (d, J = 5.4 Hz, 2H), 2.14 (s, 3H). ESI-MS: 477.10 (M+H)+ Petition 870260063548, dated 06 / 26 / 2026, p. 206 / 639 200 / 316 N-[(3,5-difluorophenyl)methyl]-3-({2-[1-(2-methoxyethyl)pyrazol-4-yl]-4-pyridyl}oxy)-2methyl-benzamide (252):

[0331] Compound 252 was synthesized from intermediate 214 (0.05 mmol) and 2-bromoethyl methyl ether (0.06 mmol) as a white solid in a 78% yield according to general method I. 1H NMR (400 MHz, DMSOd6) δ (ppm): 8.99 (t, J = 5.8 Hz, 1H), 8.36 (d, J = 5.7 Hz, 1H), 8.26 (s, 1H), 7.99 (s, 1H), 7.41-7.35 (m, 2H), 7.27-7.22 (m, 2H), 7.15-7.05 (m, 3H), 6.49 (d, J = 5.0 Hz, 1H), 4.48 (d, J = 5.9 Hz, 2H), 4.28 (t, J = 5.1 Hz, 2H), 3.70 (t, J = 5.1 Hz, 2H), 3.23 (s, 3H), 2.14 (s, 3H). ESI-MS: 479.10 (M+H)+. N-[(3,5-difluorophenyl)methyl]-3-({2-[1-(dimethylphosphorylmethyl)pyrazol-4-yl]-4pyridyl}oxy)-2-methyl-benzamide (253):

[0332] Compound 253 was synthesized from intermediate 214 (0.05 mmol) and 1-{[(dimethylphosphoryl)methoxy]sulfonyl}-4-methylbenzene (0.06 mmol) as a white solid in a 75% yield according to general method I. 1H NMR (400 MHz, DMSO-d6) δ (ppm): 9.00 (t, J = 6.0 Hz, 1H), 8.38 (d, J = 5.7 Hz, 1H), 8.28 (s, 1H), 8.07 (s, 1H), 7.41-7.35 (m, 2H), 7.28 (d, J = 2.3 Hz, 1H), 7.23 (dd, J = 7.4 Hz, 1.8 Hz, 1H), 7.13 (tt, J = 9.5 Hz, 2.3 Hz, 1H), 7.09-7.04 (m, 2H), 6.52 (dd, J = 5.7 Hz, 2.4 Hz, 1H), 4.69 (d, J = 7.5 Hz, 2H), 4.48 (d, J = 6.0 Hz, 2H), 2.14 (s, 3H), 1.46 (s, 3H), 1.42 (s, 3H). 31P NMR (162 MHz, DMSO-d6) δ (ppm): 38.43. ESI-MS: 511.10 (M+H)+ Petition 870260063548, dated 06 / 26 / 2026, p. 207 / 639 201 / 316 3-({2-[1-(ditert-butoxyphosphorylmethyl)pyrazol-4-yl]-4-pyridyl}oxy)-N-[(3,5difluorophenyl)methyl]-2-methyl-benzamide (254):

[0333] Compound 254 was synthesized from intermediate 214 (0.12 mmol) and (di-tert-butoxyphosphoryl)methyl 4-methylbenzenesulfonate (0.24 mmol) as a white solid in a 51% yield according to general method I. 1H NMR (400 MHz, DMSO-cfe) δ (ppm): 8.99 (t, J = 6.0 Hz, 1H), 8.37 (d, J = 5.7 Hz, 1H), 8.18 (s, 1H), 8.01 (s, 1H), 7.41-7.35 (m, 2H), 7.24 (dd, J = 7.2 Hz, 2.2 Hz, 2H), 7.16-7.10 (m, 1H), 7.09-7.04 (m, 2H), 6.52 (dd, J = 5.7 Hz, 2.4 Hz, 1H), 4.53 (d, J = 11.8 Hz, 2H), 4.48 (d, J = 6.0 Hz, 2H), 2.15 (s, 3H), 1.39 (s, 18H). DMSO-d6)0 (ppm): 10.07. ESI-MS: 627.15 (M+H)+. 3-({2-[1-(cyclopropylmethyl)pyrazol-4-yl]-4-pyridyl}oxy)-N-[(3,5-difluorophenyl)methyl]-2-methyl-benzamide (255):

[0334] Compound 255 was synthesized from intermediate 214 (0.05 mmol) and cyclopropylmethyl bromide (0.06 mmol) as a white solid with a yield of 56% according to general method I. 1H NMR (400 MHz, DMSOd6) δ (ppm): 8.99 (t, J = 6.0 Hz, 1H), 8.36 (d, J = 5.7 Hz, 1H), 8.33 (s, 1H), 7.98-7.97 (m, 1H), 7.41-7.35 (m, 2H), 7.28 (d, J = 2.3 Hz, 1H), 7.22 (dd, J = 7.4 Hz, 1.9 Hz, 1H), 7.13 (tt, J = 9.5 Hz, 2.4 Hz, 1H), 7.09-7.04 (m, 2H), 6.48 (dd, J = 5.7 Hz, 2.4 Hz, 1H), 4.48 (d, J = 6.0 Hz, 2H), 3.99 (d, J = 7.1 Hz, 2H), 2.15 (s, 3H), 1.31-1.21 (m, 1H), 0.56-0.51 (m, 2H), 0.40-0.36 (m, 2H). ESI-MS: 475.10 (M+H)+ Petition 870260063548, dated 06 / 26 / 2026, p. 208 / 639 202 / 316 3-({2-[1-(2,2-difluoroethyl)pyrazol-4-yl]-4-pyridyl}oxy)-N-[(3,5-difluorophenyl)methyl]2-methyl-benzamide (256):

[0335] Compound 256 was synthesized from intermediate 214 (0.05 mmol) and 2-iodo-1,1-difluoroethane (0.06 mmol) as a white solid in 50% yield according to general method I. 1H NMR (400 MHz, DMSOd6) δ (ppm): 8.99 (t, J = 6.0 Hz, 1H), 8.38 (d, J = 5.7 Hz, 1H), 8.35 (s, 1H), 8.09 (d, J = 0.4 Hz, 1H), 7.42-7.35 (m, 2H), 7.30 (d, J = 2.3 Hz, 1H), 7.23 (dd, J = 7.3 Hz, 1.9 Hz, 1H), 7.13 (tt, J = 9.5 Hz, 2.4 Hz, 1H), 7.09-7.04 (m, 2H), 6.54-6.25 (m, 2H), 4.66 (td, J = 15.1 Hz, 3.7 Hz, 2H), 4.48 (d, J = 6.0 Hz, 2H), 2.14 (s, 3H). ESI-MS: 485.10 (M+H)+. 3-{[2-(1-cyclobutylpyrazol-4-yl)-4-pyridyl]oxy}-N-[(3,5-difluorophenyl)methyl]-2-methylbenzamide (257):

[0336] Compound 257 was synthesized from intermediate 214 (0.05 mmol) and cyclobutyl bromide (0.06 mmol) as a white solid with a yield of 39% according to general method I. 1H NMR (400 MHz, DMSOd6) δ (ppm): 8.99 (t, J = 6.0 Hz, 1H), 8.39 (d, J = 0.5 Hz, 1H), 8.37-8.35 (m, 1H), 8.01 (d, J = 0.5 Hz, 1H), 7.41-7.34 (m, 2H), 7.29 (d, J = 2.1 Hz, 1H), 7.22 (dd, J = 7.4 Hz, 1.9 Hz, 1H), 7.13 (tt, J = 9.4 Hz, 2.4 Hz, 1H), 7.09-7.04 (m, 2H), 6.48 (dd, J = 5.7 Hz, 2.4 Hz, 1H), 4.85 (p, J = 8.5 Hz, 1H), 4.48 (d, J = 6.0 Hz, 2H), 2.50-2.35 (m, 4H), 2.14 (s, 3H), 1.82-1.73 (m, 2H). ESI-MS: 475.10 (M+H)+ Petition 870260063548, dated 06 / 26 / 2026, p. 209 / 639 203 / 316 3-({2-[1-(cyclobutylmethyl)pyrazol-4-yl]-4-pyridyl}oxy)-N-[(3,5-difluorophenyl)methyl]2-methyl-benzamide (258):

[0337] Compound 258 was synthesized from intermediate 214 (0.05 mmol) and (bromomethyl)cyclobutane (0.06 mmol) as a white solid in a 43% yield according to general method I. 1H NMR (400 MHz, DMSOd6) δ (ppm): 8.99 (t, J = 6.0 Hz, 1H), 8.36-8.35 (m, 1H), 8.27 (d, J = 0.5 Hz, 1H), 7.96 (d, J = 0.6 Hz, 1H), 7.41-7.35 (m, 2H), 7.27 (d, J = 2.2 Hz, 1H), 7.22 (dd, J = 7.4 Hz, 1.9 Hz, 1H), 7.13 (tt, J = 9.4 Hz, 2.4 Hz, 1H), 7.09-7.04 (m, 2H), 6.47 (dd, J = 5.7 Hz, 2.4 Hz, 1H), 4.48 (d, J = 6.0 Hz, 2H), 4.14 (d, J = 7.3 Hz, 2H), 2.76 (dt, J = 14.9 Hz, 7.5 Hz, 1H), 2.14 (s, 3H), 2.00-1.94 (m, 2H), 1.89-1.72 (m, 4H). ESI-MS: 489.10 (M+H)+. 3-({2-[1-(2-cyanoethyl)pyrazol-4-yl]-4-pyridyl}oxy)-N-[(3,5-difluorophenyl)methyl]-2methyl-benzamide (259):

[0338] Compound 259 was synthesized from intermediate 214 (0.05 mmol) and 3-bromopropionitrile (0.06 mmol) as a white solid with a yield of 56% according to general method I. 1H NMR (400 MHz, DMSOd6) δ (ppm): 8.99 (t, J = 6.1 Hz, 1H), 8.39-8.37 (m, 2H), 8.07 (d, J = 0.6 Hz, 1H), 7.42-7.35 (m, 2H), 7.28 (d, J = 2.2 Hz, 1H), 7.23 (dd, J = 7.4 Hz, 1.9 Hz, 1H), 7.13 (tt, J = 9.4 Hz, 2.4 Hz, 1H), 7.09-7.04 (m, 2H), 6.52 (dd, J = 5.7 Hz, 2.4 Hz, 1H), 4.48 (d, J = 6.0 Hz, 2H), 4.42 (t, J = 6.4 Hz, 2H), 3.10 (t, J = 6.4 Hz, 2H), 2.15 (s, 3H). ESI-MS: 474.10 (M+H)+ Petition 870260063548, dated 06 / 26 / 2026, p. 210 / 639 204 / 316 3-({2-[1-(cyanomethyl)pyrazol-4-yl]-4-pyridyl}oxy)-N-[(3,5-difluorophenyl)methyl]-2-

[0339] Compound 260 was synthesized from intermediate 214 (0.05 mmol) and 2-iodoacetonitrile (0.07 mmol) as a white solid with a yield of 14% according to general method I. 1H NMR (400 MHz, DMSO-cfe) δ (ppm): 8.99 (t, J = 6.0 Hz, 1H), 8.40-8.38 (m, 2H), 8.15 (d, J = 0.6 Hz, 1H), 7.42-7.35 (m, 2H), 7.32 (d, J = 2.2 Hz, 1H), 7.24 (dd, J = 7.3 Hz, 2.0 Hz, 1H), 7.13 (tt, J = 9.4 Hz, 2.4 Hz, 1H), 7.09-7.03 (m, 2H), 6.54 (dd, J = 5.7 Hz, 2.4 Hz, 1H), 5.53 (s, 2H), 4.48 (d, J = 6.0 Hz, 2H), 2.14 (s, 3H). ESI-MS: 460.10 (M+H)+. tert-butyl 4-[4-(4-{3-[(3,5-difluorophenyl)methylcarbamoyl]-2-methyl-phenoxy}-2pyridyl)pyrazol-1-yl]piperidine-1-carboxylate (261):

[0340] Compound 261 was synthesized from intermediate 214 (0.10 mmol) and tert-butyl 4-[(methylsulfonyl)oxy]piperidine-1-carboxylate (0.11 mmol) as a white solid in a 70% yield according to general method I. 1H NMR (400 MHz, DMSO-cfe) δ (ppm): 8.99 (t, J = 6.0 Hz, 1H), 8.37-8.35 (m, 2H), 8.00 (s, 1H), 7.41-7.35 (m, 2H), 7.29 (d, J = 2.3 Hz, 1H), 7.22 (dd, J = 7.4 Hz, 1.9 Hz, 1H), 7.13 (tt, J = 9.5 Hz, 2.4 Hz, 1H), 7.10-7.04 (m, 2H), 6.48 (dd, J = 5.7 Hz, 2.4 Hz, 1H), 4.48 (d, J = 6.0 Hz, 2H), 4.42-4.34 (m, 1H), 4.04 (d, J = 11.8 Hz, 2H), 2.91 (bs, 2H), 2.14 (s, 3H), 2.02 (d, J = 10.2 Hz, 2H), 1.85-1.75 (m, 2H), 1.42 (s, 9H). ESI-MS: 604.40 (M+H)+ Petition 870260063548, dated 06 / 26 / 2026, p. 211 / 639 205 / 316 N-[(3,5-difluorophenyl)methyl]-2-methyl-3-({2-[1-(4-piperidyl)pyrazol-4-yl]-4pyridyl}oxy)benzamide (262):

[0341] To a stirred solution of compound 261 (25 mg, 0.04 mmol) in dioxane (2 ml) was added HCl (4N in dioxane, 0.41 ml, 10 equiv.) and the mixture was stirred at room temperature overnight. The reaction mixture was diluted with EtOAc and washed with a saturated solution of NaHCO3. The organic layer was dried over Na2SO4, filtered and concentrated under reduced pressure. The crude product was purified by flash column chromatography (DCM / MeOH 100 / 0 to 90 / 10) and reversed-phase chromatography (H2O / MeOH 100 / 0 to 0 / 100) to obtain the expected compound as a white solid with a yield of 33%.1H NMR (400 MHz, DMSO-cfe) δ (ppm): 8.99 (t, J = 6.0 Hz, 1H), 8.36 (d, J = 5.7 Hz, 1H), 8.32 (s, 1H), 7.99 (s, 1H), 7.41 -7.34 (m, 2H), 7.29 (d, J = 2.3 Hz, 1H), 7.22 (dd, J = 7.3 Hz, 1.8 Hz, 1H), 7.16-7.10 (m, 1H), 7.09-7.14 (m, 2H), 6.48 (dd, J = 5.7 Hz, 2.4 Hz, 1H), 4.48 (d, J = 6.0 Hz, 2H), 4.28-4.19 (m, 1H), 3.07 (d, J = 12.3 Hz, 2H), 2.61 (d, J = 10.8, 2H), 2.14 (s, 3H), 1.98 (d, J = 10.2, 2H), 1.87-1.78 (m, 2H). ESI-MS: 504.10 (M+H)+. Petition 870260063548, dated 06 / 26 / 2026, p. 212 / 639 206 / 316 Example 9: General procedure for synthesizing analogues 263 - 277 Boronic acid, Pd(PPh3)4, Cs2CO3 1M, dioxane, 100°C D2 Method J Method NR^, Dl EA, dioxane, 100eC A / -[(3,5-difluorophenyl)methyl]-2-methyl-3-({2-[2-(1-methylpyrazol-4-yl)-4-pyridyl]-4pyridyl}oxy)benzamide (263):

[0342] Compound 263 was synthesized in a two-step procedure from intermediate 199b (0.08 mmol), 2-chloropyridine-4-boronic acid (0.08 mmol) and pinacol ester of 1-methylpyrazol-4-boronic acid (0.15 mmol) as a white solid with a yield of 23% according to the general method D2.1H NMR (400 MHz, DMSO-d6) δ (ppm): 9.01 (t, J = 6.1 Hz, 1H), 8.61-8.59 (m, 2H), 8.40 (s, 1H), 8.29-8.28 (m, 1H), 8.10 (d, J = 0.7 Hz, 1H), 7.92 (d, J = 2.3 Hz, 1H), 7.81 (dd, J = 5.2 Hz, 1.7 Hz, 1H), 7.44-7.38 (m, 2H), 7.29 (dd, J = 7.3 Hz, 2.0 Hz, 1H), 7.16-7.10 (m, 1H), 7.09-7.04 (m, 2H), 6.71 (dd, J = 5.6 Hz, 2.4 Hz, 1H), 4.48 (d, J = 6.0 Hz, 2H), 3.90 (s, 3H), 2.17 (s, 3H). Petition 870260063548, dated 06 / 26 / 2026, p. 213 / 639 207 / 316 ESI-MS: 512.10 (M+H)+. N-[(3,5-difluorophenyl)methyl]-2-methyl-3-({2-[6-(1-methylpyrazol-4-yl)-3-pyridyl]-4pyridyl}oxy)benzamide (264):

[0343] Compound 264 was synthesized in a two-step procedure from intermediate 199b (0.08 mmol), (6-chloropyridin-3-yl)boronic acid (0.08 mmol) and pinacol ester of 1-methylpyrazol-4-boronic acid (0.15 mmol) as a white solid with a yield of 15% according to general method D2. 1H NMR (400 MHz, DMSO-de) δ (ppm): 9.16 (dd, J = 2.3 Hz, 0.7 Hz, 1H), 9.01 (t, J = 6.1 Hz, 1H), 8.55 (d, J = 5.7 Hz, 1H), 8.38 (dd, J = 8.4 Hz, 2.4 Hz, 1H), 8.35 (s, 1H), 8.06 (d, J = 0.6 Hz, 1H), 7.74 (dd, J = 8.3 Hz, 0.6 Hz, 1H), 7.65 (d, J = 2.2 Hz, 1H), 7.44-7.37 (m, 2H), 7.27 (dd, J = 7.3Hz, 2.0Hz, 1H), 7.16-7.10 (m, 1H), 7.09-7.04 (m, 2H), 6.67 (dd, J = 5.7 Hz, 2.4 Hz, 1H), 4.48 (d, J = 6.0 Hz, 2H), 3.90 (s, 3H), 2.16 (s, 3H). ESI-MS: 512.10 (M+H)+ N-[(3,5-difluorophenyl)methyl]-3-{[2-(2-fluoro-4-pyridyl)-4-pyridyl]oxy}-2-methylbenzamide (265a):

[0344] Compound 265a was synthesized from intermediate 199b (1.16 mmol) and 2-fluoropyridin-4-ylboronic acid (1.39 mmol) as a white solid with a 100% yield according to general method D2. 1H NMR (400 MHz, DMSO-d6) δ (ppm): 9.00 (t, J = 5.9 Hz, 1H), 8.61 (d, J = 5.6 Hz, 1H), 8.36 (d, J = 5.3 Hz, 1H), 8.02 (d, J = 5.2 Hz, 1H), 7.85 (d, J = 2. Hz 3, 1H), 7.82 (s, 1H), 7.44-7.38 (m, 2H), 7.28 (dd, J = 6.9 Hz, 2.2 Hz, 1H), 7.16-7.04 (m, 3H), 6.78 (dd, J = 5.6 Hz, 1.9 Hz, 1H), 4.48 (d, J = 5.9 Hz, 2H), 2.16 (s, 3H). Petition 870260063548, dated 06 / 26 / 2026, p. 214 / 639 208 / 316 ESI-MS: 450.05 (M+H)+. N-[(3,5-difluorophenyl)methyl]-3-{[2-(6-fluoro-3-pyridyl)-4-pyridyl]oxy}-2-methylbenzamide (265b):

[0345] Compound 265b was synthesized from intermediate 199b (0.77 mmol) and 6-fluoro-3-pyridinylboronic acid (0.93 mmol) as a white solid with a 100% yield according to general method D2. 1H NMR (400 MHz, DMSO-d6) δ (ppm): 9.00 (t, J = 6.0 Hz, 1H), 8.90 (d, J = 2.5 Hz, 1H), 8.64-8.59 (m, 1H), 8.57-8.55 (m, 1H), 7.69 (d, J = 2.1 Hz, 1H), 7.43-7.37 (m, 2H), 7.31 (dd, J = 8.6 Hz, 2.4 Hz, 1H), 7.27 (dd, J = 7.2 Hz, 2.1 Hz, 1H), 7.13 (tt, J = 9.4 Hz, 2.4 Hz, 1H), 7.09-7.04 (m, 2H), 6.70 (dd, J = 5.7 Hz, 2.4 Hz, 1H), 4.48 (d, J = 6.0 Hz, 2H), 2.16 (s, 3H). ESI-MS: 450.05 (M+H)+

[0346] Method J: To a solution of 265 (1 equiv.) in dioxane (10 ml / mmol) were added amine derivatives (16 equiv.) and DIEA (6 equiv.). The mixture was stirred at 100 °C until completion (from 2 h to overnight). The reaction mixture was concentrated under reduced pressure. The crude product was purified by flash column chromatography (DCM / MeOH 100 / 0 to 90 / 10) and reversed-phase chromatography (HzO / MeOH 100 / 0 to 0 / 100) to obtain the expected compound. The following compound 266 is an example that illustrates the J Method: N-[(3,5-difluorophenyl)methyl]-2-methyl-3-{[2-(2-pyrrolidin-1-yl-4-pyridyl)-4pyridyl]oxybenzamide (266):

[0347] Compound 266 was synthesized from intermediate 265a (0.07 mmol) and pyrrolidine (0.53 mmol) as a white solid with a yield of 55% according to the general method J. 1H NMR (400 MHz, DMSO-cfe) δ (ppm): 9.01 (t, Petition 870260063548, dated 06 / 26 / 2026, page 215 / 639 209 / 316 J = 6.0 Hz, 1H), 8.55 (d, J = 5.8 Hz, 1H), 8.14 (dd, J = 5.3 Hz, 0.6 Hz, 1H), 7.64 (d, J = 2.2 Hz, 1H), 7.43-7.37 (m, 2H), 7.27 (dd, J = 7.3 Hz, 2.0 Hz, 1H), 7.16-7.04 (m, 5H), 6.71 (dd, J = 5.6 Hz, 2.4 Hz, 1H), 4.48 (d, J = 6.0 Hz, 2H), 3.46-3.43 (m, 4H), 2.15 (s, 3H), 1.98-1.94 (m, 4H). ESI-MS: 501.10 (M+H)+. N-[(3,5-difluorophenyl)methyl]-2-methyl-3-({2-[2-(1-piperidyl)-4-pyridyl]-4pyridyl}oxy)benzamide (267):

[0348] Compound 267 was synthesized from intermediate 265a (0.07 mmol) and piperidine (0.53 mmol) as a white solid in a 50% yield according to general method J. 1H NMR (400 MHz, DMSO-cfe) δ (ppm): 9.01 (t, J = 6.0 Hz, 1H), 8.55 (d, J = 5.6 Hz, 1H), 8.18 (d, J = 5.2 Hz, 1H), 7.70 (d, J = 2.3 Hz, 1H), 7.43-7.36 (m, 3H), 7.26 (dd, J = 7.2 Hz, 2.0 Hz, 1H), 7.17-7.04 (m, 4H), 6.69 (dd, J = 5.6 Hz, 2.4 Hz, 1H), 4.48 (d, J = 6.0 Hz, 2H), 3.60-3.58 (m, 4H), 2.16 (s, 3H), 1.62-1.55 (m, 6H). ESI-MS: 515.15 (M+H)+ N-[(3,5-difluorophenyl)methyl]-3-({2-[2-(dimethylamino)-4-pyridyl]-4-pyridyl}oxy)-2methyl-benzamide (268):

[0349] Compound 268 was synthesized from intermediate 265a (0.07 mmol) and dimethylamine (2M THF, 0.67 mmol) as a white solid in a 47% yield according to general method J. 1H NMR (400 MHz, DMSOd6) δ (ppm): 9.01 (t, J = 6.0 Hz, 1H), 8.56 (d, J = 5.6 Hz, 1H), 8.18-8.16 (m, 1H), 7.66 (d, J = 2.3 Hz, 1H), 7.43-7.37 (m, 2H), 7.27 (dd, J = 8.1 Hz, 2.7 Hz, 2H), 7.15-7.04 (m, 4H), 6.71 (dd, J = 5.6 Hz, 2.4 Hz, 1H), 4.48 (d, J = 6.0 Hz, 2H), 3.09 (s, 6H), 2.15 (s, 3H). Petition 870260063548, dated 06 / 26 / 2026, p. 216 / 639 210 / 316 ESI-MS: 475.10 (M+H)+. N-[(3,5-difluorophenyl)methyl]-2-methyl-3-{[2-(2-morpholino-4-pyridyl)-4pyridyl]oxy}benzamide (269):

[0350] Compound 269 was synthesized from intermediate 265a (0.07 mmol) and morpholine (1.07 mmol) as a white solid in 50% yield according to general method J. 1H NMR (400 MHz, DMSO-cfe) δ (ppm): 9.01 (t, J = 6.1 Hz, 1H), 8.55 (d, J = 5.7 Hz, 1H), 8.23 ​​(d, J = 5.6 Hz, 1H), 7.75 (d, J = 2.2 Hz, 1H), 7.46 (s, 1H), 7.43-7.37 (m, 2H), 7.29 (dd, J = 5.2 Hz, 1.3 Hz, 1H), 7.26 (dd, J = 7.3 Hz, 2.0 Hz, 1H), 7.13 (tt, J = 9.4 Hz, 2.4 Hz, 1H), 7.09-7.04 (m, 2H), 6.69 (dd, J = 5.6 Hz, 2.4 Hz, 1H), 4.48 (d, J = 6.0 Hz, 2H), 3.73-3.71 (m, 4H), 3.54-3.51 (m, 4H), 2.16 (s, 3H). ESI-MS: 517.15 (M+H)+ N-[(3,5-difluorophenyl)methyl]-2-methyl-3-({2-[2-(4-methylpiperazin-1-yl)-4-pyridyl]-4pyridyl}oxy)benzamide (270):

[0351] Compound 270 was synthesized from intermediate 265a (0.07 mmol) and 1-methylpiperazine (1.07 mmol) as a white solid in a 40% yield according to the general method J. 1H NMR (400 MHz, DMSO-cfe) δ (ppm): 9.01 (t, J = 6.0 Hz, 1H), 8.55 (d, J = 5.8 Hz, 1H), 8.21-8.19 (m, 1H), 7.74 (d, J = 2.2 Hz, 1H), 7.45 (s, 1H), 7.43-7.37 (m, 2H), 7.27-7.23 (m, 2H), 7.13 (tt, J = 9.4 Hz, 2.4 Hz, 1H), 7.09-7.04 (m, 2H), 6.69 (dd, J = 5.6 Hz, 2.4 Hz, 1H), 4.48 (d, J = 6.0 Hz, 2H), 3.57-3.55 (m, 4H), 2.42-2.40 (m, 4H), 2.22 (s, 3H), 2.16 (s, 3H). ESI-MS: 530.15 (M+H)+ 3-{[2-(2-amino-4-pyridyl)-4-pyridyl]oxy}-N-[(3,5-difluorophenyl)methyl]-2-methylbenzamide (271): Petition 870260063548, dated 06 / 26 / 2026, p. 217 / 639 211 / 316

[0352] Compound 271 was synthesized from intermediate 265a (0.07 mmol) and NH4OH (1.5 ml) as a white solid with a yield of 34% according to the general method J. 1H NMR (400 MHz, DMSO-cfe) δ (ppm): 9.01 (t, J = 6.1 Hz, 1H), 8.55 (d, J = 5.8 Hz, 1H), 7.98 (dd, J = 5.4 Hz, 0.6 Hz, 1H), 7.43-7.37 (m, 3H), 7.28 (dd, J = 7.3 Hz, 2.0 Hz, 1H), 7.16-7.04 (m, 4H), 7.02 (dd, J = 5.4 Hz, 1.6 Hz, 1H), 6.78 (dd, J = 5.6 Hz, 2.4 Hz, 1H), 6.03 (s, 2H), 4.48 (d, J = 6.0 Hz, 2H), 2.15 (s, 3H). ESI-MS: 447.05 (M+H)+. N-[(3,5-difluorophenyl)methyl]-2-methyl-3-{[2-(6-pyrrolidin-1-yl-3-pyridyl)-4pyridyl]oxy}benzamide (272):

[0353] Compound 272 was synthesized from intermediate 265b (0.07 mmol) and pyrrolidine (1.06 mmol) as a white solid with a 55% yield according to general method J. 1H NMR (400 MHz, DMSO-cfe) δ (ppm): 9.01 (t, J = 6.0 Hz, 1H), 8.75 (d, J = 1.9 Hz, 1H), 8.43 (d, J = 5.6 Hz, 1H), 8.13 (dd, J = 8.9 Hz, 2.5 Hz, 1H), 7.42-7.35 (m, 3H), 7.24 (dd, J = 7.5 Hz, 1.8 Hz, 1H), 7.16-7.10 (m, 1H), 7.09-7.04 (m, 2H), 6.55-6.50 (m, 2H), 4.48 (d, J = 6.0 Hz, 2H), 3.45-3.42 (m, 4H), 2.15 (s, 3H), 1.97-1.94 (m, 4H). ESI-MS: 501.10 (M+H)+ N-[(3,5-difluorophenyl)methyl]-2-methyl-3-({2-[6-(1-piperidyl)-3-pyridyl]-4pyridyl}oxy)benzamide (273): Petition 870260063548, dated 06 / 26 / 2026, p. 218 / 639 212 / 316

[0354] Compound 273 was synthesized from intermediate 265b (0.07 mmol) and piperidine (1.06 mmol) as a white solid with a 65% yield according to general method J. 1H NMR (400 MHz, DMSO-cfe) δ (ppm): 9.00 (t, J = 6.0 Hz, 1H), 8.75 (d, J = 2.2 Hz, 1H), 8.44 (d, J = 5.8 Hz, 1H), 8.13 (dd, J = 9.0 Hz, 2.5 Hz, 1H), 7.42-7.35 (m, 3H), 7.24 (dd, J = 7.4 Hz, 1.8 Hz, 1H), 7.16-7.04 (m, 3H), 6.87 (d, J = 8.9 Hz, 1H), 6.56 (dd, J = 5.7 Hz, 2.4 Hz, 1H), 4.48 (d, J = 6.0 Hz, 2H), 3.61-3.58 (m, 4H), 2.15 (s, 3H), 1.63-1.54 (m, 6H). ESI-MS: 515.20 (M+H)+. N-[(3,5-difluorophenyl)methyl]-2-methyl-3-{[2-(6-morpholino-3-pyridyl)-4pyridyl]oxy}benzamide (274):

[0355] Compound 274 was synthesized from intermediate 265b (0.07 mmol) and morpholine (1.06 mmol) as a white solid with a 65% yield according to the general method J. 1H NMR (400 MHz, DMSO-cfe) δ (ppm): 9.00 (t, J = 6.0 Hz, 1H), 8.80 (d, J = 2.2 Hz, 1H), 8.46 (d, J = 5.7 Hz, 1H), 8.20 (dd, J = 9.0 Hz, 2.5 Hz, 1H), 7.45 (d, J = 2.3 Hz, 1H), 7.40-7.36 (m, 2H), 7.25 (dd, J = 7.4 Hz, 1.9 Hz, 1H), 7.13 (tt, J = 9.5 Hz, 2.4 Hz, 1H), 7.09-7.04 (m, 2H), 6.91 (d, J = 9.0 Hz, 1H), 6.57 (dd, J = 5.7 Hz, 2.4 Hz, 1H), 4.48 (d, J = 6.0 Hz, 2H), 3.72-3.69 (m, 4H), 3.55-3.52 (m, 4H), 2.15 (s, 3H). ESI-MS: 517.15 (M+H)+ N-[(3,5-difluorophenyl)methyl]-2-methyl-3-({2-[6-(4-methylpiperazin-1-yl)-3-pyridyl]-4pyridyl}oxy)benzamide (275): Petition 870260063548, dated 06 / 26 / 2026, p. 219 / 639 213 / 316

[0356] Compound 275 was synthesized from intermediate 265b (0.07 mmol) and 1-methylpiperazine (1.06 mmol) as a white solid in a 52% yield according to general method J. 1H NMR (400 MHz, DMSO-cfe) δ (ppm): 9.00 (t, J = 6.0 Hz, 1H), 8.77 (d, J = 2.1 Hz, 1H), 8.45 (d, J = 5.8 Hz, 1H), 8.16 (dd, J = 9.0 Hz, 2.5 Hz, 1H), 7.43 (d, J = 2.2 Hz, 1H), 7.42-7.36 (m, 2H), 7.25 (dd, J = 7.4 Hz, 1.9 Hz, 1H), 7.16-7.10 (m, 1H), 7.09-7.04 (m, 2H), 6.90 (d, J = 9.0 Hz, 1H), 6.57 (dd, J = 5.7 Hz, 2.4 Hz, 1H), 4.48 (d, J = 6.0 Hz, 2H), 3.58-3.55 (m, 4H), 2,402.38 (m, 4H), 2.22 (s, 3H), 2.15 (s, 3H). ESI-MS: 530.15 (M+H)+. N-[(3,5-difluorophenyl)methyl]-3-({2-[6-(dimethylamino)-3-pyridyl]-4-pyridyl}oxy)-2methyl-benzamide (276):

[0357] Compound 276 was synthesized from intermediate 265b (0.07 mmol) and dimethylamine (2M THF, 1.06 mmol) as a white solid in a 72% yield according to general method J. 1H NMR (400 MHz, DMSOd6) δ (ppm): 9.01 (t, J = 6.0 Hz, 1H), 8.76 (dd, J = 2.5 Hz, 0.6 Hz, 1H), 8.44 (d, J = 5.8 Hz, 1H), 8.14 (dd, J = 9.0 Hz, 2.5 Hz, 1H), 7.42-7.35 (m, 3H), 7.24 (dd, J = 7.5 Hz, 1.8 Hz, 1H), 7.16-7.10 (m, 1H), 7.09-7.04 (m, 2H), 6.71 (dd, J = 9.0 Hz, 0.5 Hz, 1H), 6.55 (dd, J = 5.7 Hz, 2.4 Hz, 1H), 4.48 (d, J = 6.0 Hz, 2H), 3.08 (s, 6H), 2.15 (s, 3H). ESI-MS: 475.10 (M+H)+ 3-{[2-(6-amino-3-pyridyl)-4-pyridyl]oxy}-N-[(3,5-difluorophenyl)methyl]-2-methylbenzamide (277): Petition 870260063548, dated 06 / 26 / 2026, p. 220 / 639 214 / 316

[0358] Compound 277 was synthesized from intermediate 265b (0.07 mmol) and NhUOH (1.5 ml) as a white solid with a 69% yield according to the general J.1H NMR method (400 MHz, DMSO-cfe) δ (ppm): 9.00 (t, J = 6.0 Hz, 1H), 8.60-8.59 (m, 1H), 8.42 (d, J = 5.8 Hz, 1H), 8.01 (dd, J = 8.7 Hz, 2.5 Hz, 1H), 7.42-7.35 (m, 2H), 7.34 (d, J = 2.2 Hz, 1H), 7.24 (dd, J = 7.5 Hz, 1.8 Hz, 1H), 7.13 (tt, J = 9.4 Hz, 2.4 Hz, 1H), 7.09-7.04 (m, 2H), 6.55 (dd, J = 5.7 Hz, 2.4 Hz, 1H), 6.49 (dd, J = 8.7 Hz, 0.6 Hz, 1H), 6.28 (s, 2H), 4.48 (d, J = 6.0 Hz, 2H), 2.15 (s, 3H). ESI-MS: 447.05 (M+H)+ Example 10: General procedure for the synthesis of analogues 278-283 Boronic acid, Pd(PPhj)4, Cs2CO3 1M, dioxane, 10°C D2 Method D2 Method Boronic ester, Pd(PPh3)4, Cs2CO3 1M, dioxane, 100°C A / -[(3,5-difluorophenyl)methyl]-2-methyl-3-({2-[3-(1-methylpyrazcl-4-yl)phenyl]-4pyridyl}oxy)benzamide (278): Petition 870260063548, dated 06 / 26 / 2026, p. 221 / 639 215 / 316

[0359] Compound 278 was synthesized in a two-step procedure from intermediate 199b (0.06 mmol), (3-bromophenyl)boronic acid (0.06 mmol) and pinacol ester of 1-methylpyrazol-4-boronic acid (0.13 mmol) as a white solid with a yield of 10% according to general method D2. 1H NMR (600 MHz, DMSO-cfe) δ (ppm): 9.00 (t, J = 6.0 Hz, 1H), 8.54 (d, J = 5.6 Hz, 1H), 8.26 (s, 1H), 8.23 ​​(t, J = 1.6 Hz, 1H), 7.95 (d, J = 0.8 Hz, 1H), 7.85-7.83 (m, 1H), 7.66 (d, J = 2.3 Hz, 1H), 7.64-7.62 (m, 1H), 7.45 (t, J = 7.7 Hz, 1H), 7.43-7.37 (m, 2H), 7.27 (dd, J = 7.8 Hz, 1.4 Hz, 1H), 7.12 (tt, J = 9.4 Hz, 2.4 Hz, 1H), 7,097.05 (m, 2H), 6.66 (dd, J = 5.6 Hz, 2.4 Hz, 1H), 4.48 (d, J = 6.0 Hz, 2H), 3.88 (s, 3H), 2.17 (s, 3H). ESI-MS: 511.10 (M+H)+. N-[(3,5-difluorophenyl)methyl]-2-methyl-3-({2-[3-(2-methylpyrazol-3-yl)phenyl]-4pyridyl}oxy)benzamide (279):

[0360] Compound 279 was synthesized in a two-step procedure from intermediate 199b (0.08 mmol), (3-bromophenyl)boronic acid (0.08 mmol) and pinacol ester of 1-methyl-1H-pyrazol-5-boronic acid (0.15 mmol) as a white solid with a yield of 6% according to general method D2. 1H NMR (600 MHz, DMSO-cfe) δ (ppm): 8.99 (t, J = 6.0 Hz, 1H), 8.56-8.55 (m, 1H), 8.15 (t, J = 2.0 Hz, 1H), 8.10-8.08 (m, 1H), 7.64 (d, J = 2.1 Hz, 1H), 7.62-7.60 (m, 2H), 7.49 (d, J = 1.9 Hz, 1H), 7.42-7.37 (m, 2H), 7.27 (dd, J = 7.7 Hz, 1.4 Hz, 1H), 7.12 (tt, J = 9.4 Hz, 2.4 Hz, 1H), 7.09-7.05 (m, 2H), 6.70 (dd, J = 5.6 Hz, 2.4 Hz, 1H), 6.49 (d, J = 1.9 Hz, 1H), 4.48 (d, J = 6.0 Hz, 2H), 3.88 (s, 3H), 2.16 (s, 3H). ESI-MS: 511.15 (M+H)+ N-[(3,5-difluorophenyl)methyl]-2-methyl-3-({2-[3-(1-methylpyrazol-3-yl)phenyl]-4Petition 870260063548, of 26 / 06 / 2026, pp. 222 / 639 216 / 316 pyridyl}oxy)benzamide (280):

[0361] Compound 280 was synthesized in a two-step procedure from intermediate 199b (0.08 mmol), (3-bromophenyl)boronic acid (0.08 mmol) and 1-methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole (0.15 mmol) as a white solid with a yield of 10% according to general method D2. 1H NMR (600 MHz, DMSO-cfe) δ (ppm): 9.00 (t, J = 6.0 Hz, 1H), 8.56-8.55 (m, 1H), 8.48 (t, J = 1.6 Hz, 1H), 7.90 (ddd, J = 7.8 Hz, 1.8 Hz, 1.1 Hz, 1H), 7.85 (ddd, J = 7.7 Hz, 1.6 Hz, 1.1 Hz, 1H), 7.75 (d, J = 2.2 Hz, 1H), 7.58 (d, J = 2.2 Hz, 1H), 7.49 (t, J = 7.7 Hz, 1H), 7.43-7.37 (m, 2H), 7.28 (dd, J = 7.8 Hz, 1.3 Hz, 1H), 7.12 (tt, J = 9.3 Hz, 2.4 Hz, 1H), 7.09-7.05 (m, 2H), 6.78 (d, J = 2.2 Hz, 1H), 6.70 (dd, J = 5.6 Hz, 2.4 Hz, 1H), 4.48 (d, J = 6.0 Hz, 2H), 3.90 (s, 3H), 2.17 (s, 3H). ESI-MS: 511.10 (M+H)+. N-[(3,5-difluorophenyl)methyl]-2-methyl-3-({2-[4-(1-methylpyrazol-4-yl)phenyl]-4pyridyl}oxy)benzamide (281):

[0362] Compound 281 was synthesized in a two-step procedure from intermediate 199b (0.10 mmol), (4-bromophenyl)boronic acid (0.15 mmol) and pinacol ester of 1-methylpyrazol-4-boronic acid (0.21 mmol) as a white solid with a yield of 4% according to general method D2. 1H NMR (400 MHz, DMSO-cfe) δ (ppm): 9.01 (t, J = 6.0 Hz, 1H), 8.52 (d, J = 5.6 Hz, 1H), 8.21 (s, 1H), 8.03 (d, J = 8.5 Hz, 2H), 7.93 (d, J = 0.6 Hz, 1H), 7.66 (d, J = 8.5 Hz, 2H), 7.51 (d, J = 2.3 Hz, 1H), 7.43-7.37 (m, 2H), 7.27 (dd, J = 7.4 Hz, 1.8 Hz, 1H), 7.16-7.10 (m, 1H), 7.09-7.04 (m, 2H), 6.66 (dd, J = 5.6 Hz, 2.4 Hz, 1H), 4.48 (d, J = 6.0 Hz, 2H), 3.88 (s, 3H), 2.16 (s, 3H). Petition 870260063548, dated 06 / 26 / 2026, pp. 223 / 639 217 / 316 ESI-MS: 511.10 (M+H)+. N-[(3,5-difluorophenyl)methyl]-2-methyl-3-({2-[4-(2-methylpyrazol-3-yl)phenyl]-4pyridyl}oxy)benzamide (282):

[0363] Compound 282 was synthesized in a two-step procedure from intermediate 199b (0.10 mmol), (4-bromophenyl)boronic acid (0.15 mmol) and pinacol ester of 1-methyl-1H-pyrazol-5-boronic acid (0.21 mmol) as a white solid with a yield of 4% according to general method D2. 1H NMR (400 MHz, DMSO-cfe) δ (ppm): 9.02 (t, J = 6.0 Hz, 1H), 8.57 (d, J = 5.7 Hz, 1H), 8.15 (d, J = 8.4 Hz, 2H), 7.65 (d, J = 8.4 Hz, 2H), 7.56 (d, J = 2.3 Hz, 1H), 7.49 (d, J = 1.9 Hz, 1H), 7.44-7.37 (m, 2H), 7.29 (dd, J = 7.3 Hz, 1.9 Hz, 1H), 7.15-7.10 (m, 1H), 7.09-7.04 (m, 2H), 6.74 (dd, J = 5.6 Hz, 2.4 Hz, 1H), 6.48 (d, J = 1.9 Hz, 1H), 4.48 (d, J = 6.0 Hz, 2H), 3.90 (s, 3H), 2.17 (s, 3H). ESI-MS: 511.10 (M+H)+ N-[(3,5-difluorophenyl)methyl]-2-methyl-3-({2-[4-(1-methylpyrazol-3-yl)phenyl]-4pyridyl}oxy)benzamide (283):

[0364] Compound 283 was synthesized in a two-step procedure from intermediate 199b (0.10 mmol), (4-bromophenyl)boronic acid (0.15 mmol) and 1-methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole (0.21 mmol) as a white solid with a yield of 4% according to general method D2. 1H NMR (400 MHz, DMSO-cfe) δ (ppm): 9....

Claims

CLAIMS 1. Compound (C) or the N-oxide, pharmaceutically acceptable salt, pharmaceutically acceptable solvate or stereoisomer thereof, wherein said compound (C) is CHARACTERIZED in that it is chosen from those of formulas (I) to (VII): Formula (I) Formula (II) Formula (III) Formula (IV-c) Formula (V) Formula (VI) Petition 870250042595, dated 05 / 23 / 2025, p. 322 / 380 2 / 51 Formula (VII) wherein: - each of A is independently selected from the group consisting of cycloalkyl, heterocyclyl, aryl, heteroaryl and aralkyl, wherein said cycloalkyl, heterocyclyl, aryl, heteroaryl and aralkyl are optionally substituted with one or more substituents independently selected from the group consisting of halo, NO2, C1-6 alkyl, C2-4 alkenyl, C2-4 alkynyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, CF3, CN, OR11, SR11, N(Rii)2, OC(Rii)2O, OC(Rii)2C(Rii)2O, S(O)Ri2, SO2R12, SO2N(Rii)2, S(O)3Rii, P(=O)(ORii)2, P(=O)(Rii)2 NR11COR12, COR11,C(O)ORii, CON(Rii)2, OC(O)Rii, and OCON(Rii)2 and each optional alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heterocyclyl and heteroaryl substituent is further optionally substituted with halo, NO2, C1-6 alkyl, cycloalkyl, aryl, CF3, N(Rii)2, COR11, CON(Rii)2, OC(O)Rii, CN, or OR11; and wherein each of R11 and R12, independently of each other and in each occurrence, is selected from the group consisting of hydrogen, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, aralkyl and CF3, wherein said alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, heteroaryl and aralkyl substituents are optionally substituted with halo, C1-6 alkyl, cycloalkyl, heterocyclyl, C1-6 alkyl or aryl or heteroaryl amide, OR31 or N(R32)2, wherein each of R31 and R32, independently of each other and in each occurrence,is selected from the group consisting of hydrogen and C1-4 alkyl. - each of R4 and R'4, independently of each other and in each occurrence, is selected from hydrogen or C1-6 alkyl and z is an integer in the range of 0 to 2; provided that when z = 0, then A and R7 can together form a saturated or unsaturated chemical moiety; - each of R7, independently of each other and in each occurrence, is selected from hydrogen, C1-6 alkyl, cycloalkyl, wherein said alkyl and cycloalkyl are optionally replaced by a halogen atom, CF3, N(Rii)2, CN or OR11; and wherein each of R11, independently of the other and in each occurrence, is selected from the group consisting of hydrogen, C1-6 alkyl and CF3; - each of R3, independently of the other and in each occurrence, is selected from the group consisting of hydrogen, halo, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, cycloalkyl,heterocyclyl, aryl, heteroaryl, aralkyl, CF3, CN, OR21, SR21, N(R2i)2, NC(O)R21, NCON(R2i)2, COR21, C(O)OR21, CON(R2i)2, OC(O)R21, OCON(R2i)2, OC(R2i)2O, and OC(R2i)2C(R22)2O, wherein said alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, heteroaryl and aralkyl are optionally substituted with one or more substituents selected from halo, C1-6 alkyl, CF3, N(R2i)2, CN, or OR21; and wherein each of R21 and R22, independently of each other and in each occurrence, is selected from the group consisting of hydrogen, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, cycloalkyl, heterocyclyl, aryl, heteroaryl and aralkyl and wherein said alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, heteroaryl and aralkyl substituents are optionally substituted with halo, C1-6 alkyl, cycloalkyl, heterocyclyl, aryl, OR31 or N(R32)2, wherein each of R31 and R32, independently of each other and in each occurrence,is selected from the group consisting of hydrogen and C1-4 alkyl; each of r is an integer in the range of 0 to 3; since when R3 = NR21 and R7 = H, then R3 and NR7 can together form a saturated or unsaturated chemical moiety; - each of R2, independently of the other and in each occurrence, is selected from the group consisting of hydrogen, halo, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, cycloalkyl, heterocyclyl, aryl and heteroaryl, CF3, CN, NO2, OR21, SR21, N(R21)2, COR21, C(O)OR21, CON(R21)2, OC(O)R21, OCON(R2i)2, NC(O)R21, NCON(R2i)2, OC(R2i)2O and OC(R2i)2C(R22)2O, wherein said alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl and heteroaryl substituents are optionally substituted with one or more substituents selected from halo, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, cycloalkyl, heterocyclyl, CF3, COR21, CON(R2i)2, C(O)OR2i, N(R2i)2, CN, or OR21, and each optional substituent of alkyl, alkenyl, alkynyl,cycloalkyl, heterocyclyl, aryl or heteroaryl is additionally optionally substituted with heterocyclyl, Petition 870250042595, dated 23 / 05 / 2025, p. 324 / 380 4 / 51 N(Rii)2, or OR11; and wherein each of R21 and R22, independently of each other and in each occurrence, is selected from the group consisting of hydrogen, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, cycloalkyl, heterocyclyl, aryl, heteroaryl and aralkyl and wherein said alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, heteroaryl and aralkyl substituents are optionally substituted with halo, C1-6 alkyl, cycloalkyl, heterocyclyl, aryl, OR31 or N(R32)2, wherein each of R31 and R32, independently of each other and in each occurrence,is selected from the group consisting of hydrogen and C1-4 alkyl; each of q is an integer in the range of 0 to 2; - each of x and y are independent integers equal to 0 or 1; - R8 is selected independently from the group consisting of C6-12 alkyl, C2-6 alkenyl, C2-6 alkynyl, cycloalkyl and heterocyclyl, wherein said alkyl, alkenyl, alkynyl, cycloalkyl and heterocyclyl are optionally substituted by a halogen atom, an aryl group, an aralkyl group, CF3, N(RIi)2, CN or OR11; and wherein each of R11, independently of the other and in each occurrence, is selected from the group consisting of hydrogen, C16 alkyl, C2-6 alkenyl, C2-6 alkynyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, aralkyl and CF3, wherein said substituents of alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, heteroaryl and aralkyl are optionally substituted with halo, C1-6 alkyl, cycloalkyl, heterocyclyl,alkyl or aryl or heteroaryl amide, OR31 or N(R32)2, wherein each of R31 and R32, independently of each other and in each occurrence, is selected from the group consisting of hydrogen and C1-4 alkyl; - R9 is selected from the group consisting of hydrogen, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, cycloalkyl, heterocyclyl, N(Rii)2 and CN, wherein said alkyl, alkenyl, alkynyl, cycloalkyl and heterocyclyl are optionally substituted by a halogen atom, an aryl group, an aralkyl group, a heterocyclyl group, CF3, N(Rii)2, CN, or OR11; and wherein each of R11, independently of the other and in each occurrence, is selected from the group consisting of hydrogen, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, aralkyl and CF3, wherein said alkyl, Petition 870250042595, dated 23 / 05 / 2025, page 325 / 380 5 / 51 alkenyl, alkynyl, cycloalkyl, heterocyclyl,optionally substituted heteroaryl compounds with C1-4 alkyl, aryl, heteroaryl and aralkyl substituents are optionally substituted with halo, C1-6 alkyl, cycloalkyl, heterocyclyl, alkyl or aryl or heteroaryl amide, OR31 or N(R32)2, wherein each of R31 and R32, independently of each other and in each occurrence, is selected from the group consisting of hydrogen and C1-4 alkyl, provided that x = 1 and y = 0, R9 is different from heterocyclyl and C1-6 alkyl wherein said alkyl is optionally substituted with heterocyclyl; and provided that x = 0 and y = 0, R9 is different from hydrogen and C1-6 alkyl, wherein said alkyl is optionally substituted with heterocyclyl and N(R32)2; since when x = 0 and y = 0, R9 and R2 can together form a saturated or unsaturated cyclic chemical portion; since when x = 0 and y = 0 and when R9 and R2 together form a saturated or unsaturated cyclic chemical portion, R9 is NR11; since when x = 1 and y = 1,R9 is different from N(Rii)2; and since when x = 0, y = 0 and z = 0, R9 is different from pyrrole. - each of T is independently the chemical portion of formula (Ta) in the present document below: (Rs)n1 (Ta) wherein: - each of U, independently of the other and in each occurrence, is selected from the group consisting of C, C-halo, CR and N; wherein R is selected from hydrogen, OR11, N(Rii)2, a C1-6 alkyl or a cycloalkyl that are optionally substituted by a halogen atom, an aryl group or an aralkyl group, wherein each of R11, independently of the other and in each occurrence, is selected from the group consisting of hydrogen or C1-4 alkyl; provided that at least one U is different from N; - each of Z, independently of the others and in each occurrence, is selected from C(R)2, O, S and NR7, where R, independently of the others and in each occurrence,is selected from hydrogen or a C1-6 alkyl that is optionally substituted by a halogen atom, an aryl group or an aralkyl group, wherein R7 is selected from the group consisting of hydrogen, C16 alkyl, C1-6 alkenyl, cycloalkyl, heterocyclyl, aryl, aralkyl and CF3; - each of R5, independently of the other and in each occurrence, is selected from the group consisting of C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, aralkyl, halo, CF3, OR11, SR11, N(Rii)2, COOR11, CO(Rii)2, CON(Rii)2 and each optional substituent of alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heterocyclyl, heteroaryl, aralkyl is additionally optionally substituted with halo, C1-6 alkyl, cycloalkyl, aryl, heterocyclyl, N(Rii)2, CN, OR11, C(=O)ORii, P(=O)(ORii)2, P(=O)(Rii)2, CN or CF3 and where each of R11, independently of the other and in each occurrence,is selected from the group consisting of hydrogen, C1-6 alkyl, cycloalkyl and heterocyclyl; each of n1 is an integer in the range of 0 to 2; - each of X is independently the chemical portion of formula (Xa) in the present document below: (Bθ)η2 v=v (Xa) wherein: - each of V, independently of the other and in each occurrence, is selected from the group consisting of C, C-halo, CR and N; wherein R is selected from hydrogen, OR11, N(Rii)2, a C1-6 alkyl or a cycloalkyl that are optionally substituted by a halogen atom, an aryl group or an aralkyl group, wherein each of R11, independently of the other and in each occurrence, is selected from hydrogen or C1-4 alkyl; - each of R6, independently of the other and in each occurrence, is selected from the group consisting of C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, aralkyl, halo, CF3, OR11, SR11, N(Rii)2, COOR11, CO(Rii)2,CON(Rii)2 and each optional substituent of alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heterocyclyl, heteroaryl, aralkyl is additionally optionally substituted with halo, C1-6 alkyl, Petition 870250042595, 23 / 05 / 2025, p. 327 / 380 7 / 51 cycloalkyl, aryl, heterocyclyl, N(Rii)2, CN, OR11, C(=O)ORii, P(=O)(ORii)2, P(=O)(Rii)2, CN or CF3 and wherein each of R11, independently of the other and in each occurrence, is selected from the group consisting of hydrogen, C1-6 alkyl, cycloalkyl and heterocyclyl; each of n2 is an integer in the range of 0 to 4; - the dash link represents an optional triple bond; - Ra1 is independently selected from the group consisting of hydrogen, C1-6 alkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, aralkyl, CF3, CN, OR11, SR11, N(Rii)2, COR11, C(O)ORii, wherein said alkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl and aralkyl are optionally replaced by halo, NO2, C1-6 alkyl,C2-6 alkenyl, C2-6 alkynyl, cycloalkyl, heterocyclyl, phenyl, heteroaryl, CF3, CN, OR11, SR11, N(Rii)2, COR11 and C(O)ORii and each optional substituent of alkyl, alkenyl, cycloalkyl, phenyl, heterocyclyl, heteroaryl is additionally optionally substituted with halo, NO2, C1-6 alkyl, cycloalkyl, phenyl, N(Rii)2, CN or OR11; and wherein each of R11 is selected from the group consisting of hydrogen, C1-6 alkyl, cycloalkyl, heterocyclyl, phenyl, heteroaryl and aralkyl, wherein said substituents of alkyl, cycloalkyl, heterocyclyl, phenyl, heteroaryl and aralkyl are optionally substituted with halo, C1-6 alkyl, cycloalkyl or heterocyclyl. - Ra2 is independently selected from the group consisting of hydrogen, C1-6 alkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, aralkyl, CF3, CN, OR11, SR11, N(Rii)2, COR11, C(O)ORii, wherein said alkyl, cycloalkyl, heterocyclyl, aryl,heteroaryl and aralkyl are optionally substituted by halo, NO2, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, cycloalkyl, heterocyclyl, phenyl, heteroaryl, CF3, CN, OR11, SR11, N(Rii)2, COR11 and C(O)ORii and each optional substituent of alkyl, alkenyl, cycloalkyl, phenyl, heterocyclyl, heteroaryl is further optionally substituted with halo, NO2, C1-6 alkyl, cycloalkyl, phenyl, N(Rii)2, CN or OR11; and wherein each of R11 is selected from the group consisting of hydrogen, C1-6 alkyl, cycloalkyl, heterocyclyl, phenyl, heteroaryl and aralkyl, wherein said alkyl, cycloalkyl, heterocyclyl, phenyl, heteroaryl and aralkyl substituents are optionally replaced with halo, C1-6 alkyl, cycloalkyl or heterocyclyl; and where n3 is an integer equal to 0 or 1; provided that when the dash link represents a triple bond,n3 is 0; wherein said cycloalkyl is a monocyclic, bicyclic or tricyclic ring system of 3-6 ring members per ring; said heterocyclyl is a saturated, partially saturated or fully saturated monocyclic, bicyclic or tricyclic containing 3 to 12 carbon atoms and 1 or 2 heteroatoms independently selected from O or N; said aryl is optionally carbocyclic phenyl, naphthyl or anthracenyl fused with a 5-7 ring-membered cycloalkyl or heterocyclyl; The said heteroaryl is a monocyclic ring structure containing 5 or 6 ring atoms or a bicyclic aromatic group having 8 to 10 atoms, containing 1-3 heteroatoms independently selected from O or N.

2. Compound (C), according to claim 1 or the N-oxide, pharmaceutically acceptable salt, pharmaceutically acceptable solvate or stereoisomer thereof,CHARACTERIZED in that x and y are as defined in claim 1 and wherein: - each of A is independently selected from the group consisting of cycloalkyl, heterocyclyl, aryl, heteroaryl and aralkyl, wherein said cycloalkyl, heterocyclyl, aryl, heteroaryl and aralkyl are optionally substituted with one or more substituents independently selected from the group consisting of halo, NO2, C1-6 alkyl, C2-4 alkenyl, C2-4 alkynyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, CF3, CN, OR11, SR11, N(Rii)2, OC(Rii)2O, OC(Rii)2C(Rii)2O, P(=O)(ORii)2, P(=O)(Rii)2 NR11COR12, COR11, C(O)ORii, CON(Rii)2, OC(O)Rii, and OCON(Rii)2 and each optional substituent of alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heterocyclyl, heteroaryl is additionally optionally substituted with halo, NO2, C1-6 alkyl, cycloalkyl, aryl, CF3, N(Rii)2, CN, or OR11; and where each of R11 and R12, independently of each other and in each occurrence,is selected from the group consisting of hydrogen, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, aralkyl and CF3, wherein said alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, heteroaryl and aralkyl substituents are optionally substituted with halo, C1-6 alkyl, cycloalkyl or heterocyclyl; Petition 870250042595, dated 23 / 05 / 2025, p. 329 / 380 9 / 51 - each of R4 and R'4, independently of each other and in each occurrence, are selected from hydrogen or C1-6 alkyl; and where z is an integer equal to 1; - each of R7, independently of the other and in each occurrence, is hydrogen or C1-4 alkyl such as methyl, ethyl, propyl, isopropyl, butyl, tert-butyl, isobutyl and the like; - each of R3, independently of the other and in each occurrence, is selected from the group consisting of hydrogen, halo, C1-6 alkyl, cycloalkyl, heterocyclyl, CF3, CN, OR21 and N(R2i)2,wherein said alkyl, cycloalkyl and heterocyclyl groups are optionally substituted with one or more substituents selected from halo, C1-6 alkyl, CF3, N(R2i)2, CN or OR21; and wherein each of R21, independently of the other and in each occurrence, is selected from the group consisting of hydrogen, C1-6 alkyl, C3-6 cycloalkyl, heterocyclyl, aryl, heteroaryl and aralkyl and wherein said alkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl and aralkyl substituents are optionally substituted with halo, C1-6 alkyl, cycloalkyl, heterocyclyl or aryl; each of r is an integer equal to 0 or 1 - each of R2, independently of the other and in each occurrence, is selected from the group consisting of hydrogen, halo, C1-6 alkyl, cycloalkyl, heterocyclyl, aryl and heteroaryl, CN, OR21 and N(R2i)2, wherein said alkyl, cycloalkyl, heterocyclyl,Aryl and heteroaryl groups are optionally substituted with one or more substituents selected from halo, C1-6 alkyl, cycloalkyl, N(R2i)2, CN or OR21; wherein R21, independently of each other and in each occurrence, is selected from the group consisting of hydrogen, C16 alkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl and aralkyl. - R8 is selected from the group consisting of C6-12 alkyl, cycloalkyl and heterocyclyl groups, wherein said alkyl, cycloalkyl and heterocyclyl groups are optionally substituted by a halogen atom, CF3, N(R2i)2, CN or OR11; and wherein each of R11, independently of each other and in each occurrence, is selected from the group consisting of hydrogen and C1-6 alkyl groups. - R9 is selected from the group consisting of hydrogen, C1-6 alkyl, cycloalkyl, N(Rii)2 and CN, wherein said alkyl and cycloalkyl are optionally substituted by a halogen atom, CF3,CN or OR11; and wherein each of R11, independently of the other and in each occurrence, is selected from the group consisting of hydrogen, C1-6 alkyl, C2-6 alkenyl and CF3, wherein said alkyl and alkenyl substituents are optionally substituted with a heteroaryl group optionally substituted with a C1-4 alkyl provided that if x = 0 and y = 0, R9 is different from hydrogen and C1-6 alkyl, wherein said alkyls are optionally substituted with heterocyclyl and N(Rii)2 and provided that when x = 0 and y = 0, R9 and R2 can together form a saturated or unsaturated cyclic chemical moiety; provided that when x = 0 and y = 0 and when R9 and R2 together form a saturated or unsaturated cyclic chemical moiety, R9 is NR11; since when x = 1 and y = 1, R9 is different from N(Rii)2; and since when x = 0, y = 0 and z = 0,R9 is different from pyrrole. - each of T is independently the chemical moiety of formula (Ta) in the present document below: (Rs)n1 (Ta) wherein: - each of U is selected independently of the other and in each occurrence, from C, C-halo, CR or N; wherein R is hydrogen or C1-4 alkyl provided that at least one U is different from N. More preferably, each of U is selected, independently of the other and in each occurrence, from C, CR or N; wherein R is hydrogen or C1-4 alkyl provided that at least one U is different from N; - each of Z is, independently of the other and in each occurrence, preferably selected from the group consisting of CH2 and O, S and NR? wherein R7 is a hydrogen or a C1-4 alkyl such as methyl, ethyl, propyl, isopropyl, butyl, tert-butyl and isobutyl; - each of R5, independently of the other and in each occurrence, is preferably selected from the group consisting of C1-6 alkyl, cycloalkyl, heterocyclyl, aryl,heteroaryl, aralkyl, halo, CF3, OR11, Petition 870250042595, dated 23 / 05 / 2025, p. 331 / 380 11 / 51 N(Rii)2, COOR11, C0(Rii)2, C0N(Rii)2 and each optional substituent of alkyl, cycloalkyl, aryl, heterocyclyl, heteroaryl, aralkyl is additionally optionally substituted with halo, C1-6 alkyl, cycloalkyl, aryl, heterocyclyl, N(Rii)2, CN, OR11, C(=O)ORii, P(=O)(ORii)2, P(=O)(Rii)2, CN or CF3 and wherein each of R11, independently of the other and in each occurrence, is selected from the group consisting of hydrogen, C1-6 alkyl, cycloalkyl and heterocyclyl; each of n1 is an integer equal to 1 or 2 - each of X is independently the chemical portion of formula (Xa) in the present document below: (8β)η2 v--v < x> v=v (Xa) where: - each of V, independently of the other and in each occurrence, is selected from the group consisting of C, C-halo, CR and N; where R is hydrogen or C1-4 alkyl; - each of R6,independently of each other and in each occurrence, is preferably selected from the group consisting of C1-6 alkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, aralkyl, halo, CF3, OR11, N(Rii)2, COOR11, CO(Rii)2, CON(Rii)2 and each optional substituent of alkyl, cycloalkyl, aryl, heterocyclyl, heteroaryl, aralkyl is additionally optionally substituted with halo, C1-6 alkyl, cycloalkyl, aryl, heterocyclyl, N(Rii)2, CN, OR11, C(=O)ORii, P(=O)(ORii)2, P(=O)(Rii)2, CN or CF3 and wherein each of R11, independently of each other and in each occurrence, is selected from the group consisting of hydrogen, C1-6 alkyl, cycloalkyl and heterocyclyl; and where n2 is an integer equal to 0, 1 or 2 - the dashed link represents an optional triple bond; - Ra1 is selected independently from the group consisting of C1-4 alkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, aralkyl, wherein said alkyl, cycloalkyl, heterocyclyl,aryl, heteroaryl and aralkyl are optionally replaced by halo, NO2, C1-4 alkyl, cycloalkyl, heterocyclyl, Petition 870250042595, 23 / 05 / 2025, p. 332 / 380 12 / 51 phenyl, heteroaryl, CF3, CN, OR11, N(Rii)2 and wherein each of R11 is selected from the group consisting of hydrogen or C1-4 alkyl. - each of Ra2 is independently selected from the group consisting of C1-4 alkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, aralkyl, wherein said alkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl and aralkyl are optionally substituted by halo, NO2, C1-4 alkyl, cycloalkyl, heterocyclyl, phenyl, heteroaryl, CF3, CN, OR11, N(Rii)2 and wherein each of R11 is selected from the group consisting of hydrogen or C1-4 alkyl. wherein said cycloalkyl is a monocyclic, bicyclic or tricyclic ring system of 3-6 ring members per ring; said heterocyclyl is a saturated monocycle, bicycle or tricycle,partially saturated or fully saturated containing 3 to 12 carbon atoms and 1 or 2 heteroatoms independently selected from O or N; said aryl is optionally carbocyclic phenyl, naphthyl or anthracenyl fused with a 5-7 membered cycloalkyl or heterocyclyl ring; The said heteroaryl is a monocyclic ring structure containing 5 or 6 ring atoms or a bicyclic aromatic group having 8 to 10 atoms, containing 1-3 heteroatoms independently selected from O or N.

3. Compound (C) of formula (II) or (III), according to claim 1 or the N-oxide, pharmaceutically acceptable salt, pharmaceutically acceptable solvate or stereoisomer thereof, said compound being CHARACTERIZED in that it is of formula (II-a) or (II-b) [compounds (C) of class (II) hereinafter in this document] or of formula (III-a) [compounds (C) of class (III) hereinafter in this document]: Formula (II-a) Formula (II-b) Petition 870250042595, dated 23 / 05 / 2025,page. 333 / 380 13 / 51 Formula (III-a) wherein A, R4, R4', z, R7, R3, r, R2, q, R9 and T are as defined in any one of claims 1 to 2.

4. Compound (C) of formula (IV) or formula (VI), according to claim 1 or the N-oxide, pharmaceutically acceptable salt, pharmaceutically acceptable solvate or stereoisomer thereof, said compound being CHARACTERIZED in that it is of formula (IV-a) to (IV-c) [compounds (C) of class (IV) hereinafter in this document] or of formula (VIa) to (VI-c) [compounds (C) of class (VI) hereinafter in this document]: Formula (IV-a) Formula (IV-b) Formula (IV-c) Formula (VI-a) Formula (VI-b) Petition 870250042595, from 23 / 05 / 2025, p. 334 / 380 14 / 51 Formula (VI-c) wherein A, R4, R4', z, R7, R3, r, R2, q, T and X are as defined in any of claims 1 to 2.

5. Compound (C) of formula (VII), according to claim 1 or the N oxide, pharmaceutically acceptable salt,A pharmaceutically acceptable solvate or stereoisomer thereof, wherein said compound is CHARACTERIZED in that it is of formula (VII-a) or (VII-b) [compounds (C) of class (VII) hereinafter Formula (VII-a) Formula (VIIb) wherein A, R4, R4', z, R7, R3, r, R2, q, Ra1, Ra2 and n3 are as defined in any of claims 1 to 2.

6. Compound (C) of formula (II), according to claim 1 or the Noxide, pharmaceutically acceptable salt, pharmaceutically acceptable solvate or stereoisomer thereof, wherein said compound is CHARACTERIZED in that it is of formula (II-a-1) or (II-b-1) or (II-c-1) [compounds (C) of class (II) hereinafter in this document]: Formula (II-a-1) Petition 870250042595, 23 / 05 / 2025, p. 335 / 380 15 / 51 Formula (II-b-1) Formula (II-c-1) wherein A, R4, R3, R2 and R9 have the same meaning as defined above for formula (II); where R31 is a heteroaryl that is optionally substituted with a C1-4 alkyl,where R11' is hydrogen or C1-4 alkyl; and wherein Rbé is selected from the group consisting of hydrogen, halo, C1-4 alkyl and C16 cycloalkyl. wherein said heteroaryl is a monocyclic ring structure containing 5 or 6 ring atoms or a bicyclic aromatic group containing 8 to 10 atoms, containing 1-3 heteroatoms independently selected from O or N.

7. Compound (C) of formula (IV) or (VI), according to claim 1 or the N-oxide, pharmaceutically acceptable salt, pharmaceutically acceptable solvate or stereoisomer thereof, wherein said compound is CHARACTERIZED in that it is of formula (IV-a-1) to (IV-c-1) [compounds (C) of class (IV) hereinafter in this document] or of formula (VI-a-1) to (VI-c-1) [compounds (C) of class (VI) hereinafter in this document]: Formula (IV-a-1) Formula (IV-b-1) Petition 870250042595, of 05 / 23 / 2025, p. 336 / 380 16 / 51 Formula (VI-b-1) Formula (IV-c-1) Formula (VI-a-1) Formula (VI-c-1) where A, R4, R3, R2,T and X are as defined in any of claims 1 to 2.

8. Compound (C) of formula (VII), according to claim 1 or the Noxide, pharmaceutically acceptable salt, pharmaceutically acceptable solvate or stereoisomer thereof, said compound being CHARACTERIZED in that it is of formula (VII-a-1) or (VII-b-1) [compounds (C) of class (VII) hereafter in this document]: Formula (VII-a-1) Formula (VII-b-1) Petition 870250042595, dated 05 / 23 / 2025, p. 337 / 380 17 / 51 wherein A, R4, R3, R2, Rai, Ra2 and n3 are as defined in any one of claims 1 to 2.

9. Compound (C) of formula (II), according to claim 1 or the Noxide, pharmaceutically acceptable salt, pharmaceutically acceptable solvate or stereoisomer thereof, said compound being CHARACTERIZED in that it is of formula (II-a-2), or (II-b-2), or (II-c-2) [compounds (C) of class (II) hereafter in this document]:, 2) Formula (II-a- wherein: Formula (II-b-2) Formula (II-c-2) each of R9' is selected from the group consisting of hydrogen, CN and C3-6 cycloalkyl as cyclopropyl; each of R9” is selected from the group consisting of hydrogen, C1-4 alkyl, CN and C3-6 cycloalkyl as cyclopropyl; - each of R2 is independently selected from hydrogen or halo; - each of Rq is independently selected from the group consisting of hydrogen, CH3, OCH3 and halo, such as F or Cl; - each of Rw is independently selected from the group consisting of H, F, Cl, OCH3 or CF3; Petition 870250042595, dated 23 / 05 / 2025, page 338 / 380 18 / 51 - each of U is selected from the group consisting of C, C-R10 and N; - πιο is an integer equal to 0, 1, or 2; - each of R31' is selected from the group consisting of pyrazyl, N-methylpyrazyl, and pyridyl.- Rb' is selected from the group consisting of hydrogen, halo, C1-4 alkyl and C1-4 cycloalkyl; preferably Rb' is selected from the group consisting of Cl, CH3 and cyclopropyl; - the dash bond represents an optional double bond.

10. Compound (C) of formula (IV), according to claim 1 or the Noxide, pharmaceutically acceptable salt, pharmaceutically acceptable solvate or stereoisomer thereof, said compound being CHARACTERIZED in that it is of formula (IV-a-2-1), (IV-a-2-2), (IV-b-2-1), (IV-b-2-2), or (IV-c-2-1) to (IV-c-2-4) [compounds (C) of class (IV) hereinafter in this document]: Formula (IV-a-2-1) Formula (IV-a-2-2) Formula (IV-b-2-1) Formula (IV-b-2-2) Petition 870250042595, dated 05 / 23 / 2025, p.339 / 380 19 / 51 where: Formula (IV-c-2-1) Formula (IV-c-2-2) Formula (IV-c-2-3) Formula (IV-c-2-4) - T is, independently of each other and in each occurrence, selected from the chemical portion of formula (Taa) to (Taf) in the present document below: (Taa) (Tab) ^5 (R5)ni (Tac) / R Γ H nA nA nA A AxN TFx N (R5)ni ^X(R5)ni NAX(R5)ni (Tad) (Tae) (Taf) wherein: - each of R' is independently hydrogen, C1-4 alkyl, cycloalkyl selected from the group consisting of cyclopropyl and cyclobutyl; Petition 870250042595, dated 23 / 05 / 2025, p.340 / 380 20 / 51 heterocyclyl selected from the group consisting of oxetanyl, tetrahydropyranyl, azetdinyl and piperidinyl; wherein said alkyl is additionally optionally substituted with F, OC1-4 alkyl, P(=O)(OC1-4alkyl)2, P(=O)(C1-4alkyl)2, CN, cyclopropyl or cyclobutyl; and wherein said heterocyclyl is additionally optionally substituted with C(=O)(OC1-4alkyl), - each of R”5 is independently selected from the group consisting of hydrogen, C1-4 alkyl, CF3 and cyclopropyl; - each of n1, independently of each other and in each occurrence, is an integer equal to 0, 1 or 2.- R2 is independently hydrogen, halo, or NH2; - each of Rq is independently selected from the group consisting of H, CH3, OCH3, and halo, such as F or Cl; - each of Rw is independently selected from the group consisting of hydrogen, halo, C1-4 alkyl, CF3, OC1-4 alkyl, CN; - each of U and V are independently C, C-R10, or N; - πιο is an integer equal to 0, 1 or 2.

11. Compound (C) of formula (VI), according to claim 1 or the N-oxide, pharmaceutically acceptable salt, pharmaceutically acceptable solvate or stereoisomer thereof, said compound being CHARACTERIZED in that it is of formula (VI-a-2) to (VI-c-2) [compounds (C) of class (VI) hereafter in this document]: Formula (VI-a-2) Formula (VI-b-2) Petition 870250042595, dated 05 / 23 / 2025, p.341 / 380 21 / 51 wherein Formula (VI-c-2) - each of R”6 is independently selected from the group consisting of hydrogen, halo, C1-4 alkyl, N(R2i)2, OR21; heterocyclyl selected from the group consisting of pyrrolidyl, piperidyl, morpholinyl, piperazyl and a pyrazyl, wherein said heterocyclyl and pyrazyl are optionally substituted with C1-4 alkyl and wherein R21 is a C1-4 alkyl. - each of Rq is independently selected from the group consisting of H, CH3, OCH3 and halo, such as F or Cl. integer equal to 0, 1 or 2 - Π2 is an integer equal to 0, 1 or 2. 12.Compound (C) of formula (VII), according to claim 1 or the N-oxide, pharmaceutically acceptable salt, pharmaceutically acceptable solvate or stereoisomer thereof, said compound being CHARACTERIZED in that it is of formula (VII-a-2) [compounds (C) of class (VI) hereafter in this document]: R / Formula (VII-a-2) wherein Ra'1 is selected from the group consisting of benzyl, pyrazyl, OH, OC1-4 alkyl, NH2 and NH(C1-4 alkyl) and wherein Rq is selected from the group consisting of H, CH3, OCH3 and halo, such as F or Cl; preferably Rq is H or CH3. Petition 870250042595, dated 23 / 05 / 2025, p. 342 / 380 22 / 51 13.Compound (C) of formula (IV-a-1), (IV-b-1), or (IV-c-1), (VI-a-1), (VI-b-1) or (VI-c-2), according to claim 7 or the N-oxide, pharmaceutically acceptable salt, pharmaceutically acceptable solvate or stereoisomer thereof, CHARACTERIZED in that the compound of formula (IV-a-1), (IV-b-1), (IVc-1), (VI-a-1), (VI-b-1) or (VI-c-2) is a compound according to formula (XXXVII) to (CCLX) in this document below: 1 ° H NL O J. XL -nCT Xj XX H XXF -\J XX XJ H XJ -WX / 'XL. 1 ° H NL O A. JL —\ TT x TXH x HJ kx. J 1>X LL F |^F <ΥΤΐ'ΧΛχι;> -ίΥχτΧΧχι;) 1° HN ^χ·ΝΧ _____ .O XX XX .___ / — τ'^> i— t— N'— f \JT । XXXH XX Χξξξ-' n.